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ABSTRACT 
AIM: This thesis set out to make an original contribution to knowledge with regard to 
methods of assessing muscle size and architecture in the CKD and ESRD population, and 
to assess the ability to improve the muscle size and architecture, and symptoms of 
uraemia, by implementing an anabolic intervention (resistance exercise training) in the 
CKD population. 
OUTCOME MEASURES: Ultrasound was shown to have high validity (against gold 
standard MRI measures; ICCs: VLACSA 0.96, VL depth 0.99, fat depth 0.98) and intra-
rater reliability (ICCs: VL depth 0.98, total muscle depth 0.97, fat depth 0.99; MDC: VL 
depth 0.14cm, total muscle depth 0.19cm, fat depth 0.22cm) in measuring regional 
body composition at the mid-VL site in the CKD population. 
There were significant (p<0.01) correlations between US-derived measures of (mid-VL) 
muscle size and architecture with strength and function (larger muscle mass and/or 
pennation angle positively correlated with higher strength and/or functional 
performance).  Patient-reported uraemic symptoms were worse (p<0.01) in those with 
reduced strength and/or function. 
INTERVENTION RESULTS: An anabolic (resistance training) intervention (12-weeks, 
randomized to once [RT1 n=7] or three times [RT3 n=10] per week, 80%1RM) brought 
about significant improvements over time (p<0.01) in all measures of muscle size and 
architecture (VL depth, total muscle depth, VLACSA, pennation angle).  Interaction 
effects (group*time) were only seen in pennation angle (p<0.05) and VLACSA (p<0.01) 
where RT3 gains were greater than RT1 from week 8 onwards.   
All measures of strength, function, and uraemic symptoms improved over time 
(p<0.01) with no interaction effects (no difference from greater training frequency/ 
volume). 
CLINICAL AND RESEARCH IMPLICATIONS: The intervention results suggest 
implementing a RT form of “prehabilitation” in early stage (CKD3) patients just once 
per week is sufficient to bring about statistically and clinically important changes in 
strength and function that benefit the patient through reduced frequency and/or 
intrusiveness of uraemic symptoms (improved health-related quality of life), with 
minimal time-commitment. 
Further research should examine if there is additional benefit to the significantly 
greater increases in VLACSA and pennation angle observed in RT3, with regards to long-
term maintenance of functional improvements, and whether an RT1 or RT3 programme 
delays the progression of CKD, the need for RRT, and patient mortality. 
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CHAPTER 1 - Introduction 
 
Chronic Kidney Disease (CKD) is an important public health issue.   It is a common and 
progressive disease, and the prevalence increases with age (2012 UK Renal Registry 
annual report, 2013), which means that the disease burden will increase with our 
ageing population.  Chronic kidney disease is an independent risk factor for other 
diseases, particularly cardiovascular disease (USRDS, 2013 Annual Report; Shastri & 
Sarnak 2010).  In a minority of cases, chronic kidney disease progresses to end stage 
renal disease (ESRD), which may require renal replacement therapy (RRT) (Eriksen & 
Ingebretsen 2006; 2012 UK Renal Registry annual report, 2013).  This progression and 
the risks of other vascular events, such as stroke and heart failure, can be reduced if 
chronic kidney disease is identified and well-managed (NICE clinical guidelines 73, 
2008).  Therefore early diagnosis is essential.   
A UK population study estimated that in people with CKD there was a 4% risk of 
progression to end stage renal disease (ESRD) over a 5.5 year follow-up period (Drey et 
al 2003).  ESRD is a long-term irreversible decline in kidney function, for which renal 
replacement therapy (RRT) is required if the individual is to survive (NHS Kidney Care, 
2010). 
The incidence of RRT (new patients on RRT per year) in the UK was approximately 108 
per million population (0.01%) in 2012, an increase from 95 per million in 2001, with 
total numbers (prevalence) undergoing RRT much greater still (an increase to 861 from 
523 per million population in 2000; 0.09% total prevalence; 2012 UK Renal Registry 
annual report, 2013).   
The increased incidence and prevalence may be in part due to earlier diagnosis, 
increased awareness, and the fact the population as a whole is living longer, with 
Chronic Kidney Disease often associated with older age groups (average transfer to RRT 
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was 64.6 years old; 2012 UK Renal Registry annual report, 2013).  Whatever the reason, 
there are more individuals needing a greater healthcare provision, and because of this, 
there is an increased burden on the NHS.  
Disproportionate to the one-tenth of a percent of the UK population undergoing RRT, 
at least 2% of the NHS budget is spent on renal replacement therapy per annum (UK 
renal registry annual report, 2013).  This is massively unbalanced, and non-medical 
interventions are being investigated to reduce the impact of renal disease on both the 
individual patients, and the NHS purse (Ansell et al 2006).  Evidently more patients are 
presenting with the need to transfer to RRT, and more are living longer once on RRT, 
but the cost to the NHS is disproportionately large. 
CKD manifests in many ways, with frailty and disability a major consequence of the 
generalised wasting observed in the population (Johansen et al 2013).  Often dietary 
restrictions are imposed on CKD patients to reduce the stress on the kidneys (Goraya & 
Wesson 2012).  Alongside this, as the disease progresses other uraemic symptoms and 
hormonal changes bring about loss of appetite and fatigue, further contributing to the 
progressive atrophy, protein energy wasting, weakness, and frailty (Kim et al 2013). 
CKD patients that have been defined as frail are started on dialysis on average much 
earlier (i.e. at a higher estimated glomerular filtration rate, eGFR) than those deemed 
non-frail (Johansen et al 2013), and sadly the deterioration trajectory is amplified from 
dialysis initiation, as higher levels of dependence in performing activities of daily living 
(ADLs) are recorded in these frail patients (Johansen et al 2013).  Additionally, although 
dialysis reverses uraemia, the procedure itself alongside the residual metabolic 
imbalances, inflammation, and comorbid conditions, may allow protein energy wasting 
to develop further (Carrero et al. 2013), leading to a loss of muscle mass beyond 
normal physiological muscle wasting (Fahal 2013; Pupim et al 2005).   
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Thesis Aim 1 [Chapter 4]  
Explore the effect of CKD stage on body composition, strength and function in 
different stages of CKD (early and late stage) using standard clinical and frailty 
outcome measures. 
 
To be able to fully assess the extent of wasting in chronic kidney disease, and to later 
evaluate the ability of an intervention to bring about change, it is essential that an 
accurate record can be made of patients’ body composition at different stages of the 
disease trajectory/progression, at both the group and individual level.  Many studies 
assessing body composition in chronic wasting diseases have enlisted the use of highly 
specific and accurate equipment such as Magnetic Resonance Imaging (MRI; Bemben et 
al 2002), dual-energy x-ray absorptiometry (DEXA; Nielsen et al 1994; Emmons et al 
2011), or Computed Tomography (CT)-scans (Thomaes et al 2012; Noorkoiv et al 
2010a).   These methods are the gold standard in body composition assessment, but 
come at a high price both in efficiency and financially, and are not ideal for large 
population intervention studies.   
Other common methods to attempt to detail change in body composition include near-
bedside methods that can be implemented without disturbing the patient too much 
(unlike the gold standard methods), at relatively low cost to the research or clinical 
team undertaking the measurements, and with easy-use instructions.  Those currently 
in use include anthropometric measures such as waist, leg, or arm girth (circumference) 
(Carvalho et al 2012; Chang et al 2011), waist-to-hip ratio (Emmons et al 2011; Elsayed 
et al 2008), body mass index (Ishihara et al 2010; Catalano et al 2008), skinfold 
assessment (Chang et al 2011; Khan et al 2009), bioelectrical impedance analysis 
(Avesani et al 2001, Bellizzi et al 2006), and clinician-led subjective global assessment 
scores (Dong et al 2011; Steiber et al 2004).   
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Useful though these are for data-collection in large population studies where individual 
differences are lost to the group average, they are not accurate or specific enough to 
track or assess an individual at any one point.  These methods are largely unable to 
differentiate between muscle and fat (girth measures, body mass index [BMI], 
subjective global assessment [SGA]), and those that can (skinfold measures, 
bioelectrical impedance analysis [BIA]) are highly prone to error in repeated measures, 
especially in a populations prone to highly variable hydration status, such as CKD.  To 
truly be able to assess the size of the effect from any given intervention within an 
individual and a larger group is vital. 
Ultrasound measures of body composition have been used in non-CKD populations to 
assess muscle and fat depths (English et al 2012a; Trip et al 2009), cross-sectional area 
(Narici & Cerretelli 1998; Bamman et al 2000; Matschke et al 2010a), and muscle 
volume (Thomaes et al 2012; Martins et al 2007).    As with the near-bedside methods, 
ultrasound is minimally invasive to the patients and highly portable.  Ultrasound also 
has the added benefit of being able to assess muscle architecture (e Lima et al 2012; 
Bleakney & Maffulli 2002). 
Thesis Aim 2 [Chapter 5] 
Aim 2a: evaluate the validity of ultrasound compared to a gold standard measure 
(MRI) of body composition in CKD patients. 
Aim 2b: establish the reproducibility of ultrasound measurement of regional body 
composition (muscle and fat depths), with a view to assessing its utility as a method 
of monitoring change in CKD patients. 
 
Late presentation of ESRD (where RRT is necessary within 90 days of diagnosis) has 
reduced from 23.9% in 2006 to 19.3% in 2012 (UK renal registry annual report, 2013), 
once again likely due to an increased awareness of CKD amongst non-nephrologists, 
and the introduction of estimated GFR reporting.  In fact, most recent reporting 
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demonstrates that the majority (two-thirds) of CKD incident patients presented at least 
12 months before they needed to start RRT (2012 UK Renal Registry annual report, 
2013); ultimately leading to a greater number of patients spending longer in the pre-
dialysis period than ever before. 
It is important to emphasize that both uraemia and sarcopenia (loss of muscle mass 
and strength) are progressive diseases.  Uraemia is a clinical syndrome associated with 
fluid, metabolic abnormalities, electrolyte and hormone imbalances which develop in 
parallel with deterioration of renal function.  Some of these abnormalities start earlier 
in the course of the uraemia and others appear late (Fahal et al 2013; Kovesdy et al 
2013).   
 
Examining the body composition of patients earlier in the disease process (pre-dialysis) 
has been done before, using gold standard techniques such as DEXA (Nielsen et al 
1994), or others (BIA: Avesani et al 2001, Bellizzi et al 2006, Carvalho et al 2012), but 
mainly anthropometrics and skinfolds (Castaneda-Sceppa et al 2007, Chang et al 2007, 
Carvalho et al 2012).  Assessing muscle size and quality in pre-dialysis patients using 
ultrasound is therefore important to establish the extent of wasting prior to the need 
for RRT.   
Thesis Aim 3 [Chapter 6] 
To explore, in pre-dialysis CKD patients, the relationship between ultrasound-derived   
estimates of regional body composition (muscle and fat depth, and muscle 
architecture), and routinely employed measures for the assessment of body 
composition, physical function, and uraemic state, at this point in the disease 
trajectory. 
 
Ultimately the CKD population is seeking an intervention or rehabilitation programme 
which increases lean body mass, strength, function, health-related quality of life, and 
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reduces the level of exertional fatigue for the patient, alongside improved mortality 
and reduced hospitalization.  The intervention should also hinder the progression of 
the disease. 
Non-medical interventions to prevent or hinder protein energy wasting, decline in 
muscle mass and strength, and consequent development into worsening frailty and 
disability have been investigated in the ESRD (RRT/dialysis) population.  Using a variety 
of anabolic interventions in different combinations of nutritional supplementation 
(Jadeja & Kher 2012; Ikizler 2009), steroids, growth hormone, or testosterone 
(Johansen et al 1999; 2006; MacDonald et al 2007) and exercise (Cheema et al 2011; 
Oliveros et al 2011; Chen et al 2010) among others, has offered mixed results in these 
late-stage CKD patients, with similar interventions often reporting no change or only 
minor or not clinically significant improvements in body composition, clinical measures, 
strength, and function (Segura-Orti et al 2009; Headley et al 2002; Cheema et al 2011). 
Most studies focus on haemodialysis patients, despite this sub-group making up only a 
small fraction of patients with CKD (Perlman et al 2005).  Stages 2-4 are pre-dialysis, 
and make up the majority of patients with the disease.  Ideally, anabolic interventions 
such as exercise training should begin as soon as possible, commencing in the pre-
dialytic stage, where exercise benefits are potentially greater and more prolonged, 
allowing significant improvements throughout the varying stages of the disease 
progression.  Fitts et al (1999) found that exercise coaching and counselling was more 
beneficial in pre-dialysis patients than for those already undergoing dialysis, suggesting 
that before CKD patients approach the dialysis stage of treatment, a pre-habilitation 
intervention could maintain and aid recovery of physical capacity. 
A review of exercise interventions in CKD (Howden et al 2012) determined that 
introducing a programme of supervised resistance training to the non/pre-dialysis 
population may improve muscle function and strength, mobility and walking distance, 
and reduce inflammation.  In the catabolic state where muscle wasting is common, 
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resistance training may prevent reduction in skeletal muscle mass, and improve muscle 
mass and function. 
Thesis Aim 4 [Chapter 7] 
To evaluate the effects of frequency of a resistance training programme in patients 
with stage 3 CKD. 
 
Sub-aims of RT intervention [Chapter 7]   
 Measure and compare any change in muscle size or architecture brought about by the 
different frequencies (once or three times per week) of the RT programme. 
 Assess and compare any change from the RT programme in strength and ADL-related 
function, as well as reported patient-uraemic symptoms. 
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CHAPTER 2 - Literature Review 
 
2.1 Chronic Kidney Disease (CKD) 
2.1.1 Prevalence and Progression 
Over three million people face chronic kidney disease in the UK today; and this number 
is expected to rise over the next ten years.  Meanwhile, an estimated 13,000 people are 
killed by the disease annually in this country (Kidney Research UK, 2013).  Over 2% of 
the total NHS budget is spent on renal replacement therapy (dialysis and 
transplantation) for those with established renal failure (Ansell et al 2006).   Strategies 
aimed at earlier identification and (where possible) prevention of progression to 
established renal failure are therefore clearly required (NICE guidelines, 2008). 
 
The standard definition or criteria for a diagnosis of CKD is either (1) Kidney damage for 
three-months or longer; structural or functional abnormalities of the kidney, or (2) 
Glomerular Filtration Rate (GFR) less than 60mL/min/1.73m2  for three-months or 
longer, with or without kidney damage (KDOQI Guidelines, 2000). 
 
Chronic kidney disease (CKD) is a progressive condition, and patients are classified 
according to their degree of renal failure and hence the severity of the disease.  To 
determine at which stage an individual is presenting, the glomerular filtration rate 
(GFR) is measured.  The GFR is a measure of how quickly the kidneys are cleaning the 
blood, and is reported in millilitres per minute (mL/min).  A normal/healthy GFR is 
greater than 90 mL/min.  Table 2.1 describes the various stages of chronic kidney 
disease (CKD) and the corresponding GFR.   
 
In Stages 1 and 2 CKD, there are often few symptoms.  If CKD is identified at this stage, 
medication and lifestyle changes can slow down the disease progression and 
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potentially stop or reverse CKD depending on the initial cause.  In CKD stage three 
(CKD3), anaemia may develop and should be treated immediately.  When CKD has 
progressed to stage four (CKD4), preparations for dialysis or kidney transplant will be 
made. 
 
Table 2.1 - Stages of chronic kidney disease (CKD) 
Stage Description GFR 
Percentage of 
UK population* 
0 
“Normal kidney function”  
Healthy kidneys 
≥ 90 mL/min 64.2 
Stage 1 Kidney damage with normal or high GFR ≥ 90 mL/min 23.0 
Stage 2 Kidney damage and mild decrease in GFR 60 – 89 mL/min 7.3 
Stage 3a 
Moderate decrease in GFR 
45 – 59 mL/min 4.5 
Stage 3b 30 – 44 mL/min 0.7 
Stage 4 Severe decrease in GFR 15 – 29 mL/min 0.1 
Stage 5 
Established renal failure (ERF) 
End-stage renal disease (ESRD) 
≤ 15 mL/min or 
on dialysis 
0.0 
*Percentage data taken from britishrenal.org, FAQ 2010 
 
CKD5 (CKD stage 5) is also known as end-stage renal disease (ESRD) and is the final 
stage of the disease-process.  The clinical features of ESRD are described in Table 2.2.  
By this stage, the only options are usually a form of renal replacement therapy (RRT), 
whether by maintenance dialysis or a kidney transplant. 
 
For about 40% of adults on dialysis a kidney transplant is the treatment of choice, 
though this percentage is higher in children. If patients do not have a kidney transplant, 
dialysis is needed for the rest of the patient's life.  Two main types of dialysis are 
available, haemodialysis (HD) and peritoneal dialysis (PD).  
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At any one time in the UK, 400–800 people per million of the population need renal 
replacement in the form of dialysis (NICE guidelines, 2011). The prevalence of dialysis in 
the UK is highly age dependent; for adults aged 70–80 years it is between 1600 and 
2000 people per million (NICE guidelines, 2011).   
 
Table 2.2 – Clinical features of end-stage renal disease (ESRD) 
Musculoskeletal 
System 
 Myopathy and muscle weakness 
 Bone pain and radiographic findings (renal osteo-dystrophy) 
Respiratory System  Tachypnea 
 Dyspnea (lung oedema) 
 Pleural effusion 
Renal System  Small kidneys 
 Nocturia (urination at night) 
 Oligura (<400ml/day) or polyuria (>2.5L/day) 
Haematologic 
System 
 Anaemia 
 Bleeding tendency 
 Low resistance to infection 
Neurological 
symptoms 
 Depressed mental functions 
 Somnolence (drowsiness) 
 Peripheral neuropathy 
Skin and Mucosae  Peri-oral “uraemic frost” 
 Pruritus (itching) 
Cardiovascular 
System 
 Hypertensive heart disease 
 Arrhythmia 
 Pericarditis 
 Increased jugular venous pressure 
Gastrointestinal 
System 
 Nausea 
 Anorexia 
 Vomiting 
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2.1.2 Co-morbidities 
Many chronic kidney disease patients may have one or more co-morbidities; a disease 
or condition that exists alongside another disease.  The most common co-morbidities in 
CKD patients are diabetes and hypertension, but also include cardiovascular disease 
(CVD), congestive heart failure, lung disease, peripheral vascular disease, neurological 
problems, and malnutrition.  Some of the most common ailments and co-morbidities 
linked with CKD are detailed below. 
2.1.2.1 Cardiovascular Disease (CVD) 
People with CKD are at increased risk of cardiovascular disease (CVD), and this is the 
number one cause of death due to complications as CKD progresses to ESRD (Go et al 
2004).  Cardiovascular disease is present in 63% of patients with advanced CKD, 
compared with 5.8% of adults without CKD (USRDS, 2009 Annual Report).  Patients with 
CKD are more likely to die from cardiovascular events than progress to dialysis, and 
cardiovascular events account for 45% of deaths in dialysis patients (Shastri & Sarnak 
2010).  Prevention and treatment of cardiovascular disease in CKD involves addressing 
traditional cardiovascular risk factors, including hypertension, dyslipidemia, diabetes, 
anaemia and other metabolic abnormalities. 
2.1.2.2 Hypertension (high blood pressure) 
The prevalence of hypertension is 84% in patients with stage 4–5 CKD, compared with 
23% of adults without CKD (USRDS, 2009 Annual Report).  Additionally, up to 75% of 
CKD patients have blood pressure levels above 140/90 mmHg (Chobanian et al 2003).  
Hypertension is associated with accelerated progression of kidney disease as well as 
development and worsening of cardiovascular disease. 
2.1.2.3 Diabetes 
Diabetes mellitus increases the likelihood of CKD and risk of cardiovascular events and 
death in patients with CKD.  Patients with stage 3–5 kidney disease have an increased 
risk of hypoglycemia (low blood sugar) due to decreased medication clearance and 
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impaired kidney gluconeogenesis (generation of glucose from non-carbohydrate 
substrates) (KDOQI 2007). 
2.1.2.4 Hyperkalaemia (high blood potassium) 
Normal serum potassium levels are 3.5-5.0 mmol/L.  High blood potassium (>5.5 
mmol/L) is common in CKD patients, with more severe disease stages and diabetes 
increasing the frequency and severity of hyperkalaemia (Einhorn et al 2009).  
Hyperkalaemia can also develop due to consuming large amounts of potassium in the 
diet, acidosis, hyperglycaemia in diabetic patients, and some medications. 
2.1.1.5 Anaemia 
Anaemia can be diagnosed at any stage of CKD but is more common in patients with 
more severe CKD and becomes especially prominent in patients with stage 4–5 CKD 
(USRDS, 2009 Annual Report).  Anaemia can result from iron deficiency, B12 and folate 
deficiency, and relative erythropoietin deficiency in CKD.  However, anaemia does not 
appear to worsen over time, or it may respond to iron supplementation/therapy. 
 
2.2 Demographics of muscle wasting and physical impairment in CKD 
Patients with chronic kidney disease (CKD) are characterized by a profound decrease in 
muscle mass or atrophy, in particular at end-stage (stages 4-5) (Kouidi et al 1998).  The 
causes of this are multi-factorial in origin, though the generalized muscle wasting is 
strongly associated with a decline in functional capacity and strength that is directly 
linked with a greater risk of morbidity and mortality (Kopple et al 2005).  
 
The issue of poor physical performance and functioning in patients on dialysis has been 
noted and been under sporadic investigation for some time, following the publication 
of an article highlighting the physical activity and rehabilitation status of haemodialysis 
patients (Gutman et al 1981).  Early indications seemed to suggest it was the level of 
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anaemia that restricted an individual’s ability and capacity for exercise, activities of 
daily living, and general function.  However, later reports showed the level of 
performance remained low even after one year’s treatment with recombinant human 
erythropoietin introduced to combat the anaemia associated with renal failure (Ifudu 
et al 1994).   
 
The weakness has also in part been attributed to water and electrolyte disturbances, 
cardiac failure, malnutrition, carnitine deficiency, physical inactivity, comorbidities such 
as ischaemic heart disease, and age-related issues such as sarcopenia and other 
disabilities (reviewed by Fahal 2013).  As an individual approaches end stage renal 
disease (ESRD), exercise tolerance worsens and even high functioning ESRD patients 
display a poorer level of physical performance when matched to persons with 
comparable chronic disorders such as heart failure and chronic obstructive pulmonary 
disease (COPD). 
 
There is little to no difference between haemodialysis patients and controls in 
excitation-contraction coupling, central activation, and specific tension when expressed 
as a ratio of maximal voluntary strength to contractile cross-sectional area (Johansen et 
al 2003, Fahal et al 1997), strongly indicating that the biggest cause for muscle 
weakness and consequent poor function and performance is muscle atrophy.  The 
observed muscle fibre and contractile area atrophy is greater than in healthy controls, 
even when corrected for the different habitual activity level (Johansen et al 2003). 
 
2.3 Protein Energy Wasting and Cachexia in CKD 
Patients with chronic kidney disease (CKD) frequently exhibit substantial atrophy of 
skeletal muscle which is often associated with protein-energy wasting.  Protein-energy 
wasting (PEW) refers to the nutritional and catabolic alterations that occur in CKD.  A 
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reduced appetite and dietary restrictions often contribute to the wasting (insufficient 
calorie intake/under-nutrition), but other factors are necessary for PEW to fully 
develop (Bonanni et al. 2011), including inflammation and increased energy 
expenditure due to uraemia (Fried et al. 2006), comorbid conditions associated with 
chronic disease (low levels of physical activity, frailty), and additionally the effect of the 
dialysis procedure itself in CKD stage 5 (Carrero et al. 2013).   
 
In the most severe cases of PEW, it is referred to as cachexia (Fouque et al. 2008).  
Cachexia is highly prevalent in moderate to severe cases of CKD, including up to 75% of 
patients undergoing maintenance haemodialysis (Mak et al. 2011).  Therapies against 
muscle wasting during non-CKD specific cachexia have often concentrated on increased 
food intake, or by “normalising” the metabolic changes within the patient, however, 
cachectic patients often fail to adapt to excess protein stores and consequently persist 
in a state of negative nitrogen balance, that cannot be corrected with nutritional 
intervention alone (Ebner et al. 2013). 
 
PEW naturally develops with the progression of CKD, and is an inherent component of 
advanced disease.  Although dialysis reverses uraemia, the dialysis procedure itself 
alongside the residual metabolic derangements, inflammation, and comorbid 
conditions may allow PEW to develop or worsen (Carrero et al. 2013),  leading to a loss 
of muscle mass beyond normal physiological muscle wasting (Fahal 2013).   
 
2.4 Frailty in CKD 
Frailty has previously been defined as a biological syndrome of decreased reserve and 
resistance to stressors that results from cumulative declines across multiple physiologic 
systems, and causes vulnerability to adverse outcomes (Kim et al. 2013).  Currently it is 
assessed/diagnosed according to the presence of three or more of the following 
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criteria: unintentional weight loss (10lbs in past year), self-reported exhaustion, 
weakness (grip strength), slow walking speed, and low physical activity (Fried et al. 
2001). 
 
Frailty is observably more common in individuals with CKD than those without 
(Johansen et al. 2013) and frailty in moderate to severe CKD was more common than in 
other chronic illnesses, such as vascular disease, cancer and other degenerative 
diseases of ageing (Wilhelm-Leen et al. 2009).  Risk of frailty is increased by 
approximately 2-times in mild CKD (stages 1-3a), and 6-times in moderate to severe 
(stages 3b-5) CKD (Wilhelm-Leen et al. 2009) and is associated with increased incidence 
of adverse outcome in dialysis patients (increased hospitalization, increased death rate; 
Johansen et al 2013; Kosmadakis et al 2010). 
 
CKD patients that have been defined as frail are started on dialysis on average much 
earlier (i.e. at a higher estimated glomerular filtration rate, eGFR) than those deemed 
non-frail (Johansen et al 2013) and sadly the deterioration trajectory continues to 
accelerate, even with the initiation of dialysis, as higher levels of dependence in 
performing activities of daily living (ADLs) are recorded in these patients (Johansen et 
al. 2013).   
 
This underscores the need to intervene as early as possible in the disease trajectory of 
CKD patients with a view to slowing the descent into “frailty”.  This would hopefully 
delay these patients being put onto maintenance dialysis and protect their 
independence for longer (Johansen et al 2013). 
 
Figure 2.1 shows the multitude of factors that contribute, or exacerbate protein-energy 
wasting (PEW) in CKD, and the expected manifestations.  The most important of these 
outcomes to the patient is likely to be their health-related quality of life.  Of the factors 
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contributing to the milieu, few can be modified or adapted to attempt to relieve some 
of the negative outcomes.  These few include reduced anabolism of muscle tissue, 
physical activity levels, nutritional intake and deficiencies and co-morbidities such as 
obesity.  
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Figure 2.1 – Factors that contribute to protein energy wasting and consequent frailty  
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2.5 Mechanisms of muscle protein gain and loss 
The balance of muscle protein synthesis and degradation is vital to maintaining the lean 
body mass of an individual.  Muscular hypertrophy exists when synthesis is greater 
than degradation, and atrophy occurs in the reverse circumstances.  Muscle wasting 
can therefore be due to reduced rate of protein synthesis, or increased breakdown, or 
more commonly a combination of both.  After a great deal of research in recent years, 
it has become established that anabolism (process of construction or synthesis using 
energy) is not simply the reverse of catabolism (process of breakdown or degradation 
releasing energy), but instead a number of interactions exist between them (Glass 
2005).   
 
Contributing factors to increased degradation and reduced synthesis of protein include 
the direct and individual effect of advancing age, sedentary behaviour, poor nutrition, 
androgen deficiency, oxidative stress, metabolic acidosis, and insulin resistance.  
Inflammation also appears to up-regulate the release of hormones (ubiquitin-
proteasome pathway) that contribute to muscular atrophy (reviewed by Johansen 
2009).  The treatment for CKD and the disease itself could alter the protein balance, as 
studies in rats (Du et al 2004) and later patients with ESRD (Workeneh et al 2006) 
demonstrated an increase in hormonal (caspase-3) activity in uraemic environments.  
However, correction of acidosis in pre-dialysis (Reaich et al 1993), peritoneal dialysis 
(Graham et al 1996) and haemodialysis patients (Graham et al 1997) has shown a 
reduction of protein degradation in all three groups, though a similar decrease in 
protein synthesis was also seen. 
 
Improving the anabolic pathway appears to be the popular and most common 
therapeutic method to date and include nutritional interventions (dietary 
supplementation, or using amino acid dialysate), anabolic hormone therapy (growth 
hormone therapy, or androgen treatment), and exercise (resistance) training.   
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2.6 Body composition in CKD  
Body composition in CKD has been strongly associated with level of dependence, frailty 
and mortality.  Low adiposity (within a healthy range) in the healthy population is 
generally linked with greater health outcomes (BMI 18.5-25kg/m2 and waist 
circumference men <102cm, women <88cm, lower risk of all-cause mortality in adults 
>60 years old; Sui et al 2007).  However, in the renal disease cohort, increased BMI has 
shown beneficial links with life expectancy and disease status  up to the highest BMI 
category (>40; Kalantar-Zadeh 2005), this paradoxical relationship has also been noted 
in cholesterol levels and blood pressure (Nishizawa et al 2006). 
 
This has been referred to in the literature as the “obesity paradox” or “reverse 
epidemiology” (Park et al 2014; Speakman & Westerterp 2010; Schmidt et al 1999). It is 
possible that the increased survival rate in CKD with greater BMI is more due to the 
greater absolute volume of fat-free (lean) mass than fat mass in weightier patients.  
However in a study comparing HD patients over a period of 4-5 years, overall mortality 
(cardiovascular risk) was not predicted by fat-free (lean) mass, but instead by fat mass, 
independent of other confounding factors (Nishizawa et al 2006). 
 
This paradox has been seen to revert back to the norm following renal transplantation 
(Schold et al 2007), suggesting that it is a true biological phenomenon (Speakman & 
Westerterp 2010).  This in itself presents a problem, as questions arise as to whether 
end-stage renal patients should be encouraged to lose weight in preparation for 
transplant, or maintain a higher BMI to retain the protective obesity paradox in the 
event of continued dialysis.  Additionally, for those patients not yet on dialysis, the 
dilemma is whether they should be advised to attempt to increase their BMI for a 
potential risk reduction, or indeed reduce it to a “healthy” BMI to reduce the negative 
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effects as seen in “original epidemiology” (the obesity paradox is also apparent in CKD 
patient populations who are not on dialysis; Kovesdy & Anderson 2007). 
 
2.6.1 Regional body composition in CKD 
Patients with CKD often suffer with co-morbidities such as diabetes and CVD, with the 
latter being the biggest cause of death in the renal population (risk of CVD death is 10-
30 times greater than in the general population; Levey et al 1998).    
 
In non-diabetic, non-dialysis CKD patients, the independent factor for insulin resistance 
is the amount of total body fat (Satirapoj et al 2005).  However, the relationship 
between fat mass and inflammatory biomarkers appear to differ between truncal and 
non-truncal fat mass (Axelsson et al 2004).  Truncal fat mass is closely related to 
visceral fat which has previously been identified as a key factor in the development of 
insulin resistance, type II diabetes, premature atherosclerosis, and CVD (Lafontan & 
Berlan 2003; Arner 2003).   
 
Reduced central (truncal or intra-peritoneal) adiposity is of particular importance as 
truncal fat mass releases two to three times the volume of inflammatory cytokines than 
non-truncal fat mass (Fried et al 1998), which are associated with increased morbidity 
and mortality (Cordeiro et al 2010; Postorino et al 2011).  Though a recent study (Yuan 
et al 2013) has suggested that despite the increased production and release of serum 
hepatocyte growth factor (HGF, inflammatory cytokine) in patients with greater truncal 
fat mass, it may not be fully detrimental in the CKD5 (dialysis) population, as HGF 
attenuates the inflammatory response, and through the suppression of inflammation it 
can protect from oxidative damage (Shimizu et al 2012).   
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Total protein loss due to wasting can be very high; approximately two-thirds of which is 
skeletal muscle (chronic and critical illness, Monk et al 1996; Streat & Hill 1987; Reid et 
al 2004).  In a healthy population, immobility/inactivity alone leads to massive 
reductions in appendicular strength and skeletal muscle, with the antigravity muscles 
(calf and back) deteriorating at an accelerated rate than the non-postural muscles such 
as grip strength (Bloomfield 1997, Geboers et al 2000).   
 
Due to the increased in truncal adiposity, variable subcutaneous fat, and in particular 
the appendicular (skeletal muscle) wasting, measurement and monitoring of regional 
body composition is important in the CKD population to further explain the reverse 
epidemiology/ obesity paradox and truly assess the effect of interventions to assist the 
patient. 
 
2.6.2 Methods of body composition assessment 
Management and measurement of regional body composition is of vital importance in 
the CKD population.  Therefore an effective method of assessment is necessary to be 
able to track and monitor changes in body composition in CKD patients.  Simply using a 
BMI value can be helpful but is not ideal as it cannot differentiate between lean (fat-
free) tissue and fat mass. However some measurement tools that can differentiate 
between the different tissues are available and have previously been implemented to 
assess body composition as a one-off measure or repeated for interventions or 
longitudinal studies.   
 
2.6.2.1 Gold Standard Assessments: 
2.6.2.1.1 Dual-Energy X-ray Absorptiometry (DXA/DEXA) 
Initially used to examine bone density in osteoporosis, DEXA can give clear and 
accurate imaging assessments of the whole body in other chronic diseases and a 
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variety of sports activities to evaluate the effects of exercise, muscle atrophy and 
hypertrophy.  DEXA uses a three compartment model to account for variation in bone 
mineral content.  It has been validated against a four compartment model, which 
includes body water calculated by isotopic deuterium dilution, across a varied 
population (Prior et al 1997).  However, despite the reduction in scanning time in 
recent years (Andreoli et al 2009), the general lack of portability limits the use of DEXA 
in research in restricted spaces and on multiple sites. 
 
2.6.2.1.2 Computed Tomography (CT) 
For measurements of subcutaneous fat, computed tomography is seen as the gold 
standard as the process can distinguish between subcutaneous and visceral fat which 
can be of great importance in the diagnosis and tracking of certain metabolic disorders 
and illness.  Limitations include high ionizing radiation (x-rays) levels, financial cost, and 
relative immobility (Orphanidou 1994), making it unsuitable for repeated measures and 
near-bedside/field experiments. 
 
2.6.2.1.3 Magnetic Resonance Imaging (MRI) 
For standard imaging of muscle size, MRI scans are often used due to the high quality 
of information produced.  Once again, the limited availability and relative cost (time, 
fiscal) is high and less feasible for regular repeated measures on a broad and numbered 
subject group. 
 
2.6.2.1.4 Muscle Biopsy 
In conditions that are associated with muscle atrophy and hypertrophy, the gold 
standard for muscle filament size and number, as well as cell content, is by muscle 
biopsy.  A highly invasive procedure, often leaving the patient in unnecessary pain, it is 
often unfeasible for regular repeated measures, especially in a frail, elderly, and ill 
population.  Site selection will influence size of adipocytes (deep sites are smaller than 
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subcutaneous fat cells; Brodie 1988) and assumptions on cell number based on size will 
vary.  
 
2.6.2.2 Anthropometry and other methods of assessment: 
2.6.2.2.1 BMI, waist or limb circumference, and waist-to-hip ratio 
Body mass index (BMI), waist circumference, and waist-to-hip ratio are indirect 
anthropometrical indices commonly used in large epidemiological studies into obesity, 
health status, and generalized nutritional studies in adults.  They are simple, cheap, 
standardized and ideal for mass use in a normal or average population.   
 
BMI is the ratio of body weight to height (weight in kg/height in metres2).  Waist 
circumference and waist-to-hip ratio are simple girth measurements.  Measurements in 
this way have been useful predictors of cardiovascular and all-cause mortality in young 
adults.  However, simple measurement error such as poor posture (height measure), 
bowel status (weight), holding breath (waist circumference), or bad placement of the 
tape measure (for waist or limb circumference) will elicit an inaccurate reading. 
 
These methods cannot differentiate between fat mass (FM) and fat free mass (FFM), 
and thus do not allow for the greater muscle mass in well trained individuals, or indeed 
the sarcopaenic effect of ageing, for example, a reduction in FFM and increased FM, 
decrease in height, repositioning of fat from peripheral areas to central, and loss of 
gluteal muscle bulk (Gallagher et al 2000; Roubenoff & Hughes 2000). 
 
2.6.2.2.2 Skinfold thickness measurements 
Skinfold thickness uses a two-component model, which assumes that there is a fixed 
proportion of water, protein, and mineral in FFM, despite their variation between 
individuals, and are influenced by age, gender, ethnicity, genetics, diet, and exercise.  
From a technical angle, skinfold caliper operators require extensive training and 
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practice and even the most skilled technician can vary site location, skin selection, and 
pinch between measures.  Clearly this method only measures subcutaneous fat (fat 
below the skin) and is less accurate for very lean/thin or obese subjects.   
 
2.6.2.2.3 Underwater/ hydrostatic weighing (hydro-densitometry) 
Underwater weighing (also a two-component model like skinfold thickness), though 
relatively accurate and consistent (good for assessing changes in body fat) the process 
can be uncomfortable for the subject (full submersion), time consuming, with 
equipment very cumbersome and lacks mobility in the same way as MRI, CT, and DEXA.   
 
2.6.2.2.4 Urine analysis – 24hr creatinine levels, and 3-methylhistidine excretion 
Urine sampling has previously been used to measure the level of skeletal muscle loss 
(levels of either creatinine or 3-methylhistidine within a sample) following different 
modes and intensities of exercise; studying the effect of muscle breakdown with acute, 
chronic, eccentric, aerobic forms of exercise.  Protein loss in chronically ill patients is 
particularly notable in renal disease, and it is often used to initially diagnose the 
condition.   
 
Exercise (increased protein breakdown) can lead to increased markers in urine if 
inadequate dietary protein is available to replace stores (nothing available for 
synthesis; Campbell et al 2002).  A fall over time in urinary nitrogen can be due to 
increased retention of nitrogen in the body from the onset of a resistance training (RT) 
intervention (Campbell et al 2002); the shift in urinary nitrogen excretion reflects a 
training-induced conservation of body nitrogen (favouring protein synthesis and 
anabolism; Campbell et al 1995). 
 
After a creatinine controlled diet (meat-free), a complete 24-hour urine sample is 
collected and analysed for creatinine content.  An alternative is to use plasma or serum 
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creatinine.  It is directly proportional to total body muscle mass, however it is time-
consuming (24-hour collection), can be awkward for the subject, dietary restriction 
needs to be employed before each collection, and there can be daily variation in 
creatinine excretion (Lemann & Doumas 1987). 
 
An alternative excretory product found in urine is 3-methylhistidine (3MH), it is 
proportional to total muscle mass, and has strong correlations with total body 
potassium and FFM (Brodie 1988).  However, 24-hour urine collection is still necessary 
along with a meat-free/controlled diet (Wang et al 1998). 
 
2.6.2.2.5 Total body potassium (TBK) 
Potassium (K) is a measureable element in vivo, and the use of total body potassium 
(TBK) as an index of body composition has a long history in nutritional research.  Body 
potassium is distributed entirely in the fat-free mass (FFM) compartment, and a large 
proportion exists in skeletal muscle mass (~60% of TBK in skeletal muscle, Wang et al 
2003).  TBK provides an estimate of body cell mass, the metabolically active lean tissue 
of the body, and is often considered the reference value for the assessment of true 
lean mass (Corcoran et al 2000).  The determination of TBK is based on the fact that the 
proportion of total potassium found in human tissues as 40K is constant at 0.0118% of 
total potassium (Burmeister 1965; Forbes & Hursch 1961).  Therefore, by measuring 40K 
it is possible to calculate total-body potassium. As potassium is distributed almost 
entirely within the intracellular compartment of fat-free mass, and using the ratio of 
total-body potassium to fat-free mass, once TBK is known it is possible to calculate fat-
free mass and total-body fat. 
 
The test procedure requires the participant to lie still on a bed which passes under the 
detectors.  The participant must first be shielded from naturally occurring radiation in 
the environment, using concrete, lead or steel. Once the external radiation is 
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minimized, the subject’s natural radiation as 40K (potassium) is measured through the 
use of scintillation counters. The radiated 40K is measured over a specified time period 
and from this TBK is estimated; these detectors count the naturally occurring 
radioactive emissions from the potassium (K) in the body. 
 
As with DEXA, CT and MRI, this method of body composition assessment requires 
highly sensitive and expensive equipment, with limited availability.  The equipment is 
not easily accessible and restrictions exist for any participants having undergone any 
radioactive medical procedures in the previous week (e.g. X-rays, CT scans, 
mammograms, or radiotherapy). 
 
2.6.2.2.6 Bioelectrical Impedance Analysis (BIA)  
BIA measures the body’s resistance to flow (impedance) of alternating electrical 
current at a designated frequency between points of contact on the body.  The 
conductive nature of water in body tissue allows measurement of body impedance, 
indirectly providing information regarding the tissue content; highly conductive tissue 
(intracellular and extracellular water; ICW ~55%, ECW ~45%, summed to total body 
water, TBW), and less conductive tissue (high resistance; adipose/body fat).   
 
Single-frequency BIA phase angle and impedance are measured at 50kHz.  Reactance 
and resistance can be calculated precisely at this current, and is inversely related to 
extracellular fluid content, fat, or excess fluid (Piccoli & Codognotto 2004, Piccoli et al 
2005, Pillon et al 2004).  Some devices report an estimation of lean mass from these 
figures, though should be interpreted cautiously, and are likely not valid in a renal 
dialysis population where excess fluid is common (Tattersall 2009).  Multiple-frequency 
BIA measures reactance and resistance at multiple frequencies (5-1000kHz) to 
differentiate between extracellular (frequency 0kHz) and intracellular fluid 
(extrapolated “infinite” kHz measures extracellular and intracellular) (Cole & Cole 
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1941), allowing estimations of lean and adipose mass (most fluid in adipose is 
extracellular, and most fluid in lean tissue is intracellular). 
 
BIA is portable, simple to use, quick, cheap and has no subject height or weight 
restrictions.  It is a useful tool for clinical studies using repeated measures to monitor 
progress, but may be less suitable for large (cross-sectional) epidemiological studies 
with diverse population unless validated in different environments (higher skin 
temperature decreases impedance; Gudivaka et al 1996), and specific populations 
(ethnicity, disease-state) (Dehghan & Merchant 2008).  BIA is not a measure of muscle 
quality, but instead of quantity. 
 
Typically whole-body BIA analysis has required single electrodes positioned on the 
dorsal surface of the foot, ankle, wrist, and hand on one side of the body, but it has 
been suggested that using these four single-site electrodes can cause error in repeated 
TBW measurements (Moon et al 2009).  By fixing the distance between electrodes 
(distance 5cm between wrist site and hand site and 5cm between ankle and foot site; 
Moon et al 2010; Cornish et al 1999; Kyle et al 2004; haemodialysis patients; Kaysen et 
al 2005) this reproducibility error can be reduced (for repeated measures).  However, 
small errors could be clinically insignificant as BIA could not detect a change in TBW of 
1.4% in a 70kg reference man (Elsen et al 1987).  Often seen as a more accurate 
method of measurement, it has previously been suggested that the need for constant 
and consistent hydration status between measures can greatly limit the power and 
significance of the results (Campbell et al 1995).  
 
Whole body BIA assessment rests on the assumption that the body is one large cylinder 
with the same resistivity throughout.  This does not allow for the relative impact of the 
trunk which contributes little to resistance (~10%) but contains a large conductor 
volume (~50%; Lukaski et al 1986).  For larger individuals, or those with unusual body 
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mass distribution, segmental BIA is more suited, overcoming these large assumptions 
by separating the legs, arms, and trunk and altering the respective resistance for each 
(Organ et al 1994).  Segmental multi frequency BIA has shown body fat percentage 
deviations in validation (Shafer et al 2009) against a gold standard (DEXA) by 1.56% 
(underestimate in normal weight), 0.58% (overweight), and 3.4% (obese), 
demonstrating increasing inaccuracies with increasing adiposity (Deurenberg 1996); 
however, the biological significance is considered small and within the precision of the 
BIA and DEXA instruments (2%) (Shafer et al 2009). 
 
BIA has been shown to have high inter-rater reproducibility on repeated measures 
(Segal et al 1991) and has been highly correlated with hydrostatic weighing, DEXA and 
isotopic deuterium dilution techniques in a number of populations (healthy; Basile et al 
2008, healthy lean to obese; Anderson et al 2012, haemodialysis; Dou et al 2011, 
healthy children and adults; Erceg et al 2010, Jensky-Squires et al 2008, breast cancer; 
Gupta et al 2008, lung cancer; Gupta et al 2009, elderly hyponatraemic; Hoyle et al 
2011).  Errors could arise from the possible inaccurate measurement of resistance in 
the body torso, suggested through the greater inaccuracies found with greater central 
adiposity (36% variation attributed to waist circumference; Shafer et al 2009). 
 
Phase Angle (a direct measurement from BIA with no need for height and weight 
information) has been shown to have significantly and consistently high sensitivity and 
specificity with three standardized nutritional assessments and screening tools 
routinely used worldwide to categorize hospital admissions and chronic patients 
(Nutritional Risk Screening Tool 2002, Kondrup et al 2003, Subjective Global 
Assessment questionnaire, and Albumin levels, Kyle et al 2012).  Phase angle also 
correlated significantly with FFM in controls and patients.  Generally, a low phase angle 
(below 5° in men, 4.6° in women; Kyle et al 2012, over 5.4 normal, 4.5-5.4 borderline, 
under 4.4 abnormal; Selberg & Selberg 2002) is representative of poor nutritional 
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status, with phase angles between 4.5 and 5.6° associated with short-term survival in 
cancer patients (Gupta et al 2004, Toso et al 2000).  Elderly patients with phase angle 
below 3.5° had four times the hospital mortality than those between 5.0-5.5° (Wirth et 
al 2010). 
 
The biological meaning of phase angle is not entirely understood but it is considered a 
strong indicator for cell health (high phase angle, better cell function). The smaller 
phase angle seen in otherwise healthy elderly participants (Kyle et al 2012) reflects 
their general reduction in physical function and health (Barbosa-Silva et al 2005) 
alongside reduced skeletal muscle mass (and therefore intracellular water, possibly 
influenced further by oedema).  Patients in rehabilitation programmes have improved 
phase angle when compared to seriously ill patients but still lower than healthy age-
matched controls (Gunn et al 2008).  Higher phase angle has been noted with greater 
maximal quadriceps strength (Gunn et al 2008). 
 
There have been recent suggestions of utilizing BIA in predictions of VO2max without 
exercise testing.  Stahn et al (2008) assessed 115 healthy individuals of varying weight 
and fitness level, and found strong correlations between intracellular resistance and 
VO2max (r=0.89), significantly superior to predictions based on anthropometry.  The 
group concluded this model (using BIA) is most appropriate (and with the highest level 
of accuracy) for subjects with relatively low (<2.5Lmin-1) aerobic fitness levels, though 
currently do not recommend use in clinical settings. 
 
2.6.2.2.6.1 BIA use in chronic and critical illness 
Segmental multi-frequency BIA is appealing to use clinically to assess an ill or diseased 
population because of the potential to assess fluid distribution (Steijaert et al 1997).  
Dialysis must control the body’s fluid accurately to maintain optimal health; however, 
many tools currently used to assess fluid removal are imprecise and excessive fluid 
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removal carries immediate health risks.  Current controls in place are monitoring blood 
pressure, body weight, and changes in blood volume but these can be affected by a 
number of medications such as anti-hypertensives.   
 
Optimal or normal fluid content can be estimated from height, weight, and body fat 
percentage using multi-frequency BIA, then subtracting this value from total body fluid 
content (from BIA), the excess fluid can be estimated (Chamney et al 2002, Moissl et al 
2006). Multiple-frequency segmental BIA can be used to calculate excess fluid volume 
to within 1-2 litres (Tattersall 2009) and in nutritional assessment as an objective 
measure of body composition. 
 
Given a specific population reference range, it is possible to assess hydration status 
using a standard nomogram using resistance and reactance (scaled for height).  This is 
possible with a whole body single-frequency BIA model (Piccoli et al 2004, Piccoli et al 
2005, Pillon et al 2004) or pricier whole body multiple-frequency (Lopot et al 2002, 
Lindley et al 2005, Katzarski et al 1996).  Segmental multi-frequency BIA can account 
for fluid shifts within the body (between segments) possibly caused by change in 
posture such as during or after dialysis.  Fluid shifts and changes in body composition 
have also been observed using BIA in elective surgical cardiac patients (CABG) post-
operatively (Feyrer et al 2003). 
 
A recent study group (Nakao et al 2007) used multi-frequency BIA to establish a Body 
Protein Index (BPI) to evaluate whole body somatic protein stores as a potential new 
marker to assess nutritional status in chronic renal failure and patients on maintenance 
dialysis.  This successfully highlighted that patients with a longer dialysis history 
showed a tendency to lower BPI compared to those with a shorter history, despite no 
difference in age. 
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2.6.2.2.7 Ultrasound (US)  
With the development and increased prevalence of wasting diseases worldwide it has 
become necessary to use techniques of investigation which procure lower costs 
through efficiency of application and validity of measures.  Easily accessible and cheap 
(often used) measures with low training requirements, such as mid-thigh circumference 
(MTC), have been shown to have low correlation with generalised FFM (Campbell et al 
1995).  Clearly there is a need for a more accurate measurement of muscle and fat.  
High resolution ultrasonography has been used internationally for subcutaneous scans 
and research as it is non-invasive and requires no prerequisites for the patient (stability 
in status, level of cognition; Bemben 2002; Whittaker & Stokes 2011).   
 
In recent years, muscle imaging has called upon the use of brightness (B)-mode 
ultrasonography.  Originally used to measure fat deposits and skin folds in animal 
husbandry, B-mode ultrasound been adopted by researchers seeking to accurately 
measure muscle thickness and localised muscle cross-sectional area in humans.  
Equipment is inexpensive in comparison to other clinical methods such as MRI or DEXA, 
and can be taken to the patient at their bedside, in a research laboratory, or other non-
clinical site.  Examples of ultrasound use in the measurement and assessment of body 
composition is shown in Table 2.3 in other (non-CKD) populations.  
 
High resolution ultrasound (US) has shown great potential as an alternative (near-
bedside/patient) method to assess muscle and fat mass at specific anatomical sites; it 
has been shown to accurately measure change in muscle size resulting from anabolic 
interventions and also to monitor the effects of ageing and disuse in a variety of 
populations though most were healthy and of working age (knee-joint injury, Uremović 
et al 2004; healthy men, Miyatani et al 2002; Miyatani et al 2004; healthy adults and 
patients with multiple organ failure, Campbell et al 1995; older men and women, 
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Bemben 2002; critically ill hemiplegic, Moukas 2002; working age healthy, Sanada et al 
2006; healthy adults, Ahtiainen et al 2010).  
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Table 2.3 -  Studies using Ultrasound to assess body composition (non-CKD) (grouped by study design and ordered alphabetically by author) 
Author, year, 
journal 
population 
type 
study design  
Area/ body-
site 
investigated  
US 
used  
Participant 
number n (m,f) 
and further 
details 
intervention 
details 
time/ 
duration 
Mode of 
assessment (US 
site/measure) 
pre 
intervention
(baseline 
values) 
post 
interventio
n values 
actual 
change 
reported 
% 
change if 
reported 
 (p)- 
value 
group 
difference 
(p) 
COMPARATIVE AND CROSS-SECTIONAL STUDIES 
Abe et al 2011 
inactive 
elderly 
comparative 
(young vs old 
women) 
8 sites: 
anterior and 
posterior 
B-
mode 
US 
elderly: 157F 
67.9±6.3yrs (range 
60-85yrs) 
  
bicep brachii 
MTH/limblength 
mm/cm 
 
0.81 ± 0.14 
   
<0.001 
Journal of Geriatric 
Physical Therapy 
34 (4): 168-73 
   
5 MHz 
height 149±5cm 
weight 52.2±6.5kg 
BMI 23.6±2.6 
  
triceps brachii 
MTH/limblength 
mm/cm 
 
0.84 ± 0.19 
   
0.273 (ns) 
     
 
young: 152F   
abdomen 
MTH/height cm/m  
0.51 ± 0.11 
   
<0.001 
     
25.3±4.3yrs (range 
20-34yrs) 
Height 158±5cm 
  
subscapula 
MTH/height cm/m  
1.16 ± 0.26 
   
0.004 
     
Weight 52±5.2kg  
BMI 20.7±2.1   
quadriceps 
MTH/limblength 
mm/cm 
 
0.98 ± 0.19 
   
<0.001 
        
hamstrings 
MTH/limblength 
mm/cm 
 
1.52 ± 0.18 
   
<0.001 
        
triceps surae 
MTH/limblength 
mm/cm 
 
1.65 ± 0.16 
   
0.032 
        
tibialis anterior 
MTH/limblength 
mm/cm 
 
0.70 ± 0.08 
   
0.105 (ns) 
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Table 2.3 (continued) – US to assess body composition 
Author, year, 
journal 
population 
type 
study design  
Area/ body-
site 
investigated  
US 
used  
Participant 
number n (m,f) 
and further 
details 
intervention 
details 
time/ 
duration 
Mode of 
assessment (US 
site/measure) 
pre 
intervention
(baseline 
values) 
post 
intervention 
values 
actual 
change 
reported 
% 
change if 
reported 
 (p)- 
value 
group 
differenc
e (p) 
COMPARATIVE AND CROSS-SECTIONAL STUDIES         
Birtles et al 
2002 
chronic 
exertional 
compartment 
syndrome 
comparative 
(healthy vs 
patients) 
anterior 
tibial muscle 
B-mode 
US 
Exp: 20 (14M) 
Age 27.6 ± 4.7yrs 
Weight 85.8 ± 10.7kg 
BMI 27.7 ± 3.6 
isometric 
exercise of 
AT group 
1 session 
muscle thickness 
mm 
28.7 ± 1.0 31.0 ± 1.1 
 
8 <0.05 ns 
Med Sci Sports 
Exerc 34 (12): 
1900-6 
   
7.5 MHz 
and 5-10 
MHz 
Con (healthy): 22M 
33 ± 10.4yrs 
Weight 72.6±10.4kg 
BMI 23.3±2.8 
         
Bleakney & 
Maffulli 2002 
intramedullary 
nailing 
self-
controlled 
(compared 
to healthy 
leg) 
quadriceps 
8cm 
linear 
array 
13  
Age 43.2years 
Range 16-82yrs 
immobilisation 
VL pennation 
angle  
15.4 range 
10-21    
0.0002 
J Sports Med 
and Phs Fitness 
42 (1): 120-5 
 
cross-
sectional  
7.5 MHz 
   
VL muscle fibre 
length mm  
64.9 range 
56-78    
0.002 
  
(2 patients 
longitudinal)   
 
  
rectus femoris 
ACSA cm2  
3.7 range 0.8-
8.0    
0.0004 
     
 
  
anterior MTH of 
quadriceps  mm  
24.4 range 
14-33    
0.001 
Hakkinen et al 
2005 
rheumatoid 
arthritis 
comparative 
(women with 
RA vs 
healthy) 
thigh 
convex 
trans-
ducer 
patients: 21F 
44±9yrs (range 32-
56yrs) 
Height 165±6cm 
Weight 63.7±13.4kg 
combined 
strength 
and 
aerobic 
21 weeks 
quadriceps 
femoris MTH cm 
4.75 ± 0.65 
 
0.35 7.4 <0.001 0.81 (ns) 
Clin Exp 
Rheumatol 23 
(4): 505-12 
   
5MHz 
healthy: 12F 
42±9yrs (range 32-
56yrs) 
Height 163±5cm 
Weight 62.6±6.8kg 
 
3 session 
every 
2weeks 
subcutaneous fat 
cm 
3.08 ± 1.41 
 
-0.38 -12.3 <0.001 0.10 (ns) 
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Table 2.3 (continued) – US to assess body composition 
Author, year, 
journal 
population 
type 
study design  
Area/ body-
site 
investigated  
US 
used  
Participant 
number n (m,f) 
and further 
details 
intervention 
details 
time/ 
duration 
Mode of 
assessment (US 
site/measure) 
pre 
intervention
(baseline 
values) 
post 
intervention 
values 
actual 
change 
reported 
% 
change if 
reported 
 (p)- 
value 
group 
difference 
(p) 
COMPARATIVE AND CROSS-SECTIONAL STUDIES 
Kubo et al 
2007 
elderly men 
comparative 
study 
knee extensors 
and plantar 
flexors 
B-
mode 
US 
elderly: 17M 
70.4±4.8yrs 
 
  
knee extensor MTH 
mm  
29.8 ± 5.3 
   
<0.001 
Journal of 
Gerontology 
62a (11): 1252-
8 
   
7.5 
MHz 
 Height 159.7±6.7cm 
Weight 59.7±8.7kg   
KE MTH/thigh length 
mm/cm  
0.81 ± 0.15 
   
<0.001 
     
young: 19M 
26.4±3.7yrs   
plantar flexor MTH 
mm  
62.7 ± 6.9 
   
<0.001 
     
Height 171.4.8cm 
Weight 71.8±11.8kg   
PF MTH/thigh length 
mm/cm  
1.78 ± 0.19 
   
ns 
Matschke et al 
2010a 
cachectic 
with 
rheumatoid 
arthritis 
comparative 
(wasted RA 
vs healthy) 
vastus lateralis 
 
RA: 14 (3M, 11F) 
61.6±3.3yrs (range 22-
72yrs) 
  
VL PCSA cm2 
 
31.3 SEM 2.3 
  
0.07 (ns) 
 
J Rheumatol 37 
(2): 282-4     
healthy: 14 (3M, 11F) 
  
pennation angle 
 
8.5 SEM 0.4 
  
0.07 (ns) 
 
     
62.2±3.5yrs (range 22-
76yrs)   
VL volume cm3 
 
391.2 SEM 21.4 
  
0.01 
 
Matschke et al 
2010b 
rheumatoid 
arthritis 
comparative 
study 
quadriceps 
7.5 
MHz 
linear 
probe 
RA: 23 (7M,16F) 
60 SEM 2 yrs (range 22-
72yrs) 
  
VL PCSA cm2 
 
34.2 ± 1.9 
   
<0.05 
Med Sci Sports 
Exerc 42 (12): 
2149-55 
    
 Height 165±1cm 
weight 75.5±3.1kg   
VL pennation angle at 
rest  
8.85 ± 0.3 
   
<0.05 
     
healthy: 23 (7M, 16F) 
60 SEM 3 yrs (range 22-
76yrs) 
  
VL pennation angle at 
contraction  
11.7 ± 0.5 
   
ns 
     
Height 168±2cm 
Weight 73.6±2.6kg   
VL fascicle length at 
rest cm  
13.4 ± 0.5 
   
0.06 (ns) 
        
VL fascicle length at 
contraction cm  
11.3 ± 0.6 
   
ns 
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Table 2.3 (continued) – US to assess body composition 
Author, year, 
journal 
population 
type 
study design  
Area/ body-
site 
investigated  
US 
used  
Participant 
number n (m,f) 
and further 
details 
intervention 
details 
time/ 
duration 
Mode of 
assessment (US 
site/measure) 
pre 
intervention
(baseline 
values) 
post 
intervention 
values 
actual 
change 
reported 
% 
change if 
reported 
 (p)- 
value 
group 
difference 
(p) 
COMPARATIVE AND CROSS-SECTIONAL STUDIES         
da Silva et al 
2012a 
exercise 
induced 
bronchospas
ms (EIB) in 
obese 
comparative 
(EIB vs nonEIB) 
visceral 
and subcut 
fat 
 
EIB: 15 (12F,3M) 
16±1yrs 
Height 170±0cm 
Weight 99±18kg 
 
Con (Non EIB): 20 
(12F,8M) 17±1.6yrs 
weight loss 
programme - 
nutrition, 
psychological, 
and physical 
interventions 
one year visceral fat cm 3.8 ± 0.9 2.0 ± 0.7 -1.7 ± 1.0 
 
<0.001 ns 
Respir Care 57 
(4): 572-82     
height 170±10cm 
weight 102±13kg  
3times/ 
wk 
subcutaneous 
fat cm 
4.0 ± 1.1 3.0 ± 0.7 -0.9 ± 1.1 
 
<0.001 ns 
da Silva et al 
2012b 
asthmatic 
obese 
comparative 
(asthmatic vs 
non-asthmatic) 
visceral 
and subcut 
fat 
 
asthmatics: 26 
(20F,6M) 
16±1.1yrs 
Height 170±10cm 
Weight 112±19kg 
weight loss 
programme - 
nutrition, 
psychological, 
and physical 
interventions 
one year visceral fat cm 4.2 ± 1.4 2.5 ± 0.9 
  
<0.05 
 
Pediatric 
Pulmonology 
47: 8-17 
    
non-asthmatics: 50 
(33F,17M) 
17±1.4yrs 
Height 168±10cm 
Weight 101±15kg 
 
3times/ 
wk 
subcutaneous 
fat cm 
3.9 ± 0.9 3.0 ± 0.8 
  
ns 
 
Young et al 
1982 
knee injury 
self controlled 
(compared to 
healthy leg) 
quadriceps 
 
14 (10, 4)  
Age (median) 25years   
non wasted quadriceps ACSA 
cm2 male 
80.0 range 64-
89     
Clinical Science 
62: 227-34     
Age (range) 19-44yrs 
  
non wasted quadriceps ACSA 
cm2 female 
52.8 range 43-
57     
        
non wasted quad fibre area 
um2 male 
4669 range 
3370-7400     
        
non wasted quad fibre area 
um2 female 
3411 range 
2780-4100     
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Table 2.3 (continued) – US to assess body composition 
Author, year, 
journal 
population 
type 
study 
design  
Area/ body-site 
investigated  
US 
used  
Participant number 
n (m,f) and further 
details 
intervention 
details 
time/ 
duration 
Mode of 
assessment (US 
site/measure) 
pre 
intervention
(baseline 
values) 
post 
intervention 
values 
actual 
change 
reported 
% 
change if 
reported 
 (p)- 
value 
group 
difference 
(p) 
LONGITUDINAL/ PROSPECTIVE COHORT 
Gruther et al 
2008 
critically ill longitudinal quadriceps 
high 
resolution 
real-time 
US 
17 (14M, 3F) 
55±17yrs 
Height 174±12cm 
Weight 84±21kg 
 
28 days 
quadriceps 
femoris MTH  
-ve 
correlation 
with length of 
stay 
  
<0.01 
 
J Rehabil Med 
40: 185-9               
Uremovic et al 
2004 
knee joint 
injury 
longitudinal 
m. 
quadriceps 
7.5 MHz 
linear 
probe 
patients: 30 
(21m, 9f) 
30.6±10.3yrs 
Weight 
74.6±12.8kg 
Height 
173±6.8cm 
physical rehab 
after 
immobilisation 
6 weeks 
rectus femoris 
volume  mm3 
13953 ± 2812 15688 ± 3487 
  
<0.001 <0.01 
Coll Antropol 
28 suppl 2: 
227-33 
 
Self-
controlled: 
injured leg vs 
healthy leg 
  
control: 30 
30.2± 6.9yrs 
Weight 71±8.5kg 
Height 
172.5±6.2cm 
  
vastus 
intermedius 
volume mm3 
13234 ± 2736 14936 ± 2555 
  
<0.001 <0.001 
CASE STUDY 
Reid et al 2008 
critically ill - 
Addison's 
disease 
case study 
bicep brachii, 
forearm, thigh  
1F 
38 years old 
ICU stay 33days 
Admission weight 
69kg 
BMI 25.3 
"intensive physical 
rehab" and 
"nutrient-dense 
nutritional support 
regimen" 
12 
months 
body mass and 
fat mass  
regained body 
mass due to 
body fat 
increases 
    
Critical Care 12 
(3): R79     
Discharge weight 
↓11.2kg, ↓16.2%   
lean mass 
  
+2.5kg after 
discharge  
ns 
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Table 2.3 (continued) – US to assess body composition 
Author, year, 
journal 
population 
type 
study 
design  
Area/ body-
site 
investigated  
US used  
Participant 
number n (m,f) 
and further 
details 
intervention details 
time/ 
duration 
Mode of 
assessment (US 
site/measure) 
pre 
intervention
(baseline 
values) 
post 
intervention 
values 
actual 
change 
reported 
% 
change if 
reported 
 (p)- 
value 
group 
difference 
(p) 
NON-RANDOMISED CONTROLLED TRIALS         
Gibson et al 
1988 
simple distal 
third fracture 
of tibia 
nonRCT quadriceps 
grey-scale 
US 
exp: 7m 
age 26yrs (range 18-
49yrs) 
electrical muscle 
stimulation 
6 -7 weeks 
quadriceps 
CSA cm2 
53.3 ± 11.3 50.9 ± 9.0 
  
<0.05 
 
The Lancet , 
October 
pp767-70 
immobilisati
on (in cast)   
3.5 MHz 
con: 14m 
age 48yrs 
range 19-76yrs 
 
1 hr/day 
       
Kawakami et al 
2001 
healthy men nonRCT quadriceps B-mode US 
9 Ex: 5, Con: 4 
 
immobilsation 
(head down bed 
rest) 
20 days 
TRAINED 
pennation 
angle 
17.7 ± 2.3 17.6 ± 1.8 
 
-0.2 ± 4.4 
  
European 
Journal of 
Applied 
Physiology 84: 
7-12 
   
7.5 MHz 
Age range 18-28yrs 
Height 172 ± 4.6cm 
Weight 68.4 ± 10.6kg  
isometric 
exercise (leg 
extension) 
 
UNTRAINED 
pennation 
angle 
19.8 ± 3.9 19.5 ± 4.1 
 
-1.4 ± 2.8 
  
Moukas et al 
2002 
critically ill 
hemiplegic 
nonRCT 
hemiplegic 
upper arm 
M-mode 
US 
37 (23m, 14f) 
58 ± 13yrs 
immobilsation 
and drug therapy 
4 days 
all patients 
muscle mass 
cm 
2.49 ± 0.59 1.99 ± 0.51 
- 0.49 ± 
0.20 
- 20.09 ± 
6.83 
<0.001 
 
Clinical 
Nutrition 21(4): 
297-302 
   
10 MHz 
linear array 
high res 
  
measured 
on day 1 
and 10 
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Table 2.3 (continued) – US to assess body composition 
Author, year, 
journal 
population 
type 
study 
design  
Area/ body-site 
investigated  
US used  
Participant 
number n (m,f) 
and further 
details 
intervention 
details 
time/ 
duration 
Mode of 
assessment (US 
site/measure) 
pre 
intervention 
(baseline 
values) 
post 
intervention 
values 
actual 
change 
report
ed 
% 
change if 
reported 
 (p)- 
value 
group 
difference 
(p) 
UNCONTROLLED TRIALS            
Abe et al 1997 healthy uncontrolled 
9 sites: anterior 
and posterior 
B-mode 
US 
8 (4, 4) bed rest 20 days 
anterior foream 
MTH mm 
19.8 SE 1.4 19.3 SE 1.4 
 
-2.5 
  
J Gravitat 
Physiol 4(1): 
s10-14 
    
Age 20.9 ± 1.7yrs 
  
anterior upper 
arm MTH mm 
24.8 SE 2.0 25.1 SE 2.2 
 
1.2 
  
     
Height 169.5 ± 6.5 
cm   
posterior upper 
arm MTH mm 
31.5 SE 1.8 30.9 SE 1.8 
 
-1.9 
  
        
abdomen MTH 
mm 
13.3 SE 0.8 14.4 SE 0.7 
 
8.3 <0.05 
 
        
subscapular MTH 
mm 
19.3 SE 1.2 17.8 SE 1.1 
 
-7.8 <0.05 
 
        
anterior thigh 
MTH mm 
52.8 SE 2.0 50.5 SE 1.9 
 
-4.4 
  
        
posterior thigh 
MTH mm 
57.6 SE 2.5 56.4 SE 2.5 
 
-2.1 
  
        
anterior leg MTH 
mm 
29.3 SE 1.9 28.6 SE 1.9 
 
-2.4 
  
        
posterior leg MTH 
mm 
65.4 SE 2.2 63.3 SE 2.2 
 
-3.2 <0.05 
 
Galvao et al 
2006 
prostate 
cancer 
uncontrolled upper arm, thigh 
B-mode 
US 
10M 
70.3±8.3ys (range 
59-82yrs) 
PRT 20 weeks 
bicep brachii 
MTH cm 
2.69 ± 0.54 2.91 ± 0.57 
 
3.5 ± 6.9 ns 
 
Med Sci Sports 
Exerc 38 (12): 
2045-52 
   
5 MHz 
Weight 
80.2±10.9kg 
BMI 27.4±3.3 
 
twice/ 
week 
tricep brachii 
MTH cm 
1.94 ± 0.26 2.33 ± 0.49 
 
5.5 ± 17.0 ns 
 
        
quadriceps MTH 
cm 
2.15 ± 0.30 2.46 ± 0.41 
 
15.7 ± 12.1 0.05 
 
        
hamstrings MTH 
cm 
4.52 ± 0.74 4.53 ± 0.89 
 
0.2 ± 10.0 ns 
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Table 2.3 (continued) – US to assess body composition 
Author, year, 
journal 
population 
type 
study 
design  
Area/ body-site 
investigated  
US used  
Participant 
number n (m,f) 
and further 
details 
intervention 
details 
time/ 
duration 
Mode of 
assessment (US 
site/measure) 
pre 
intervention
(baseline 
values) 
post 
intervention 
values 
actual 
change 
reported 
% 
change if 
reported 
 (p)- 
value 
group 
difference 
(p) 
RANDOMISED CONTROLLED TRIALS 
Bernardes et al 
2012 
pelvic organ 
prolapse 
RCT 
levator ani 
muscle 
2-D 
transperi
neal US 
Exp (“group2”): 
21 
56.7±10.7yrs 
BMI 28.8±3.9 
pelvic floor 
muscle training 
and 
hypopressive 
exercises 
12 weeks CSA muscle cm2 1.4 ± 0.3 1.8 ± 0.5 
  
0.001 
 
Sao Paulo 
Medical 
Journal 130 (1): 
5-9 
   
4-7MHz 
Con (“group3”): 
16 
58.7±10.4yrs 
BMI 29.7±2.7 
         
Candow et al 
2008 
healthy 
elderly men 
RCT 
elbow, knee, 
ankle flexors 
and extensors 
B-mode 
US 
C+P: 10M 
67.3±3.1yrs 
Weight 
82.5±2.8kg 
Height 
177.2±2.1cm 
 
RT with creatine 
+protein,  
10 weeks 
muscle thickness 
cm CP (creatine 
protein) 
      
Med Sci Sports 
Exerc 40 (9): 
1645-52 
    
Cr: 13M 
65.5±2.7yrs 
Weight 86±5.4kg 
RT with creatine 
alone 
3times/ wk elbow flexor 2.9 ± 0.2 3.1 ± 0.2 
 
9.0 ± 6 <0.05 
 
     
Height 
175.4±2.3cm   
elbow extensor 4.3 ± 0.3 4.7 ± 0.3 
 
11.6 ± 5 <0.05 
 
     
Con (pla): 12M 
64.1±3.1yrs 
RT + placebo 
 
knee flexor 4.9 ± 0.3 5.2 ± 0.2 
 
7.0 ± 5.2 <0.05 
 
     
Weight 
82.9±2.9kg   
knee extensor 3.3 ± 0.3 3.8 ± 0.3 
 
13.6 ± 4.7 <0.05 
 
     
Height 
178.3±1.3cm   
ankle plantar 
flexors 
3.8 ± 0.3 4.3 ± 0.2 
 
14.1 ± 5.0 <0.05 
 
        
ankle dorsi flexors 2.3 ± 0.1 2.5 ± 0.3 
 
4.6 ± 5.1 ns 
 
        
combined mth 
   
10 ±  5.2 
 
<0.05 
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Table 2.3 (continued) – US to assess body composition 
Author, year, 
journal 
population 
type 
study design  
Area/ body-
site 
investigated  
US 
used  
Participant 
number n (m,f) 
and further 
details 
intervention 
details 
time/ 
duration 
Mode of 
assessment (US 
site/measure) 
pre 
intervention
(baseline 
values) 
post 
intervention 
values 
actual 
change 
reported 
% 
change if 
reported 
 (p)- 
value 
group 
difference 
(p) 
RANDOMISED CONTROLLED TRIALS 
        
Cr (creatine only) 
      
Candow et al 
2008 
continued from previous page 
    
elbow flexor 2.8 ± 0.2 3.0 ± 0.2 
 
8.8 ± 3.7 <0.05 
 
        
elbow extensor 4.1 ± 0.2 4.5 ± 0.2 
 
11.4 ± 4.3 <0.05 
 
        
knee flexor 4.5 ± 0.2 4.8 ± 0.2 
 
9.4 ± 3.6 <0.05 
 
        
knee extensor 3.3 ± 0.2 3.6 ± 0.2 
 
11.3 ± 3.7 <0.05 
 
        
ankle plantar flexors 3.5 ± 0.2 3.9 ± 0.3 
 
13.8 ± 4 <0.05 
 
        
ankle dorsi flexors 2.1 ± 0.1 2.3 ± 0.2 
 
7.9 ± 6.7 ns 
 
        
combined mth 
   
10.4 ± 4.3 
 
<0.05 
Cornish et al 
2009 
healthy 
untrained 
>60yrs 
RCT 
elbow and 
knee 
extensors 
and flexors 
B-
mode 
US 
51 
 
65.4±0.8yrs 
PRT with/out 
nutritional 
supplementation 
12 weeks 
FEMALE elbow flexor 
MTH cm 
2.9 ± 0.7 3.2 ± 0.7 
  
<0.01 
 
Applied 
Physiology, 
Nutrition and  
   
5MHz 
placebo: 14m, 
12f  
3days/ 
week 
FEMALE elbow 
extensor MTH cm 
3.7 ± 1.3 4.6 ± 0.7 
  
<0.01 
 
Metabolism 34 
(1): 49-59     
supplement 
group: 14m, 11f   
FEMALE knee flexor 
MTH cm 
5.1 ± 1.7 5.1 ± 1.7 
   
<0.05 
        
FEMALE knee 
extensor MTH cm 
3.5 ± 0.7 4.0 ± 0.7 
  
<0.01 
 
        
MALE elbow flexor 
MTH cm 
3.6 ± 0.4 4.0 ± 0.7 
  
<0.01 
 
        
MALE elbow extensor 
MTH cm 
4.4 ± 1.1 5.2 ± 1.1 
  
<0.01 
 
        
MALE knee flexor 
MTH cm 
5.2 ± 1.5 6.1 ± 1.1 
   
<0.05 
        
MALE knee extensor 
MTH cm 
3.4 ± 0.4 3.4 ± 0.4 
  
<0.01 
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Table 2.3 (continued) – US to assess body composition 
Author, year, 
journal 
population 
type 
study 
design  
Area/ body-
site 
investigated  
US used  
Participant 
number n (m,f) 
and further 
details 
intervention 
details 
time/ 
duration 
Mode of 
assessment (US 
site/measure) 
pre 
intervention
(baseline 
values) 
post 
intervention 
values 
actual 
change 
reported 
% 
change if 
reported 
 (p)- 
value 
group 
difference 
(p) 
RANDOMISED CONTROLLED TRIALS 
Gerovasili et al 
2009 
critically ill RCT quadriceps 
GE Vivid 
7 US 
exp: 13 (6M,7F) 
59±23yrs 
electrical muscle 
stimulation of 
quadriceps and 
peroneous longus 
muscles 
2-9days 
after 
admission 
right rectus 
femoris cross-
sectional 
diameter cm 
1.42 ± 0.48 1.31 ± 0.45 - 0.11 ± 0.06 -8 ± 3.9 0.001 <0.05 
Critical Care 13 
(5): R161    
7.5 MHz 
con: 13 (8M,5F) 
56±19yrs  
55 mins/ 
day 
right vastus 
intermedius cross 
sectional 
diameter cm 
0.91 ± 0.39 0.81 ± 0.38 -0.10 ± 0.05 -12.5 ± 7.4 0.001 <0.05 
Gruther et al 
2010 
critically ill 
(ICU) - acute 
and long 
term 
RCT 
knee 
extensors 
high 
resolutio
n real-
time 
stimulation 
group acute 
patients: 8 
(7M,1F) 
neuromuscular 
electrical 
stimulation 
4 weeks 
ACUTE PATIENTS 
quadriceps 
femoris (vastus 
intermedius and 
rectus femoris) 
MTH 
28.9 ± 6.6 18.3 ± 3.2 -10.6 -36.7 0.02 ns 
J Rehabil Med 
42: 593-7     
stimulation 
group longterm 
patients: 8 
(7M,1F) 
 
5times/ 
wk 
LONGTERM 
PATIENTS 
quadriceps 
femoris 
18.4 ± 4.2 19.3 ± 3.8 0.09 4.9 0.036 0.013 
     
control acute: 9 
(8,1) 
control longterm: 
8 (4,4) 
  
 (vastus 
intermedius and 
rectus femoris) 
MTH 
      
     
Total: 55±15yrs 
         
 
Presented as mean ± standard deviation unless otherwise stated; IQR = interquartile range; SEM = standard error of the mean; SE = 
standard error; RCT = randomised controlled trial; nonRCT = non randomised controlled trial; Xover = crossover design; exp = 
experimental group; co/con = control group; pla = placebo group; MTH = muscle thickness; VL = vastus lateralis; CSA = cross sectional 
area; PRT = progressive resistance training; 2-D = 2-dimensional; US = ultrasound or ultrasonography; ns = non-significant result
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Ultrasound imaging produces a two-dimensional view based on transmission and 
reflection of high-frequency waves in a given plane.  This is a visualisation of the 
different structures of tissues below the surface.  In the longitudinal axis, it allows the 
view of a whole fascicle to be captured and analysed for length and pennation angle. 
 
Placement and orientation of the ultrasound probe will affect the picture produced, as 
it alters the “slice” of the tissue to be examined.  Placement refers to the skin-probe 
interface, and will have little effect on the measurement outcome, provided that the 
probe is placed along the median longitudinal axis of the muscle (Kawakami et al 2000; 
Narici et al 1996), with a clearer image being produced using a water-soluble gel over 
the head of the probe to provide acoustic contact without depressing the dermal 
surface (Miyatani 2002). 
 
Further validation of US for use in structural assessment is possible and has been 
attempted using a geometric model to examine fascicle contraction in three-
dimensions (examining probe orientation over the muscle) instead of the two-
dimensional assumptions (Kawakami et al 2000; Klimstra et al 2007).  However, results 
have been variable; suggesting orientation of the probe on the skin should continue to 
be standardized at the beginning of an experimental protocol for consistency for all 
assessors, participants, and interventions, until further validation can be confirmed. 
 
When using US for analysis of subcutaneous fat, it is essential that the measurement 
protocol is standardized and the investigator is well-trained through repeated 
measures (the threat to measurement error is minimized by enhancing the 
measurement reliability of the operator and protocols), as less experienced individuals 
may compress the skin (causing compression of fat and false low reading; Orphanidou 
et al 1994) or position the transducer at an angle not perpendicular to the skin (over-
measurement/inaccurate reading; Orphanidou et al 1994, Pillen et al 2003). 
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2.6.2.2.7.1 Validity and reliability of Ultrasound in body composition measures 
Ultrasound measurement of varying sites on the body is susceptible to inter-observer 
variability and has been shown to be affected by practice and/or learning effects during 
both image capture and analysis phases.  Limitations can be broken down into: (1) 
technique-related (transducer ideally held perpendicular to skin surface, direct 
compression of subcutaneous fat avoided, Orphanidou et al 1994); (2) anatomy-
related; (3) disease-related (severe neuromuscular disorders can lead to unclear muscle 
outlines, Pillen et al 2003); and (4) patient factors (Rutten et al 2006) such as age 
(Moukas et al 2002), obesity, and possibly gender (Orphanidou et al 1994) for analysis 
of diagnostic power.  Controlling for these factors prior to measurement is possible, 
although it can often rely on the experience and sensibilities of the operator and 
analytical team.   
 
For usable results from US, reliability must apply to both the image reading and 
acquisition, as the reading is only as good as the quality of the image (Joshua et al 
2006).  Training and constant practice is essential for accurate repeated measurements.  
For instance, in echocardiographic imaging of cardiac conditions the American College 
of Cardiology/American Heart Association recommend “level 2” training as a minimum 
– 150 studies performed and 300 interpretations under supervision (Seward et al 2002; 
Kobal et al 2004).  Although the World Health Organisation (WHO 1998) suggest that 
10% of the time spent training should be devoted to analysis of small parts (as opposed 
to abdominal, obstetric, and gynaecological examinations) implying that 30-50 practice 
(training) image-captures would be sufficient to establish a highly reproducible method 
by an individual (intra-rater reliability). 
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Table 2.4a summarizes studies reporting the validity of ultrasound against other 
measures of muscle mass or body composition assessment (in non-CKD).  Table 2.4b 
similarly describes studies reporting the reliability of the ultrasound in repeated 
measures (in non-CKD). 
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Table 2.4a - Studies examining validity of Ultrasound, in healthy and unwell groups (ordered by population type and alphabetically by author) 
Reference 
population 
type 
Tissue/area 
investigated  
ultrasound used 
(type and 
frequency) 
Participant 
number 
N (m,f) 
Participant 
details 
Validity 
compared 
to… 
Mode of 
assessment (US 
site/measure) 
Correlation 
co-efficient 
ACUTE OR CHRONIC ILLNESS        
Emmons et al 2011 
Spinal cord 
injury (SCI) 
abdominal fat 3C- RS SCI: 24 males 
44 ± 10yrs 
BMI 26.2 ± 5.4 
DEXA 
Subcut and 
visceral fat 
SCI : “not 
correlated”  
Ultrasound in Med & Biol 
37 (5): 734-41 
  
2-5MHz with 
curvilinear 
transducer 
healthy: 20 
males 
39 ± 11yrs 
BMI 27.6 ± 4.8 
  
Healthy: 
“correlated”  
Thomaes et al  2012 
coronary 
artery disease 
quadriceps 
muscle 
B-mode US 20 
68.3 ± 7.3yrs 
BMI 26.8 ± 2.8 
CT rectus femoris 
0.92 
(0.81 - 0.97) 
BMC Medical Imaging 
12:7 
   (Older)     
HEALTHY INDIVIDUALS        
Bemben 2002  
(abstract only) 
healthy post-
menopausal 
upper arm, 
thigh 
5MHz transducer 
38f post-
menopause 
85older (m+f)  
58.9 ± 0.7yrs 
 
65.0 ± 0.4yrs 
MRI rectus femoris 0.9 
J Strength Conditioning 
Research 16(1): 103-8 
   
10 young 
mixed (m+f) 
26.1 ± 2.4yrs    
Cartwright et al 2013 cadavers 
skeletal 
muscle 
18-MHz linear-
array transducer 
4 cadavers  
actual 
measure 
(by 
dissection) 
bicep brachii/ 
brachialis 
complex (mid-
arm) 
0.993 
Muscle & Nerve 47 (4): 
515-21 
      tibialis anterior 0.992 
Mendis et al 2010 healthy 
anterior hip 
muscle 
real-time portable 
US 
9 (5m, 4f) 24.3 ± 3.5yrs MRI iliopsoas 0.86-0.88 
J Orthop Sports Phys Ther 
40 (9): 577-81 
  
4 MHz curved 
linear array 
transducer 
 
Height: 172.0 ± 
11.2cm 
 sartorius 0.81-0.82 
     
Weight: 69.6 ± 
14.5kg 
 rectus femoris 0.85-0.89 
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Table 2.4a (continued) – validity of ultrasound 
Reference 
population 
type 
Tissue/area 
investigated  
ultrasound used 
(type and 
frequency) 
Participant 
number 
N (m,f) 
Participant 
details 
Validity 
compared 
to… 
Mode of 
assessment (US 
site/measure) 
Correlation 
co-efficient 
HEALTHY INDIVIDUALS        
Noorkoiv et al 2010a 
healthy, 
young 
upper leg 
B-mode US 
(extended field of 
view) 
6m 28.7 ± 4.6yrs CT 
vastus lateralis 
ACSA 
0.951 -0.998 
(p<0.000) 
Eur J Appl Physiol 109 (4): 
631-9 
  
10MHz linear 
array probe 
(60mm width) 
     
Pineau et al 2007 
healthy, 
middle-aged 
body fat A-mode 41f, 48m 
48.4 ± 17.7yrs 
BMI 28.5 ± 7.7 
DEXA 
mid-thigh and 
intra-abdominal 
0.98 
Ann Nutr Metab 51 (5): 
421-7 
        
Volz & Ostrove 1984 
(abstract only) 
healthy, 
young 
fat thickness 
portable 
ultrasonoscope 
66f 18-26yrs 
skinfold 
calipers 
 0.75-0.86 
Med Sci in Sport and 
Exercise 16 (1): 97-102 
        
 
Presented as mean ± standard deviation unless otherwise stated; IQR = interquartile range; SEM = standard error of the mean; SE = 
standard error; MTH = muscle thickness; VL = vastus lateralis; ACSA = anatomical cross sectional area; 2-D = 2-dimensional; US = 
ultrasound or ultrasonography; ns = non-significant result; DEXA = dual energy x-ray absorptiometry; MRI = magnetic resonance 
imaging; CT = computed tomography; A-mode = amplitude mode; B-mode = brightness mode; BMI = body mass index
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Table 2.4b - Studies examining reliability of Ultrasound, in healthy and ill groups (arranged by population type and alphabetically by author) 
Reference 
population 
type 
Tissue/area 
investigated 
ultrasound used 
(type and 
frequency) 
Participan
t number 
N (m,f) 
Participant 
details 
Reliability  US site /measure 
Correlation 
co-efficient 
ACUTE AND CHRONIC ILLNESS        
Dudley-Javoroski et al 2010 
spinal cord 
injury (SCI) 
vastus lateralis, 
patellar tendon, 
soleus, Achilles 
tendon 
B-mode US 16 
26 ± 4.5yrs 
Height: 174 ± 
7.1cm 
Weight: 74.4 ± 
13kg 
intra-rater 
reliability 
 0.58-0.95 
Ultrasound Med Biol 36 
(10):1594-607 
  5-12MHz transducer   
inter-rater 
reliability 
 0.62-0.74 
Staehli et al 2010 Osteoarthritis vastus lateralis B-mode US 20 post-op 
61.5 ± 5.3yrs 
BMI 27.3 ± 2.3 
intra-rater 
reliability 
VL thickness 
0.888 
(0.778-
0.945) 
J Electromyography and 
Kinesiology 20 (6): 1058-65 
Total knee 
arthroplasty 
(TKA) 
 10-15MHz 10 pre-op 
59.6 ± 6.0yrs 
BMI 27.5 ± 2.8 
 VL pennation angle 
0.624 
(0.345-
0.801) 
Yang et al 2009 
urinary 
incontinence 
pelvic floor  209f 
50.8 ± 11.9yrs 
BMI 24.4 ± 3.9 
intra-observer 
reliability 
 0.825-0.886 
Ultrasound Obstet Gynecol 
33(4): 465-71 
     
inter-observer 
reliability 
 0.827-0.891 
HEALTHY INDIVIDUALS         
Bemben 2002 (abstract only) 
healthy post-
menopausal 
upper arm, thigh 5MHz transducer 
38f post-
meno 
85m+f  
58.9 ± 0.7yrs 
 
65.0 ± 0.4yrs 
intra-rater 
reliability 
rectus femoris, 
biceps brachii 
0.72-0.99 
J Strength Conditioning 
Research 16(1): 103-8 
        
Cartwright et al 2013 healthy skeletal muscle 
18-MHz linear-array 
transducer 
4 healthy  
intra-rater 
reliability 
bicep brachii/ 
brachialis complex 
(mid-arm) 
0.984 
Muscle & Nerve 47 (4): 515-21       tibialis anterior 0.999 
      
inter-rater 
reliability 
bicep brachii/ 
brachialis complex 
(mid-arm) 
0.981 
       tibialis anterior 0.998 
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Table 2.4b (continued) - reliability of ultrasound 
Reference 
population 
type 
Tissue/area 
investigated 
ultrasound used 
(type and 
frequency) 
Participant 
number 
N (m,f) 
Participant details Reliability 
 US site 
/measure 
Correlation 
co-efficient 
HEALTHY INDIVIDUALS         
Chumlea & Roche 1986 
(abstract only) 
healthy, 
elderly 
 A-mode  65-99yrs “elderly” 
inter-observer 
reliability 
 < 68% 
American Journal of 
Physical Anthropolgy 71 (3): 
351-7 
        
Demura et al 1999 
healthy, 
young 
triceps and 
subscapular 
B-mode 16m 
21.6 ± 3.6yrs  
height: 170 ± 5.6cm 
Weight: 64.8±7.4kg 
test-retest reliability 
triceps 
(mm) 
r > 0.95 
Applied Human Science 18 
(2): 43-51 
   15f 
20.4±0.95yrs 
Height: 160±4.5cm 
Weight: 55.3±6.0kg 
 
subscapula
r (mm) 
r > 0.92 
Hides et al 2007 healthy 
abdominal 
muscles: 
B-mode 
19 (11f, 
8m) 
20.3± 5.0yrs 
Height: 172.0± 9.8cm 
Weight: 64.5 ±11.4kg 
intra-rater (rptd 
measure of same 
image) 
 0.98-0.99 
J Orthop Sports Phys Ther 
37(8): 480-6 
 
internal obliques 
and transverse 
abdominus 
   
intra-rater ( of 3 
images) 
 0.62-0.82 
      
intra-rater (over 2 
days) 
 0.69-0.85 
Lin et al 2009 healthy neck muscles 
10MHz linear array 
tranducer 
10 (7f + 
3m) 
Female: 23.9±2.9yrs 
BMI 19.5±1.9 
intra-session 
reliability 
 0.87-0.99 
J Orthop Sports Phys Ther 
39(12): 850-7 
    
Males: 22.7±1.5yrs 
BMI 21.5±2.1 
inter-session 
reliability 
 0.90-0.98 
McMeeken et al 2004 healthy 
tranverse 
abdominus 
B-mode, 7.5MHz 
curvilinear 
transducer 
13 (6m+4f) 
39.7 SEM 2.3yrs 
BMI 23.9 SEM 0.8 
intra-rater (between 
days) B-mode 
transverse 
abdominus 
0.981 
Clin Biomech 19(4): 337-42   
M-mode, 5MHz 
curvilinear 
transducer 
  
intra-rater (between 
days) M-mode 
 0.989 
      
between instruments 
(B vs M-mode) 
 0.817 
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Table 2.4b (continued) - reliability of ultrasound 
Reference 
population 
type 
Tissue/area 
investigated 
ultrasound used 
(type and 
frequency) 
Participant 
number 
N (m,f) 
Participant 
details 
Reliability 
 US site 
/measure 
Correlation 
co-efficient 
HEALTHY INDIVIDUALS         
Mota et al 2012 (abstract 
only) 
healthy abdominal muscle  24f  
intra-rater 
reliability 
rectus 
abdominus 
0.74 - 0.90 
J Orthop Sports Phys Ther 
42 (11): 940-6 
     
inter-rater 
reliability 
rectus 
abdominus 
> 0.90 
Muller et al 2013 
female 
athletes 
adipose tissue 
(subcutaneous fat) 
B-mode 19f 
19.5 ± 3.3yrs 
BMI 21.3 ± 2.3 
inter-rater 
reliability 
triceps (mm) 0.966 
British Journal of Sports 
Medicine 47 (16): 1036-43 
(footballers + 
gymnasts) 
     
subscapular 
(mm) 
0.917 
       biceps 0.811 
       iliac crest 0.982 
       subraspinale 0.96 
       abdominal 0.985 
       front thigh 0.972 
       medial calf 0.953 
       overall 0.968 
Noorkoiv et al 2010a 
healthy, 
young 
upper leg 
B-mode US 
(extended field of 
view) 
6m 28.7 ± 4.6yrs inter-day reliability 
vastus lateralis 
ACSA 
0.982 
(0.892-0.997) 
(p=0.001) 
Eur J Appl Physiol 109 (4): 
631-9 
  
10MHz linear array 
probe (60mm width) 
     
Noorkoiv et al 2010b healthy quadriceps muscle B-mode US 10m 28 ± 5yrs 
inter-rater 
digitizing reliability 
vastus lateralis 
0.97 
(0.88 - 0.99) 
J Applied Physiol 109 (6): 
1974-9 
     
intra-session 
reliability 
 
0.99 
(0.95 - 1.00) 
      
inter-session 
reliability 
 
0.95 
(0.80 - 0.99) 
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Table 2.4b (continued) - reliability of ultrasound 
Reference 
population 
type 
Tissue/area 
investigated 
ultrasound used 
(type and 
frequency) 
Participant 
number 
N (m,f) 
Participant 
details 
Reliability 
 US site 
/measure 
Correlatio
n co-
efficient 
HEALTHY INDIVIDUALS         
O'Sullivan et al 2007 
healthy, 
asymptomatic 
shoulder injury  16 (12f, 4m) 20-41 years 
intra-rater intra-
image (within 
scan) reliability 
thickness 
measure of 
lower trapezius 
0.99 
(0.98-1.0) 
J Orthop Sports Phys Ther   
8MHz linear probe 
(40mm footprint) 
  
intra-rater 
between-scan 
reliability 
 0.90-0.99 
      
intra-rater 
between day 
reliability 
 0.89-0.91 
      
inter-rater 
reliability 
 
0.88 
(0.73-0.96) 
Raj et al 2012a older healthy 
vastus lateralis and 
gastrocnemius 
B-mode real-time 21 (11m, 10f) 
68.1 ± 5.2yrs 
Height: 164.8 ± 
8.9cm 
Weight: 73.7 ± 
10.3kg 
intra-rater 
reliability 
muscle 
thickness 
0.96-0.97 
Clin Physiol Function 
Imaging 32(1): 65-70 
  
10MHz probe 
frequency 
   
pennation 
angle 
0.85-0.87 
       fascicle length 0.80-0.90 
Thomaes et al  2012 
Coronary 
arterial 
disease (CAD) 
quadriceps muscle B-mode US 25 
68.6 ± 4.6yrs 
BMI 26.3 ± 3.0 
intra-rater 
reliability 
 
0.97 
(0.92 - 0.99) 
BMC Medical Imaging 12:7   
12 MHz linear array 
transducer 
     
Volz & Ostrove 1984 
(abstract only) 
healthy, 
young 
fat thickness 
portable 
ultrasonoscope 
66f 18-26yrs 
test-retest 
reliability 
triceps, biceps, 
subscapula, 
suprailiac, 
abdomen, calf, 
thigh 
0.87-0.99 
Medicine and Science in 
Sport and Exercise 16 (1): 
97-102 
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Table 2.4b (continued) - reliability of ultrasound 
Reference 
population 
type 
Tissue/area 
investigated 
ultrasound used 
(type and 
frequency) 
Participant 
number 
N (m,f) 
Participant details Reliability 
 US site 
/measure 
Correlation 
co-efficient 
HEALTHY INDIVIDUALS         
Yoshida et al 2010 (abstract 
only) 
healthy   37m 
21.9 ± 2.4yrs 
Height: 172.9 ± 
5.3cm 
intra-rater 
reliability 
 0.91-0.98 
J Sports Rehabilitation 
19(2): 149-60 
    Weight: 66 ± 7.2kg 
inter-rater 
reliability 
 0.97 
Presented as mean ± standard deviation unless otherwise stated; IQR = interquartile range; SEM = standard error of the mean; 
SE = standard error; MTH = muscle thickness; VL = vastus lateralis; ACSA = anatomical cross sectional area; 2-D = 2-dimensional; 
US = ultrasound or ultrasonography; ns = non-significant result; DEXA = dual energy x-ray absorptiometry; MRI = magnetic 
resonance imaging; CT = computed tomography; A-mode = amplitude mode; B-mode = brightness mode; BMI = body mass 
index
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For reasonable precision in reliability, it is suggested that at least 50 participants over 
three trials are used, measuring the random error (‘noise’) between trials (within sports 
medicine and science; Hopkins 2000).  Error/variation can be examined by (1) within 
subject variation, (2) systematic change in mean, (3) retest correlation. 
Minimising within subject variation allows smaller changes to be detected in 
performance or health of a participant.  It is the random variation in a measure when 
an individual is tested many times.  The random variability is usually shown as standard 
deviation (SD), also known as standard error of measurement or typical error in a 
measurement.  Typical error generally increases as the absolute value of measure 
increases, although the percentage/proportion remains similar (coefficient of variation 
or CV), allowing direct comparison of measures, irrespective of calibration and/or 
scaling and can compare the reliability and variation between different modes of 
measure or equipment. 
With correct application of technique, through experience and training and 
controlling/allowing for other factors (time of day/posture/anatomical sites), 
ultrasound has been deemed accurate for use in repeated measures (tracking 
development and detriment). It is also a valid tool compared to a variety of “gold 
standard” techniques in non-renal populations (Table 2.4b; ICCs consistently >0.80). 
 
2.6.2.2.7.1.1 Limitations of validity and reliability studies of ultrasound to date 
Of the studies reporting validity of ultrasound measurements to a gold standard 
technique (Table 2.4a), only two studies were in in acute or chronic illness, totalling 64 
participants (one study compared to DEXA, one to CT).  The remaining studies focused 
instead on able-bodied or healthy participants (six studies, >200 participants, 2 MRI, 1 
CT, 1 DEXA, 1 dissection, 1 skinfold calipers) with an age range from 18 to 65yrs.  
General consensus for these few studies is that US was more well-correlated to the 
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gold standard in the able-bodied (healthy) individuals than in the acutely or chronically 
ill participants (r>0.85).  However, this cannot conclusively show that utilizing US for 
assessing body composition in the chronically ill is not possible, as the studies severely 
lack in number. 
 
Reliability of ultrasound measures (Table 2.4b) were similarly lacking in numbers of 
studies in the acute or chronically ill populations, with only three studies (summative 
n=255) examining either inter- or intra-rater reliability.  However, correlations ranged 
from 0.58 to 0.99, suggesting that US is repeatable and reliable, though would require 
further assessment by new “observers” in new populations.  In healthy populations, a 
greater number of studies (16 studies, 166 participants, age range 18-99years) have 
shown high repeatability with both intra- and inter-observer correlations exceeding 
0.90 for at least one measurement site in each study. 
 
2.6.2.3 Summary for measures of body composition 
Table 2.5 summarizes the advantages and disadvantages for each potential 
measurement technique discussed earlier. 
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Table 2.5 – Advantages and disadvantages of different body composition measurement 
techniques 
Technique Advantages Disadvantages 
Dual-energy X-ray 
Absorptiometry 
(DEXA/DXA) 
 High accuracy and sensitivity 
 Gold standard for bone mineral 
density 
 Quick and painless for the patient 
 Exposure to radiation 
 Expensive to use 
 Limited access/availability  
 Very obese may exceed the weight 
limit of the compartment 
Computed (axial) 
tomography (CT or 
CAT scan) 
 High accuracy and sensitivity 
 Gold standard for brain scans, 
organ, and bone assessment 
 Patient time: 5-10 minutes 
 Exposure to radiation 
 Expensive to use 
 Limited access/availability 
Magnetic 
Resonance Imaging 
(MRI) 
 High accuracy and sensitivity 
 Gold standard for imaging any part 
of the body 
 Expensive to use 
 Limited access/availability 
 Patients discomfort (claustrophobia) 
 Patient time: 15-90 minutes 
Muscle biopsy 
 High sensitivity for assessing small 
tissue samples 
 Gold standard for diagnosis of 
muscle tissue disease 
 Can assess muscle quality 
 Patient discomfort and apprehension 
 Safety issues/ infection 
 Requires local anaesthetic 
 Patient time: 30 minutes plus recovery 
(10 days before stitches removed) 
Body mass index 
(BMI)= Weight(kg)/ 
height(m)2 
 Easy to perform/calculate in large 
population groups 
 Simple, and standardized 
 No skill required 
 Patient time: 1-5 minutes 
 Cannot differentiate between muscle 
and fat  
 Does not consider fat repositioning 
with age (peripheral to central) 
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Table 2.5 (continued) – advantages and disadvantages of body composition measures 
Technique Advantages Disadvantages 
Waist or limb girth 
(circumference) 
 Easy to perform/calculate in large 
population groups 
 Simple, and standardized 
 No skill required 
 Patient time: 1-5 minutes 
 Large potential for error (site specific) 
 Cannot differentiate between muscle 
and fat 
 Does not consider loss of gluteal bulk 
with ageing 
Waist-to-hip ratio 
 Easy to perform/calculate in large 
population groups 
 Simple, and standardized 
 No skill required 
 Patient time: 1-5 minutes 
 Cannot differentiate between muscle 
and fat 
Skinfold thickness 
(calipers) 
 Inexpensive after initial outlay for 
equipment 
 Simple and quick 
 Extensive training required by operator 
 Large potential for error (site specific) 
 Less accurate in very lean/ thin 
participants, and obese, than 
participants in the “mid-range” 
Underwater/ 
hydrostatic 
weighing 
 High accuracy and sensitivity 
 Gold standard for measuring body 
volume 
 Cost and labour intensive 
 Patient discomfort and apprehension 
 Safety issues 
 Limited access/availability 
Urine analysis 
(creatinine or 3-
methyl-histidine) 
 Highly sensitive  
 Used as a proxy to measure 
muscle breakdown 
 3-MH in urine is proportional to 
total muscle mass 
 Requires 24-hour collection of urine by 
patient  
 Inconvenient for participant 
 Creatinine assessment imposes a 
limited diet in previous 24-hours 
(meat-free) 
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Table 2.5 (continued) – advantages and disadvantages of body composition measures 
Technique Advantages Disadvantages 
Total body potassium 
(TBK) 
 Highly sensitive 
 Measures radiation (40K) as a 
proxy for FFM 
 Expensive 
 Limited access/availability 
 Imposes restriction on participants (no 
radiographic medical procedures in 
previous week) 
Bio-electrical 
Impedance Analysis/ 
Spectroscopy  
(BIA/ BIS) 
 High accuracy and sensitivity 
 Portable  
 Inexpensive after initial outlay for 
equipment 
 Can differentiate between fat and 
muscle 
 Patient time: 10-20 minutes 
 Hydration condition must be 
maintained by participant 
 Cannot observe muscle quality 
Ultrasound (US) 
 Moderate accuracy and sensitivity  
 Reliable /repeatable 
 Inexpensive after initial outlay for 
equipment 
 Portable 
 Can differentiate between tissues 
 Requires extensive training by 
operator 
 Patient time: 20-45 minutes 
 
 
Studies investigating the wasting and rehabilitation of the quadriceps found 
insignificant differences between gold standard techniques and US, concluding that the 
level of precision is high enough to use ultrasound for this type of research (Tables 
2.4a-b).  There are limitations and risks associated with the use of US (such as the 
accuracy of individual results); however, considering the “gold standard” expense and 
availability for use at varying anatomical sites and tissue type, alongside radiation 
exposure, anaesthesia (increased risk to children; Pillen et al 2003) and time 
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constraints, the relative ease and accessibility of US has become a standard and well-
accepted alternative in clinical and field settings to assess body composition.   
 
2.7 Anabolic interventions to affect body composition in Chronic Kidney Disease 
Loss of skeletal muscle mass is due to reduced protein synthesis, increased 
degradation, or an imbalance between the two (Fearon et al 2012; Balstad et al 2014).  
Anabolic therapy stimulates metabolic pathways to increase muscle mass.  Potential 
anabolic effects on muscle mass should be targeted in cachexia (general wasting) 
prevention and treatment, but anti-catabolic effects (to decrease the breakdown of 
protein) are also of vital importance.  The need for additional protein to overcome the 
negative balance and malnutrition cannot be solved by simply increasing protein intake 
in food, as this in turn can aggravate uraemia (Workeneh & Mitch 2010).  Therefore 
anabolic interventions to increase protein production and reduce loss are vital. 
 
Table 2.6 shows studies to date that have assessed body composition in Chronic Kidney 
Disease across several stages of the disease trajectory.  Many of these studies were 
cross-sectional or longitudinal, whereas others have intervened with some form of 
anabolic therapy.  Measurement techniques employed include BIA, anthropometry 
(limb and trunk girth/circumference), skinfold thickness, DEXA, CT, near-infrared, 
ultrasound, and standard BMI. 
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Table 2.6 - Studies examining body composition in CKD (non-dialysis and dialysis) patients  (ordered by CKD stage, study design,  and alphabetically by 
author) 
Author, year, journal CKD stage  study design  participant number n 
(m,f) and further 
details 
intervention  time/ 
duration 
Mode of 
assessment 
and outcome 
measures 
pre 
intervention 
(baseline 
values) 
post 
intervention 
(final values) 
actual / 
percentage 
change 
reported 
significance 
(p) 
group 
difference 
(p) 
PRE (NON) DIALYSIS STUDIES                   
PRE (NON) DIALYSIS STUDIES - CROSS-SECTIONAL AND COMPARATIVE STUDIES 
Avesani et al 2001 
pre-dialysis 
diabetic 
comparative 
diabetic CRF vs 
non-diabetic 
diabetic CRF:  
24 (18m, 6f)  
57±10.6yrs 
none   
lean body mass 
kg diabetic 
  52 ± 9.1       
Nephrology Dialysis 
Trnsplantation 16: 556-
60 
    
non-diabetic CRF:  
24 (18m, 6f) 
55.4±11.3yrs 
    
lean body mass 
kg non-diabetic 
  51 ± 8.3     ns 
            
body fat % 
diabetic 
  24.7 ± 10.6       
            
body fat % non-
diabetic 
  24.6 ± 8.61     ns 
Bellizzi et al 2006 CKD3-5 comparative CKD: 84 (49m, 35f) none    
BIA fat free mass 
kg male 
  57.3 ± 9.2   
<0.05 
gender 
difference 
<0.05 
Journal of the American 
Society of Nephrology 
17: 1481-7 
CKD3 (n=32)    
CKD3 (n=32) 
65.8±10.9yrs 
BMI 26.6±4.4 
    
BIA fat free mass 
kg female 
  41.9 ± 6.9       
  CKD4 (n=31)    
 CKD4 (n=31) 
62.9±11.6yrs 
BMI 26.1±4.2 
    
BIA body cell 
mass kg male 
  26.0 ± 4.3   
<0.05 
gender 
difference 
<0.01 
  CKD5 (n=21)    
 CKD5 (n=21) 
60.1±16.2yrs 
BMI 25.5±5.3 
    
BIA body cell 
mass kg female 
  15.3 ± 2.5     <0.01 
      
healthy control 
matched: 604 
(298M,306F)   
    
BIA fat mass % 
male 
  20.3 ± 7.1   
<0.05 
gender 
difference 
<0.01 
      
 
    
BIA fat mass % 
female 
  30.4 ± 7.3       
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Table 2.6 (continued) – body composition in CKD 
Author, year, journal CKD stage  study design  participant number n 
(m,f) and further 
details 
intervention  time/ 
duration 
Mode of 
assessment 
and outcome 
measures 
pre 
intervention 
(baseline 
values) 
post 
intervention 
(final values) 
actual / 
percentage 
change 
reported 
significance 
(p) 
group 
difference 
(p) 
PRE (NON) DIALYSIS STUDIES - CROSS-SECTIONAL AND COMPARATIVE STUDIES 
Carvalho et al 2012 CKD 3-4 
cross sectional 
and longitudinal 
44 (66%M)  none 
12 
months 
total body fat 
% male 
25.9 ± 7.7 26.4 ± 7.4   ns   
Nephrology Dialysis 
Transplantation 27: 
1423-8 
CKD3 (n=25) 
CKD4 (n=19) 
  
 62.9±13.9yrs 
BMI 25.5±5.1 
    
total body fat 
% female 
38.1 ± 6.8 38.4 ± 7.0   ns   
            
waist 
circumference 
cm male 
89.5 ± 11.1 90.1 ± 12.1   ns   
            
waist 
circumference 
cm female 
88.6 ± 12.7 89.2 ± 9.4   ns   
            
mid-arm 
muscle 
circumference 
(% of healthy 
matched) 
85.9 ± 11.4 89.7 ± 13.9   0.01   
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Table 2.6 (continued) – body composition in CKD 
Author, year, journal CKD stage  study design  participant number n 
(m,f) and further 
details 
intervention  time/ 
duration 
Mode of 
assessment 
and outcome 
measures 
pre 
intervention 
(baseline 
values) 
post 
intervention 
(final values) 
actual / 
percentage 
change 
reported 
significance 
(p) 
group 
difference 
(p) 
PRE (NON) DIALYSIS STUDIES - COHORT STUDIES (PROSPECTIVE, RETROSPECTIVE ETC) 
Castaneda-Sceppa et al 
2007 
CKD 3-4 
Longitudinal 
(prospective 
cohort) 
780 (62%M) none  
12 
months 
arm muscle 
area cm2 male 
46 ± 12 45 ± 11  -1.0 ± 5.8 ns   
Journal of Renal 
Nutrition 17 (5): 314-22 
    52±12yrs      
arm muscle 
area cm2 
female 
29 ± 12 29 ± 13 0.1 ± 7.8 ns   
Chang et al 2011 non-dialysis 
prospective 
cohort 
(observational) 
128 (60M, 68F)  none 
for pre-
dialysis 
period  
mid-arm 
circumference 
(cm) 
28.0 ± 3.6         
Nephrology Dialysis 
Tranplantation 26: 
3588-95 
CKD1 (n=9)    
 Total: 60.7±14.8yrs 
Height 159.2±7.3cm 
Weight 62.9±10.7kg 
  
~33.8 ± 
9.2 
months 
triceps skinfold 
thickness mm 
21.7 ± 9.2         
  CKD2 (n=35)         
mid-arm 
muscle 
circumference 
cm 
21.3 ± 3.4         
  CKD3a (n=18)         
mid-arm 
muscle area 
cm2 
36.9 ± 11.4         
  CKD3b (n=17)         
total body fat 
% 
27.1 ± 9.9         
  CKD4 (n=31)         
BIA total body 
fat kg 
17.4 ± 7.2         
  
CKD5 non-
dialysis (n=18) 
        
BIA lean body 
mass kg 
45.2 ± 9.2         
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Table 2.6 (continued) – body composition in CKD 
Author, year, journal CKD stage  study design  participant number n 
(m,f) and further 
details 
intervention  time/ 
duration 
Mode of 
assessment 
and outcome 
measures 
pre 
intervention 
(baseline 
values) 
post 
intervention 
(final values) 
actual / 
percentage 
change 
reported 
significance 
(p) 
group 
difference 
(p) 
MIXED STAGE STUDIES                       
MIXED STAGE STUDIES - CROSS-SECTIONAL AND COMPARATIVE STUDIES 
Khan et al 2009 all stages cross sectional  40 (23m, 17f) none    
triceps skinfold 
thickness mm 
13.3 ± 4.12         
Journal of Renal 
Nutrition 19 (4): 275-82 
    
 55±12.2yrs 
Height 161±6cm 
Weight 61.6±11.7kg 
    
biceps skinfold 
thickness mm 
10.07 ± 3.5         
       BMI 24.2±4.3     
mid-arm 
circumference cm 
23.1 ± 3.15         
            
mid-arm muscle 
circumference cm 
19.6 ± 2.1         
            
waist-to-height 
ratio 
0.92 ± 0.08         
Nielsen et al 1994 predialysis comparative pre-d: 30 (20m, 10f)  none   
DEXA lean body 
mass kg pre-d 
  47.8     
<0.05 to 
control 
Advances in Peritoneal 
Dialysis 10: 99-103 
"severe" CKD4 
GFR 
<30ml/min 
pre-dialysis, PD, 
normal/ healthy 
PD: 20 (11m, 9f)     
DEXA lean body 
mass kg PD 
  47.2     
<0.05 to 
control 
  
and dialysis 
(PD) 
  control: 62 (12m, 50f)     
DEXA lean body 
mass kg control 
  43.6       
MIXED STAGE STUDIES - COHORT STUDIES (PROSPECTIVE, RETROSPECTIVE, ETC) 
Dumler & Kilates 1999 
pre-dialysis, 
HD, and 
transplant 
prospective 
cohort 
pre-dialysis: 35 
(54%M, 46%F) 
61±12yrs 
none  
9 
months 
HD BIA body cell 
mass 
  24 ± 7       
Mineral and Electrolyte 
Metabolism 25: 397-9 
    
Weight 91±24kg 
BMI 30.9±6.6 
    
HD BIA fat free 
mass 
  54 ± 14       
      
HD: 58  (57%M,43%F) 
71±16yrs 
BMI 24.5±4.9 
    
pre-d BIA body 
cell mass 
  28 ± 8     
<0.01 to 
HD and 
transplant 
            
pre-d BIA fat 
free mass 
  62 ± 17     
<0.01 to 
HD and 
transplant 
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Table 2.6 (continued) – body composition in CKD 
Author, year, journal CKD stage  study design  participant number n 
(m,f) and further 
details 
intervention  time/ 
duration 
Mode of 
assessment 
and outcome 
measures 
pre 
intervention 
(baseline 
values) 
post 
intervention 
(final values) 
actual / 
percentage 
change 
reported 
significance 
(p) 
group 
difference 
(p) 
DIALYSIS - HD                       
DIALYSIS - HD  - CROSS-SECTIONAL AND COMPARATIVE STUDIES         
Bross et al 2010 HD 
cross sectional 
observational 
118 (68m, 50f)  
49.4±11.5yrs 
none    DEXA body fat %   28.9 ± 10.1       
American Journal of 
Kidney Diseases 55 (5):  
  validation  BMI 27±6     
Near infrared 
(NIR) body fat % 
  26.4 ± 10.4       
885-96            
tricep skinfold 
for body fat % 
  31.0 ± 8.4       
Huang et al 2010 HD 
Comparison 
study 
1709 
high or low 
dialysis dose 
  
triceps skinfold 
thickness mm 
16.3 ± 7.9         
Kidney International 77 
(7): 624-9 
    
Age mean 58yrs 
BMI mean 25.2 
    
mid-arm muscle 
circumference 
cm 
24.8 ± 3.8         
Ishihara et al 2010 HD 
cross sectional 
comparison  
80 (54m, 26f) none  30 years 
triceps skinfold 
thickness mm 
8.1 ± 4.6         
Blood Purification 33(3): 
161-5 
  
 by dialysis 
duration 
 65.4±12.3yrs 
Height 161.4±10cm 
Weight 54.9±13.3kg 
    
mid-upper arm  
muscle area 
cm2 
39.4 ± 10.3         
       BMI 20.9±3.6     TSF mm <10yrs 9.2 ± 5.3         
            TSF mm >30yrs 6.5 ± 4.2       <0.05 
            
MAMA cm2 
<10yrs 
1.01 ± 0.22         
            
MAMA cm2 
>30yrs 
0.79 ± 0.13       <0.001 
Kaizu et al 1998 HD comparison 45 (21m, 24f) 
one dialysis 
session 
  
body weight kg 
high IL6 
    
 -1.9 ± 0.7 (-
4%) 
  <0.05 
American Journal of 
Kidney Diseases 31 (1):  
  
low 
inflammation  
 59.1±1.9yrs (range 
23-80yrs) 
    
body weight kg 
low IL6 
     ↑     
93-100    
vs high 
inflammation  
      
MAMA cm2 
high IL6 
     ↓     
            
MAMA cm2 low 
IL6 
        <0.05 
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Table 2.6 (continued) – body composition in CKD 
Author, year, journal CKD stage  study design  participant number N 
(m,f) and further 
details 
intervention  time/ 
duration 
Mode of 
assessment 
and outcome 
measures 
pre 
intervention 
(baseline 
values) 
post 
intervention 
(final values) 
actual / 
percentage 
change 
reported 
significance 
(p) 
group 
difference 
(p) 
DIALYSIS - HD  - CROSS-SECTIONAL AND COMPARATIVE STUDIES         
Kato et al 2011 HD cross sectional 
161 (113m, 48f) 
 
 none   
Abdominal 
visceral fat area 
cm2 
83.3 ± 68.2         
Nephrology dialysis 
Transplantation 26: 1967-
76 
    
 61±11yrs 
BMI 20.7±2.8 
    
abdominal 
subcutaneous 
fat area cm2 
127.8 ± 63.6         
            
thigh muscle 
area cm2 
180.8 ± 57.4         
MacDonald et al 2004 HD comparative 
ESRD 17 (12M,5F) 
58±3.4yrs 
Height 167.4±1.9cm 
BMI 26.6±1.1 
 none   
DEXA total fat 
mass kg 
25.1 ± 2.9       ns 
Journal of Renal Nutrition 
14 (4): 248-52 
  
cross-
sectional 
healthy 17 (12M,5F) 
55.5±2.7yrs 
Height 170.8±2.4cm 
BMI 26.4±0.6 
    
DEXA bone 
mineral content 
kg 
2.3 ± 0.1       <0.05 
            
DEXA 
appendicular 
lean mass kg 
17.6 ± 0.9       <0.05 
DIALYSIS - HD - COHORT STUDIES (PROSPECTIVE, RETROSPECTIVE, AND LONGITUDINAL) 
Kalantar-Zadeh et al 2012 HD 
retrospective 
cohort 
121,762 (45%F) 
62±15yrs 
usual 
dialysis care 
up to 5 
years 
dry weight kg 75.4 ± 21.1         
American Journal of 
Epidemiology 175 (8): 
793-803 
  
regression 
analysis 
 
Dry weight 
75.4±21.1kg 
Height 168±11cm 
BMI 26.8±7.0 
  
~738 
days 
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Table 2.6 (continued) – body composition in CKD 
Author, year, journal CKD stage  study design  participant number n 
(m,f) and further 
details 
intervention  time/ 
duration 
Mode of 
assessment 
and outcome 
measures 
pre 
intervention 
(baseline 
values) 
post 
intervention 
(final values) 
actual / 
percentage 
change 
reported 
significance 
(p) 
group 
difference 
(p) 
DIALYSIS - HD - COHORT STUDIES (PROSPECTIVE, RETROSPECTIVE, AND LONGITUDINAL) 
de Oliveira et al 2012 HD 
follow up 
(prospective 
cohort) 
143 (83m, 60f) 
usual 
dialysis care 
12 
months 
triceps skinfold 
thickness mm 
male 
10.25 ± 4.72       
<0.001 
gender 
difference 
Journal of Renal Nutrition 
22 (3): 307-16  
    
52.2±16.6yrs (range 
20-83yrs) 
BMI mean 23.0  
    
triceps skinfold 
thickness mm 
female 
14.88 ± 6.39         
            
mid-arm 
circumference 
(cm) male 
28.00 ± 4.18       ns 
            
mid-arm 
circumference 
cm female 
26.88 ± 4.30         
            
mid-arm muscle 
circumference 
cm male 
24.78 ± 3.30       
<0.001 
gender 
difference 
            
mid-arm muscle 
circumference 
cm female 
22.23 ± 2.95         
            
mid-arm muscle 
area cm2 male 
49.74 ± 13.11       
<0.001 
gender 
difference 
            
mid-arm muscle 
area cm2  
female 
40.02 ± 10.97         
            
Adductor 
pollicis muscle 
thickness mm 
male 
12.34 ± 1.55       
<0.001 
gender 
difference 
            
adductor pollicis 
muscle 
thickness mm 
female 
11.19 ± 1.51         
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Table 2.6 (continued) – body composition in CKD 
Author, year, journal CKD stage  study design  participant number n 
(m,f) and further 
details 
intervention  time/ 
duration 
Mode of 
assessment 
and outcome 
measures 
pre 
intervention 
(baseline 
values) 
post 
intervention 
(final values) 
actual / 
percentage 
change 
reported 
significance 
(p) 
group 
difference 
(p) 
DIALYSIS - HD - COHORT STUDIES (PROSPECTIVE, RETROSPECTIVE, AND LONGITUDINAL) 
Takahashi et al 2003 HD 
prospective 
longitudinal 
46 (28m, 18f) 
usual 
dialysis care 
4 years 
DEXA lean body 
mass kg 
38.6 ± 7.8  37.1 ± 7.7   <0.01   
Clinical Nephrology 59 (5): 
373-8 
    
 52±11.4yrs 
BMI 21±2.4 
    DEXA fat kg 11.5 ± 5.6 12.3 ± 6.0   <0.05   
            DEXA fat % 22.1 ± 10.3 23.8 ± 10.0   <0.05   
DIALYSIS - HD - RANDOMISED CONTROLLED TRIALS 
Hansen et al 2000 HD RCT 
GH: 9 (5m, 4f) 
44.4yrs  
(range 18.4-63.9yrs) 
injections: 
growth 
hormone 
(GH) 
6 
months 
DEXA total fat 
mass kg 
11.5 SEM 2.14 8.45 SEM 1.58 
3.05 SEM 
0.75 
<0.001 0.005 
Clinical Nephrology 53 (2): 
99-107 
    
pla: 11 (7m, 4f) 
48.3yrs (range 18.8-
68.5yrs) 
  daily 
DEXA lean tissue 
mass kg 
43.6 SEM 3.83 
46.75 SEM 
3.93 
3.14 SEM 
0.42 
<0.001 0.0001 
Mortelmans et al 1999 HD RCT 16 (9m, 7f) 
parenteral 
nutrition 
9 
months 
body weight kg 54.8 ± 10.1 57.1 ± 10.7 > 2.0 <0.05   
Journal of Parenteral and 
Enteral Nutrition 23 (2): 
90-5 
    
 66±10yrs 
Weight 54.8±10kg 
BMI 20±3 
  
during 
dialysis 
(3/ 
week) 
triceps skinfold 
thickness mm 
8.1 ± 4.2 9.7 ± 48   <0.05   
            
arm muscle 
circumference 
cm 
21.6 ± 3.4 22.3 ± 3.3   0.07 (ns)   
DIALYSIS - PD                       
Soreide et al 1992 PD longitudinal 8m 
usual 
dialysis care 
6-8 
months 
Near infrared 
(NIR) body fat % 
19.8 ± 2.9 22.5 ± 3.0   <0.05   
Advances in Peritoneal 
Dialysis 8: 173-6 (abstract) 
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Table 2.6 (continued) – body composition in CKD 
Author, year, journal CKD stage  study design  participant number n 
(m,f) and further 
details 
intervention  time/ 
duration 
Mode of 
assessment 
and outcome 
measures 
pre 
intervention 
(baseline 
values) 
post 
intervention 
(final values) 
actual / 
percentage 
change 
reported 
significance 
(p) 
group 
difference 
(p) 
DIALYSIS - HD AND PD                       
DIALYSIS - HD AND PD - CROSS-SECTIONAL OR COMPARATIVE STUDIES 
Saxenhofer et al 1992 ESRD comparative HD: 11m  none   CT muscle mass       ns   
Clinical Nephrology 38 (4): 
219-23 (abstract) 
(HD vs PD) HD vs PD PD: 11m     
CT body fat 
distribution 
      ns   
DIALYSIS - HD AND PD - COHORT STUDIES (PROSEPCTIVE, RETROSPECTIVE, ETC) 
Antunes et al 2010 HD and PD prospective 
79 (48m,31F) 
60 IQR 50-71 yrs 
usual 
dialysis care 
  
survivors BIA 
body fat % 
  
29.2 IQR 
(21.7, 36.8) 
      
Renal Failure 32 (9): 1055-
9 
  
survivors vs 
non-survivors 
 BMI 24.1 IQR 21.5-
27.2 
    
non survivors 
BIA body fat % 
  
38.2 IQR (28, 
42.6) 
    0.017 
Pupim et al 2005 ESRD prospective 
142 (91M,51F) 
52.8±1yrs 
usual 
dialysis care 
12 
months 
body weight kg       ns   
Kidney International 68:  
2368-74 
    
Weight 74.2±1.2kg 
BMI 24.9±0.4 
    
lean body mass 
kg 
    -1.6     
            fat mass kg     1.6     
DIALYSIS - HD AND PD - RANDOMISED CONTROLLED TRIALS 
MacDonald et al 2007 
CKD 5 (HD or 
PD) 
RCT 
34 (29M,5F) 
~55yrs 
nandrolone 
deconate 
24 
weeks 
DEXA 
appendicular 
lean mass kg 
high dose 
19.9 SEM 1.1 21.9 SEM 1.2 3.148 0.008 
<0.05 to 
control and 
low dose 
Nephron Clinical Practice 
106: 125-35 
      
low/mediu
m/ high 
dose 
once/wk 
DEXA total lean 
mass kg high 
dose 
50.4 SEM 2.3 55.4 SEM 3.0 3.388 0.001 
<0.05 to all 
groups 
Johansen et al 1999 
HD (20) and PD 
(9)  
RCT 
29 (23m, 6f) 
47±13yrs 
BMI 25.8±6.6 
nandrolone 
deconate or 
placebo 
6 
months 
body weight kg     1.8 ± 2.3 0.03 ns 
Journal of the American 
Medical Association 281: 
1275-81 
    drug: 14 placebo: 15   
once/ 
week 
lean body mass 
kg 
    4.5 ± 2.3 <0.001 0.005 
            body fat kg      -2.4 ± 2.9 0.02   
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Presented as mean ± standard deviation unless otherwise stated; IQR = interquartile range; SEM = standard error of the mean; SE = 
standard error; RCT = randomised controlled trial; nonRCT = non randomised controlled trial; Xover = crossover design; exp = 
experimental group; co/con = control group; pla = placebo group; MTH = muscle thickness; VL = vastus lateralis; CSA = cross sectional 
area; PRT = progressive resistance training; 2-D = 2-dimensional; US = ultrasound or ultrasonography; ns = non-significant result; HD 
= haemodialysis treatment; PD = peritoneal dialysis treatment; ESRD = end-stage renal disease; CT = computed tomography; DEXA = 
dual energy x-ray absorptiometry; MAMA = mid-arm muscle area; TSF = total skinfold; BIA = bioelectrical impedance analysis; 
CKD1…5 = stage of disease (1-5) 
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2.7.1 Nutritional Interventions 
Starvation or amino acid insufficiency leads to decreased protein synthesis and 
possibly increased protein degradation.  However, inadequate dietary intake is not 
likely to be the principal cause of muscle atrophy as many CKD patients do not have 
a net negative muscle protein balance compared to healthy controls (Lim & Kopple 
2000, Ikizler 2009).  Studies investigating nutritional supplementation have not 
directly measured muscle protein balance, but have demonstrated an increase in 
serum albumin concentration, possibly due to increased liver protein synthesis, or 
the effect of reducing inflammation (Cano et al 2007; Friedman & Fadem 2010). 
 
For CKD patients undergoing regular peritoneal dialysis, an amino acid dialysate (or 
amino acid and glucose dialysate when compared to glucose alone) has previously 
brought about an anabolic effect (Kopple et al 1995; Delarue et al 1999; Tjiong et al 
2005).  Though clearly this needs further investigation in peritoneal dialysis and for 
use in haemodialysis patients, and is not viable for dialysis-independent patients 
(non-dialysis).   
 
Total parenteral nutrition or TPN (HD only; Mortelmans 1999; Table 2.6) involves 
feeding a person intravenously, bypassing the usual process of eating and digestion.  
Positive effects can be the easy addition of calories into the body, but as the 
authors of this study noted in the discussion, much of the intake may have been 
transformed into fat (not protein or muscle).   
 
2.7.2 Anabolic Hormone therapy 
Administration of exogenous growth hormone (Hansen 2000; Table 2.6) has an 
anabolic effect through the increase of protein synthesis with no change in the rate 
of degradation; although patients with inflammation (high levels of c-reactive 
protein) may not respond.  Nandrolone Deconoate (in dialysis reviewed by 
Johansen 1999; MacDonald 2007; Table 2.6) is an anabolic steroid known to elicit 
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“positive effects” including muscle growth, appetite stimulation, and increased red 
blood cell production and bone density.  Clinical studies have also shown anabolic 
steroids to be effective in treating anaemia (aplastic anaemia, van Hengstum et al 
1979; fanconi anaemia, Rose et al 2014).  Potential negative effects of the 
intervention can vary (Hinterberger & Vierhapper 1993; Kuipers 1998), but include 
possible damage to the cardiovascular system if taken in very high doses (Sullivan et 
al 1999), which may exclude some of the CKD population from their use.  Though 
supplementation has shown positive results in muscle mass in intervention trials 
(alone or in combination with resistance training; Johansen et al 2006; Johansen et 
al 1999), additional information is needed before testosterone replacement therapy 
can be widely recommended due to its side-effects, especially in women (Workeneh 
& Mitch 2010).   
 
2.7.3 Limitations of these anabolic (non-exercise) intervention studies 
Out of a total of 25 studies: 17 took place in patients already undergoing regular 
dialysis (eleven in HD, one in PD, five in mixed dialysis forms), three studies used all 
stages (dialysis and pre-dialysis), with only five studies purely examining pre-dialysis 
patients, despite them making up the majority of the CKD population.  Of the 25 
studies, only four were RCTs.  The largest study found (>100,000 participants) was a 
retrospective cohort study examining the effect of usual dialysis care over a five 
year period (Kalantar-Zadeh et al 2012).  
 
Total participant number in other treatment groups and at different stages were 
reported as 245 (mixed stage studies) and 1084 (non-dialysis dependent studies).  
The male/female split was largely representative of the general CKD population 
(Chronic Renal Failure: approximately twice as many males up to age 75 years, then 
three-times as many males than females over 75 years, Jungers et al 1996; the 
overall risks of all-cause mortality and cardiovascular mortality are higher in men at 
all levels of kidney function, Nitsch et al 2013) for those that reported it.  However 
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there were no anabolic interventions where body composition was assessed as a 
primary outcomes measure in non-dialysis and mixed stage studies (all comparative, 
cross-sectional, or longitudinal observation/cohort studies).  
 
In the dialysis dependent studies the focus has been primarily HD, though this is 
expected as a larger proportion of dialysis patients undergo HD than PD (<2% of 
dialysis patients use PD in the UK and most countries worldwide; Oxford Handbook 
of Dialysis 2004).  The 17 studies here in dialysis patients (11 HD, 1 PD, 5 HD or PD) 
totaled over one-hundred thousand patients, of which fewer than 100 were 
included in RCTs (n=99).  As with earlier-stage studies, males made up a larger 
proportion of the sample and were thus representative of the standard CKD 
population in ESRD.   
 
2.7.4 Exercise training 
With regards to the mechanisms of muscle protein turnover, few studies have 
investigated the effect of exercise training on CKD patients specifically.  One study - 
Kopple et al (2007) - examined HD patients assigned to different exercise groups 
(strength, endurance, half-strength plus half-endurance) or a control, trained 
approximately 21-weeks, and examined changes in markers of protein synthesis and 
degradation.  All three exercising groups showed similar changes in these factors, 
contrary to the expectation of greater changes in the resistance/strength training 
group.  Conversely, endurance exercise appeared to suppress the rate of protein 
degradation more than the strength training.  However the extent of the 
suppression was not of the same magnitude as the increased synthesis in all 
exercising groups.  Actual muscle size or structure were not measured in the study, 
nor was muscle strength or endurance capacity, so how these chemical markers 
translate to potential benefits is unclear. Thus further study into the response to 
exercise is required in both dialysis and non-dialysis CKD patients. 
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It had previously been assumed that due to the extensive wasting observed in CKD 
patients, any exercise stimulus would bring about an anabolic (or anti-catabolic 
effect).  However investigation comparing a control group with three different 
training interventions in CKD5 HD patients (RT only, endurance/aerobic only, mixed 
RT plus endurance/aerobic training; Kopple et al 2007) reported increased muscle 
IgF-1 mRNA (insulin-like growth factor 1; plays an important role in growth and has 
anabolic effects. mRNA; codes for the chemical blueprint of protein during protein 
synthesis) in response to exercise but no increase in muscle size, which was 
surprising.  Another study (Wang et al 2009) examined this phenomenon in animal 
models (using mice), once again comparing RT (muscle overload) and endurance 
(treadmill running) exercise.  Findings indicated that whilst endurance exercise did 
bring about reduced catabolism (muscle proteolysis), it did not improve (increase) 
protein synthesis whereas RT group improved both measures (reduced catabolism 
and increased anabolism), thereby highlighting the benefit of resistance/strength 
training over endurance/aerobic exercise in a population vulnerable to muscle 
wasting. 
 
2.7.4.1 Resistance/Strength training 
Essential for the maintenance and restoration of lean mass, resistance exercise 
increases the rate of anabolism, and leads to a greater proportion of weight gain as 
lean tissue, not fat mass.  Defined as muscle movement against a resistance, it is a 
potent anabolic stimulus, promoting muscle growth and strengthening in 
asymptomatic, healthy individuals (Frontera et al 1988). 
 
Resistance training is often implemented in rehabilitation programmes (easy and 
low risk) and studies regularly show an improvement in strength; positively 
affecting other outcome measures, including the ability to perform simple and more 
complex ADLs (Casaburi 2005).  Promotion of resistance training alone has often 
been discouraged and avoided as many hypotheses suggest that strength training 
using high load would compromise the capillarisation and oxidative potential of the 
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muscle fibres.  Green et al (1999) tested this hypothesis, showing that 12-weeks of 
high resistance training (regime typical of exercise testing studies) did not 
negatively affect either, even in the presence of muscle fibre hypertrophy. 
 
Strength gains through (progressive) resistance training would effectively reduce 
the patients’ perception of muscular fatigue during and following a training session 
(or performance of any activity) which is often a major limiting factor in 
rehabilitation programmes (Hamilton et al 1995).  As increased fatigability during 
exercise can partially be attributed to a reduced oxidative capacity of the skeletal 
muscle (Maltais et al 1996) also improved through a programme of strength training 
in older (healthy) subjects (Frontera 1990). 
 
Increases/improvements in muscular strength and power through PRT has not 
always been associated with subsequent benefits in function (functional 
performance) as other factors (unaffected by strength training) may still influence 
the level of disability experienced (Ouellette et al 2004).  There is conflicting 
evidence in this area, particularly when examining the effects of resistance training 
alone (without aerobic intervention; Weiss et al 2000) as the training can lack 
specificity and application to functional tests which assesses muscular endurance 
and velocity (timed stair climb, timed up and go, 6-min walk test).  The conflicting 
data often arises as exercise duration, intensity, frequency, and sets/reps, alongside 
use of varying outcome measures leads to a lack of comparability. 
 
Strength gains in healthy subjects are generally brought about through an 
amalgamation of muscular hypertrophy and improved neural recruitment.  Neural 
improvement is suggested when there is a proportionally greater strength gain than 
there is increase in cross-sectional area (hypertrophy).  Structural adaptation is 
attributable for increased strength when utilising equipment with unfamiliar 
movement patterns (i.e. apparatus which the subjects have not trained on).  Muscle 
fibre hypertrophy has been shown to have a delayed response to training, only 
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being observed after several weeks (7 weeks; Green et al 1999), with the specificity 
of the training programme dictating whether a differential increase in area is 
observed between fibre types.   
 
A further delay has been experienced in capillarisation (increased number of 
capillary-fibre contact points), as many shorter programmes do not report this 
adaptation with training (Hather et al 1991, McCall et al 1996, noticeable at 
12weeks; Green et al 1999).  Programme specificity and focus on movement type 
has been suggested to also influence the capillary-to-fibre (C-F) area ratio, as 
concentric contraction alone appears to have no effect on C-F ratio, compared to 
interventions utilising both concentric and eccentric movement such as free-weight 
training. 
 
Observations during and following combination exercise showed that resistive 
training induced proportionally less dyspnea (shortness of breath) than an aerobic 
component and was therefore tolerated well by COPD patients (Bernard et al 1999, 
Simpson et al 1992).  Although high intensity strength training could be problematic 
for those already suffering from the effects of bone-wasting or injury (including 
fractures), the effects on bone density in those with potential to develop 
osteoporosis could be beneficial, helping to postpone onset of the disease (Bernard 
et al 1999, Heinonen et al 1996).  Minimising muscular atrophy has been shown to 
aid the attenuation of bone mineral loss, demonstrating a strong correlation 
between normalisation of muscle mass and normalisation of bone mass (Bloomfield 
et al 1997, Zeman et al 1991). 
 
In an otherwise healthy population, neuromuscular decrements (decreased motor-
neuron excitability) from 5weeks enforced immobilisation were shown to be fully 
reversible with 18weeks of strength training (Sale et al 1982; Bloomfield et al 1997). 
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In both the healthy and ill, trained and untrained population, studies have shown 
varying results in strength, size, power, and endurance measures following a range 
of interventions.  Current ACSM guidelines would recommend low repetitions, high 
resistance (for optimal gains in strength) and high reps, low weight (for endurance), 
performed 3-4 times per week, increasing sessions as experience grows.  This is a 
contentious issue as many studies have shown contradictory findings, especially 
with regard to the number of sets (of repetitions) and training sessions to be 
performed each week (Smith & Bruce-Low 2004), suggesting that training a muscle 
group in a single set (to muscular failure), no more than twice per week (and often 
just once) showed no difference in outcome measures than training at 3, 4, or 5 sets 
in each session. 
 
Ideas have been put forward that isolating an area to be trained (e.g. only lower 
body) will lead to greater gains (localised strength and muscle mass) than whole-
body training (same intervention for lower body, plus upper work).  However, it has 
shown to have no significant effect between the two groups (Campbell et al 2002) 
as the number of muscle groups involved in training did not affect the extent of 
muscle hypertrophy (even in the absence of adequate protein intake). 
 
2.7.4.2 Endurance/ Aerobic exercise 
Aerobic activity training as part of patient rehabilitation has been strongly 
associated with improved exercise endurance and tolerance (Bernard et al 1999), 
quadriceps fatigability, and HRQoL (Mador et al 2004; Casaburi et al 2005) but with 
little effect on muscle atrophy and weakness (no strength gains).  Force 
maintenance (muscular endurance) can take longer to return following a period of 
immobilisation/inactivity in an otherwise healthy population, and is often found to 
still be lower than previous levels even after muscular strength (weight bearing 
exercises) has fully recovered (Tesch et al 1991; Bloomfield 1997).   
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Influencing factors of muscle strength and mass may  require less time for recovery 
than those contributing to muscular endurance as disuse causes loss of efficiency in 
O2 delivery and utilisation (fall in oxidative enzyme activity in vastus lateralis and 
soleus; Hikida et al 1989). It is thus vital that any intervention program design is 
aware of an increased risk of bone fracture and injury (even with 
normalisation/recovery of muscular strength) in osteopaenic-prone groups 
(Bloomfield 1997). 
 
Continuous exercise training (20mins at ≥70% max exercise capacity) has been 
shown to be effective (clinically important improvements in HRQoL) when the 
protocol is achieved fully (Puhan et al 2006).  However survivors and patients of 
critical and chronic illnesses are often unable to tolerate continuous exercise in this 
way, leading to lower levels of success and long term adherence to the prescribed 
intervention.  Interval training has had reportedly lower levels of dyspnea 
(shortness of breath), and generally greater adherence/compliance, although the 
level of effectiveness (in comparison) has been debated.  Evidence implies that little 
difference exists between the outcomes measured after 15 sessions (over 3weeks; 
Puhan et al 2006), with significantly greater adherence for protocol completion and 
throughput (Coppoolse et al 1999; Vogiatzis et al 2002; Sabapathy et al 2004 – all in 
COPD patients) and increased short-term maximal capacity above that seen in 
continual intensity training interventions.  This shows a practical and successful 
method of initiating exercise in patients unable to tolerate large amounts of higher 
intensity exercise.  A greater volume of work is accumulated with continuous 
exercise, and benefits of this could be useful to the patient and researcher later in 
the development of strength and tolerance. 
 
Supported upper extremity endurance exercise was implemented alongside general 
physiotherapy to investigate the impact and practicality of the intervention in 
critically ill patients (instead of just the usual lower-extremity exercise routinely 
performed).  Training early on in recovery (within 96 hours of weaning from 
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mechanical ventilation) later improved exercise tolerance (more so in those with 
higher baseline inspiratory muscle strength) significantly (Porta et al 2005).  The 
effect of this physiotherapy was unaffected by patient age, BMI, or length of stay in 
an intensive care unit (ICU).  Aerobic training for 7-weeks has been shown to 
improve exercise tolerance and aerobic capacity (Burini et al 2006), but functional 
gain relies on a specific task being performed/trained, highlighting that endurance 
exercises may train cardiopulmonary responses to set workloads, though it may not 
modify the course of illness or its clinical expression significantly. 
 
2.7.4.3 Combination exercise programmes 
Programmes/interventions of this nature are often varied in their ratio 
(aerobic/resistance).  Theoretically, a combined protocol should offer the joint 
benefits of each component.  However, mixed approaches are often limited by 
time, and thus a full programme of each is not offered, but a pooling of their 
truncated versions. 
 
The question must therefore arise as to whether this is appropriate and effective.  
Examining patients with COPD in rehabilitative studies (Bernard et al 1999) has 
shown that the additional strength training alongside current aerobic practice can 
be well-tolerated despite the severity of the disease, with the combination of 
aerobic and resistance exercises bringing about greater improvement in muscular 
strength and endurance, and muscular hypertrophy, than with aerobic alone.   
 
2.7.5 Exercise Intervention Research in CKD 
A review of anabolic interventions in end-stage renal disease (CKD5, Storer 2009) 
examined exercise interventions (endurance, combination, resistance programmes) 
and androgen and growth hormone therapies to determine what improvements 
could made in physical function.  Progressive resistance training offers the greatest 
potential for producing an anabolic effect (Galvao et al 2005) but due to the 
significant atrophy, chronic catabolism, and uraemic myopathy in these patients a 
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large “adaptation window” is open providing the often weak stimuli implemented in 
endurance programmes to bring about skeletal muscle anabolism (Storer 2009).  In 
contrast to PRT in healthy individuals, Storer noted no significant increases in lean 
body mass or reduction in fat mass, although the trained quadriceps muscle cross-
sectional area did increase (Johansen et al 2006).  
 
Resistance training has been utilised as an adjunct therapy to muscle atrophy in 
CKD, using light handheld weights to develop strength and functional capabilities 
more specific for activities of daily life (ADLs).  A review by Kouidi (2002) 
recommended resistance training following the main aerobic/interval part of a 
training session, or on a separate day.  Some studies have successfully shown 
advantages of PRT prior to aerobic exercises (Oh-Park et al 2002; Ridley et al 1999) 
with greater compliance, as often patients would complain of fatigue post-aerobic 
component, unable to complete the resistance exercises, if PRT followed aerobic.  
Increasing muscular endurance (low weight, high repetitions) and strength (high 
weight, low repetitions) should be progressed by increasing sets as the desired 
workload is attained.  
 
A study of resistance training to mitigate (lessen) the effects of a low-protein diet, 
demonstrated that training at 80% 1RM, 3 times/week, led to an increase in GFR 
from 24.8 to 26.4mL/min in 12 weeks, compared to the control group whose GFR 
fell in the same period (30.0mL/min to 28.0mL/min, group difference p<0.05; 
Castaneda et al 2001).  As dialysis is generally initiated at a GFR value of 15ml/min 
or less, this indicates a positive clinical effect of resistance training that overcomes 
the necessary implementation of a low-protein diet.  This clinical improvement 
occurred alongside strength gains of approximately one-third (knee extension ↑47 
± 24%, leg press ↑ 29 ± 15%) compared to a control decline or no significant change 
(p<0.001; Castaneda et al 2001).  These participants were pre-dialysis (CKD3b-4) 
patients, where increasing the GFR is an additional step away from dialysis, and 
nearer to health. 
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Over the years of investigation it has been demonstrated that physical functioning 
and exercise capacity can be improved in these patients when a programme of 
exercise has been introduced before, during, or after  dialysis, improving muscle 
mass and strength, physical functioning, and health-related quality of life as well as 
clinical outcomes such as blood pressure control and urea clearance.  Sadly, with all 
this robust data, a standard rehabilitation programme of exercise or referral 
scheme is yet to be established and only recently a report has shown that two-
thirds of haemodialysis patients are frail with an even greater proportion in older 
and diabetic populations (Johansen et al 2007). 
 
Ultimately the CKD population is seeking an intervention or rehabilitation 
programme which increases lean body mass, strength, function, health-related 
quality of life, and reduces the level of exertional fatigue for the patient alongside 
improved mortality and reduced hospitalization which also hinders the progression 
of the disease.  Performing ADLs competently involves short bursts of activity, often 
of relatively high intensity.  Therefore basing any improvements on measures of 
exercise capacity and oxygen uptake (such as when implementing an endurance 
intervention), whilst important, do not truly reflect the functional limitation of the 
CKD patient.  However PRT during dialysis may be limited by equipment and 
maneuverability and therefore may not provide the stimulus required to affect 
muscle size, lean body mass, and fat mass.  Due to the initial low training loads and 
volumes, it may be necessary for a longer training session and intervention period 
for significant adaptation to take place.   
 
Table 2.7a shows studies that have utilized resistance training exercise as an 
intervention in CKD.  Table 2.7b explores the same studies, extracting further detail 
regarding outcome measures and results.    
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Table 2.7a - Resistance training intervention studies in Chronic Kidney Disease (ordered by 
CKD stage and alphabetically by author) 
Author, year, journal 
study 
design 
CKD stage 
1-5  
Participant 
number n (M, 
F) and further 
details 
intervention type  intensity 
when 
performed  
Time/ 
duration of 
intervention 
PRE (NON) DIALYSIS             
RANDOMISED CONTROLLED TRIALS      
Balakrishnan et al 
2010 
RCT CKD 3-4 
control 10 
(9M, 1F) 
control = low protein 
diet + attention 
control (flexibility 
stretches) 
  
supervised 
@ university 
12 weeks 
Clin J Am Soc 
Nephrol 5 (6): 996-
1002 
  
"moderate 
to severe" 
Ex 13 (8M, 5F) 
ex = low protein diet + 
45mins PRT 
80% 1RM   
3times/ 
week 
linked to Castaneda 
2001 and 2004 
    
Total: 
64±10yrs 
Weight 
80.7±15.1kg 
BMI 28.1±4.9  
RT 3x8 @80%1RM 
chest, legpress, lat 
pulldown, knee 
extension and flexion, 
flexibility stretches 
      
Castaneda et al 
2001 
RCT  
GFR 
~27.5ml/ 
min/1.73m2 
          
Annals of Internal 
Medicine 135(11): 
965-76 
              
Castaneda et al 
2004 
RCT pre-dialysis 
Ex (RT): 14 
(8m,6f) 
65±9yrs 
BMI 29.3±6.6 
RT + low protein diet 80% 1RM 
supervised 
at university 
12 weeks 
American Journal of 
Kidney Diseases 43 
(4): 607-16 
  
"moderate 
to severe" 
CKD 
Con: 12 
(9m,3f) 
64±12yrs 
BMI 26.8±2.7 
control: low protein 
diet (0.6g/kg/day) + 
attention control 
exercise/stretches 
assessed 
by RPE 
  
3 times/ 
week 
NON RANDOMISED, CONTROLLED TRIALS 
Heiwe et al 2001 
NonRCT 
(self-
selected 
grouping) 
pre-dialysis 
GFR <= 
25ml/ min 
CKD exercise 
n=16 (9m, 7F) 
76±7yrs 
PRT(3x 20reps)  
knee extension left, 
KE right, static 
endurance of quads 
(5secs), then 30min 
low intensity general 
ex 
60% 1RM 
low 
weight, 
high reps 
supervised 
3 times/ 
week 
Nephron 88: 44-56 
 
  
CKD control 
n=9 (6M, 3F) 
72±6yrs 
control - maintained 
sedentary lifestyle   
  12 weeks 
Heiwe et al 2005 
NonRCT  
(self-
selected 
grouping) 
pre-dialysis 
GFR <= 
25ml/ min 
CKD exercise 
n=7 (4M, 3F) 
76±8yrs 
healthy 
exercise n=6 
(2M, 3F) 
71±4yrs 
PRT (3x 20reps) knee 
extension left, KE 
right, static endurance 
of quads (5secs), then 
30min low intensity 
general ex 
60% 1RM 
low 
weight, 
high reps 
supervised 
3 times/ 
week 
Am J Phys Med 
Rehab 84: 865-74  
  
CKD control 
n=5 (4M, 1F) 
71±5yrs 
 control - maintained 
sedentary lifestyle  
  12 weeks 
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Table 2.7a (continued) – resistance training in CKD 
Author, year, journal 
study 
design 
CKD stage 
1-5  
Participant 
number n (M, 
F) and further 
details 
intervention type  intensity 
when 
performed  
Time/ 
duration of 
intervention 
DIALYSIS – HD               
RANDOMISED CONTROLLED TRIALS 
Cheema et al 2007a 
for methods : Cheema et 
al 2006 
  
Ex: 24 (17m, 7f) 
con 25 (17m, 8f) 
 
      
American Society of 
Nephrology 18: 
1594-1601 
Hemodialysis 
International 10:303-10 
  
Total: 62.6±14.2yrs 
Weight 75.7±18.3kgs 
Height 165.6±10.2cm 
BMI 27.5±5.8 
      
Cheema et al 2007b 
"PEAK 
study" 
phase2  
HD 12 week n=19     intradialytic 24wks 
American Journal of 
Kidney Diseases 50 
(4): 574-84 
randomly assigned to 
24wks training, or 12wk 
control then 12wk 
training 
24 week n=20       
3 times/ 
week 
Cheema et al 2011 RCT HD Ex (13: 9, 4) 
PRT (2x8reps initial 
load 0-15kg) 
RPE 15-17 
"high" 
intradialytic 12 weeks 
Eur J Appl Physiol 
111: 1437-45 
"PEAK" 
study phase 
1 
  
control (18: 
12, 6) 
Control: usual care     
3times/ 
week 
      
Total : 
63.7±14.3yrs 
Weight 
74.8±183.5kg 
Height 
164.4±10.3cm 
BMI 27.6±5.8  
RT: usual care + shoulder press, side 
should raise, tricep extension, bicep 
curl, external shoulder rotation 
(with free weights), seated knee 
extension, supine hip flexion, 
supine hip abduction, supine 
straight leg raise (with ankle 
weights), seated hamstring curls 
(with therabands), bilateral leg raise 
  
    
Chen et al 2010 RCT HD 
control 22 
(11M, 11F) 
66.9±13.4yrs 
Dry weight 
72.9±±20.8kg 
BMI 27.7±7.8 
control: attention 
control flexibility 
stretches 
aim 
moderate 
on 
modified 
RPE 
(6/10) 
~60%1RM 
intradialytic 
48 sessions 
(24 wks) 
Nephrol Dial 
Transplant 25(6): 
1936-43 
    
Ex 22 
(12M,10) 
71.1±12.6yrs 
Dry weight 
71.2±17.7kg 
BMI 25.7±7.1 
RT: 2x8reps ankle 
weights, lower body 
exercise only: 0.5lbs-
20lbs 
actual  
RPE <6 
  twice/week 
DePaul et al 2002 RCT HD   
progressive resistance 
isotonic exercise on a 
cycle ergometer 
    12 weeks 
Am J Kidney Disease 
40 (6): 1219-29 
(abstract only) 
      
control: non-
progressive range of 
motion exercise 
    
3 times/ 
week 
Dong et al 2011 RCT HD 
Con 17 
(12m,5f)  
Control = nutritional 
high protein drink 
70% 1RM 
30-mins 
pre-dialysis 
6 months 
J Ren Nutr 21 (2): 
149-59 
    
Ex 15 (9m,6f) 
Total: n=32 
43.2±13.1yrs 
BMI 28.4±6.3 
Ex = drink + PRT  
 
RT: 3x12reps leg press 
@ 70% 1RM 
    
every 
dialysis 
session 
~3/wk 
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Table 2.7a (continued) – resistance training in CKD 
Author, year, journal 
study 
design 
CKD stage 
1-5  
Participant 
number n (M, 
F) and further 
details 
intervention type  intensity 
when 
performed  
Time/ 
duration of 
intervention 
DIALYSIS – HD               
RANDOMISED CONTROLLED TRIALS 
Johansen et al 2006 RCT HD 
79 (49m,30f) 
56±13yrs 
(range 26-
88yrs) 
    intradialytic 12 weeks 
Journal of the 
American Society of 
Nephrology 17: 
2307-14 
    
control1: 
placebo n=20 
(14,6) 
weekly injection 
placebo  
  supervised 
3 times/ 
week 
      
experimental
1: nandrolone 
n=19 (10,9) 
weekly injection of 
nandrolone 
decanoate (M200mg, 
F100mg) 
      
      
control2: RT 
n=20 (12,8) 
knee extension, hip 
abduction, hip flexion, 
ankle dorsi and 
plantar flexion 2x 
10reps --> 3x10reps 
60% 3RM     
      
experimental
2: nandrolone 
+ RT n=20 
(13,7) 
nandrolone + RT  60% 3RM     
Oliveros et al 2011 
RCT (pilot 
study) 
HD 
Ex (5: 5,0) 
46±13yrs 
Dry weight 
74.5±5.5kg  
Combination: moderate intradialytic 16 weeks 
Rev Med Chil 139 
(8): 1046-53 
    
control (6: 
3,3)  
52.2±17yrs 
Dry weight 
73.3±9.3kg  
Aerobic (20-25mins) : 
continuous pedalling 
40-60%HRR 
(aerobic) 
  
3times/ 
week 
Spanish  
translated in google 
    
 
RT (20-25 mins): 
therabands, knee extn 
uni and bilaterally 
use Borg 
RPE 13 
    
Orcy et al 2012 RCT HD 
RT: n=13m 
55.8±18.3yrs 
BMI 25.3±2.7 
RT: 30mins RT; twice 
through elbow 
flexors, shoulder 
flexors, hip flexors, 
hip abductors, 
hamstrings; 2x10-
15reps. 
subjective 
perception 
during 
dialysis 
10 weeks 
Physiotherapy 
Research 
International 17: 
235-43 
    
RT+aerobic: 
n=13 (9m,4f) 
56.9±14.8yrs 
BMI 23.9±3.5 
30mins RT; elbow 
flexors, shoulder 
flexors, hip flexors, 
hip abductors, 
hamstrings; 2x10-
15reps. 
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Table 2.7a (continued) – resistance training in CKD 
Author, year, journal 
study 
design 
CKD stage 
1-5  
Participant 
number n (M, 
F) and further 
details 
intervention type  intensity 
when 
performed  
Time/ 
duration of 
intervention 
DIALYSIS – HD               
RANDOMISED CONTROLLED TRIALS 
Segura-Orti et al 
2009 
RCT HD 
Total: 
55.6±17.6yrs 
RT  RPE 12-14 intradialytic 
24 weeks/ 
6months 
Clinical Nephrology 
71 (5): 527-37 
control/ 
placebo = 
low 
intensity 
aerobic 
  
 A (RT): 17 
(11m,6f) 
Dry weight 
64.9±13kg 
BMI 24.6±2.6 
4 progressive 
exercises: knee 
extension, unilateral 
triple extension (hip, 
knee, ankle)  
3 x 15 reps 
  supervised 
3 times/ 
week 
        
isometric contraction 
of ankle flexors, 
quads, hip extensor 
      
      
B (Aero/ 
control): 8 
(7m,1f) 
Dry weight 
72.4±7.8kg 
BMI 24.9±2.2 
  
Aero /placebo: 
stationary bike 
continuous cycling 
RPE 11     
Song & Sohng 2012 RCT HD 
PRT n=20 
(8m,12f) 
52.1±12.4yrs 
(range 31-
74yrs) 
Dry weight 
54.9±5kg 
PRT vs usual care 
PRT (3 x 10-15 reps): 
6upper body and 6 
lower body 
strengthening 
exercises - therabands 
and ankle sandbags 
RPE 11-15 
in waiting 
time for 
dialysis 
12 weeks 
J Korean Acad Nurs 
42 (7): 947-56 
    
Control n=20 
(12m,8f) 
54.6±10.1yrs 
(range 37-
70yrs) 
 Dry weight  
57±9.6kg 
 
    
30min 
3/week 
Van Vilsteren et al 
2005 
RCT HD 
96 total 
 
Ex: 5363%M 
52±15yrs 
RT + aero vs usual 
care 
RPE 12-16 
pre-dialysis 
RT + 
intradialytic 
aerobic 
12 weeks 
Nephrol Dial 
Transplant 20: 141-6 
    
 
Con: 43 
70%M 
58±16yrs 
5-10min warm up, 
20min exercise 
(calisthenics, steps, 
flexibility, low weight 
resistance), 5-10min 
cool down 
"low-
moderate
" ~60% 
max 
  
2-3 times/ 
week 
NON-RANDOMISED, CONTROLLED TRIALS 
Segura-Orti et al 
2008 
nonRCT 
ESRD/ 
HD 
Ex : 8 RT   intradialytic 6 months 
Nefrologia 28 (1): 
67-72(abstract) 
 Self-
selected 
grouping 
  Control: 8 
isometric and isotonic 
exercises on lower 
limbs 
  supervised   
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Table 2.7a (continued) – resistance training in CKD 
Author, year, journal 
study 
design 
CKD stage 
1-5  
Participant 
number n (M, 
F) and further 
details 
intervention type  intensity 
when 
performed  
Time/ 
duration of 
intervention 
DIALYSIS – HD               
CROSSOVER AND SELF-CONTROLLED TRIALS 
Headley et al 2002 
crossover/ 
self-
controlled 
HD 
10 (7M, 3F) 
42.8±4.4yrs 
(range 24-
67yrs) 
PRT RPE<=15 
supervised + 
one session 
unsupervised 
12 weeks  
Am J of Kidney 
Disease 40 (2): 355-
64 
6wks 
control/ no 
intervention 
  
 Height range 
156.2-
182.9cm 
Weight 
90±4.9kg 
(range 63.5-
123.9kg) 
1x10 --> 3 x 15reps 
if RPE 
dropped 
to 10-12, 
added 
weight 
  
2/week + 
1/week 
theraband 
at home 
MacDonald et al  
2005 
self-
controlled 
(pilot study) 
HD 9 (7m, 2f) 
High intensity interval 
training 
"high" 
RPE > 17 
during 
intense 
bouts 
intra-dialytic 12 weeks 
Clin Physiol Funct 
Imaging 25: 113-8 
12-weeks 
pre-
intervention
- 12-week 
intervention 
    
2-min intensive 
cycling, 2-min active 
recovery, 15 times 
RPE ~ 7 
for active 
recovery  
  
3 times/ 
week 
(min of 36 
sessions) 
Nindl et al 2004  
Growth Hormone & 
IGF Research 14 (3): 
245-50 
 Self-
controlled 
(6wks prior 
to baseline 
measures) 
HD  
 7M,3F 
42.8±144.5yrs 
Height 
172.7±10.1cm 
Weight 
90±15.6kg 
9 strength exercise using machines: 
double leg press, leg extension, leg 
curl, chest press, compound row, 
lateral raise, bicep curl, tricep 
extension, abdominal curl 
  
    
NO CONTROL 
Bullani et al 2011 
no control 
group 
HD 11 (8m, 3F)  
PRT - 3x20reps 
"moderate intensity" 
moderate intradialytic 2/week 
Journal of Renal 
Nutrition 21 (1): 61-
65 
 (pilot study)   
70±10.7yrs 
(range 53-
84yrs) 
foot extension, knee 
extension, hip flexion 
and extension 
  supervised 4.5-6months 
        
using elastic 
resistance bands 
    
total of 36 
sessions 
Presented as mean ± standard deviation unless otherwise stated; IQR = interquartile range; 
SEM = standard error of the mean; SE = standard error; RCT = randomised controlled trial; 
nonRCT = non randomised controlled trial; Xover = crossover design; exp = experimental 
group; co/con = control group; pla = placebo group; MTH = muscle thickness; VL = vastus 
lateralis; CSA = cross sectional area; PRT = progressive resistance training; 2-D = 2-
dimensional; US = ultrasound or ultrasonography; ns = non-significant result; HD = 
haemodialysis treatment; PD = peritoneal dialysis treatment; ESRD = end-stage renal 
disease; CT = computed tomography; DEXA = dual energy x-ray absorptiometry; MAMA = 
mid-arm muscle area; TSF = total skinfold; BIA = bioelectrical impedance analysis; CKD1…5 = 
stage of disease (1-5); RPE = rate of perceived exertion 
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2.7.5.1  Limitations in design of these resistance training (RT) studies (Table 2.7a) 
As with the non-exercise CKD studies, the majority of research has been conducted 
using patients already undergoing dialysis; HD (17), PD (0), mixed stage (0), pre-
dialysis (5).  The few studies of resistance training in pre-dialysis/non-dialysis have 
combined exercise with a change in diet (Castaneda 2001, 2004; Balakrishnan 
2010), so whether the effect was limited by the lack of protein in the diet is unclear 
as there may be a greater/more significant effect when diet is uncontrolled, or at 
least be easier to implement.  The other pre-dialysis studies used low weight with 
high repetitions which could be classed as more aerobic than purely strength 
(resistance) training (Heiwe 2001, 2005).  Heiwe (2001 and 2005) also did not 
randomize the groups (self-selected/ nonRCT).  
 
From these studies an additional question has arisen: as there is no information 
regarding different frequency of training; most studies (dialysis and pre-dialysis) 
implemented the training intervention three times per week compared to a control 
group as standard; is that volume of training necessary for statistically and clinically 
relevant results? 
 
2.7.5.2 Limitations in outcomes and results of these RT studies (Table 2.7b) 
Outcome measures predominantly examined body composition and strength with 
some functional measures, however there is little information on the clinical 
implications in the non/pre-dialysis studies (eg. health-related quality of life, or 
change in symptoms prevalence or intensity), though they were often reported in 
dialysis (HD) studies. 
 
RCTs in dialysis show mixed results.  Measures of muscle strength reported no 
significant difference after training in two studies (Segura-Orti 2009; Headley 2002) 
compared to a highly significant (p<0.01) improvement in another (Cheema 2011).  
Body composition (muscle mass) assessments showed similar inconsistencies as 
three studies again found no significant difference in muscle size after training 
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(MacDonald 2005; Dong 2011; Cheema 2011) compared to two studies 
demonstrating highly significant (p<0.01) improvements (Song & Sohng 2012; Chen 
2010), with varying levels of significance for both positive and negative change in 
other studies. 
 
In comparison, despite there being fewer studies in pre/non-dialysis patients, 
similar exercise interventions (to those in HD patients) have brought about highly 
significant improvements in strength (Castaneda 2004; Heiwe 2001, 2005) 
suggesting that the effect is smaller when intervening in patients already in dialysis 
compared to those non-dialysis (NDD) patients. 
 
In this selection of studies (tables 2.7a and 2.7b) it would also appear that 
combining resistance (strength) training with aerobic (endurance) training seems to 
have a negative effect on strength outcome measures (Van Vilsteren 2005), or 
impose a non-significant limitation (Oliveros 2011).  
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Table 2.7b – Resistance training studies in CKD (outcome measures and results) 
Author, year, 
journal 
Mode of assessment  
pre 
intervention/ 
baseline values 
post 
intervention 
values 
actual change 
reported 
% change 
if reported 
significance 
(p) 
group 
difference 
(p) 
PRE (NON) DIALYSIS              
RANDOMISED CONTROLLED TRIALS 
Balakrishnan et al 
2010 
vastus lateralis biopsy: 
MtDNA 
        
Ex: +1306 
p=0.22 (ns)  
 
p=0.001 
Clin J Am Soc 
Nephrol 5 (6): 996-
1002 
          
 Co: -3747 
p=0.04   
  
linked to Castaneda 
2001 and 2004 
              
Castaneda et al 
2004 
dietary compliance (% of 
prescription) 
  108  ±  8         
American Journal of 
Kidney Diseases 43 
(4): 607-16 
body weight kg 84.6 ± 15.8 84.8 ± 16.2 0.2 ± 2.6     0.049 
AND 
Castaneda et al 
2001 
type I muscle fibre area 
um2 
3887 ± 1566 4821 ± 1411 934 ± 1486 24 ± 31   0.031 
Annals of Internal  
type II muscle fibre area 
um2 
3626 ± 1216 4437 ± 1393 811 ± 1479 22 ± 29   0.045 
Medicine  muscle strength kg 298 ± 106 384 ± 123 86 ± 45     0.001 
135(11): 965-76  c-reactive protein mg/L 7.8 6.1 -1.7     0.049 
  serum il-6 (pg/ml) 11.3 6.9 -4.2     0.012 
  serum transferrin (mg/dl) 178 ± 32 258 ± 52 80 ± 25     0.042 
  serum albumin (g/dl) 3.7 ± 0.3 3.8 ± 0.2 0.1 ± 0.2     0.091 (ns) 
  
relationship total body 
potassium and muscle 
strength 
      r=0.36 0.05   
  relationship il-6 and crp       r=0.46 0.04   
  
relationship il-6 and type I 
fibres 
      r=-0.58 0.02   
  
relationship il-6 and type 
II fibres 
      r=-0.68 0.005   
  
relationship il-6 and 
muscle strength 
      r=-0.49 0.05   
  
relationship crp and 
muscle strength 
      r=-0.45 0.03   
  
relationship crp and 
serum albumin 
      r=-0.47 0.05   
  adherence to training   91 ±  9         
  GFR ml/min/1.73m2 24.76 26.35 1.18     0.048 
  chest press kg 24.0 ± 10.4 31.8 ± 12.9   34 ± 12   <0.001 
  lat pulldown kg 26.4 ± 7.5 33.9 ± 10.0   29 ± 14   <0.001 
  leg press kg 167.4 ± 102.3 210.9 ± 129.0   29 ± 15   0.001 
  knee extension kg 39.9 ± 17.8 55.9 ± 22.4   47 ± 24   <0.001 
  knee flexion kg 39.8 ± 13.6 55.8 ± 13.6   44 ± 22   <0.001 
  total body potassium kg 101.6 ± 25.2 105.8 ± 23.9 1.9 ± 7.9 4 ± 8   0.014 
  
mid-thigh muscle area 
cm2 
108.9 ± 29.5 111.3 ± 29.6 2.42 ± 8.35     0.113 (ns) 
NON-RANDOMISED, CONTROLLED TRIALS  
Heiwe et al 2001 knee ext strength 1RMkg 8 ± 5 13 ± 5     <0.0001   
Nephron 88: 44-56 
quad dynamic musc 
endurance, reps 
37 (14-57) 48 (30-101)     0.004   
  
quad static musc 
endurance, secs 
28 (12-60) 32 (15-150)     ns   
  6MWT m 390 ± 128 452 ± 99     0.002   
  TUG secs 11 (9-46) 9 (7-27)     0.004   
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Table 2.7b (continued) – RT in CKD (outcome measures) 
Author, year, 
journal 
Mode of assessment  
pre 
intervention/ 
baseline values 
post 
intervention 
values 
actual change 
reported 
% change 
if reported 
significance 
(p) 
group 
difference 
(p) 
PRE (NON) DIALYSIS              
RANDOMISED CONTROLLED TRIALS 
Heiwe et al 2005 knee ext strength 1RM kg 5 (3-12.5) 7 (5-12)     0.0104   
Am J Phys Med 
Rehab 84:  
quadricep static 
endurance, reps 
37 (28-57) 55 (43-101)     ns   
865-74  muscle fibre area         ns ns 
  muscle fibre proportion         ns ns 
DIALYSIS - HD               
RANDOMISED CONTROLLED TRIALS 
Cheema et al 2007a 
CT mid-thigh muscle 
CSA cm2 
104.2 ± 25.6   1.2  ±  5.8     0.4 (ns) 
American Society of 
CT mid-thigh muscle 
attenuation  
85.7  ±  2.5    - 0.1 ± 0.9     0.04 
Nephrology 18:  CT mid-thigh fat cm2 73.8 ± 35.1   0.9 ± 7.7     0.95 (ns) 
1594-1601  
CT mid-thigh subcut 
fat cm2 
61.7 ± 27.5   0.5 ± 7.2     0.93 (ns) 
Cheema et al 2006 
strength kg (sum 3 
measures: knee ext, 
tri, hip abductors) 
98.1 ± 36.6   15.2 ± 15.4     0.002 
Hemodialysis 6MWT m 496.6 ± 133.3   16.7 ± 40.5     0.16 (ns) 
International  mid-thigh circumf cm 47.5 ± 6.0   0.7 ± 1.1     0.04 
10:303-10  mid arm circumf cm 30.1 ± 4.0   0.4 ± 1.4     0.004 
for methods  mid-calf circumf cm 35.3 ± 3.8   0.2 ± 1.2     0.41 (ns) 
  
SF36 physical function 
(0-100) 
73.5 ± 26.3   7.6 ± 11.8     0.02 
  SF36 vitality (0-100) 57.7 ± 22.2   2.8 ± 16.3     0.02 
  
geriatric depression 
scale (0-30) 
7.2 ± 7.1    - 0.3 ± 3.6     0.11 (ns) 
Cheema et al  adherence/compliance   76.5 ± 22.2         
2007b 
CT mid-thigh muscle 
CSA cm2 
103.11 ± 23.81   1.82 ± 3.25     0.04 
American Journal of 
CT mid-thigh muscle 
attenuation  
85.56 ± 2.70   0.19 ± 1.32     0.31 (ns) 
Kidney Diseases  KE strength kg 45.1 ± 19.5   13.8 ± 16.1   <0.001 0.36 (ns) 
50 (4): 574-84   
hip abduction strength 
kg 
22.3 ± 8.8   6.8 ± 3.8   <0.001 0.09 (ns) 
  tricep strength kg 27.8 ± 11.6   5.6 ± 7.7   0.002 0.17 (ns) 
  
strength kg (sum 3 
measures: knee ext, 
tri, hip abductors) 
95.2 ± 35.3   26.2 ± 21.3   <0.001 0.34 (ns) 
  
specific tension 
kg/cm2 
0.22 ± 0.08   0.07 ± 0.08   0.003 0.34 (ns) 
  6MWT m 496.0 ± 138.9   36.3 ± 50.6   <0.001 0.53 (ns) 
  mid arm circumf cm 29.9 ± 3.8   0.6 ± 2.0     0.36 (ns) 
  mid-calf circumf cm 35.0 ± 3.8   0.5 ± 1.0     0.34 (ns) 
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Table 2.7b (continued) – RT in CKD (outcome measures) 
Author, year, 
journal 
Mode of assessment  
pre 
intervention/ 
baseline values 
post 
intervention 
values 
actual change 
reported 
% change 
if reported 
significance 
(p) 
group 
difference 
(p) 
DIALYSIS - HD               
RANDOMISED CONTROLLED TRIALS 
Cheema et al  compliance/adherence   85  ± 14 %         
2011 il-1B (pg/ml) 2.0 ±  1.5   0.5   ns ns 
Eur J Appl il-6 (pg/ml) 
7.2 range 
(3.4-18.5) 
  
7.5 range 
(3.4-17.2) 
  ns ns 
Physiol 111: 1437-45   il-8 (pg/ml) 
18.1 range 
 (13.2-152.9) 
  
23.7 range 
(12.2-209.6) 
  ns ns 
  il-10 (pg/ml) 
2.1 range  
(0-8.9) 
  
2.2 range  
(0-18.1) 
  ns ns 
  il-12 (pg/ml) 2.5 ± 1.3   0.2   ns ns 
  tnf-a (pg/ml) 1.8 ± 1.0   1.1   ns ns 
  
relationship thigh 
muscle csa and il-6 
      r=-0.49 0.008   
  
relationship thigh fat 
and il-6 
      r=-0.43 0.03   
  
relationship thigh 
subcut and il-6 
      r=-0.52 0.01   
  
relationship thigh 
subcut fat and il-8 
      row= -0.42 0.05   
Chen et al 2010 Short Physical 
Performance Battery 
Score (SPPB) 
5.0 IQR(5.2) 7.0 IQR(7.2)   21.1 
IQR(43.1) 
  0.03 
Nephrol Dial 
Transplant  
SPPB score change due 
to STS5 
       -16.4  ± 
43.3 
  0.04 
25(6): 1936-43  knee extensor 
strength kg 
11.4 ± 5.0 15.8 ± 5.0   44.9 ± 26.3   0.0001 
  DEXA whole body lean 
mass kg 
45.8 ± 8.9 47.9 ± 9.9   4.2 ± 5.6   0.0001 
  DEXA leg lean mass kg 6.9 ± 1.7 7.2 ± 2.0   5.0 ± 7.6   0.0001 
  DEXA whole body fat 
mass % 
31.3 ± 10.4 29.6 ± 9.8    -2.6 ± 16.9   0.02 
  HRQoL PhysActivity 
(PASE) score 
47.5 IQR(45.9) 57.5 IR(69.3)   10.3 
IQR(88.1) 
  0.0001 
  HRQoL SF36 physical 
score 
46 ± 12 54 ± 12   21 ± 36   0.02 
  HRQoL SF36 mental 
score 
37 ± 11 37 ± 9   6 ± 27   ns 
  ADL disability 
summary score 
6.3 ± 0.9 7.0 ± 1.4   10.5 ± 21.1   0.02 
  adherence/compliance   85 ±15 %         
DePaul et al 2002 submaximal exercise 
test (W) 
    14 (CI, 2-26)   <0.05   
Am J Kidney  muscle strength (lbs)     45 (CI, 9-81)   <0.05   
Disease 40 (6): 6MWT         ns   
1219-29  SF36         ns   
(abstract only) symptoms score         ns   
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Table 2.7b (continued) – RT in CKD (outcome measures) 
Author, year, 
journal 
Mode of assessment  
pre 
intervention/ 
baseline values 
post 
intervention 
values 
actual change 
reported 
% change 
if reported 
significance 
(p) 
group 
difference 
(p) 
DIALYSIS - HD               
RANDOMISED CONTROLLED TRIALS 
Dong et al 2011 
Strength - 1 RM leg press 
lbs 
459 ± 117 582 ± 147 
all cohort 
p=0.001 +84lbs 
    
t3 p=0.07 
(ns)  t6 
p=0.12 (ns) 
J Ren Nutr 21 (2): 
149-59 
body composition by BIA 
and DEXA 
    
all cohort body 
weight p=0.02 
+0.6kg 
    
all other 
measures NS 
  
Subjective Global 
Assessment - 7 scale 
method 
n=13/15 n=9/10     ns ns 
  c-reactive protein  (mg/L) 4.3 IQR(1.9, 13.3) 2.6 IQR(1.3, 8.3)     ns ns 
  adherence/compliance   LP weight: 71-82% success       
      attendance "excellent"       
Johansen et al 2006 adherence to training 89 ± 8         
Journal of the  RT+nandrolone              
American  body weight kg 73.2 ±  23.1 75.1 ± 23.0 1.8 ± 2.9       
Society of  lean body mass kg 47.2 ± 14.4 50.1 ± 15.1 3.0 ± 2.4       
Nephrology 17:  fat kg 19.2 ± 8.3 18.6 ± 7.9  - 0.6 ± 1.1       
2307-14  quadriceps csa cm2 39.5 ± 9.3 46.2 ± 12.7 6.7 ± 5.3     0.43 (ns) 
  strength KE 3RM lbs 16.7 ± 8.7 24.9 ± 8.4 8.2 ± 6.2       
  strength hip abduction 3RM lbs 10.3 ± 4.6 18.1 ± 6.0 7.8 ± 4.6       
  strength hip flexion 3RM lbs 9.7 ± 4.7 16.9 ± 8.3 7.2 ± 5.5       
  isokinetic KE@90 Nm 43.6 ± 26.9 49.9 ± 27.8 6.3 ± 11.0       
  isokinetic KE@120 Nm 35.5 ± 23.2 45.6 ± 26.2 10.2 ± 9.7       
  HRQoL SF36 physical score 49.7 ± 26.9 56.3 ± 30.6 6.6 ± 10.8       
  nandrolone alone             
  body weight kg 64.0 ± 12.9 66.5 ± 13.5 2.5 ± 3.5   0.04   
  lean body mass kg 45.7 ± 9.3 49.0 ± 9.0 3.3 ± 2.0   <0.0001   
  fat kg 16.4 ± 13.6 15.8 ± 14.1  - 0.7 ± 1.8   0.0009   
  quadriceps csa cm2 46.6 ± 15.7 50.9 ± 16.9 4.2 ± 4.3   <0.0001   
  strength KE 3RM lbs 13.0 ± 7.1 14.4 ± 7.3 1.4 ± 2.3   0.99 (ns)   
  strength hip abduction 3RM lbs 9.1 ± 6.0 9.2 ± 6.3 0.1 ± 2.2   0.66 (ns)   
  strength hip flexion 3RM lbs 6.4 ± 6.1 7.4 ± 6.6 1.0 ± 2.5   0.41 (ns)   
  isokinetic KE@90 Nm 30.7 ± 22.4 41.3 ± 26.3 10.6 ± 23.9   0.36 (ns)   
  isokinetic KE@120 Nm 33.3 ± 27.5 39.5 ± 30.6 6.2 ± 14.1   0.38 (ns)   
  HRQoL SF36 physical score 55.4 ± 34.7 58.9 ± 29.7 3.6 ± 10.1   0.63 (ns)   
  RT alone             
  body weight kg 76.5 ± 21.5 78.0 ± 21.3 1.6 ± 2.0   0.51 (ns)   
  lean body mass kg 47.5 ± 12.3 47.1 ± 11.2  - 0.3 ± 3.0   0.66 (ns)   
  fat kg 22.4 ± 11.3 24.5 ± 11.1 2.2 ± 2.9   0.05   
  quadriceps csa cm2 47.9 ± 13.9 49.1 ± 13.5 1.2 ± 4.0   0.02   
  strength KE 3RM lbs 14.0 ± 8.4 22.6 ± 11.6 8.6 ± 6.9   <0.0001   
  strength hip abduction 3RM lbs 8.5 ± 5.2 15.4 ± 6.9 6.9 ± 5.0   <0.0001   
  strength hip flexion 3RM lbs 7.6 ± 5.3 13.7 ± 6.8 6.1 ± 4.3   <0.0001   
  isokinetic KE@90 Nm 39.2 ± 25.1 46.8 ± 28.9 7.6 ± 12.3   0.77 (ns)   
  isokinetic KE@120 Nm 35.1 ± 23.9 43.9 ± 26.1 8.8 ± 12.4   0.08 (ns)   
  HRQoL SF36 physical score 50.0 ± 24.7 61.5 ± 30.8 11.5 ± 15.4   0.03   
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Table 2.7b (continued) – RT in CKD (outcome measures) 
Author, year, 
journal 
Mode of assessment  
pre 
intervention/ 
baseline values 
post 
intervention 
values 
actual change 
reported 
% change 
if reported 
significance 
(p) 
group 
difference 
(p) 
DIALYSIS - HD               
RANDOMISED CONTROLLED TRIALS 
Oliveros et al 2011 6MWT (metres) 596 ±  79 630 ± 85 34.4   0.05 0.037 
Rev Med Chil 139 (8): 
1046-53 
Quad strength - right leg (kg) 15.4 ±  5 19.3 ±  3.9 3.86   0.03 0.027 
Spanish translated in Quad strength - left leg (kg) 18 ± 4.4 21  ±  4 3   0.02 0.054 (ns) 
google HRQoL (SF-36)         ns ns 
  Depression (Beck BDI-I) 10.6 ±  4.9 13.4 ± 8.0     ns ns 
  
c-reactive protein (hsCRP) 
pre-dialysis (mg/L) 
6.2 range 
(5.3-12.3) 
6.2 range 
(5.4-7.4) 
    ns ns 
  IL-6 (pg/ml) pre-dialysis 
3.77 range 
(2.76-22.6) 
4.95 range 
(2.51-5.04) 
    ns ns 
  TNF-a (pg/ml) pre-dialysis 
19 range  
(17-22.2) 
18.7 range 
(14.8-29.7) 
    ns ns 
Orcy et al 2012 RT alone: 6MWT 431.0 ± 108.7 411.7 ± 113.6  - 19.3 ± 53.9   0.24 (ns) 0.02 
Physiotherapy 
Research 
RT alone: adherence to 
training % 
  85 ± 12         
International 17  combi: 6MWT 440.5 ± 108.8 480.2 ± 108.7 39.7 ± 61.4   0.04   
 235-43 
combi: adherence to training 
% 
  72 ± 15         
Segura-Orti et al 
2009 
adherence/compliance   80.1         
Clinical  STS10 (secs) 24.2 ± 13.2 18.8 ± 7.9  - 5.4 ± 10.6 22.3 ns 0.003 
Nephrology 71  STS60 (count) 28.8 ± 11.2 33.9 ± 12.6 5.1 ± 5.8 17.7 0.05 0.0005 
(5): 527-37  6MWT (metres) 432.5 ± 109.3 481.0 ± 100.3 48.5 ± 60.8 11.2 0.01 0.003 
  
right leg peak force (kg) knee 
extensor @90 
25.2 ± 9.3 27.9 ± 9.4 1.5 ± 4.2   ns ns 
  
left leg peak force (kg) knee 
extension @90 
25.4 ± 10.2 28.0 ± 10.1 1.2 ± 4.6   ns ns 
  
graded exercise test/ Bruce 
protocol (mins) 
4.9 ± 2.3 5.8 ± 2.7 1.0 ± 1.8   ns ns 
  
graded exercise test/ Bruce 
protocol (METS) 
5.7 ± 2.0 6.6 ± 2.7 0.9 ± 1.9   0.043 ns 
  HRQoL (SF-36) physical 42.7 ± 8.4 44.7 ± 8.7     ns ns 
  HRQoL (SF-36) mental 45.1 ± 9.7 46.5 ± 13.5     ns ns 
Song & Sohng 2012 participation rate in PRT %   88         
J Korean Acad  skeletal muscle mass 21.4 ± 3.6 22.2 ± 3.7 0.8 ± 1.0     0.002 
Nurs 42 (7):  body fat % 27.5 ± 9.4 26.0 ± 8.9  - 1.5 ± 3.7     0.02 
947-56  grip strength kg 26.3 ± 8.5 28.7 ± 9.0 2.4 ± 2.8     0.465 (ns) 
  leg muscle strength kg 33.0 ± 15.3 37.3 ± 19.0 4.3 ± 8.7     0.027 
  sit up (count over 30secs) 7.9 ± 7.3 8.2 ± 7.7 0.4 ± 2.0     0.754 (ns) 
  balance (secs) 7.4 ± 12.0 7.9 ± 15.0 0.6 ±8.2     0.967 (ns) 
  
quality of life - physical 
component 
64.5 ± 13.0 72.5 ± 9.8 7.9 ± 9.9     0.002 
  
quality of life - mental 
component 
62.9 ± 15.9 69.4 ± 13.7 6.5 ± 11.6     0.014 
  total cholesterol (mg/dL) 163.8 ± 31.0 148.7 ± 26.2  - 15.1 ± 31.1     0.017 
  triglycerides (mg/dL) 143.6 ± 88.1 118.3 ± 63.3  - 25.3 ± 62.4     0.012 
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Table 2.7b (continued) – RT in CKD (outcome measures) 
Author, year, 
journal 
Mode of assessment  
pre 
intervention/ 
baseline values 
post 
intervention 
values 
actual change 
reported 
% change 
if reported 
significance 
(p) 
group 
difference 
(p) 
DIALYSIS - HD               
RANDOMISED CONTROLLED TRIALS 
Van Vilsteren et al 
2005 
completion of programme %   88         
Nephrol Dial  reaction time (ms) 234.67 ± 43.9 208.51 ± 36.0     0.002   
Transplant 20:  muscle strength 26.3 ± 14.6 20.42 ± 7.5     0.05   
141-6  SF36 - physical functioning 56.5 ± 28.0 62.5 ± 28.0     0.22 (ns)   
  SF36 - mental health 72.1 ± 17.4 76.2 ± 18.9     0.20 (ns)   
  SF36 - vitality 53.6 ± 16.8 66.1 ± 15.3     0.001   
  
SF36 - general health 
perception 
41.3 ± 19.2 51.8 ± 15.9     0.001   
  SF36 - health change 50.0 ± 24.4 67.1 ± 26.0     0.021   
  SF36 - symptom score 22.5 ± 8.6 23.5 ± 9.1     0.06 (ns)   
NON-RANDOMISED, CONTROLLED TRIALS  
Segura-Orti et al 
2008 
6MWT 399.57 ±  39.56 471.71 ± 70.63     <0.01   
Nefrologia 28  STS10 (secs) 22.52 ± 4.77 17.71 ± 1.79     <0.05   
(1): 67-72 STS60 (count) 28.57 ± 5.12 31.42 ± 2.443     <0.05   
(abstract)  HRQOL (SF36) physical             
  HRQOL (SF36) mental 41.74 ± 9.25 50.61 ± 12.13     <0.05 <0.05 
CROSSOVER AND SELF-CONTROLLED TRIALS 
Headley et al 2002 attendance %   87.7 ± 11.6         
Am J of Kidney 
Disease 40 (2): 355-
64 
skinfold thicknesses fat (%) 18.8 ± 2.0 19.6 ± 1.7     <0.05 <0.05 
MacDonald et al  
2005 
work done per session (kpm) 2336.7 ± 548.6 8728.9 ± 1571.0     <0.001   
Clin Physiol  DEXA fat mass kg 20.3 ± 3.7 20.8 ± 3.7     ns ns 
Funct Imaging  DEXA lean mass kg 48.3 ± 3.0 47.8 ± 3.2     ns ns 
 25: 113-8 BIA ICW litres 19.9 ± 1.9 19.7 ± 1.7     ns ns 
  BIA ECW litres 16.4 ± 1.0 15.3 ± 1.2     <0.05 <0.05 
  Sit to stand 30 ~11.5 ~13.5   20 <0.05 <0.05 
  knee extension N 23.5 ± 4.2 28.0 ± 4.0   19 <0.05 <0.05 
Nindl et al 2004 leg extension peak force 90 123.5 ± 16.9 139.1 ± 19.3   12.7 ± 3.6 <0.05 <0.05 
Growth Hormone & 
IGF Research 
leg extension peak force 120 111.9 ± 14.8 121.8 ± 19.1     ns ns 
14 (3): 245-50  leg extension peak force 150 101.8 ± 18.0 107.3 ± 20.1     ns ns 
  grip strength right kg 40.0 ± 4.7 40.7 ± 4.7     ns ns 
  grip strength left  kg 37.7 ± 4.7 39.3 ± 4.9     ns ns 
  6MWT 521.9 ± 48.5 546.5 ± 54.2     <0.05 <0.05 
  gait speed 20ft - normal cm/s 132.4 ± 7.1 131.3 ± 8.1     ns ns 
  gait speed 20ft - max 185.5 ± 13.0 195.9 ± 15.4     <0.05 <0.05 
  STS 10 20.6 ± 1.8 17.8 ± 1.9     <0.05 <0.05 
  Total IGF-I ng/ml 320.2 ± 136.5 267.1 ± 129.5     0.039 <0.05 
  Ternary IGF-I 25.3±123.6 206.2 ± 115.4     0.048 <0.05 
  IGF-I/ IGFBP-3 (x10) ratio 4.83 ± 1.49 3.72 ± 1.72     0.003 <0.05 
NO CONTROL 
Bullani et al 2011 Tinetti score 23.9 ±  3.9 25.7 ± 3.5     0.022   
Journal of Renal  TUG secs 12.1 ± 6.6 10.0 ± 5.8     0.0156   
Nutrition 21 (1):  One-leg balance secs 15.7 ± 17.8 21.6 ± 21.6     0.084 (ns)   
 61-65 6MWT m 307 ±  155 351 ± 176   14.5 0.0639 (ns)   
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Presented as mean ± standard deviation unless otherwise stated; IQR = interquartile 
range; SEM = standard error of the mean; SE = standard error; RCT = randomised 
controlled trial; nonRCT = non randomised controlled trial; Xover = crossover design; 
exp = experimental group; co/con = control group; pla = placebo group; MTH = 
muscle thickness; VL = vastus lateralis; CSA = cross sectional area; PRT = progressive 
resistance training; 2-D = 2-dimensional; US = ultrasound or ultrasonography; ns = 
non-significant result; HD = haemodialysis treatment; PD = peritoneal dialysis 
treatment; ESRD = end-stage renal disease; CT = computed tomography; DEXA = 
dual energy x-ray absorptiometry; MAMA = mid-arm muscle area; TSF = total 
skinfold; BIA = bioelectrical impedance analysis; CKD1…5 = stage of disease (1-5); 
RPE = rate of perceived exertion 
 
 
2.8 Early Interventions for improving body composition, strength and function, 
alongside general well-being and health-related quality of life in CKD 
Exercise training in the general population can increase exercise capacity, strength, 
and health-related quality of life, control or reduce hypertension and diabetes, and 
increase survival rate (Mendes et al 2011; Zwolinsky et al 2013).  The high 
prevalence of co-morbidities in the renal disease population (such as diabetes, 
cardiovascular disease, obesity, and ageing) would therefore indicate the 
importance of exercise training and/or regular physical activity in this population to 
reduce the burden of disease on each individual.  Dialysis patients also have a 
severe lack of muscular strength highlighted particularly in a study on a more 
elderly and debilitated dialysis population (Painter et al 2000).  Training to avoid 
muscular atrophy, and encourage hypertrophy, is important in an elderly 
population, as knee extensor strength has been shown to be inversely related to 
risk of falling in both healthy and chronically ill populations.  Results of baseline 
physical functioning (sit-to-stand-to-sit test) averaged only 15% of normal age-
predicted values (Painter et al 2000).   
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It can be theorized that this lack of strength is due to denervation from uraemia 
and/or disuse and any initial increases in strength could be due to improved 
neuromuscular activation as is expected in healthy resistance training subjects.  
However, deconditioning and atrophy is thought to start early in the process of 
chronic renal failure, and often continues following renal transplantation, (Kettner-
Melsheimer et al 1987; Miller et al 2002), supporting evidence that a form of 
training to hinder muscle atrophy is required from onset of the disease process.  
Unfortunately, the focus of care seems to be on disease management, not 
prevention, and as such exercise is under-used as a therapeutic tool.   
 
2.8.1 Pre-dialysis 
Most studies focus on haemodialysis patients (43% of all UK patients using HD out 
of the total number requiring RRT; Renal Registry Report, 2013), despite this sub-
group making up only a small fraction of the total number of patients with CKD (4% 
risk of progression to ESRD over a 5.5 year follow-up period, Drey et al 2003; 5-10% 
total population of kidney disease patients, Renal Registry Report). It is CKD stages 
2-4 (pre-dialysis) that actually make up the majority of patients with the disease 
(Table 2.1).   
 
Exertional fatigue (increased sense of effort in relation to performing a task) is 
present in patients with moderate CKD, with greater contribution from anaerobic 
processes (increased lactate production and respiratory exchange ratio) to energy 
production when undertaking simulations of activities of daily living (CKD3b and 
CKD4; MacDonald et al 2012), suggesting that already at this level there is a 
limitation to oxygen delivery, extraction or utilisation.   
 
Previous papers have shown normal oxygen utilization in CKD through 
mitochondrial function (Thompson et al 1994, Barany et al 1991, Miro et al 2002), 
so indicating that decreased oxygen delivery alongside a lack of compensatory 
increased cardiac output (as with healthy individuals), leads to increased use of 
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anaerobic processes, increased lactate production, greater muscular fatigue and 
perceived exertion during submaximal ADLs (MacDonald et al 2012).  Increasing 
oxygen extraction to compensate for the reduced oxygen delivery may also be 
limited in this population as the mitochondrial mass is often reduced (Shah et al 
2009; MacDonald et al 2012) by the muscle atrophy and deconditioning observed 
early on in the disease process (Kettner-Melsheimer et al 1987; Miller 2002), 
supporting evidence that a form of resistance training to hinder muscle atrophy is 
required from onset (increased mitochondrial content in skeletal muscle following 
12-weeks of resistance training; Balakrishnan et al 2010). 
 
Poor lipid profiles in rat models have been implicated in the progression of CKD 
(Scheuer et al 2000), and improvements in renal function have been demonstrated 
after exercise training to treat hyperlipidaemia in nephritic rats (Osato et al 1990).  
Studies of CKD3 patients undertaking endurance training have also shown 
improvements in GFR associated with increased HDL, and decreased LDL and TAG 
(Toyama et al 2010), though not all studies have found an endurance exercise 
intervention improves the profile and GFR (Headley et al 2012, Boyce et al 1997, 
Eidemak et al 1997).  This may be due to the lack of intensity high enough to elicit a 
change in the blood lipid and haematology variables. 
 
Improved (reduced) HR at rest and during ambulation has been seen following 
these endurance interventions, as would be expected based on the normal exercise 
response in healthy individuals, with HR recovery data suggesting an enhancement 
of parasympathetic tone, a decrease in sympathetic tone, or a combination of both 
(Headley et al 2012).  A recent study has shown a link between elevated resting HR 
and low HR variability with increased risk of ESRD and CKD-related hospitalization 
(Brotman et al 2010). 
 
Ideally, training should begin as soon as possible, commencing in the pre-dialytic 
stage, where exercise benefits appear to be greatest and most prolonged, allowing 
96 
 
significant improvements throughout the varying stages of the disease progression - 
functional capacity for ADLs (activities for daily life), aerobic capacity, muscle 
strength, blood pressure are all influenced without increasing the stress on renal 
function (Clyne 1991; Boyce 1997; Kouidi 2002).  Fitts et al (1999) found that 
exercise coaching and counselling was more beneficial in pre-dialysis patients than 
for those in dialysis, suggesting that as people approach the dialysis stage of 
treatment a pre-habilitation intervention could maintain and aid recovery of 
physical capacity on cessation of dialysis management, although interventions 
shorter than 12-weeks in certain populations may be inconsequential (Heiwe et al 
2001). 
 
Resistance training in pre-dialysis patients has shown to reduce the effects of 
catabolism of a low-protein diet and uraemia by ameliorating muscle mass 
(hypertrophy of type 1 and 2 muscle fibres), strength, protein use and nutritional 
status (Castaneda et al 2001), resisting the decline into disability and allowing a 
continued higher health-related quality of life (Kouidi 2002).  Heiwe et al (2001) 
showed with resistance training at 60% 1RM brought about an increase in 
quadriceps strength of 60% and 70% and dynamic muscular endurance of 53% and 
79% in the CKD group and healthy controls respectively, allowing the authors to 
conclude that the skeletal muscle of CKD patients responds to resistance training in 
a similar way to healthy muscle. 
 
A review of exercise interventions in CKD (Howden et al 2012) determined that 
introducing a programme of supervised resistance training to the non/pre-dialysis 
(NDD) population may improve muscle function and strength, mobility and walking 
distance, and reduce inflammation as the anabolic stimulus of resistance exercise 
training may reverse the catabolic state of CKD by decreasing chronic inflammation.  
In the catabolic state where muscle wasting is common, resistance training may 
prevent reduction in skeletal muscle mass and improve muscle mass and function. 
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2.9 Overview of the Literature and Thesis study aims. 
 CKD is a progressive condition. 
 The prevalence of CKD is increasing as the population ages. 
 CKD is associated with uraemic sarcopaenia, muscular atrophy, and malnutrition 
as a result of protein-energy wasting. 
 CKD patients have increasing risk for frailty as the disease progresses, thereby 
reducing health-related quality of life through greater dependence on family, 
medication, and the NHS. 
 Renal replacement therapy (RRT) in the form of haemodialysis (HD), exacerbates 
some aspects of muscle wasting, an effect that is amplified in diabetic patients. 
 
Thesis Aim 1 (Chapter 4):  
Explore the effect of CKD stage on body composition, strength and function in 
different stages of CKD (early and late stage) using standard clinical and frailty 
outcome measures. 
 
 Greater survival rates have been observed in late-stage CKD patients with higher 
body mass index.  This counter-intuitive phenomenon has been termed “reverse 
epidemiology” or the “obesity paradox” and has been documented in particular in 
ESRD patients on HD. 
 It is therefore vital not just to stop muscular wasting (protein energy wasting), but 
also reduce excessive, sudden, or unplanned fat loss. 
 First, it must be possible to accurately monitor and assess wasting in these 
patients, and later to evaluate the effectiveness of counter-measure interventions.  
 Therefore, valid and reliable tools to assess body composition are essential to 
observe, investigate, and maintain a protective level of fat and fat-free mass.  
 Most CKD body composition research has utilized DEXA, CT, MRI, anthropometry 
(skinfolds, limb circumference, waist-to-hip ratio, etc), BIA, and BMI.  Limitations 
are present for each (Table 2.5), ranging from the most expensive and time 
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consuming (gold standards - DEXA, CT, MRI), to those unable to differentiate 
between fat and fat-free mass (anthropometry and BMI). 
 High-resolution ultrasonography has previously been used in other populations to 
measure regional body composition, and can differentiate between muscle, fat, 
and bone, as well as produce images of muscle architecture.  However, the clinical 
utility of the method has not yet been established for people with CKD. 
 
Thesis Aim 2 (Chapter 5): 
Aim 2a: evaluate the validity of ultrasound compared to a gold standard measure 
(MRI) of body composition in CKD patients. 
Aim 2b: establish the reproducibility of ultrasound measurement of regional 
body composition (muscle and fat depths), with a view to assessing its utility as a 
method of monitoring change in CKD patients. 
 
 Anabolic interventions to improve body composition of CKD patients by promoting 
protein synthesis, and preventing protein catabolism should be introduced. 
 These should be implemented as early in the disease trajectory as possible in 
order to  
1. delay the progression to a later stage of CKD and the need for dialysis, and  
2. allow patients to present in the best possible shape for dialysis (ie with 
limited atrophy and frailty characteristics). 
 Examining the body composition of patients earlier in the disease process (pre-
dialysis) has been done before using DEXA and/or BIA, but mainly using 
anthropometrics and skinfolds.   
 Using ultrasound to assess regional body composition, muscle size and 
architecture in pre-dialysis patients may be important to establish the extent of 
wasting prior to the need for dialysis, with greater accuracy, and to increase our 
understanding of the links between architecture of the muscle and objective 
(strength and function) and patient-reported (health-related quality of life) 
outcomes.  
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Thesis Aim 3 (Chapter 6): 
To explore, in pre-dialysis CKD patients, the relationship between ultrasound-
derived   estimates of regional body composition (muscle and fat depth, and 
muscle architecture), and routinely employed measures for the assessment of 
body composition, physical function, and uraemic state, at this point in the 
disease trajectory. 
 
 Interventions in early-stage CKD should be focused on increasing lean body mass 
(protein) via anabolic interventions (such as increased/ improved nutrition or 
hormone therapy), without exposing patients to further co-morbidities often 
associated with increased adiposity (obesity; metabolic syndrome, CVD, diabetes). 
 Exercise interventions have proved effective in other chronic illnesses at bringing 
about changes in body composition and physiology, though the focus has often 
been on aerobic (endurance) exercise.   
 Recent investigations have demonstrated that aerobic (endurance) exercise, 
though having anti-catabolic effects, does not promote anabolism whereas 
resistance training brings about anti-catabolic changes and anabolism. 
 Resistance (strength) training is an effective anabolic intervention to increase body 
mass without placing strain on the cardio-respiratory system, so can be performed 
by those with a chronic or critical illness. 
 
Thesis Aim 4 (Chapter 7): 
To evaluate the effects of frequency of a resistance training programme in 
patients with stage 3 CKD. 
 
Sub-aims of  RT intervention (Chapter 7):   
 Measure and compare any change in muscle size or architecture brought about by 
the different frequencies (once or three times per week) of the RT programme. 
 Assess and compare any change from the RT programme in strength and ADL-
related function, as well as reported patient-uraemic symptoms. 
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CHAPTER 3 - General Methods  
 
3.1 Overview of the Project 
3.1.1 Study 1 [Chapter 4] 
Using standard assessment tools frequently employed in both clinical and research 
groups, patients early in the CKD process (CKD3) were compared to late stage 
(CKD5/ ESRD/ dialysis dependent) patients by assessing their body composition, 
strength, and function. 
 
3.1.2 Study 2 [Chapter 5] 
Results from Study 1 highlighted that there was indeed a clinical and statistical 
difference between the two stages in each measure, with CKD5 being demonstrably 
weaker than the “healthier” CKD3 patients.  However, the anthropometric tests and 
other techniques to assess body composition were unable to differentiate between 
lean tissue (protein/ muscle) and non-lean tissue (fat), thus it could not be 
determined at this stage whether there was a correlation or relationship between 
the notable loss of strength and function, and the atrophy of muscle (loss of muscle 
mass), or whether the weakness is due to other factors within the disease and 
treatment process. 
 
Therefore a tool was needed that can measure muscle and fat separately, allowing 
for oedema or other inflammation as well as being time-efficient and financially 
viable for routine use.  Ultrasound (US) was tested for reliability (for repeated 
measures) and validity against a gold standard (MRI) for assessing whole and 
regional body composition. 
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3.1.3 Study 3 [Chapter 6] 
Using the validated and reliable Ultrasound (US) from Study 2, the relationship 
between US-derived indices of regional body composition (muscle and fat) and 
strength and function were explored in early stage CKD (CKD3) patients in order to 
assess whether functional and neuromuscular correlates of muscle mass and 
muscle architecture are correlated with patient-reported uraemic symptoms. 
 
3.1.4 Study 4 [Chapter 7] 
In Study 3 it was observed that there are strong correlations between the different 
measures of muscle mass and architecture, uraemic symptoms, and markers of 
strength and function, in early stage CKD (CKD3).   
An exercise intervention programme was therefore implemented in early-stage 
(CKD3) patients, with the intention to develop muscle through resistance (strength) 
training and thereby assess the prime factors involved in bringing about the  
improvement (or at least impaired loss) of strength, function, and health-related 
quality of life (HRQoL) in these CKD patients. 
 
3.2 Participant Recruitment 
All participants were recruited from a single hospital outpatient unit. 
Comparing strength and function (Study 1) and the different correlations between 
muscle size, strength and function (Study 3) between CKD3 and CKD5 – Patients 
were approached for inclusion if they had been diagnosed with CKD stage 3 (CKD3: 
30 ≤ GFR ≤ 59 mL/min) or stage 5 (CKD5: GFR ≤ 15 mL/min).   
Ultrasound Validity and Reliability (Study 2) - Twenty (18 male, 2 female) CKD5 
patients undergoing continuous ambulatory peritoneal dialysis (CAPD) volunteered 
to participate in the study.   
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Resistance Training Intervention (Study 4) - Forty-five consecutively presenting 
CKD3 patients were approached, of which twenty-eight patients initially showed 
interest in participating and received information packs including participant 
information sheet, informed consent form, and investigator contact details.  
Twenty-two returned the informed consent and agreed to attend for pre-
randomisation assessments.  Twenty patients took part in the baseline assessments. 
 
3.2.1 Inclusion and exclusion criteria 
Participants in each study were included if they were 18-years of age or over, were 
independently mobile, were fluent in written and spoken English and were able to 
give consent.  Patients were excluded if they had any diagnosis of unstable angina 
or amputation that would mean they were unable to fully participate in the 
programme. 
Patients were included in the main intervention (resistance training) study if they 
had been diagnosed with Chronic Kidney Disease Stage 3 (moderately reduced 
kidney function), had not transferred to dialysis treatment, with a Glomerular 
Filtration Rate (GFR) in the range 30-59 (45-59, CKD3a; 30-44, CKD3b).  Patients 
were excluded from the study if they had any known skin conditions or allergies 
which may be affected by either the Ultrasound conductive jelly or the adhesive 
connectors for the Bioelectrical Impedance Analyser. 
 
3.2.2 Ethical approval 
Ethical approval was obtained from the local NHS Ethical Advisory Committee and 
Internal University Ethics Committee. 
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3.2.3 Consent 
When participants attended their initial appointment with the principle investigator 
they were given an opportunity to ask any further questions and were advised that 
they could withdraw from the study at any point.  Participants then provided 
written informed consent.  The completed consent form was kept by the researcher 
and a second copy by the participant. 
 
3.3 Outcome measures 
All outcome measures were taken by a single assessor (blinded to group allocation) 
highly experienced in ultrasonography, anthropometry, and measures of physical 
strength and function, in both a clinical and laboratory setting. 
 
3.3.1 Body composition assessments 
3.3.1.1 Body Mass Index (BMI) - Height and Weight 
Participants were weighed and measured for height wearing light clothing and with 
no footwear. Body weight was measured to the nearest 0.1 kg on a GSE digital 
platform scale, model 350 (GSE Scale Systems, www.gse-inc.com).  Height was 
measured to the nearest 0.5 cm using a wall-mounted stadiometer (model S100; 
Ayrton Corp); participants stood upright with arms hanging at their sides. 
Body mass index (BMI) was calculated using [weight (kg)/height (metres)2].   
 
3.3.1.2 Subjective Global Assessment (SGA)  
SGA combines self-report, clinical assessment, and simple bedside evaluation.    
Factors assessed include weight change over the past six months and two weeks, 
dietary intake, GI (gastro-intestinal) symptoms persisting over two-weeks, 
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functional capacity, subcutaneous tissue and muscle wasting, and oedema and 
ascites (fluid accumulation in the abdomen).  Fluid shifts or ascites must be 
considered carefully when interpreting change in body weight.   
The 7-point SGA is an expansion of the rating categories for nutrition status (original 
SGA had three ratings: A, B, and C), increasing the spectrum to a seven-point scale 
from 1 (severely malnourished) to 7 (well-nourished).  Several studies have 
reported a reproducibility rate of 80% using SGA in the assessment of hospitalised 
patients (inter-observer reliability, Detsky et al 1987). 
SGA was assessed using a standard form and scoring system by a registered health 
professional. 
 
3.3.1.3 Anthropometric assessment - Limb circumferences (thigh and upper arm)  
Limb circumferences were measured using a flexible tape-measure (to the nearest 
0.1 cm) on the right side of the participant's body unless affected by disability or 
disease.  All measures were taken with the participant standing and relaxed with as 
little tension in the measured limb as possible.  The tape measure was held 
perpendicular to the bone where possible (i.e. not necessarily horizontal to the 
floor).   
Measurements were taken twice and the mean was reported.  
Mid-arm circumference (MAC) was assessed at the mid-point of the upper arm, 
determined from the length of the humerus (bone) from  the greater tubercle of the 
humerus (shoulder joint) to the lateral epicondyle of the humerus (elbow joint) as 
found through gentle palpation of the relevant joints.   
Mid-thigh circumference (MTC) was assessed at the mid-point of the femur (bone) 
as located through gentle manipulation and palpation of the greater trochanter (hip 
joint) and the lateral epicondyle of the femur (knee). 
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3.3.1.4 Bioelectrical Impedance Analysis (BIA) 
Whole body multi-segmental bioelectrical impedance spectroscopy/analysis was 
used to measure total body water, fat and fat free mass.  Bioelectrical impedance 
analysis devices measure the change in impedance in body tissues by sending 
detectable electrical signals through the body.  The method is based on the 
principle that fat-free mass (FFM) contains virtually all of the conducting 
electrolytes and water in the body which provide a good electrical pathway, 
whereas fat or fat-containing tissues produce a poor electrical pathway.   
 
This has been validated in a number of populations, including healthy middle-aged 
(analysis against DEXA, segmental ICC 0.85-0.92, except truncal ICC 0.69, and whole-
body ICC 0.88-100, Ling et al 2011; truncal ICC 0.94-0.99, appendicular ICC 0.63; 
Karelis et al 2013), the morbidly obese (against DEXA, truncal FFM ICC 0.788, 
appendicular FFM ICC 0.318-0.860, truncal FM ICC 0.643, appendicular FM ICC 
0.287-0.558, Jimenez et al 2012) and athletes (against hydrostatic weighing and 
skinfolds, FFM ICC 0.96, Utter & Lambeth 2010), and has regularly been used in 
research where body composition assessment is necessary. 
 
Measurements of whole and segmental body composition were taken using a 
Bioelectrical Impedance Analyser that could assess body composition in under one-
minute (Tanita MC-780-MA multi-frequency segmental body composition analyser, 
Tanita Europe, Amsterdam).  Participant height and weight were recorded, along 
with age, ethnicity (caucasian/non-caucasian), and body-type (athletic/standard).   
Participants stood upright, with weight distributed evenly.  Bare feet were placed 
on the sensitive metal foot-plate, and bare hands gripped the handles securely, with 
arms hanging loosely by their sides (Figure 3.1). 
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Figure 3.1 – BIA equipment in use 
 
 
To ensure complete passage of the electrical current through the body, the 
investigator was careful to ensure no skin was touching at joints (such as thighs, or 
the upper arm touching the trunk); participants were encourage to wear 
comfortable (well-fitting) clothes, to hinder any potential short circuit which could 
give invalid readings. 
 
3.3.1.5 Ultrasound (US) Imaging  
All ultrasound measurements were performed with a brightness mode (B-mode), 
real time portable ultrasound system (SonoSite® 180 Plus, SonoSite Inc, 
Washington, USA) using a 50mm, 7.5MHz linear array probe.  Participants lay supine 
for a period of 20 minutes prior to any measurements being taken to allow fluid 
shifts to occur (Berg et al, 1993).  Compression of the tissues was kept to an 
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absolute minimum by using generous amounts of water-soluble transmission gel 
and maintaining a consistent low pressure with the ultrasound probe throughout 
scanning.  Participants were instructed to relax the leg muscles during all 
measurements.  All ultrasound measurements were performed on the right-hand 
side of the body. 
 
3.3.1.5.1 Muscle and fat depth/thickness measurements 
Muscle and fat thickness measurements were recorded in the axial plane along the 
mid-sagittal line of the VL at the mid-femur.  Once the image was located, the 
screen was frozen and the system callipers were used to measure tissue 
thicknesses.   
 
Figure 3.2a – Screenshot from Sonosite US at mid-VL in the axial plane (ID has been 
redacted) 
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Figure 3.2b – Zoom of screenshot, showing the border between subcutaneous fat, 
VL and total muscle, and bone 
 
 
Fat thickness was measured as the distance between the dermal surface and the fat 
- VL muscle interface.  VL muscle thickness was measured as the distance between 
the fat - VL muscle interface and the VL muscle - vastus intermedialis (VI) interface, 
thus examining the VL muscle only.  Total muscle thickness was measured as the 
distance between the fat - VL muscle interface and the VI muscle - bone interface 
(see Figure 3.2b – ultrasound image).  The accuracy of thickness measurements 
using this ultrasound technique has been established previously on human cadavers 
(Miyatani et al 2000).  
 
 
3.3.1.5.2 Anatomical cross sectional area (ACSA) 
Anatomical cross sectional area (ACSA) of the vastus lateralis (VL) muscle was 
examined at mid-femur with the ultrasound probe held transversely, perpendicular 
to the dermal surface allowing a view of the muscle in the axial plane.  Mid-femur 
was considered to be the distance halfway between the apex of the greater 
trochanter and the apex of the lateral epicondyle both of which were identified by 
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ultrasound.  The probe was moved in a straight line from the lateral to the medial 
edge of the VL over echo-absorptive external markers that were placed on the skin.  
 
 All ultrasound scans were recorded onto VHS videotape and then acquired via 
frame-capture software (Adobe Premier v5.1, Adobe Systems).  The external 
markers used cast acoustic shadows on each image that acted as reference points 
to allow later reconstruction of the ACSA image on computer (Figure 3.3).  The 
reconstructed ACSA images were measured using image analysis software (NIH 
Image version 1.6, National Institute of Health, Bethesda, USA). 
 
 
Figure 3.3 – Reconstructed VL ACSA at mid-femur length 
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3.3.1.5.3 Muscle architecture  
Resting pennation angle and fascicle length of the VL muscle was measured using 
ultrasonography.  Images were obtained along the mid-sagittal line of the VL at the 
mid-femur length (as described above).   
 
Figure 3.4a – Screenshot from Sonosite US of mid-VL in the sagittal plane.  
 
 
 
Figure 3.4a clearly shows the individual muscle fascicles (fibres) of the vastus 
lateralis, and the external marker shadow cast from the copper wire (the white dot, 
circled in red).  Pennation angle was measured as the angle between the echoes of 
the deep aponeurosis and the echoes from the interspaces among fascicles 
(Fukunaga et al 1997).   
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Figure 3.4b – Zoomed in view of screenshot showing borders of fat, muscle, bone, 
and pennation angle of the muscle fibre 
 
 
 
Fascicle length, defined as the length of the fascicle between the deep and 
superficial aponeurosis, was calculated using the following equation:  
                  [ 
   
    
 ] 
Mth  =  measured VL muscle thickness  
       = measured pennation angle (Abe et al 2001).  
 
The ultrasound probe was positioned along the sagittal plane perpendicular to 
dermal surface to provide an image that included both the superficial and deep 
aponeurosis.  Ultrasound scans were recorded on VHS videotape to enable 
subsequent analysis using the aforementioned image analysis software. The 
accuracy of ultrasound to assess the architecture of muscle has been previously 
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validated against direct anatomical inspection on cadavers (Kawakami et al 1993; 
Narici et al 1996). 
 
3.3.1.6 Magnetic Resonance Imaging (MRI) 
Using a 0.2T magnetic resonance imaging (MRI) extremities scanner (E-Scan, 
ESAOTE Biomedica, Genova, Italy) with a flexible coil, axial plane scans were 
obtained for the left leg of all participants at mid-femur length.  Axial plane scans 
were acquired using a T1 weighted spin echo profile with the following parameters - 
time to echo: 16ms; repetition time: 38ms; field of view: 160 x 160mm. 
 All participants lay supine for 20 minutes prior to and during the scanning 
procedure.   
 
Figure 3.5 - MRI scan of the VL at mid femur length.   
Note the middle oil capsule denotes the mid-VL point as marked on the skin. 
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Oil capsules were placed lightly on the surface of the skin along the mid-femur 
length line to highlight this point precisely on the MRI scan; the oil capsules are 
clearly visible on T1 weighted MR images (Figure 3.5).  The capsules were oriented 
in a manner such to allow the examiner to identify precisely the mid-VL point.  ACSA 
of the VL muscle was determined at the mid femur length. VL muscle thickness and 
fat thickness were obtained at mid-VL (as described earlier) from the MRI scans.  
Images were analysed using digitizing software (NIH Image). 
 
3.3.2 Functional tests 
A standard warm-up was preformed prior to any exercise assessments (Functional 
and Strength), using an unloaded cycle ergometer for 5 minutes.  Rest was taken as 
required throughout the assessments. 
 
3.3.2.1 Sit-to-stand 5 (STS5) and sit-to-stand 60 (STS60) 
Standing up from a seated position is a common and essential activity which 
enables other activities to take place.  This is an important component to 
maintaining independence for the more frail population and has been validated as a 
measure of function by Goldberg et al (2012) in older (older females) and frailer 
populations (with balance disorders, Whitney et al 2005). 
The STS tests were performed with a standard height chair (42cm) with no arm 
rests.  To avoid aiding the movement (by raising the arms during the upward 
motion), the participants were asked to keep their hands on their waist or across 
the chest throughout the test (Bohannon 1995).  The movement was first 
demonstrated by the assessor before being performed by the participant.  The test 
was started with “3-2-1-Go!” whereon the participants would begin.   
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STS5:  Time was recorded over the period needed to complete five sit-to-stand-to-
sit movements.  The movement was self-paced and allowed for as many rests as 
necessary. 
STS60:  A full count of “one” would be tallied once the participant had stood fully 
upright, and returned to the seat (sit-to-stand-to-sit).  This procedure was repeated 
as many times as they were able in 60-seconds; self-paced, and allowing for as 
many rests as were necessary within the minute (Bohannon 1995). 
 
3.3.2.2 North Staffordshire Royal Infirmary walk test (NSRI walk test) 
The North Staffordshire Royal Infirmary walk test (NSRI walk test; Mercer et al 
1998) involved a walk along a straight length of hospital corridor for 50-metres, 
followed by a stair-climb of 22 steps (3.3-metre elevation, individual step height 
15cm) then immediately back to the start via descent of the same stairs, and 50-
metre walk.  
As described by Mercer et al (1998), participants were instructed that to complete 
the course they should “walk as quickly as possible” (Mercer et al 1998, p2024).  
The corridor and stairs were well-lit and with little traffic.  Flooring was non-slip, 
and participants wore flat, comfortable shoes.   
Total time and splits for each component were recorded using an electronic 
stopwatch by the assessor/investigator.  Time was recorded and reported in 
seconds.  
 
3.3.2.3 Seven-day Physical Activity Recall (PAR) 
A standard questionnaire/interview was used to determine the level of activity 
performed by each participant over the previous seven days.  The Seven-Day 
Physical Activity Recall (PAR) interview was originally developed for use in the 
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Stanford Five-City Project in the early 1980s (Sallis et al 1985).  Because it is a 
general-purpose measure of physical activity that has been evaluated many times 
over the years it is widely used in epidemiologic, clinical, and behaviour-change 
studies.   
The PAR is a semi-structured interview that estimates an individual's time spent in 
physical activity, strength, and flexibility activities for the seven days prior to the 
interview.  The general interview format is as follows: an interviewer asks the 
participant to recall time spent sleeping and doing physical activities for the past 
seven days.  The interviewer guides the participant through the recall process, day-
by-day, to determine duration and intensity of the physical activities. 
Although the PAR is designed to include a variety of physical activities, such as 
aerobic exercise, work-related activities, gardening, walking, recreation and leisure-
time physical activities, only physical activities of moderate intensity and greater are 
counted.  From hours spent in moderate, hard and very hard intensity physical 
activities, total kilocalories expended over the seven-days can be estimated. 
 
3.3.3 Strength tests 
A standard warm-up was preformed prior to any exercise assessments (Functional 
and Strength), using an unloaded cycle ergometer for 5 minutes.  Rest was taken as 
required throughout the assessments.  Each strength test was repeated for a total 
of three attempts, recording all but using only the best score for analysis.  The 
movement was first demonstrated by the assessor before being performed by the 
participant.  Each strength test was performed on the same side of the body as the 
body composition (muscle and fat depth) measures. 
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3.3.3.1 Handgrip dynamometry 
A standard grip dynamometer (Lafayette Instrument, Lafayette, IN) with adjustable 
grip for hand size, was used.  Participants stood with arms loosely by their sides, 
gripping the device in the suitable hand, thumb forward.  Instructed not to lift their 
arm, bend their elbow, or raise their shoulders, participants squeezed the device as 
hard as possible and then relaxed (Chang et al 2011).  The score was recorded and 
the device zeroed for the next attempt.  The best of three attempts was used. 
If unable to stand, participants were provided with the same seat that had been 
used for the functional tests, but were still instructed to have their arms straight 
and loose at the sides. 
Hand-grip strength was measured using a dynamometer as a direct marker for 
upper body strength.  It has also been shown to be an appropriate proxy marker for 
mobility (timed-up-and-go, r=-0.59, p<0.0001) and HRQoL (physical component of 
SF36, r=0.38, p<0.01, mental component of SF36, r=0.32, p<0.01) of hospital 
inpatients (Jakobsen et al 2010), and as an independent predictor of renal outcomes 
in non-dialysis CKD patients (Chang et al 2011), allowing handgrip strength 
measurement to be used as a reliable and inexpensive tool in clinical practice to 
assess the nutritional status of patients with NDD CKD (malnutrition-inflammation 
score, Amparo et al 2013). 
 
3.3.3.2 Leg press and Knee extension peak isometric force @45degrees 
Methods described by Gleeson et al (2002) were repeated for knee extension and 
leg press peak force with the three static maximal voluntary actions separated by a 
recovery period of 120-seconds (2-minutes).  The participant was situated in an 
upright seated position on the dynamometer with the knee flexed passively to 45° 
(0° = full knee extension). 
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The lower leg was supported in position 0.1-metres proximal to the lateral 
malleolus by a rigid adjustable system.  The latter system incorporated a load cell 
(RDP Electronics Ltd, Wolverhampton, UK: range 0–1000 N) interfaced to a voltage 
signal recording system that provided analogue-to-digital conversion of muscle 
force (Cambridge Electronic Design Ltd, UK: 1902 medically isolated programmable 
amplifier/filter [zero amplification; no filtering]; 1401 plus laboratory I/O interface 
[12-bit ADC; sampling at 4 kHz]) (Gleeson et al 2002). 
Participants were seated with the angle between the back and seat of the 
dynamometer chair set at 120° and the angle between the chair and horizontal 
frame set at 10° to the horizontal.  The axis of rotation of the dynamometer was 
aligned with the anatomical axis of the knee joint (Gleeson et al 2002). 
To measure the knee extension isometric peak force (KE PF), the participants were 
instructed to push forward against the ankle strap in a “kick” motion.  Care was 
taken to avoid lifting the leg during the movement, or pulling the foot backwards 
prior to the movement (avoid gaining momentum).  Participants were instructed to 
aim to straighten their leg (although the foot and leg would not move).   
For the leg press isometric peak force (LP PF), the participants were instructed to 
pull back and down against the ankle strap as if to bring the foot to their bottom. 
 
3.3.4 Uraemic Symptoms 
Uraemic symptoms affecting HRQoL were measured using the Leicester Uraemic 
Symptom Score (LUSS).  LUSS is a five-point Likert scale that evaluates symptom 
number (LUSS 1), frequency (LUSS 2) and intrusiveness (LUSS 3) of a selection of 
eleven symptoms commonly associated with kidney problems (sleep disturbance, 
muscle spasm/stiffness, excessive tiredness, pain in joints/bones, loss of muscle 
strength/power, poor concentration/mental alertness, restless legs, impotence/lack 
of sex drive, shortness of breath, itching, and loss of appetite).  It was developed 
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and validated for use in the dialysis population by Wright & Stein (1993) (Wright et 
al 1994) and is widely used to assess patients’ perception of the severity of the 
illness. 
LUSS1: The number of uraemic symptoms experienced by the individual.  Score: 0-
11. 
LUSS2: The frequency of each symptom is rated on a scale ranging from 0 to 4 (0 = 
never, 4 = every day). 
LUSS 3: The perceived intrusiveness of each symptom is rated on a scale ranging 
from 0 to 4 (0 = not at all intrusive, 4 = extremely intrusive) 
Total score: The summative score is 0-99. 
 
3.4 Main (Resistance training) Intervention  
3.4.1 Initial 1-RM assessment 
The one-repetition maximum (1-RM) method can be defined as the maximum 
amount of weight lifted just one time, using proper form during a standard 
weightlifting exercise (McArdle et al 2001).  The initial estimate of the individual’s 1-
RM was made using an assessment of submaximal effort and the following equation 
for untrained individuals (submaximal 7 to 10-RM represents approximately 68% of 
the 1-RM score): 
1-RM (kg) = 1.554 x (7 to 10-RM weight, kg) – 5.181 (Braith et al 1993) 
The initial weight, believed to be close to the person’s maximum lifting capacity, is 
selected, and then weight is progressively added in small increments (usually 1.0-
5.0kg increments in a healthy population, so adjusted to 0.5-2.5kg increments in 
this population) until the person reaches their maximum lifting capacity; 1-RM.  The 
rest interval during successive attempts was a minimum of one-minute to provide 
enough recovery time before lifting the next heavier load (McArdle et al 2001). 
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3.4.2 Resistance training programme 
Each supervised training session started with of a short (five-minute) aerobic warm-
up on a mechanically braked (unloaded) cycle ergometer.  This was followed by the 
main training intervention:  
A series of lower extremity exercises were performed using fixed weight machines 
(knee extension, leg press, calf raise, hamstring curl) and bodyweight-resisted 
exercises (lunges, squats) were performed (45 minutes).   
Participants completed 3 sets of 8 repetitions at 80% of the individual’s one 
repetition maximum (3x8reps @ 80% 1RM).  The recovery period between sets was 
one-minute, with two-minutes between each different exercise. 
The main (resistance training) part of the intervention session was followed by a 
short cool-down (identical to the aerobic warm-up: five-minutes on the unloaded 
cycle ergometer) and general stretching of the trained muscle groups. 
Total session time was one-hour.   
 
Progression/adaptation: 1-RM was amended as required (when an individual could 
surpass the prescribed dose of 3 sets of 8 repetitions).  The results of the fortnightly 
measure of leg press and knee extension peak force were used as a guide for 
advancement and progression. 
.  
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CHAPTER 4 - Strength, Function, and Body composition of 
CKD patients at different stages of the disease trajectory 
(CKD3 vs CKD5) 
 
4.1 Introduction 
Muscle wasting is a common manifestation of Chronic Kidney Disease (CKD) and is a 
direct contributor to the development of weakness and frailty observed in this 
population (Delgado et al 2013; Fouque et al 2008; Ebner et al 2013; McIntyre et al 
2006). 
 
Frailty and weakness through the decrease in physical strength and function has 
clearly been seen in dialysis patients of all ages, with the rate of deterioration in 
ESRD much greater than in healthy age-matched controls (Painter 2005; Johansen 
et al 2007).  The reduced function has also been observed in the pre-dialysis stage, 
though the great majority of studies have focussed on ESRD patients (already 
undergoing maintenance dialysis).  Some studies have endeavoured to quantify 
markers of function in a “general pre-dialysis” population (Padilla et al 2008; Heiwe 
et al 2001) and more recently in the individual stages (CKD stages 2-5; Hiraki et al 
2013) to determine the extent of the loss of strength and function, at what stage it 
is initiated, and when it becomes significantly life-affecting and life-limiting. 
 
The link between muscle wasting and frailty allows assessment of the latter by 
markers of the former.  Nutritional status encompasses protein-energy status, and 
atrophy of both lean and fat mass.  Assessing nutritional status in CKD patients is 
important to monitor the extent of atrophy throughout the disease progression, to 
limit the resultant frailty where possible.  Recommended and frequently used tools 
of assessment of nutritional status of late-stage CKD (dialysis dependent) include 
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regular (monthly, semi-annual, or annual) assessment of body weight, BMI, 
anthropometrics (mid-arm circumference, and skinfold thicknesses), body 
composition, clinical measures (serum albumin, creatinine, cholesterol, blood urea 
nitrogen), dietary interview and subjective global assessment (Kamimura et al 
2005).   
 
Function has been strongly linked to nutritional status (stratified by subjective 
global assessment score), often allowing simple objective measures to be used as 
markers for other more complex measures (handgrip strength strongly correlated to 
lean body mass measured by DEXA, anthropometry, and creatinine kinase; 
Heimburger et al 2000).  Malnutrition has also been strongly associated with low 
body fat percentage (by DEXA), high serum c-reactive protein (inflammatory 
marker) and being female (Heimburger et al 2000).  The suggestion that indices of 
physical function could be used as a proxy for nutritional state is therefore not 
unique, and utilising the proxy measure in times where the direct measure is not 
available or accessible is commonplace. 
 
Reduced function is also strongly correlated with increased risk of death in CKD 
patients (Painter & Roshanravan 2013) and low serum albumin (hypo-albuminemia) 
has been previously identified as the most powerful predictor of death in ESRD 
patients (Lowrie 1994).  However, a recent study of this widely-used biomarker of 
nutritional status, has found it to be less correlated with other measures of 
nutritional status than previously thought, as over-hydration and protein loss into 
the urine and dialysate reduce serum albumin concentrations (Gama-Axelsson et al 
2012).  Reduced function increases dependence, frailty and morbidity in the renal 
population (Kaysen & Eiserich 2003) so monitoring individual changes accurately 
and regularly is essential in ongoing treatment. 
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Presently, no single marker can be regarded as the model to assess nutritional 
status in CKD patients, as various other factors such as metabolic alterations and  
fluid overload are common (Fouque et al 2007).   
 
4.1.1 Aims and hypotheses 
The primary aim of this cross-sectional, comparative study was to quantify the 
difference between two distinct stages of the CKD trajectory (CKD3 early in the 
disease process and CKD5/ ESRD where dialysis has been initiated) using 
recommended assessment tools that are commonly employed and locally available 
in hospitals, clinics, and research. 
It was hypothesized that patients in the final stage of CKD (CKD5/ ESRD) would 
present with significantly decreased muscle mass (measured anthropometrically 
and by SGA) and this would be associated with a decline in physical function, 
activity levels, and an increase in patient-reported uraemic symptoms. 
 
4.2 Methods 
4.2.1 Participants 
All participants were recruited from a single hospital outpatient unit.   
All participants were informed of the protocol and procedures to be used, and 
informed written consent was obtained from each, as approved by the appropriate 
local NHS Scientific Merit and Ethics Committee. 
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4.2.2 Assessments 
4.2.2.1 Clinical and Physical Demographics 
Body mass index (BMI) was calculated using [weight (kg)/height (metres)2].  Body 
fat percentage was calculated using the BIA available within the hospital/ clinic. 
As part of the usual care of each patient, a standard blood draw was performed by a 
trained phlebotomist/nurse and analysed for haemoglobin (Hb) and serum albumin 
levels. 
 
4.2.2.2 Subjective Global Assessment (SGA)  
SGA combines self-report, clinical assessment and simple bedside evaluation.  
Factors assessed include weight change over the past six months and two weeks, 
dietary intake, GI (gastro-intestinal) symptoms persisting over two-weeks, 
functional capacity, subcutaneous tissue and muscle wasting, and oedema and 
ascites.  SGA was assessed by a registered health professional, using a standard 
form and scoring system. 
 
4.2.2.3 Anthropometric assessment - Limb circumferences (thigh and upper arm)  
Limb circumferences were measured using a flexible tape-measure (to the nearest 
0.1cm) on the right side of the participant's body unless affected by disability or 
disease.  The tape measure was held perpendicular to the bone where possible (i.e. 
not necessarily horizontal to the floor).  All measures were taken with the 
participant standing and relaxed with as little tension in the measured limb as 
possible.  Measurements were taken twice, and the mean was reported.  
Mid-arm circumference (MAC) was assessed at the mid-point of the upper arm, 
determined from the length of the humerus (bone) from  the greater tubercle of the 
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humerus (shoulder joint) to the lateral epicondyle of the humerus (elbow joint) as 
found through gentle palpation of the relevant joints.   
Mid-thigh circumference (MTC) was assessed at the mid-point of the femur (bone) 
as located through gentle manipulation and palpation of the greater trochanter (hip 
joint) and the lateral epicondyle of the femur (knee). 
 
4.2.2.4 Strength and Function 
Muscle strength was assessed using a handgrip dynamometer (Lafayette 
Instrument, Lafayette, IN) and Knee Extension peak isometric force assessed at 45° 
(KE PF 45) (Gleeson et al 2002).   Results were based on the best of three attempts.  
Sit-to-stand 60 (STS60, number of complete sit-to-stand movements within 60 
seconds) and sit-to-stand 5 (STS5, time taken to complete five sit-to-stand 
movements) were performed from a standard chair height of 0.42 metres.  
 
4.2.2.5 Health-related Quality of Life (HRQoL) 
Uraemic symptoms affecting HRQoL were measured using the Leicester Uraemic 
Symptom Score (LUSS).  LUSS is a five-point Likert scale that evaluates symptom 
number (LUSS 1), frequency (LUSS 2) and intrusiveness (LUSS 3) of a selection of 
eleven symptoms commonly associated with kidney problems (sleep disturbance, 
muscle spasm/stiffness, excessive tiredness, pain in joints/bones, loss of muscle 
strength/power, poor concentration/mental alertness, restless legs, impotence/lack 
of sex drive, shortness of breath, itching, and loss of appetite).   
Participants were also asked to recall their physical activity over the last week 
(Physical Activity Recall). 
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4.2.3 Statistics 
Following normality checks of the data distribution, standard statistical methods 
were used for the calculation of mean and standard deviations where appropriate. 
Independent samples t-tests were used to evaluate differences between the two 
groups.  Significance (two-tailed) was accepted at p<0.05. 
 
4.3 Results 
All results are presented as mean ± standard deviation unless otherwise stated.  
Tables 4.1-4.4 show group demographics and differences.  Tables 4.5-4.6 show the 
groups split by gender for the same outcome measures. 
 
Table 4.1 - Participant characteristics 
 
CKD Stage 3 
30 ≤ GFR ≤ 59 mL/min 
CKD Stage 5 
GFR ≤ 15 mL/min 
Sample size  n (M:F) 51 (28:23) 105 (70:35) 
Age (years) 59.9 ± 13.9 56.6 ± 14.6 
Height (cm) 165.2 ± 9.3 167.4 ± 13.9 
Weight (kg) 77.3 ± 14.2 78.5 ± 16.7 
BMI (kg/m2) 28.1 ± 4.5 28.3 ± 6.1 
Total body fat (%) 32.5 ± 9.0 30.0 ± 11.8 
Time on dialysis (months) NDD 35.0 ± 36.3 
GFR (mL/min) 45.7 ± 7.0 On dialysis 
Presented as mean ± standard deviation; BMI = body mass index; GFR – glomerular 
filtration rate; NDD = non dialysis dependent  
There were no significant differences (p>0.05) in physical demographics between 
the two groups.  
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Table 4.2 – Clinical and physical measures routinely used to assess extent of 
malnutrition in CKD and other chronically and critically ill patients   
 
CKD Stage 3 
N (M:F) 
CKD Stage 5 
N (M:F) 
difference 
Hb (g/dL) 
13.7 ± 1.8 
50 (27:23) 
11.5 ± 1.3 
121 (80:41) 
(-) 2.2 ** 
Albumin (g/L) 
41.8 ± 3.0 
50 (27:23) 
38.2 ± 4.3 
121 (80:41) 
(-) 3.6 ** 
SGA (score)   
Max score = 7 
6.3 ± 0.9 
51 (28:23) 
5.9 ± 1.4 
29 (19:10) 
(-) 0.4 
Mid-arm circumference 
MAC (cm) 
33.8 ± 3.9 
51 (28:23) 
29.7 ± 3.8 
48 (32:16) 
(-) 4.1 ** 
Mid-thigh circumference 
MTC (cm) 
52.5 ± 5.9 
51 (28:23) 
47.9 ± 5.1 
31 (21:10) 
(-) 4.6 ** 
Presented as mean ± standard deviation; *denotes significance at the p<0.05 level, 
** p<0.01.  Numbers in italics show actual participant number for that outcome 
measure as N (M:F);   (+) represents CKD5 > CKD3, (-) represents CKD5 < CKD3; Hb = 
haemoglobin; SGA = subjective global assessment, where 1=severely malnourished, 
7=well-nourished 
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Table 4.3 – Objective measures of muscular strength and endurance 
 
CKD Stage 3 
N (M:F) 
CKD Stage 5 
N (M:F) 
difference 
Sit-to-stand 5 (seconds) 
16.2 ± 10.7 
50 (27:23) 
13.0 ± 6.9 
115 (77:38) 
(-) 3.2 * 
Sit-to-stand 60 (count) 
21.9 ± 9.3 
48 (26:22) 
21.5 ± 7.5 
44 (31:13) 
(-) 0.4 
Handgrip (kg) 
27.4 ± 11.8 
50 (27:23) 
31.3 ± 10.0 
72 (48:24) 
(+) 3.9 * 
Knee extension peak force  
KE PF 45 (Newtons) 
303.7 ± 134.5 
39 (20:19) 
254.0 ± 72.0 
55 (39:16) 
(-) 49.7 * 
Presented as mean ± standard deviation; *denotes significance at the p<0.05 level, 
** p<0.01.  Numbers in italics show actual participant number for that outcome 
measure as N (M:F);  (+) represents CKD5 > CKD3, (-) represents CKD5 < CKD3 
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Table 4.4 – Patient reported activity and HRQoL (uraemic symptoms) 
Presented as mean ± standard deviation; *denotes significance at the p<0.05 level, 
** p<0.01.  Numbers in italics show actual participant number for that outcome 
measure as N (M:F);  (+) represents CKD5 > CKD3, (-) represents CKD5 < CKD3
 
CKD Stage 3 
N (M:F) 
CKD Stage 5 
N (M:F) 
difference 
Physical Activity Recall 
(kcal/kg/day) 
35.4 ± 2.8 
51 (28:23) 
34.9 ± 3.0 
30 (20:10) 
(-) 0.5  
Complete seven-day 
PAR (kcal/week) 
247.6 ± 19.9 
51 (28:23) 
157.0 ± 113.9 
30 (20:10) 
(-) 90.6 ** 
LUSS 1 (number) 
Max score = 11 
5.9 ± 2.4 
51 (28:23) 
8.0 ± 2.3 
72 (47:25) 
(+) 2.1 ** 
LUSS 2 (frequency) 
Max score = 44 
14.5 ± 7.4 
51 (28:23) 
20.5 ± 9.1 
72 (47:25) 
(+) 6.0 ** 
LUSS 3 (intrusiveness) 
Max score = 44 
8.5 ± 6.4 
51 (28:23) 
15.9 ± 8.6 
72 (47:25) 
(+) 7.4 ** 
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Table 4.5 – Gender-specific participant physical characteristics 
 
CKD Stage 3 CKD Stage 5 
Group difference 
(CKD3 v CKD5) 
Male Female 
Gender 
difference 
Male Female 
Gender 
difference 
(+) = CKD5 > CKD3 
(-) = CKD5 < CKD3 
N 28 23 (+) = M > F 
(-) = M < F 
70 35 (+) = M > F 
(-) = M < F 
Male Female 
Age (years) 59.8 ± 15.2 60.2 ± 12.4 (-) 0.3 58.9 ± 15.0 53.5 ± 13.3 (+) 5.4 (-) 0.9 (-) 6.7 
Height (cm) 170.9 ± 7.6 158.3 ± 5.9 (+) 12.6 ** 173.1 ± 7.4 156.4 ± 18.1 (+) 16.9 ** (+) 2.2 (-) 1.7 
Weight (kg) 80.2 ± 15.0 73.8 ± 12.6 (+) 6.4 83.7 ± 16.4 73.4 ± 16.9 (+) 10.3 ** (+) 2.5 (-) 0.4 
BMI (kg/m2) 27.3 ± 3.9 29.1 ± 5.0 (-) 1.8 28.1 ± 5.2 29.3 ± 8.1 (-) 1.2 (+) 0.8 (+) 0.2 
Body fat (%) 26.3 ± 5.7 40.0 ± 6.1 (-) 13.7 ** 24.0 ± 8.4 43.5 ± 4.7 (-) 19.5 ** (-) 2.3 (+) 3.5 
Time on dialysis 
(months) 
NDD NDD 
0 23.2 ± 21.4 35.9 ± 39.7 (-) 12.7   
GFR (mL/min) 45.7 ± 8.5 45.7 ± 4.7 0 On dialysis On dialysis 0   
Presented as mean ± standard deviation; *denotes significance at the p<0.05 level, ** p<0.01; BMI = body mass index; GFR = 
glomerular filtration rate  
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Table 4.6 – gender-specific group differences (clinical, strength, function, and uraemic symptoms) 
 
CKD Stage 3 CKD Stage 5 
Group difference  
(CKD3 v CKD5) 
Male Female 
Gender 
difference 
Male Female 
Gender 
difference 
(+) = CKD5 > CKD3  
(-) = CKD5 < CKD3 
N (%) 55% [n] 45% [n] 
(+) = M > F 
(-) = M < F 
67% [n] 33% [n] 
(+) = M > F 
(-) = M < F Male Female 
Hb (g/dL) 14.8 ± 1.6 [27] 12.4 ± 1.2 [23] (+) 2.4 ** 11.5 ± 1.3 [80] 11.2 ± 1.2 [41] (+) 0.3 (-) 2.2 (-) 1.2 
Albumin (g/L) 41.9 ± 3.0 [27] 41.7 ± 3.0 [23] (+) 0.2 38.3 ± 4.4 [80] 38.1 ± 3.8 [41] (+) 0.2 (-) 3.5 (-) 3.7 
SGA (score) 6.3 ± 1.1 [28] 6.2 ± 0.7 [23] (+) 0.1 5.7 ± 1.6 [19] 6.8 ± 0.5 [10] (-) 1.1 (-) 0.6 (+) 0.6 
MAC (cm) 33.2 ± 3.8 [28] 34.4 ± 4.0 [23] (-) 1.2 30.2 ± 4.7 [32] 29.6 ± 4.6 [16] (+) 0.6 (-) 3.0 (-) 4.8 
MTC (cm) 50.1 ± 5.2 [28] 55.5 ± 5.5 [23] (-) 5.4 ** 48.7 ± 6.9 [21] 47.9 ± 4.1 [10] (+) 0.8 (-) 1.4 (-) 7.6 
STS5 (secs) 12.8 ± 5.0 [27] 20.2 ± 14.2 [23] (-) 7.4 * 11.8 ± 4.3 [77] 14.1 ± 7.4 [38] (-) 2.3 (-) 1.0 (-) 6.1 
STS60 (count) 24.6 ± 9.6 [26] 18.7 ± 8.1 [22] (+) 5.9 * 23.8 ± 6.2 [31] 19.8 ± 8.5 [13] (+) 4.0 (-) 0.8 (+) 1.1 
Handgrip (kgs) 35.7 ± 9.5[27] 17.6 ± 3.8 [23] (+) 18.1 ** 35.9 ± 7.8 [48] 22.0 ± 7.0 [24] (+) 13.9 ** (+) 0.2 (+) 4.4 
KE PF 45 (Newtons) 382.6 ± 120.1 [20] 220.7 ± 93.7 [19] (+) 161.9 ** 285.4 ± 62.3 [39] 230.5 ± 54.4 [16] (+) 54.9 ** (-) 97.2 (+) 9.8 
PAR (kcal/kg/day) 35.8 ± 3.1 [28] 34.8 ± 2.5 [23] (+) 1.0 35.1 ± 2.4 [20] 34.6 ± 4.0 [10] (+) 0.5 (-) 0.7 (-) 0.2 
LUSS1 (number) 5.5 ± 2.2 [28] 6.4 ± 2.5 [23] (-) 0.9 7.6 ± 2.3 [47] 8.7 ± 2.2 [25] (-) 1.1 (+) 2.1 (+) 2.3 
LUSS2 (frequency) 12.7 ± 6.3 [28] 16.7 ± 8.1 [23] (-) 4.0 18.5 ± 8.8 [47] 24.2 ± 8.6 [25] (-) 5.7 * (+) 5.8 (+) 7.5 
LUSS3 (intrusiveness) 7.3 ± 6.0 [28] 9.9 ± 6.8 [23] (-) 2.6 14.3 ± 8.3 [47] 18.9 ± 8.4 [25] (-) 4.6 * (+) 7.0 (+) 9.0 
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Presented as mean ± standard deviation; *denotes significance at the p<0.05 level, ** p<0.01; [n] = actual participant number available 
for analysis; Hb = haemoglobin; SGA = subjective global assessment, where 1=severely malnourished, 7=well-nourished; MAC = mid-
arm circumference; MTC = mid-thigh circumference; STS5 = sit-to-stand 5; STS60 = sit-to-stand 60; KEPF45 = knee extension peak force 
at 45 degrees; PAR = physical activity recall; LUSS = Leicester Uraemic Symptom Score 
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4.4 Discussion 
As hypothesized, the data showed statistical differences between the two groups, 
with the CKD5 (dialysis dependent) population performing worse in clinical (lower 
haemoglobin and plasma protein/albumin levels; Table 4.2), nutrition/body 
composition measures (smaller limb circumference; Table 4.2), strength (lower knee 
extensor maximal isometric force; Table 4.3), and HRQoL (increased burden, 
frequency, or intensity of uraemic symptoms; Table 4.4).  Counter-intuitively, there 
were also significant differences in handgrip strength and STS5 (Table 4.3), with 
both of these measures showing CKD5 patients were stronger and faster. 
However, there was no statistical difference in other objective measures of function 
(sit-to-stand 60; Table 4.3), or subjective global assessment (Table 4.2), body 
weight, body fat percentage, or BMI (Table 4.1).  This was potentially due to an 
uneven gender split within groups (a greater proportion of male participants in the 
CKD5 group) and further exploratory analysis initially supported this theory (Tables 
4.5 and 4.6). 
 
4.4.1 Gender Difference 
As expected, males were significantly taller with a lower percentage body fat than 
females (Table 4.5) and had statistically significant higher maximal handgrip and 
knee extensor (KEPF45) strength (Table 4.6) in both groups CKD3 and CKD5.  Males 
were better performers in functional speed (STS5: faster/shorter time is superior) 
and endurance (STS60: higher count is superior) in both CKD3 and CKD5, but had no 
statistical advantage over the females in the CKD5 group (Table 4.6).   
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Despite handgrip strength being similar in both groups (though non-significantly 
higher in CKD5 for both genders; table 4.6), knee extensor strength was 
dramatically and significantly (p<0.01) different in males between CKD3 and CKD5.   
 
Both genders were within the normal range for haemoglobin in the “healthier” 
(CKD3) group, though males had higher concentrations (Hb, p<0.01; Table 4.6) as is 
anticipated across a standard sample of males and females (although normal values 
for Hb in the general population differ by gender, this has not been addressed in 
most study designs of anaemia in CKD). However, males appear to again lose this 
advantage by stage 5 as the level of anaemia was very similar between genders and 
likely “stabilised” as patients below 11.5 g/dL are treated for anaemia according to 
the NICE guidelines on anaemia in CKD (NICE clinical guideline 114, 2011). 
 
This would suggest that despite males performing statistically better than their 
female counterparts early in the disease process (CKD3) their advantage is largely 
lost by the point of receiving maintenance dialysis (CKD5) when both genders 
appear to be as weak and functionally limited as each other.  This is also reflected in 
reverse; measures of mid-thigh circumference (MTC) revealed females having a 
greater thigh circumference in the healthier (CKD3) population than males (p<0.01) 
though it was significantly depleted by CKD5, reducing to levels below that of males 
in both stages CKD3 and CKD5 (MTC, Table 4.6).   
 
The disproportionate number of females to males in one group (relatively even split 
in CKD3, but twice as many males as females in group CKD5; Table 4.1) may have 
skewed some of the data in one group.  However, analyses comparing demographic 
data (height, weight, haemoglobin and percentage body fat) which are known to be 
affected by gender showed no overall group difference, so data could be pooled 
within each group. 
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4.4.2 Body composition and Markers of Malnutrition 
There were no significant differences (p>0.05) between CKD3 and CKD5 patients in 
weight, BMI, percentage body fat (Table 4.1) and subjective global assessment 
(Table 4.2).  However, the anthropometric measures (limb circumferences; Table 
4.2) show highly significant (p<0.01) levels of wasting, also seen in the clinical 
results (Hb and Albumin, p<0.01; Table 4.2).   
 
It has been well established that Hb levels fall as kidney function declines, as 
replicated in this study.  Lower Hb levels have also been associated with increased 
cardiovascular abnormalities/events, increased hospitalisation, increased mortality, 
increased transfusion requirements and reduced health-related quality of life 
(O’Mara 2008).  Haemoglobin is important for the transport of oxygen around the 
body and this reduced carrying-capacity could contribute to reduced energy levels 
and increased fatigue associated with advanced CKD. 
 
Conversely, in this study there were no significant differences in serum albumin 
levels between genders or the different stages of the disease process despite serum 
albumin previously being used as a marker for malnutrition, strongly indicating that 
levels should theoretically be reduced as the disease stage worsens, with strong 
links between low serum albumin (hypo-albuminemia) and death in ESRD patients 
(Lowrie et al 1994).  However, the results of this study do support previous research 
undertaken examining each stage (pre-dialysis CKD2-5), with serum albumin falling 
consistently (but not significantly) as CKD progresses  (CKD3 4.18 ± 0.3 g/dL, CKD5 
3.82 ± 0.4 g/dL, Table 4.2; CKD2 4.2 ± 0.3 g/dL, CKD3 4.0 ± 0.3 g/dL, CKD5 3.8  ± 0.3 
g/dL, Hiraki et al 2013). 
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SGA (subjective global assessment) is by definition a subjective measure and hence 
open to a degree of error.  It could be considered too broad a measure and unable 
to detect small changes in protein stores to truly assess nutritional status (or 
malnutrition).  Research has suggested that SGA is only capable of discriminating 
between best and worst nourished patients, and has reported a large number of 
(haemodialysis) patients with strong evidence of significant malnutrition 
(determined by other clinical and physical measures) presented with a “normal” 
SGA score (Jones et al 2004), inferring that SGA is only truly sensitive enough to 
detect differences at a group level but certainly not for individual measures.  The 
results of this study support the advice that SGA is not to be used alone but 
alongside other measures to determine the level of malnutrition (Cooper et al 2002; 
Kamimura et al 2005), including those used here (body weight and BMI, percentage 
body fat, and limb circumference) that describe a significant level of wasting by late-
stage CKD. 
 
4.4.3 Strength, Function, Activity, and Health-related Quality of Life 
Isometric strength, measured by knee extensor (p=0.02) dynamometry, was 
significantly lower in the CKD5 group compared to CKD3.  These results are 
consistent and in contrast with previous research where pre-dialysis patients (CKD2-
3) have been compared to their equivalents in later-stages of CKD (CKD4) or already 
undergoing maintenance dialysis (CKD5/ESRD); CKD 2-3 were significantly better 
than CKD 4-5 in handgrip strength (different to present results) and knee 
extension(consistent with present results) (Hiraki et al 2013).   
 
Functional measures examining speed (time taken to perform five sit-to-stand 
movements) were (unusually) significantly (p<0.05) slower in CKD3 than CKD5 
(CKD3: 16.2 ± 10.9 seconds, CKD5: 13.0 ± 6.9 seconds, p=0.03), though the measure 
examining muscular endurance over one minute (STS60: the number of sit-to-stand 
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movements performed in sixty seconds), was not significantly different between 
groups (CKD3: 21.9 ± 9.3, CKD5: 21.5 ± 7.5, p=0.85). 
 
The unaffected STS60 (functional muscular endurance) is counter-intuitive; 
decreased Hb (to the point of being categorised as anaemic) should affect 
performance as oxygen uptake capabilities are significantly reduced.  Conversely, 
previous research has shown that even with stable Hb levels, function has been 
seen to decline in CKD patients, though that particular study used a group of 
patients further along in the disease trajectory (mix of CKD3-4 patients; Leikis et al 
2006) than in the present analysis (mid-CKD3 in the pre-dialysis group only).  
Combining this information with that from Hiraki et al (2013) who demonstrated 
significant differences between CKD3 and CKD4 in strength assessments, we can 
infer that there may be a significant decline in STS60 (functional endurance) when 
patients progress to CKD4. 
 
There were no differences between patient groups (or gender) in physical activity 
recall (PAR) which measures patient-reported activity levels over the previous seven 
days to calculate average energy expenditure per day.  Low levels of physical 
activity and poor physical functioning are strongly associated with mortality and 
poor clinical outcomes in adult patients with CKD (Painter & Roshanravan 2013).  
The lack of variation in PAR between the two stages was unexpected as research 
and anecdotal evidence points to a reduced level of activity once patients are 
undergoing dialysis or even in late stage CKD5 before commencing/transferring to 
regular (maintenance) dialysis (Figure 2.1).  When objectively measured (by 
accelerometer), physical activity has been found to be positively associated with 
GFR; greater (healthier) GFR with higher levels of physical activity (Hawkins et al 
2011).  However, this was not evident here, suggesting that patient physical activity 
recall is not sensitive enough to detect similar changes to those observed by 
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objective assessment, despite it being validated and deemed reliable in a series of 
studies. 
 
Unsurprisingly, uraemic symptom number, frequency, and intrusiveness were 
significantly (p<0.01) more prevalent and problematic in CKD5 patients that CKD3 
(Table 4.4). 
 
4.4.4 Summary 
The results of this study appear mixed with regards to the consistency with the 
current literature.  The expectation and hypothesis was that individuals later in the 
disease process (CKD5) would fare worse than those earlier (CKD3) in all measures.  
However this was not seen to be the case in either handgrip strength (CKD5 were 
stronger) or STS5 (CKD5 performed faster).   
 
Activities such as the endurance-based STS60 appeared unaffected by CKD stage, 
whilst lower-body strength (KEPF45) was significantly reduced in CKD5.  Whether 
these last results are directly due to protein (muscle) wasting or other factors 
associated with later stages, such as actual treatment (dialysis), anaemia, nutrient 
loss or deficiencies from dialysis treatment or dietary changes, or reduced physical 
activity (though this was not observed here; PAR, Table 4.4) cannot be determined 
from the results of this study. 
 
4.5 Study Limitations 
The main limitation of this study is that it was a cross-sectional or “snapshot” study 
only and not longitudinal, so individual differences within each group were not 
controlled for.  With a longitudinal study where participants were followed from 
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CKD3 to ESRD, data may be more robust and potentially demonstrate greater 
significance. 
 
Other possible limitations did arise as not all measures were collected for all 
participants, once again affecting the statistical power as sample size numbers were 
distinctly smaller for certain measures in the CKD5 group (CKD5: SGA, n=13; MAC, 
MTC, STS60, n=18; PAR, n=30; KEPF, n=31).  The male/female ratio remained 
constant, thus for these smaller sample sizes there were occasionally too few 
females to perform gender specific analyses between groups (CKD3 female 
compared to CKD5 females). 
 
The disproportionate number of females to males in one group (relatively even split 
in CKD3, but twice as many males than females in group CKD5) may also be 
considered a limitation as it has potential to skew some of the data in one group.  
However, analyses comparing demographic data (height, weight, haemoglobin, and 
percentage body fat) which are known to be affected by gender showed no overall 
group difference, thus data could be pooled within each group. 
 
4.6 Conclusions 
There is a statistical difference between CKD3 (early stage, pre-dialysis) and CKD5 
(end-stage, dialysis dependent) in some measures of strength, function, HRQoL 
(uraemic symptoms), and malnutrition, with CKD5 faring worse across a number of 
outcome measures. 
 
It appears that SGA, BMI, body weight and percentage body fat are not precise 
enough assessment tools to distinguish between early-stage CKD (CKD3) and end-
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stage (dialysis dependent) CKD (CKD5) at the individual level that is readily picked 
up by the anthropometric measures of limb size (mid-arm and mid-thigh 
circumference).  The anthropometric measures used here were sensitive enough to 
detect the change between the groups (different disease stages).  However, simple 
measures of limb circumference cannot differentiate and determine whether the 
observed atrophy is predominantly due to fat loss, lean tissue/protein/muscle loss, 
or an even proportion of both. 
 
4.7 Implications for research 
Regular monitoring of patients across the disease trajectory is vital to prevent 
excessive wasting and/or loss of function and to intervene appropriately and in a 
timely manner.  This monitoring must be specific and accurate enough to be able to 
report individual changes in both regional and whole-body changes.  Consequently, 
there is a need for a valid method of assessment of regional body composition that 
can distinguish between muscle and fat which is easily used, quick, accurate, 
reliable and sensitive to change. 
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CHAPTER 5 - The utility of high-resolution Ultrasound (US) 
imaging for the assessment of regional body composition in 
stage 5 chronic kidney disease patients undergoing 
continuous ambulatory peritoneal dialysis (CAPD CKD5) 
 
5.1 Introduction 
The prevalence of malnutrition and loss of muscle mass in end-stage renal disease 
(ESRD) can be an overwhelming complication of chronic uraemia (England & Price 
1995).  Malnutrition is consistently linked to increased mortality, morbidity and 
reduced health-related quality of life (HRQoL) in the dialysis (CKD5) population 
(Lowrie & Lew 1990) with muscle wasting recognized as one of the hallmark 
characteristics of renal disease (Kopple 1999).  Malnutrition and reduced muscle 
mass have both been implicated in the functional decline of CKD patients (Brodin et 
al 2001; Fahal et al 1997) and in the ageing population (Russ et al 2012; Cesari et al 
2009).   
 
Skeletal muscle wasting in dialysis patients can be influenced by many individual 
factors (inactivity, sarcopaenia/ageing, medical treatment and comorbidities such 
as CVD, diabetes; Pupim et al 2005, peripheral vascular disease; Segura 2010), but is 
largely driven by the independent or interactive effects of malnutrition, disuse 
atrophy and a greater proportion of protein catabolism than protein synthesis 
(Workeneh & Mitch 2010).  As the largest reservoir of protein within the body, 
skeletal muscle mass can serve as an excellent indicator of protein balance and 
hence may be clinically useful in assessing and monitoring the patient as the disease 
progresses. 
 
In CKD stage 5 (CKD5) patients most body composition research (cross-sectional and 
interventional) to date has focused on patients undergoing haemodialysis (HD) with 
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peritoneal dialysis (PD) patient under-represented in the literature.  This is partly 
due to the greater accessibility and availability of HD patients whilst dialyzing in 
hospital.  Despite this, some comparative studies have been published that highlight 
the similarities and differences in the aetiology of wasting between the two 
principal CKD5 dialysis modalities (McIntyre et al 2006) and in some of the 
underlying muscle fibre characteristics (Sakkas et al 2004).   
 
Patients treated with PD are often malnourished, presenting with low protein levels 
and decreased fat free (lean) mass (Vasselai et al 2008) but often with increased 
overall adiposity (greater visceral fat/subcutaneous fat ratio; Pellicano et al 2011).  
This may be partially attributed to the glucose-based dialysate used in PD as the 
increased availability of glucose in the dialysate promotes greater uptake and 
assimilation by the body (Schmidt & Salahudeen 1999), thereby potentially masking 
the extent of the underlying muscular atrophy.  This may be unique in the dialysed 
population; however, a recent study (van Biesen et al 2013) used matched pair 
analysis to directly compare body composition and volume overload in HD and PD 
patients, finding no significant difference between the two groups though both had 
significantly less favourable results to a healthy reference population (reduced lean 
tissue mass and greater fat mass in both HD and PD populations than healthy; van 
Biesen et al 2013).  
 
Additional factors contributing to the protein-energy malnutrition have been 
described elsewhere in a consensus statement for the International Society of Renal 
Nutrition (Carrero et al 2013; Figure 2.1) and include co-morbidities and 
interactions between metabolic acidosis, inflammation, endocrine/hormonal 
disorders, physical activity, drugs, genetic components and the effect of ageing.  
 
Measures of speed, agility, and strength show peritoneal dialysis patients are less 
able in comparison to healthy age-matched controls, despite similar muscle mass 
(Brodin et al 2001).  Hand-grip strength, as a surrogate marker for protein stores, 
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has been observed to be a good predictor of outcomes in dialysis patients (Wang et 
al 2005; Stenvinkel et al 2002).  It is debatable whether the uraemia or the 
treatment itself is the main cause of this functional disability, or the summation of 
other factors including inflammation, but it remains the case that there is an 
underlying weakness that grows as the disease intensifies (Johansen et al 2007) and 
thus would benefit from being routinely monitored.   
 
Anthropometric measures such as skinfold thicknesses and waist and limb 
circumferences are routinely taken with the intention of monitoring the nutritional 
status of CKD patients.  However, basic measures such as limb circumference do not 
allow accurate composition analysis of the limb being measured (Roubenoff & 
Hughes 2000) and skinfold measures using calipers are highly prone to error - no 
matter how well trained and experienced the technician - as skin calipers have been 
shown to overestimate the subcutaneous fat thicknesses of the thigh in individuals 
with higher fat values (Selkow et al 2011). 
 
The accurate measurement of muscle mass is therefore an important research and 
clinical tool for assessing change from an intervention, monitoring 
progression/deterioration associated with this stage of CKD or from disuse and 
frailty-related ageing.  Direct measurement of muscle mass is not always feasible by 
means of Magnetic Resonance Imaging (MRI) or other reference methods (e.g. total 
body potassium or DEXA) due to financial or time costs, general patient access, or 
the sheer volume of patients that need to be monitored.   
 
High resolution ultrasound (US) has shown great potential as an alternative (near-
bedside/patient) method to assess muscle and fat mass at specific anatomical sites; 
it has been shown to accurately measure change in muscle size resulting from 
anabolic interventions and also to monitor the effects of ageing and disuse in a 
variety of populations though most were healthy and of working age (knee-joint 
injury, Uremović et al 2004; healthy men, Miyatani et al 2002; Miyatani et al 2004; 
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healthy adults and patients with multiple organ failure, Campbell et al 1995; older 
men and women, Bemben 2002; critically ill hemiplegic, Moukas 2002; working age 
healthy, Sanada et al 2006; healthy adults, Ahtiainen et al 2010).  
 
Ultrasound is a relatively expedient method of this type of data acquisition and has 
been shown to safely produce high quality images of muscle size and structure 
(Table 2.3).  Equipment is inexpensive in comparison to other clinical methods such 
as MRI or DEXA and can be taken to the patient at their bedside, in a research 
laboratory or other non-clinical site.   
 
A recent literature review (English et al 2012a) indicated that there was good 
reliability (intra and inter-rater, same day and separate day test-retest reliability, all 
described as “generally high” with intra-class correlations greater than 0.7, 
coefficient of variations were “low” between 1.2-7.4%) for measuring muscle size 
across a number of limb sites in healthy populations. However, there is currently 
very limited evidence for the reliability of ultrasound to measure muscle size in 
clinical populations in general and none in CKD patients (English et al 2012a). 
 
The purpose of this study was to examine the validity, reliability (reproducibility and 
potential sensitivity) and clinical utility of a US method compared to MRI for the 
assessment of quadriceps muscle (vastus lateralis, VL) anatomical cross-sectional 
area (ACSA), muscle thickness, and fat thickness in stage 5 CKD patients undergoing 
continuous ambulatory peritoneal dialysis therapy. 
 
5.2 Methods 
5.2.1 Participants 
Twenty (18 male, 2 female) stage 5 CKD patients undergoing continuous ambulatory 
peritoneal dialysis (CAPD) for an average of 30.7 ± 32.2 months volunteered to 
participate in this cross-sectional study (Table 5.1).   
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All participants were recruited from a single hospital dialysis unit.   
 
Table 5.1 - Participant/subject characteristics (n = 20, 18M, 2F) 
Age (years) 56.5 ± 16.7  (median 60, range 17-79) 
Height (cm) 170.1 ± 7.4 
Mass (kg) 78.0 ± 15.4 
BMI (kg/m2) 26.8 ± 3.8 (median 26.3, range 19.9-38.7) 
PD dialysis vintage (months) 30.7 ± 32.2 
Presented as mean ± standard deviationunless otherwise stated; BMI = body mass 
index; PD = peritoneal dialysis 
 
All participants were informed of the protocol and procedures to be used, and 
informed written consent was obtained from each, as approved by the appropriate 
local NHS Scientific Merit and Ethics Committee.  Participants attended two 
sessions, seven days apart.   
 
Ultrasound assessments were performed in both sessions at a similar time of day, 
and MRI measurements were made during the second visit only.  US and MRI 
measurements were acquired in a counter-balanced fashion.  All data was acquired 
with dialysate in the peritoneal cavity. 
 
Strength data was obtained in the second laboratory session after completion of all 
US and MRI assessments. 
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5.2.2 Measurements 
All ultrasound measures were taken by a single assessor, highly experienced in 
ultrasonography in both a clinical and laboratory setting. 
 
5.2.2.1 Ultrasound (US) 
All US measurements were attained in brightness mode (B-mode) via a portable 
ultrasound system (SonoSite® 180 Plus, SonoSite Inc., Bothell, Washington, USA) 
using a 7.5MHz linear array probe. Participants lay supine for a period of 20 minutes 
prior to any measurements being taken to allow fluid equilibration to occur (Berg et 
al 1993).  The probe head was coated with water-soluble transmission gel which 
provided acoustic contact without depressing the dermal surface (Miyatani et al 
2002).  Compression of the tissues was kept to an absolute minimum by 
maintaining a consistent low pressure with the US probe throughout scanning. 
 
All assessments were undertaken after identification of the measurement sites by 
palpitation and then US scanning of the key anatomical landmarks.  The skin surface 
was marked with a non-permanent marker and an angioma (mole) map was 
constructed for each participant to ensure the correct location and placement of 
the probe for repeat assessments. 
 
5.2.2.1.1 Anatomical Cross Sectional Area (ACSA) 
ACSA of the vastus lateralis (VL) was examined by US at mid-femur (identified as the 
distance half way between the apex of the greater trochanter and the apex of the 
lateral epicondyle) with the ultrasound probe held transversely, perpendicular to 
the skin, thus allowing a view of the muscle in the axial plane. The probe was moved 
in a straight line from the lateral to the medial edge of the VL over external markers 
that were placed on the skin.  All scans were captured on video-tape to allow 
subsequent analysis.   
 
 146 
 
The external markers cast an acoustic shadow on each image which acted as 
reference points allowing the ACSA image to be reconstructed on a computer using 
imaging software (Adobe Photoshop, Adobe Systems Inc., California, USA).  These 
reconstructed ACSA images were then measured using digitizing software (NIH 
image, National Institute of Health, Bethesda, Maryland, USA). 
 
 
5.2.2.1.2 Depth or Thickness measurements 
US muscle and fat thickness measurements were recorded in the axial plane at the 
mid-femur length/mid-VL width intersect (defined as mid-VL).  Once the image was 
located the screen was frozen and the systems calipers were used to measure tissue 
thicknesses.  Calipers were removed to capture a second image for later analysis. 
 
Fat thickness was measured as the distance between the skin surface and the fat/VL 
interface (or tissue plane).  VL muscle thickness was measured as the distance from 
the fat/VL tissue plane to the VL/VI tissue plane. All ultrasound measurements were 
performed on the left leg and were repeated after seven days. 
 
5.2.2.2. Magnetic Resonance Imaging (MRI) 
A 0.2T magnetic resonance imaging (MRI) extremities scanner (E-Scan, ESAOTE 
Biomedica, Genova, Italy) with a flexible coil was used to obtain axial plane scans at 
mid femur length for the left leg of all participants. 
 
Axial plane scans were acquired using a T1 weighted spin echo profile with the 
following parameters - time to echo: 16ms; repetition time: 38ms; field of view: 160 
x 160mm.  All participants lay supine for 20 minutes prior to and during the 
scanning procedure.  Oil capsules were placed lightly on the surface of the skin 
along the mid-femur length line to highlight this point precisely on the MRI scan; 
the oil capsules are clearly visible on T1 weighted MR images.  The capsules were 
oriented in a manner such to allow the examiner to identify precisely the mid-VL 
point.  ACSA of the VL muscle was determined at the mid femur length. VL muscle 
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thickness and fat thickness were obtained at mid-VL (as described above) from the 
MRI scans.  Images were subsequently analyzed using digitizing software (NIH 
Image J). 
 
5.2.2.3. Strength and function assessments  
Participants performed a short aerobic warm-up using a cycle ergometer for five 
minutes prior to the strength assessments.  Rest was taken as required throughout 
assessments. 
 
Peak force (PF) during knee extension (KE) exercise at a joint angle of 45 degrees 
was measured on the dominant leg using an isometric dynamometer (described 
first by Gleeson et al 2002, and in Chapter 3, above).  Participants practiced a few 
times to standardize the “kicking” motion.  The best of three maximal knee 
extensions was then recorded, with a two minute rest between each attempt. 
 
Sit-to-stand 60 (STS60) was measured as described in Chapter 3 (Methods).  A full 
count of “one” was tallied once the participant had stood fully upright, and 
returned to the seat (sit-to-stand-to-sit).  This procedure was repeated as many 
times as they were able in 60-seconds; self-paced, and allowing for as many rests as 
were necessary within the minute. 
 
5.2.3 Statistics 
Following normality checks of the data distribution, standard statistical methods 
were used for the calculation of mean and standard deviations where appropriate.  
Validity assessments (US measures and MRI) were determined by ICC, using a two-
way random effects model (absolute agreement definition) (Rankin & Stokes 1998).   
Intra-observer reliability/repeatability for US measurement of the VL muscle, 
muscle thickness and ACSA was tested with an intra-class correlation coefficient 
(ICC) using a one-way random effects model (Shrout & Fleiss 1979). 
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Typical error (standard error of the measurement, SEM) was assessed for both 
intra-observer reliability of the ultrasound method, and as validity between US and 
MRI.  SEM was calculated using the equation SDdiff/√2, where SDdiff is the standard 
deviation of the difference scores between the two tests.  The minimally detectable 
change (MDC) of the US and MRI methods were defined using a 95% confidence 
interval and the equation (1.96)(√2)(SEM), (Weir 2005).  Relationships between 
measures of muscle mass and muscle strength were assessed using Pearson’s 
correlation coefficient. 
 
Significance was set at p<0.05. 
 
5.3 Results 
All results are presented as mean ± SD and to two decimal places (2dp) unless 
otherwise stated. 
 
5.3.1 Validity of US measurements 
Ultrasound and MRI were highly and significantly correlated (ICC for ACSA 0.953, 
95%CI [0.885, 0.982], p=0.000, VL muscle thickness 0.988, 95%CI [0.970, 0.995], 
p=0.000, and fat thickness 0.978, 95%CI [0.912, 0.994], p=0.000, Table 5.2) with no 
significant difference between the two methods (p>0.2 for all measures).   
 
This was initially graphed with the line of equality between methods to 
demonstrate the correlation (figs 5.1a-c), before further assessing the limits of 
agreement using the Bland-Altman (1986) method. The line of equality represents 
perfect agreement between the methods (where x=y).  Any data-points away from 
this line demonstrate a bias or level of disagreement. 
 
  
 149 
 
Figure 5.1a - Comparison of MRI and US measures of VL ACSA  
 
 
 
 
Figure 5.1b - Comparison of MRI and US measures of VL thickness   
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Figure 5.1c - Comparison of MRI and US measures of fat thickness.   
 
 
 
 
Table 5.2 summarizes the validity of Ultrasound measurement of the vastus lateralis 
(VL) muscle ACSA, muscle thickness, and subcutaneous fat compared to MRI 
measures. 
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Table 5.2 – US validity at mid-VL site compared to MRI (to two decimal places) 
 N US MRI 
ICC 
(95% CI) 
Absolute 
difference 
Typical error   
(95% CI) 
Limits of 
Agreement 
ACSA (cm2) 19 17.82 ± 2.82 18.07 ± 2.92 0.95 (0.88, 0.98) 0.25 ± 0.86 0.61 (0.46, 0.90) 1.81 
VL thickness 
(cm) 
20 1.91 ± 0.37 1.91 ± 0.36 0.99 (0.97, 0.99) 0.00 ± 0.06 0.04 (0.03, 0.06) 0.12 
Fat thickness 
(cm) 
10 0.75 ± 0.60 0.70 ± 0.52 0.98 (0.91, 0.99) 0.03 ± 0.07 0.05 (0.04, 0.09) 0.17 
Presented as mean ± standard deviation; ACSA = anatomical cross-sectional area; VL 
= vastus lateralis; ICC = intra-class correlation; US = ultrasound; MRI = magnetic 
resonance imaging 
 
 
 
The mean (average) differences between ultrasound and MRI for ACSA (0.25 ± 0.86 
cm2) and VL thickness (0.00 ± 0.06 cm) show MRI yielding slightly higher values than 
US for each muscle index, with fat thicknesses marginally lower (-0.03 ± 0.07 cm).   
 
Bland-Altman (1986) analyses were then performed and graphed (Figures 5.2a-c) of 
the two methods being compared (MRI and US) to illustrate the agreement 
between them, with the average of two methods along the (horizontal) x-axis 
(MRI*US/2) and difference of methods (MRI-US) on the (vertical) y-axis.  Limits of 
agreement (1.96*SD) are shown with the dashed line and mean (absolute 
difference) by the solid line. 
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Figure 5.2a – VL ACSA Bland-Altman graph; average of two methods along the x-
axis, and difference of methods on the y-axis   
Limits of agreement (1.96*SD) are shown with the dashed line, and mean (absolute 
difference) by the solid line. 
 
 
 
Figure 5.2b – VL muscle thickness Bland-Altman graph 
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Figure 5.2c – Fat thickness Bland-Altman graph; average of two methods along the 
x-axis, and difference of methods on the y-axis   
Limits of agreement (1.96*SD) are shown with the dashed line, and mean (absolute 
difference) by the solid line. 
 
 
The sample size was too small to comment on whether accuracy changes with 
tissue size, and despite the limits of agreement being quite narrow; they may still 
have been affected by the one or two outliers.   
 
Therefore, logarithmic transformations were performed to remove any skew, and 
further investigate any linearity and correlations.  The modulus of the previously 
calculated average and difference were used in the log-transformation, and the new 
data was plotted (Figures 5.3a-c); logaverage along the x-axis and log│difference│ on the 
y-axis.  Limits of agreement (1.96*SD) are shown with the dashed line, and mean by 
the solid line.    
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Figure 5.3a – VL ACSA log-transformed Bland-Altman graph; log average along the x-
axis, and log│difference│ on the y-axis. 
 
 
Figure 5.3b – VL log-transformed Bland-Altman graph; log average along the x-axis, 
and log│difference│ on the y-axis. 
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Figure 5.3c – Fat thickness log-transformed Bland-Altman graph; log average along 
the x-axis, and log│difference│ on the y-axis.  
 
 
 
 
5.3.2 Intra-rater reliability/repeatability of Ultrasound 
The two consecutive sets of ultrasound measures (taken seven days apart) were 
highly correlated in the direct measures taken at the mid VL site; VL muscle 
thickness (ICC 0.981, 95%CI [0.953, 0.992], p=0.000) and fat thickness (ICC 0.992, 
95%CI [0.980, 0.997], p=0.000; Figures 5.4a-b).  The line of equality represents 
perfect agreement between the measures (where x=y).  Any data-points away from 
this line demonstrate a level of disagreement. 
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Figure 5.4a - Intra-rater Reliability using ultrasound for the measurement of VL 
muscle thickness   
 
 
Figure 5.4b - Intra-rater Reliability using US for the measurement of fat thickness at 
the mid-VL point   
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Table 5.3 summarizes the intra-rater reliability of Ultrasound measures of the 
vastus lateralis (VL) muscle thickness, and same site subcutaneous fat thickness. 
 
 
 
Table 5.3 – Intra-rater reliability of ultrasound at mid-VL point (to two decimal 
places) 
 N US 1 (cm) US 2 (cm) ICC (95% CI) 
Typical error 
(95% CI) 
MDC 
(cm) 
Mid-VL thickness (cm) 20 1.91 ± 0.37 1.92 ± 0.35 0.98 (0.95, 0.99) 0.05 (0.04, 0.07) 0.14 
Total muscle thickness 
(cm) 
10 1.83 ± 0.44 1.83 ± 0.42 0.97 (0.88, 0.99) 0.07 (0.05, 0.13) 0.19 
Fat thickness (cm) 20 0.95 ± 0.83 0.96 ± 0.83 0.99 (0.98, 1.00) 0.08 (0.06, 0.11) 0.22 
Presented as mean ± standard deviation; VL = vastus lateralis; US = ultrasound; ICC = 
intra-class correlation; MDC = minimal detectable change 
 
 
5.3.3 Relationships between measures 
Table 5.4 shows the relationships between the different measures of muscle and fat 
at the mid-VL site (VL ACSA, total muscle depth, VL-only depth, and fat depth).   
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Table 5.4 – Correlations between the different US-derived measures of muscle and 
fat and the mid-VL point 
 
Total muscle 
thickness 
VL thickness Fat thickness 
VL ACSA 
R=0.530 
p =0.020 * 
n=19 
R=0.582 
p=0.009 ** 
n=19 
R=0.305 
p=0.204 
n=19 
Total muscle 
thickness 
 
R=0.989 
p=0.000 ** 
n=22 
R=0.267 
p=0.229 
n=22 
VL thickness   
R=0.326 
p=0.138 
n=22 
Results presented as Pearson’s r, significance, n; **significance is at the p<0.01 level 
(two-tailed), *significance is at the p<0.05 level (two-tailed); n = sample size used in 
analysis; ACSA = anatomical cross sectional area  
 
 
 
Table 5.5 describes the principal correlations between the measurements of muscle 
and fat using US and knee extension peak force (muscle strength). Relationships 
between body composition and strength measures showed good correlation 
between knee extension peak force (KE PF) and all muscle size measures using US.   
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Table 5.5 – Correlations between strength and US-derived measures of muscle and 
fat at the mid-VL point 
 N Mean ± SD R 
Knee extension peak force 45 
(Newtons) 
22 254.14 ± 108.00 KE PF45 
ACSA (cm2) 19 17.82 ± 2.82 0.61 (p=0.006**) 
Total muscle thickness (cm) 22 3.58 ± 0.68 0.49 (p=0.022*) 
VL thickness (cm) 22 1.93 ± 0.37 0.50 (p=0.018*) 
Fat thickness (cm) 22 1.11 ± 0.99 0.23 (p=0.23) 
Results presented as Pearson’s r, significance 
**significance is at the p<0.01 level (two-tailed), *significance is at the p<0.05 level 
(two-tailed); ACSA = anatomical cross sectional area; KEPF45 = knee extension peak 
force at 45 degrees 
 
The functional measure assessed (STS60) showed no significant correlations to any 
measure of muscle size or fat depth (p>0.1, n=20). 
 
All muscle size measures showed significant relationships (p<0.05) to each other 
with very high correlations between the same measure, independent of method 
(MRI and US gave similar results; US or MRI ACSA r=0.96, p=0.000, n=19; VL 
thickness r=0.99, p=0.000, n=20). This suggests that either method could be used. 
 
 
5.4 Discussion 
5.4.1 Validity of US to MRI measures 
The results of this study indicate that in comparison with MRI measurements, the 
use of 2-D B-mode ultrasonography (US) is a valid means of characterizing VL 
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muscle ACSA and thickness as well as subcutaneous fat at the same site in CKD5 
patients receiving peritoneal dialysis therapy (Table 5.2).   
 
The typical error in this study (Table 5.2) equates to 2.6% (VL ACSA), 1.8% (VL 
thickness) and 6.0% (fat thickness).  This is in-line with previous US-MRI validation 
studies (in non-renal disease populations) that have used US to measure the 
quadriceps muscle (VL ACSA ICC 0.905, error 0.38cm2, healthy participants, 
Ahtiainen et al 2010; VL ACSA ICC 0.999, healthy participants, Reeves et al 2004;  
4.4% error against CT, coronary arterial disease patients, Thomaes et al 2012)  and 
other sites (hip, ICC 0.81-0.89, healthy participants, Mendis et al 2010; lower 
trapezius, r=0.77, healthy/asymptomatic participants, O’Sullivan et al 2009).   
 
US scans are able to clearly distinguish between muscle, fat, and connective tissue 
(Esformes et al 2002) and also allow accurate selection of measurement sites.  This 
method can provide information on ACSA changes along the entire muscle length in 
response to training, disuse, and sarcopenia (Reeves et al 2004).   
 
Given that clinical disturbances such as fluid accumulation and muscle wasting are 
very common in CKD, measures that can distinguish between tissues (unlike BMI, 
body mass, limb circumference) and accurately reflect excess body fat are very 
useful.  The ability to quickly and accurately assess change in the CKD population 
may contribute to further explanations and associations with prognosis or mortality, 
such as ongoing research into the obesity paradox/reverse epidemiology (Morales 
& Praga 2012; discussed in Chapter 2, above). 
 
5.4.2 Reliability and repeatability of US measures 
In addition, the US measurements were found to be highly repeatable (Table 5.3) in 
this sample of patients. 
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Fluid status has been shown to affect reliability of body composition measurement 
techniques, but an earlier study in a very similar population (CKD patients also 
undergoing PD) has shown that multi-frequency (MF) BIA, DEXA, and skinfolds 
assessment all had much wider limits of agreement between methods (range 
2.9±7.2% to 5.7±7.8%) (Konings et al 2003) than the repeated measures with US in 
this study.   
 
Fat measurement error was greater and more variable (Table 5.3, repeatability, 
10.0%) than VL muscle thickness using US (Table 5.3, VL depth 2.4%).  The larger 
variation observed may in part be due to some compression of the subcutaneous 
fat beneath the probe during the procedure, but other studies have also found 
lower repeatability in measures of subcutaneous fat where participants were 
classed as overweight or obese (ICC 0.92, Bazzocchi et al 2011) as in this participant 
group (Table 5.1, BMI 27, range 20-39). 
 
The reported ICC of repeated measures of VL muscle depth (0.98, Table 5.3) of the 
thigh is well within, and at the better end of the range of acceptable-to-excellent 
reliability seen in other studies of both healthy and unwell populations (ICC 0.72-
0.99; Miyatani et al 2002; Matschke et al 2010b; Reeves et al 2004; Bemben 2002; 
Thoirs & English 2009; English et al 2012b).  Previously, repeated measurement of 
ACSA have been reported with “good” reproducibility in young healthy subjects (ICC 
0.87, rectus femoris, e Lima et al 2012); lower than the accuracy found in the direct 
depth measurement in this CKD5 patient study.  The variation in error between VL 
muscle measures is small but notable; ACSA measurement error is marginally higher 
than measures of VL depth as there is more scope for the accumulated inflation of 
small errors during image collation. 
 
The benefits of using US in cachectic patients to assess muscle quality and 
architecture have been previously alluded to (Matschke et al 2010b).  Alongside the 
demonstrated validity and reliability of this method for CKD patients, US is clearly a 
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useful tool for comparative and interventional research studies, especially with the 
increased expediency of the US method and the reduction in participant burden 
(compared to other reference methods),  the advantages are even more apparent.   
 
 
5.4.3 Concurrent validity (relationship between measures of muscle size) 
This study also investigated the relationship between the VL thickness and VL 
anatomical cross-sectional area (VL ACSA).  Unsurprisingly, VL thickness, total 
muscle thickness, and VL ACSA are highly correlated with each other (Table 5.4, 
p<0.05), with VL thickness particularly well correlated to both total muscle and VL 
ACSA (p<0.01).   
 
Using a thickness measure as an alternative to ACSA has been investigated in other 
studies and found to provide very similar degrees of correlation (and therefore 
information) with slightly better concordance in the lower extremities (upper thigh 
r=0.922-0.949, p<0.001, Ogawa et al 2012; mid-quadriceps, r=0.91, Abe et al 1997) 
compared to the arm muscles (mid-upper arm, r=0.870-0.915, p<0.001, Akagi et al 
2008).   
 
This highly significant correlation between these measures means a direct thickness 
measure might be able to provide acceptably similar information for monitoring and 
assessment purposes as the ACSA would.  It is a more expedient process and 
measure in comparison to the more time-intensive image reconstruction and 
measurement of ACSA.  By using one clear image at a single site, researchers and/or 
clinicians can minimize the risk of both measurement and processing errors.  
 
5.4.4 Relationship between regional body composition and strength 
The ability to measure regional body composition with greater accuracy and assess 
muscle size and structure by ultrasound (VL thickness, total muscle thickness, ACSA) 
 163 
 
as a potential proxy for the measurement or assessment of strength (assessed here 
by knee extension peak force; KE PF) in CKD patients has not been extensively 
researched. 
 
Knee extension requires significant quadriceps activity, especially at knee angles of 
15-65° (where zero degrees is straight leg, or full knee extension), with the Vasti 
muscles being most predominantly used at angles less than 45° (Escamilla et al 
1998).  The KE PF45 assessed maximal strength at a 45° knee bend, and was 
significantly associated with each measure of the VL muscle size in this study (VL 
thickness p<0.05, total muscle thickness p<0.05, VL ACSA p<0.01, Table 5.5). 
 
Associations between muscle size and maximal strength are well established, and 
often by adjusting results for an established measure of muscle size (e.g. muscle 
volume, anatomical and physiological cross sectional area; Bamman et al 2000) 
thereby assessing strength per unit of muscle, strength differences between 
population groups often disappear.  Previous studies have assessed muscle size by 
way of volume, anatomical cross-sectional area (ACSA), physiological cross-sectional 
area (PCSA) and muscle layer thickness.  In these, muscle ACSA has often 
demonstrated the most significant correlation to the strength measure used (tricep 
surae ACSA [r=0.733] and PCSA [r=0.715] were both better correlated/predictors of 
strength [maximal voluntary contraction] than volume [r=0.649], Bamman et al 
2000), though authors of more recent publications have disagreed despite there 
being little difference in the results (muscle volume [r=0.760-0.926] better than 
ACSA [r=0.784-0.906] of elbow flexors, Akagi et al 2009; and the quadriceps [volume 
correlation 0.776, ACSA correlation 0.730], Blazevich et al 2009).  In the present 
study, only the ACSA and thickness of the muscle of the quadriceps (at the mid-VL 
site) were examined and calculated to be correlated to maximal strength (knee 
extension peak force).  In this study (Table 5.5), VL ACSA was shown to be most 
significantly correlated (p<0.01) closely followed by both the total muscle thickness 
and VL thickness (p<0.05). This suggests that the more extensive the information 
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available about the muscle size, the greater the correlation or predictive value 
potential.   
 
5.5 Limitations  
The greatest limitation of this study, apart from the small sample size, is the lack of 
information regarding the hydration status of the participants.  With this additional 
information it may have been possible to account for some of the measurement 
error; oedema has been shown to fill the interstitial space between body tissues, 
rendering tissue boundaries less definite. 
 
The decision to examine the mid vastus lateralis point allowed direct associations 
between muscle size and strength to be investigated.  However, measuring the 
muscle and subcutaneous fat at only this site means the validity and reliability of US 
cannot necessarily be applied to all body-sites.  In recent years, evidence has been 
accumulating on the negative effects of abdominal obesity and the relationship with 
the development of CKD (Cuppari 2013; Zoccali et al 2012) whether measured using 
gold standards tools (computed tomography in non-dialysed CKD; Kamimura et al 
2013), or simpler methods such as waist circumference (CKD stages 1-4; Kramer et 
al. 2011) or waist-to-hip ratio (non-CKD at baseline; Elsayed et al 2008), and the 
long-term association with mortality (PD patients, Choi et al 2013).   
Finally, the study only used one assessor when examining reliability and therefore 
the results are for intra-rater use alone. We do not know if another assessor (inter-
rater) would show a similar level of accuracy in their measures.  Generalization for 
use by a multitude of clinicians is not possible without further inter-rater reliability 
testing or training. 
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5.6 Conclusions 
Valid assessment of regional body composition can be achieved via high-resolution 
ultrasound in CAPD CKD5 patients.  In these patients there was high correlation 
between VL ACSA and VL muscle thickness in the axial plane, with all US measures 
highly repeatable and characterized by low measurement error. 
 
VL thickness measured by US in the axial plane also has potential to be used as a 
marker of maximal strength (knee extension peak force at 45 degrees) and vice 
versa, though larger participant numbers are required to develop prediction 
equations or a reference sample for clinical use. 
 
5.7 Implications for research 
The validity and reliability of the US in repeated measures (in comparison to the 
gold standard MRI) could be applied to the general CKD population as the results 
are in line with previous studies in non-PD patients. However, the relationship 
between muscle size and strength may not be directly applied to other populations 
until a consensus has been agreed upon as to the differential wasting in the dialyzed 
population (greater differences between genders than between dialysis modality, 
van Biesen et al 2013).   
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CHAPTER 6 – Are whole and regional body composition 
indices, physical function, and uraemic symptoms related in 
non-dialysis dependent stage 3 CKD patients (NDD CKD3)? 
 
6.1 Introduction 
Observations from cross-sectional data (Table 4.4 and 4.6) have established that 
there is a deterioration in physical function and uraemic symptoms across the 
disease trajectory (from CKD3 to CKD5). 
 
The clinical syndrome of uraemia is associated with fluid, metabolic abnormalities, 
electrolyte and hormonal imbalances which develop in parallel with deterioration of 
renal function, some of which start early in the disease trajectory (by CKD3) 
whereas others appear much later (reviewed by Fahal et al 2013).  Using patient-
reported uraemic symptom as a general guide to the progression of CKD, alongside 
the known increased frailty and dependence reported in the literature (Johansen et 
al 2013), it is likely that there would be a greater manifestation of symptom 
number, frequency, and intrusiveness into the life of a patient in the later stages of 
CKD than early to moderate stages.  A study examining pre-dialysis CKD (stage 3b-4) 
patients observed the most commonly reported symptoms to be sleep disturbance, 
excessive tiredness and loss of muscle strength (Aulakh et al 2012), highlighting that 
muscle strength and exercise capacity are important contributors to the HRQoL and 
general well-being of patients with pre-dialysis CKD. 
 
Other uraemic symptoms that appear early in the disease process include being 
easily fatigued, muscle stiffness, and spasms (Aulakh et al 2012).  Fatigue, defined 
as the failure to sustain force of power output (Edwards et al 1981) is often 
reported by patients already on dialysis (Fahal et al 2013).  However, people 
 167 
 
with chronic kidney disease experience high levels of fatigue and are able to engage 
in fewer daily activities regardless of whether they are pre-dialysis (NDD) or are 
receiving either peritoneal or haemodialysis (Bonner et al 2010).  A potential 
contributor to fatigue, more generalised wasting, and other common symptoms is 
the effect of loss of appetite in CKD.  The loss of desire for food (defined as 
anorexia) is a commonplace symptom of uraemia in the CKD population, and 
typically develops when glomerular filtration rate (GFR) is 10-25% below normal 
and increases with the progression towards ESRD (Bergstrom et al 1999, Carrero et 
al 2009). This is possibly due to the retention of fluids and the reduced clearance 
rate (by the kidneys) of one or more appetite suppressants. 
 
Health-related quality of life (HRQoL) is also distinctly reduced by end-stage renal 
disease (Amro et al 2014).  Many studies have also suggested that HRQoL is already 
affected in “healthier” CKD patients, prior to the initiation of renal replacement 
therapy, implying that the initial decline originates at an earlier phase of the disease 
trajectory (comparing HRQoL using the Schedule for the Evaluation of Individual 
Quality of Life [SEIQOL] and LUSS; Pugh-Clarke et al 2006).    
 
Protein energy wasting (PEW) is characterised by a decline in body protein mass and 
energy reserves and is an often underappreciated condition in early to moderate 
stages of CKD, despite it being a strong predictor of adverse outcomes (Kovesdy et 
al 2013). PEW is apparent in at least 20-25% of patients diagnosed with early to 
moderate CKD and increases as the disease progresses towards end-stage (dialysis-
dependent) renal disease (Kovesdy et al 2013). The loss of body protein mass (and 
energy reserves) manifests as muscular atrophy, and generalised wasting, alongside 
fatigue, difficulty concentrating, and trouble sleeping (Novak et al 2008). 
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Although some previous studies have examined the body composition of patients 
earlier in the disease process (pre-dialysis) using gold standard techniques such as 
DEXA (Nielsen et al 1994) others have relied upon BIA (Avesani et al 2001, Bellizzi et 
al 2006, Carvalho et al 2012) but mainly using anthropometrics and skinfolds 
(Castaneda-Sceppa et al 2007, Carvalho et al 2012).   
 
As previously mentioned (section 4.6) these tools are not able to distinguish 
between tissue (muscle and fat), and those that do (such as BIA) cannot comment 
on site-specific response to training, or other intervention, such as architectural 
adaptation (pennation angle, fibre length).  Assessing muscle size and architecture 
in pre-dialysis patients using ultrasound is therefore important to establish the 
extent of wasting prior to the need for RRT. 
 
6.1.1 Aims and Hypotheses 
The previous study investigating validity and reliability of US (Chapter 5, above) 
clearly demonstrated that there are strong relationships between muscular 
isometric strength (measured by knee extensor peak force at 45 degrees) and US 
measures of the vastus lateralis (VL) muscle anatomical cross-sectional area (ACSA) 
and VL muscle depth in patients undergoing continuous ambulatory peritoneal 
dialysis (CKD5).   
 
The aim of this study was to explore whether any relationships between body 
composition, physical function and uraemic symptom score were affected by the 
method of characterising body composition.  It was hypothesized that strength and 
physical function would correlate positively with muscle size and architecture, and 
negatively with uraemic symptoms (LUSS). 
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6.2 Methods 
6.2.1 Participants 
All participants were recruited from a single hospital outpatient unit.   These are the 
same cohort of CKD3 patients who volunteered for Study 1 (Chapter 4, above). 
All participants were informed of the protocol and procedures to be used and 
informed written consent was obtained from each, as approved by the appropriate 
local NHS Scientific Merit and Ethics Committee. 
 
6.2.2 Assessments 
Data collected previously included ultrasound (US) measures of the vastus lateralis 
(VL) muscle thickness (or depth) and muscle fibre pennation angle at the mid-VL 
point, total muscle thickness and fat thickness at the same site.  Ultrasound images 
at the mid-VL site were taken in the sagittal plane (to observe muscle 
structure/architecture). 
Anthropometric (mid-thigh and mid-arm circumference; section 3.3.1), strength 
(handgrip, knee extension peak force at 45 degrees, leg press peak force at 45 
degrees; section 3.3.3), functional measures (sit-to-stand 5, sit-to-stand 60, North 
Staffordshire Walk test, physical activity recall; section 3.3.2), and health-related 
quality of life (Leicester Uraemic Symptom Score; section 3.3.4) were all collected as 
described previously (Chapter 3). 
 
6.2.3 Statistics 
Following normality checks (Shapiro-Wilks test) of the data distribution, standard 
statistical methods were used for the calculation of mean and standard deviations 
where appropriate. 
Correlations between measures were calculated using Pearson’s r in SPSS v21.0. 
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Significance (two-tailed) was set to be accepted at p<0.05. 
 
6.3 Results 
All data are presented as mean and standard deviation (mean ± SD), and to two 
decimal places (2dp), unless otherwise stated. 
Participant demographics are shown in Table 6.1, and correlations in Tables 6.2-6.6. 
 
6.3.1 Correlations (within assessment type) 
6.3.1.1 Anthropometric measures (MTC, MAC) 
There was a highly significant correlation between the two different 
anthropometric (MAC, MTC) measures (r=0.81, p=0.00, n=51).   
 
6.3.1.2 Strength measures (KE PF 45, LP PF 45, handgrip) 
Handgrip strength was highly correlated to peak isometric strength of the knee 
extensor muscles (KEPF45; r=0.79, p=0.00, n=39) and leg press peak force (LPPF45; 
r=0.68, p=0.00, n=47).  Unsurprisingly, LPPF45 and KEPF45 were also significantly 
correlated (r=0.66, p=0.00, n=39).  
 
6.3.1.3 Functional measures (STS5, STS60, NSRI walk test, PAR) 
Sit-to-stand (functional) measures were significantly (negatively) correlated to each 
other, as would be expected (high STS60 and low STS5 is preferable; r= -0.72, 
p=0.00, n=48).   
The walk test (NSRI) was also significantly correlated with both STS tests in CKD3.  
As with STS5, a low score (time in seconds) in the walk test is preferable, so the 
positive (highly significant) correlation between walk test and STS5 was expected 
(r=0.76, p=0.00, n=48), as was the negative (highly significant) correlation between 
STS60 and walk test (r= -0.65, p=0.00, n=46).  
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PAR was correlated to all other measures of strength (r=0.32-0.39, p<0.05, n=39-50) 
and function (r=0.39-0.41, p<0.01, n=48-50). 
 
6.3.1.4 Health-related Quality of Life (Uraemic Symptoms) 
Unsurprisingly, LUSS were highly correlated to each other; LUSS 2 (frequency) and 
LUSS 3 (intrusiveness) in particular (all correlates r=0.57-0.85, p<0.01, n=51).   
 
6.3.2 Correlations between outcome measures 
Correlations between outcome measures are shown in Tables 6.2, 6.4, and 6.5, with 
summary Tables (6.3 and 6.6)  
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Table 6.1 - Participant characteristics (CKD3: 30 ≤ GFR ≤ 59 mL/min) 
  N Mean ± SD (1dp) 
Demographics 
Age (years) 51 59.9 ± 13.9 
Height (cm) 51 165.2 ± 9.3 
Weight (kg) 51 77.3 ± 14.2 
BMI 51 28.1 ± 4.5 
Total body fat (%) 51 32.5 ± 9.0 
Clinical 
measures 
GFR (mL/min) 51 45.7 ± 7.0 
Hb (g/dL) 50 13.7 ± 1.8 
Albumin (g/L) 50 41.8 ± 3.0 
Serum Creatinine (umol/L) 50 162.1 ± 57.5 
CO2 (mmol/L) 46 27.0 ± 3.3 
Urea (mmol/L) 49 15.1 ± 21.1 
Ultrasound 
measures at 
mid-VL site 
VL ACSA (cm2) 42 17.5 ± 3.6 
VL depth (cm) 51 2.2 ± 0.4 
Total muscle depth (cm) 51 3.9 ± 0.7 
Fat depth (cm) 51 1.3 ± 1.0 
VL pennation angle (degrees) 43 16.1 ± 2.5 
Anthropometry 
Mid-arm circumference (cm) 51 33.8 ± 3.9 
Mid-thigh circumference (cm) 51 52.5 ± 5.9 
Isometric muscle 
strength 
Handgrip (kg) 50 27.4 ± 11.8 
KE PF 45 (Newtons) 39 303.7 ± 134.5 
Leg press peak force (Newtons) 47 267.1 ± 141.4 
Physical 
Function and 
Activity 
Sit-to-stand 5 (secs) 50 16.2 ± 10.9 
Sit-to-stand 60 (count) 48 21.9 ± 9.3 
NSRI walk test (secs) 48 102.1 ± 48.9 
Physical Activity Recall 
(kcal/kg/day) 
51 35.4 ± 2.8 
HR Quality of 
Life (Uraemic 
Symptoms) 
LUSS 1 (number) 51 5.9 ± 2.4 
LUSS 2 (frequency) 51 14.5 ± 7.4 
LUSS 3 (intrusiveness) 51 8.5 ± 6.4 
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Table 6.2 – Relationship between US measures of subcutaneous fat, muscle size and architecture, with other routinely-used clinical 
outcome measures 
 
 
 
Anthropometry Strength Physical Function and Activity 
HR Quality of life 
 (uraemic symptoms) 
MTC  MAC  KE PF 45  LP PF 45 Handgrip  STS5  STS60  NSRI walk  PAR LUSS 1 LUSS 2 LUSS 3 
VL ACSA 
(N) 
-0.20  
(42) 
-0.01  
(42) 
0.35 *  
(34) 
0.43 ** 
(41) 
0.45 ** 
(42) 
-0.03 
(41) 
-0.09 
(40) 
-0.23 
(39) 
0.09 
(42) 
- 0.04 
(42) 
- 0.06 
(42) 
0.06 
(42) 
Pennation angle 
(N) 
-0.36 *  
(43) 
-0.31 *  
(43) 
0.35 * 
(35) 
0.28 
(42) 
0.17 
(43) 
-0.33 * 
(42) 
0.45 ** 
(41) 
-0.37 * 
(40) 
0.12 
(43) 
-0.42 ** 
(43) 
- 0.46 ** 
(43) 
- 0.51 ** 
(43) 
VL depth 
(N) 
0.44 **  
(51) 
0.38 **  
(51) 
-0.12 
(39) 
0.30 * 
(47) 
0.08 
(50) 
-0.07 
(50) 
0.13 * 
(48) 
-0.07 
(48) 
0.18 
(51) 
- 0.03 
(51) 
- 0.07  
(51) 
0.08 
(51) 
Total muscle depth 
(N) 
0.50 **  
(51) 
0.53 **  
(51) 
0.13 
(39) 
0.30 * 
(47) 
0.31 * 
(50) 
-0.13 
(50) 
0.19 * 
(48) 
-0.20 
(48) 
0.25 
(51) 
0.06 
(51) 
- 0.01 
(51) 
0.06 
(51) 
Fat depth 
(N) 
0.67 **  
(51) 
0.41 ** 
 (51) 
-0.65 **  
(39) 
- 0.49 ** 
(47) 
-0.67 ** 
(50) 
-0.44 ** 
(50) 
-0.42 ** 
(48) 
0.35 * 
(48) 
-0.21 
(51) 
0.21 
(51) 
0.32 * 
(51) 
0.20 
(51) 
Presented as Pearson’s Correlation Coefficient (r) where * denotes significance at p<0.05, and ** at p<0.01, (N) is number of participants 
VL = vastus lateralis; ACSA = anatomical cross sectional area; MTC = mid-thigh circumference; MAC = mid-arm circumference; KEPF45/LPPF45 = 
knee extension/ leg press peak force at 45 degrees; STS5 = sit-to-stand 5; STS60 = sit-to-stand 60; NSRI walk = North Staffordshire Royal Infirmary 
walk test; PAR = physical activity recall; LUSS = Leicester Uraemic Symptom Score 
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Table 6.3 – Overview of significant correlations with US-derived measures of 
regional body composition at the mid-VL point 
 
* significance at p<0.05, ** p<0.01,  (+) positive correlation, (-) negative correlation; 
VL = vastus lateralis; ACSA = anatomical cross sectional area; MTC = mid-thigh 
circumference; MAC = mid-arm circumference; KEPF45/LPPF45 = knee extension/ leg 
press peak force at 45 degrees; STS5 = sit-to-stand 5; STS60 = sit-to-stand 60; NSRI 
walk = North Staffordshire Royal Infirmary walk test; PAR = physical activity recall; 
LUSS = Leicester Uraemic Symptom Score; Hb = haemoglobin; BMI = body mass 
index 
 VL ACSA (cm2) 
VL Pennation 
angle (degrees) 
VL depth 
(cm) 
Total muscle 
depth (cm) 
Fat depth (cm) 
Demographics 
(-) Age * 
(-) Body fat % * 
(+) Height ** 
(-) BMI * 
(-) Age ** 
(+) Weight ** 
(+) BMI ** 
(-) Age ** 
(+) Weight ** 
(+) Height ** 
(+) BMI ** 
(+) Body fat % ** 
(-) Height ** 
(+) BMI ** 
Anthropometry  
(-) MTC * 
(-) MAC * 
(+) MTC ** 
(+) MAC ** 
(+) MTC ** 
(+) MAC ** 
(+) MTC ** 
(+) MAC ** 
Clinical (+) Hb ** (+) Hb *  
(+) Hb * 
(+) serum Cr * 
(-) Hb ** 
Isometric 
muscle strength 
(+) Handgrip ** 
(+) KEPF45 * 
(+) LPPF45 ** 
(+) KEPF45 * (+) LPPF45 * 
(+) Handgrip ** 
(+) LPPF45 * 
(-) Handgrip ** 
(-) KEPF45 ** 
(-) LPPF45 ** 
Physical 
Function and 
Activity 
 
(-) STS5 * 
(+) STS60 ** 
(-) NSRI walk * 
(+) STS60 * 
(+) STS60 * 
(-) NSRI walk * 
(+) STS5 ** 
(-) STS60 ** 
(+) NSRI walk * 
HR Quality of 
Life (Uraemic 
Symptoms) 
 
(-) LUSS 1 ** 
(-) LUSS 2 ** 
(-) LUSS 3 ** 
  (+) LUSS 2 * 
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Table 6.4 – Relationship of HR QoL (uraemic symptoms; LUSS) with patient demographics and selected clinical variables 
 
Basic demographics Clinical measures 
Age Weight  Height  BMI Body fat % Hb Albumin Serum Cr CO2 Urea 
LUSS 1 (number) 
(N) 
- 0.33 * 
(51) 
0.18 
(51) 
- 0.10 
(51) 
0.24 
(51) 
0.11 
(51) 
- 0.09 
(50) 
- 0.10 
(50) 
- 0.23 
(50) 
- 0.03 
(46) 
0.03 
(49) 
LUSS 2 (frequency) 
(N) 
- 0.17 
(51) 
0.25 
(51) 
- 0.17 
(51) 
0.41 ** 
(51) 
0.28 * 
(51) 
- 0.17 
(50) 
- 0.10 
(50) 
- 0.16 
(50) 
- 0.01 
(46) 
- 0.05 
(49) 
LUSS 3 (intrusiveness) 
(N) 
- 0.11 
(51) 
0.30 * 
(51) 
- 0.10 
(51) 
0.42 ** 
(51) 
0.20 
(51) 
- 0.16 
(50) 
- 0.07 
(50) 
-0.08 
(50) 
- 0.07 
(46) 
- 0.00 
(49) 
Presented as Pearson’s Correlation Coefficient (r) where * denotes significance at p<0.05, and ** at p<0.01, (N) is number of 
participants; LUSS = Leicester Uraemic Symptom Score; Hb = haemoglobin; BMI = body mass index; CO2 = carbon dioxide in blood serum 
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Table 6.5 – Relationship of patient-reported uraemic symptoms (LUSS) with other routinely-used clinical outcome measures 
 
Anthropometry Strength measures Functional measures 
MTC  MAC  KE PF 45  LP PF 45 Handgrip  STS5  STS60  NSRI walk  PAR 
LUSS 1 (number) 
(N) 
0.27  
(51) 
0.31 *  
(51) 
- 0.19 
(39) 
-0.08 
(47) 
-0.04 
(50) 
0.21 
(50) 
-0.26 
(48) 
0.13 
(48) 
0.01 
(51) 
LUSS 2 (frequency) 
(N) 
0.39 ** 
 (51) 
0.40 **  
(51) 
-0.33 * 
(39) 
-0.23 
(47) 
-0.15 
(50) 
0.46 **  
(50) 
-0.52 ** 
(48) 
0.40 ** 
(48) 
-0.14 
(51) 
LUSS 3 (intrusiveness) 
(N) 
0.40 **  
(51) 
0.35 *  
(51) 
-0.27  
(39) 
-0.16 
(47) 
-0.10  
(50) 
0.39 ** 
(50) 
-0.49 ** 
(48) 
0.35 * 
(48) 
-0.12  
(51) 
Presented as Pearson’s Correlation Coefficient (r) where * denotes significance at p<0.05, and ** at p<0.01, (N) is number of 
participants 
LUSS = Leicester Uraemic Symptom Score; MTC = mid-thigh circumference; MAC = mid-arm circumference; KEPF45/LPPF45 = knee 
extension/ leg press peak force at 45 degrees; STS5 = sit-to-stand 5; STS60 = sit-to-stand 60; NSRI walk = North Staffordshire Royal 
Infirmary walk test; PAR = physical activity recall 
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Table 6.6 – Overview of factors significantly associated with patient-reported 
uraemic symptoms 
* significance at p<0.05, ** p<0.01,  (+) positive correlation, (-) negative correlation 
VL = vastus lateralis; MTC = mid-thigh circumference; MAC = mid-arm 
circumference; KEPF45/LPPF45 = knee extension/ leg press peak force at 45 degrees; 
STS5 = sit-to-stand 5; STS60 = sit-to-stand 60; NSRI walk = North Staffordshire Royal 
Infirmary walk test; PAR = physical activity recall; LUSS = Leicester Uraemic 
Symptom Score; Hb = haemoglobin; BMI = body mass index 
  
 
LUSS 1  
(number) 
LUSS 2  
(frequency) 
LUSS 3  
(intrusiveness) 
Basic (-) age * 
(+) BMI ** 
(+) body fat % * 
(+) weight * 
(+) BMI ** 
Clinical    
US measures at 
mid-VL point 
(-) pennation angle ** 
(+) fat depth *  
(-) pennation angle ** 
(-) pennation angle ** 
Anthropometry (+) MAC * 
(+) MTC ** 
(+) MAC ** 
(+) MTC ** 
(+) MAC * 
Strength  (-) KEPF45 *  
Function  
(+) STS5 ** 
(-) STS60 ** 
(+) NSRI walk ** 
(+) STS5 ** 
(-) STS60 ** 
(+) NSRI walk * 
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6.4 Discussion 
It was hypothesized that strength and function would be positively correlated with 
muscle size and architecture, and negatively with uraemic symptoms.  Uraemic 
symptoms were indeed negatively correlated with both strength and function (the 
greater the reported frequency and intrusiveness of the symptoms, the weaker and 
less functional the participants were).  However, the relationships between US-
derived measures of muscle size and architecture, with objectively measured 
strength and function were more complex (Table 6.3). 
 
Patient-reported uraemic symptoms assessed using the Leicester Uraemic Symptom 
Score (LUSS) were significantly correlated to pennation angle of the VL muscle at 
the mid-VL point (LUSS1 p=0.005, LUSS2 p=0.002, LUSS3 p=0.000) in CKD stage 3 
patients.  The negative relationships (Table 6.2) indicate that improved muscle 
architecture (larger pennation angle) is correlated with lower LUSS scores (fewer 
and less frequent or intrusive symptoms) and thus assumed better quality of life. 
 
There were no significant correlations in this population between patient-reported 
uraemic symptoms and clinical measures (Table 6.6).  This suggests that patient 
perception of muscular weakness, fatigue, and other uraemic symptoms in CKD are 
largely unrelated to clinical measures of renal function; this has also been observed 
in other samples (CKD stage 3b-4; Aulakh et al 2012).  Despite the association of 
haemoglobin (Hb) with muscle size and architecture (Table 6.3) and with physical 
performance measures (Aulakh et al 2012), the lack of association between uraemic 
symptoms and clincical measures is interesting, and may warrant further 
investigation considering psychological and lifestyle factors as well as individual and 
group co-morbidities. 
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6.4.1 Ultrasound-derived measures of body composition 
This is the first study to explore the relationship between patient-reported uraemic 
symptoms (as an indication of HRQoL) and muscle size and architecture using 
ultrasound in CKD patients, especially outside of the renal replacement (dialysis) 
therapy population. 
 
6.4.1.1 Muscle size (VLACSA, VL depth, total muscle depth) and architecture 
(pennation angle) 
Muscle size was significantly correlated to age, demonstrating that an older 
individual has reduced muscle mass, as would be expected based on recent data in 
healthy populations (quadriceps thickness, Strasser et al 2013).  It was also 
observed in the same research study (Strasser et al 2013) that in younger 
populations, quadriceps muscle thickness is significantly correlated with BMI (as 
observed here, Table 6.3). 
 
Pennation angle is important in CKD as it represents the health or quality of the 
muscle, and potential force production.  This is reflected in the results that 
pennation angle is well correlated to measures of function (STS5, STS60, and NSRI 
walk; Table 6.3) and strength (KEPF45, Table 6.3); however, the non-significant 
correlations with LPPF45 (r=0.28, p=0.07, n=42) and handgrip strength (r=0.17, 
p=0.26, n=43) were surprising.  
 
Based on the correlations presented in Table 6.3, it appears that muscle 
architecture (pennation angle) is more related to functional performance (r=0.33-
0.45) whereas muscle size (VL ACSA) is a stronger predictor of maximal strength 
(r=0.35-0.45).  John et al (2013) reported poor correlation between change in 
muscle size (cross-sectional area) and change in functional ability too. This may 
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suggest that even with reduced muscle size, functional performance could be 
maintained so long as quality of the muscle is maintained (muscle pennation angle 
remains wide).  Other research in dialysis patients has documented reduced muscle 
force, selective structural changes and signiﬁcant muscle wasting in the presence of 
normal skeletal muscle physiology (Fahal et al 1997), once again indicating that loss 
of muscle mass is linked more to loss of strength than change in architecture, and 
that detrimental changes in muscle architecture may occur later in the disease 
process, alongside the reduction in functional ability. 
 
6.4.1.2 Fat depth 
Fat depth has most correlations when examining all outcome measures, but may be 
due to the fact that most of the composition assessments can be driven by fat more 
than muscle (BMI, % body fat, MTC, MAC).  However, fat also has the most 
significant correlations with strength and function.  It has been suggested previously 
that retaining greater adiposity is advantageous in the CKD population, which may 
be due to the theory that fat is muscle-saving (Ikizler 2008).  However, the relative 
influence of fat mass or muscle mass on the obesity paradox (where greater BMI in 
dialysis patients appears to confer lower hazard ratio for mortality) is difficult to 
evaluate because of limited epidemiologic evidence, unclear mechanistic processes 
to explain the obesity paradox, and the lack of definitive evidence from intervention 
studies (Park et al 2014). 
 
Fat depth and KEPF45 are negatively (and highly significantly) correlated in this 
sample of CKD3 patients (r=-0.63, p=0.00, n=39). However, this is in contrast with 
the previous study where r=0.23, p=0.23, n=22 (Chapter 5).  Admittedly, the 
previous study used significantly sicker patients (CKD5, already undergoing 
peritoneal dialysis for an average of 30-months; Table 5.1) than in this study; 
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though other than the disease stage, other demographics were markedly similar 
(age, weight, BMI; Table 5.1). 
 
6.4.2 Health-related Quality of life (uraemic symptoms) 
The number of patient-reported uraemic symptoms (LUSS 1) is (significantly) 
negatively correlated with age, indicating that the older the individual, the fewer 
uraemic symptoms they seem to report.  This may be as many of the symptoms 
listed are often associated with the general ageing process (e.g. pain in 
joints/bones, loss of muscle strength/power, poor concentration/mental alertness) 
and so may not have appeared noticeably worse to the patients.  This has been 
observed in a both the healthy and ill populations, and the literature describes an 
expected annual loss in strength (maximal voluntary contraction) of approximately 
1.5% per year after the age of fifty (Strasser, 2013; Doherty 2003; Ivey et al 2000; 
Lauretani et al 2003).  Additionally, it has been observed in the wider community 
that older individuals tend to complain (report pain, weakness, and fatigue) less 
than younger individuals as they believe it to be an expected result of ageing 
(Avlund et al 2007; Rush et al 2013). 
 
Correlations show higher reported frequency (LUSS 2) and intrusiveness (LUSS 3) of 
uraemic symptoms linked with reduced strength and function (Table 6.5), increased 
fat percentage, BMI (Table 6.4), and lower muscle quality (pennation angle, Table 
6.2).  These are also observably common results of the ageing process (Scott et al 
2011).  Data regarding which of the listed uraemic symptoms were most commonly 
reported in this sample of early stage CKD patients was not analysed, limiting the 
ability to discuss the nature of the correlations more directly.  If it is assumed that 
the most prevalent reported were in line with previous reports - (1) sleep 
disturbance; (2) excessive tiredness; (3) loss of strength; (4) itching; (5) muscle 
stiffness and (6) restless legs (Aulakh et al 2012) - then the correlation with muscle 
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size and structure, and the previously established relationship with strength and 
function, becomes clearer. 
 
6.5 Study Limitations 
The two main limitations of this study are (1) the relatively small sample size, and 
(2) it was not possible for all outcome measures to be obtained across the entire 
sample.  For a study of correlations between measures, a larger sample would be 
preferable to allow correction for factors such as age, BMI, or even strength or 
functional results.  However, the fifty-one participants were closely mixed by 
gender (28M:23F) and were representative of the average CKD3 population 
(borderline between CKD stages 3a and 3b).   
 
6.6 Implications for research 
Examining correlations between outcome measures allows the research community 
to potentially use one measure as a proxy (in repeated measure) for another in the 
event that certain data is not collected (eg. BMI for body fat percentage, education 
level for cognitive ability), this is routinely done by clinicians and researchers alike 
(Clinton 2004).  In this exploratory correlational study, sit-to-stand-60 was well 
(negatively) correlated to patient-reported uraemic symptoms (LUSS2, frequency, 
r=0.52; LUSS3, intrusiveness, r=0.49) as was pennation angle of the VL muscle 
(STS60, r=0.45, LUSS1, number, r=0.42, LUSS2, frequency, r=0.46, LUSS3, 
intrusiveness, r=0.51).  To determine whether these could be used as proxy 
measures would require further testing in a larger sample. 
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6.7 Conclusions  
There are significant and relatively strong correlations between patient-reported 
(perceived) uraemic symptoms and objectively measured strength, function and 
regional body composition (site-specific muscle size and quality) in pre-dialysis CKD 
(stage 3) patients.  Recently a two year follow-up study observed greater muscle 
mass loss in pre-dialysis patients than those already undergoing dialysis at study 
initiation (John et al 2013).  Therefore, intervening early (pre-dialysis) to hinder this 
accelerated loss of muscle - and consequent loss of strength and/or function on the 
road to frailty - is vital in this population. 
 
Having established the relationships between the manifestations of chronic kidney 
disease symptoms, such as muscle wasting, loss of strength, and other such uraemic 
symptoms assessed by the quality of life measure (LUSS) in this study, it is necessary 
to test whether an anabolic intervention (such as resistance training) can affect 
these symptoms, and whether the response will be quantifiably the same across the 
complete array of uraemic symptoms (i.e. will a ten percent increase in strength 
equate to a ten percent improvement in uraemic symptoms score). 
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CHAPTER 7 – Does frequency of (resistance) exercise training 
influence outcome over a 12-week period in people with 
stage 3 Chronic Kidney Disease (CKD3)? 
 
7.1 Introduction 
Frailty is observably more common in individuals with CKD than those without 
(Johansen et al 2013). Additionally, frailty in moderate to severe CKD is more 
common than in other chronic illnesses such as vascular disease, cancer, and other 
degenerative diseases of ageing (Wilhelm-Leen et al 2009).  Risk of frailty is 
increased by approximately 2-times in mild CKD (stages 1-3a) and 6-times in 
moderate to severe (stages 3b-5) CKD (Wilhelm-Leen et al 2009) and is associated 
with increased incidence of adverse outcome in dialysis patients (increased 
hospitalisation, increased death rate; Johansen et al 2013; Kosmadakis et al 2010). 
 
CKD patients that have been defined as frail are started on dialysis on average much 
earlier (i.e. at a higher estimated glomerular filtration rate, eGFR) than those 
deemed non-frail (Johansen et al 2013) and sadly the deterioration trajectory is 
increased from dialysis initiation, as higher levels of dependence in performing 
activities of daily living (ADLs) are recorded in these patients (Kurella-Tamura et al 
2010).  This demonstrates the need to intervene early to slow the decline into 
“frailty”, and therefore delay these patients being transferred onto maintenance 
dialysis, and protect their independence for longer.   
 
The need for additional protein to overcome the negative balance and malnutrition 
cannot be solved by simply increasing protein intake in food, as this in turn can 
aggravate uraemia (Workeneh & Mitch 2010).  Therefore anabolic interventions to 
increase protein production and reduce loss are vital. 
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In healthy individuals, resistance training is a proven anabolic intervention with 
long-term benefits (Ikizler 2011).  Using resistance training to maintain function has 
been recommended for frail elderly populations whose strength levels may become 
a greater limiting factor for their activities of daily living than their cardiac function 
(Pendergast et al 1993; Hurley et al 2011).  Additionally, maintaining optimal muscle 
mass and function with ageing plays an important role in preventing or delaying the 
onset of chronic diseases and critical illness (Wolfe 2006; Hurley et al 2011), often 
highlighted through a reduced need for medical intervention (Cawthon et al 2009; 
Suetta et al 2007). 
 
Resistance training (RT) has also been reported to reduce muscle catabolism and 
counteract weight loss and malnutrition (assessed by total body potassium and 
leucine oxidation) in pre-dialysis CKD4 patients (Castaneda et al 2001, 2004), and 
corrected protein synthesis, reduced muscle proteolysis (breakdown), and 
increased muscle progenitor cell number and activity (compared to treadmill 
running which only corrected/reduced muscle proteolysis) in CKD mice (Wang et al 
2009).  Despite it being recommended that RT be initiated early in the pre-dialysis 
stage (Kouidi 2002; Clyne 2004) there are very few published reports of RT in 
pre/non-dialysis dependent (NDD) patients. 
 
Resistance training has been introduced in mixed/combination and strength-specific 
interventions in end-stage renal disease (CKD5) patients undergoing dialysis 
(Chapter 2, Table 2.6.) where strength, function, and muscle mass is already 
massively reduced in comparison to earlier in the disease process (pre-dialysis).  The 
results of these later studies have demonstrated beneficial and statistically 
significant changes in muscle size, strength and function to the participants (Dong et 
al 2011; Chen et al 2010; Cheema et al 2006, 2007). 
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A systematic review of exercise interventions in CKD highlighted the lack of RCTs 
investigating resistance training, as most research to date has focused on 
cardiovascular programmes (Heiwe & Jacobson 2011).  The authors commented 
that resistance training had a significant beneficial effect on muscular strength but 
there were too few included studies (in the meta-analysis) using cardiovascular 
exercise or mixed cardiovascular and resistance training, to be able to draw 
conclusions concerning the type of exercise required for optimal enhancement of 
muscular strength.  There is also great variability in the results of these studies as 
they implemented different programmes (varying session duration, exercise 
intensity, intervention length, and exercise modality) and assessed and reported 
results using a variety of measures for similar outcomes (Heiwe & Jacobson 2011). 
 
In order to develop and prescribe the most effective exercise intervention 
programme for CKD patients, further research needs to be undertaken into exercise 
mode, frequency, and intensity (Smart et al 2013), to elucidate the greatest or most 
efficient dose-response relevant to the CKD population.   
 
There appears to be little information in the published literature regarding the 
associations between muscle size (thickness, cross-sectional area), architecture 
(pennation angle), function (force, sit-to-stand, walk tests), and the self-reported 
score of uraemic symptoms by the patient, or the possibility for 
improvements/change through an intervention programme, whether exercise, 
nutritional, or pharmacologically based.  Indeed, a literature search revealed few 
studies examining changes in the reporting of number, frequency, or intrusiveness 
of uraemic symptoms from an intervention, apart from at the initiation of dialysis as 
part of the usual care-process (improved symptom scores using the Pittsburgh 
Symptom Score Index over the 12-months following initiation of peritoneal dialysis; 
Novak et al 2008) and a prospective comparative study in which CKD4 and CKD5 
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pre-dialysis patients who undertook an exercise programme also recorded a 
significant reduction in uraemic symptoms using the Leicester Uraemic Symptom 
Score after one-month of activity, maintained to six-months (Kosmadakis et al 
2012).   
 
7.1.1 Summary 
The loss of muscle mass and strength are important determinants of survival in CKD 
(Bonanni et al 2011) and a variety of other chronic illnesses (cardiac failure, Anker 
et al 2004; cancer, Kadar et al 2000; sarcopenia, Metter et al 2004; Morley et al 
2009), and an anabolic intervention (resistance training) may have an effect on the 
progression of CKD-related protein-energy wasting through the modification of risk 
factors such as malnutrition (negative protein balance), inflammation, and physical 
inactivity.   
 
The response to an exercise intervention with pre-dialysis CKD patients has been 
shown to be equal to the response in non-CKD (healthy) age-matched controls, 
unlike patients later in the disease-process who may be limited in their 
improvement in strength and function (Heiwe et al 2001).  Therefore intervening in 
pre-dialysis stages has the greatest potential for large improvements that would be 
beneficial to the patient; to potentially hinder the progression of protein-energy 
wasting (rat studies, Heifets et al 1987; Osato et al 1990), and related functional 
decline. 
 
7.1.2 Study aims and hypotheses 
The aim of this study was to investigate the effectiveness of resistance training as a 
countermeasure to the established muscle wasting associated with chronic kidney 
disease (Hurley et al 2011).  The secondary aim was to explore the effects of 
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training frequency upon the individual’s body composition, regional muscle size and 
architecture, and associated strength and functional capacity, as well as any 
changes and associations between these measures and the self-reported uraemic 
symptoms in these pre-dialysis CKD3 patients.  
It was hypothesized that the effects of exposure to the intervention (resistance 
training programme) once per week (RT1) would be significantly different from 
those patients exposed three times per week (RT3), due to an established dose-
response relationship (RT3>RT1). 
 
7.2 Methods 
7.2.1 Participants 
Forty-five consecutively presenting CKD3 patients were approached at a routine 
outpatient clinic.  Twenty-eight patients initially showed interest in participating 
and received information packs including participant information sheet, informed 
consent form and investigator contact details.  Twenty-two returned the informed 
consent and agreed to attend for pre-randomisation assessments.  Twenty patients 
took part in the baseline assessments (Figure 7.1, participant flow). 
 
Pre-randomisation (baseline) assessments took place at the Renal Rehabilitation 
gymnasium at a UK National Health Service University Hospital.  All assessments 
were made by a single investigator and included measurement of (1) whole body 
composition; (2) regional body composition; (3) muscle architecture; (4) 
neuromuscular performance, including peak isometric strength; (5) physical 
function; and (6) uraemic symptoms. 
Following these assessments, participants were randomly assigned using a 
computerised block randomisation programme to either a low frequency (one 
session per week, RT1) or higher frequency (three sessions per week, RT3) 
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resistance training group.  Participants in both groups completed a 12-week 
programme of lower extremity strengthening exercises. 
 
7.2.2 Intervention 
Each supervised training session consisted of a short (five minute) aerobic warm-up 
on a mechanically braked cycle ergometer (Monark, Sweden) followed by a series of 
lower extremity exercises using fixed weight machines (knee extension, leg press, 
calf raise, hamstring curl) and bodyweight-resisted exercises (lunges, squats).  In 
each session participants completed 3 sets of 8 repetitions at 80% of the individual’s 
one rep max (80% 1RM).   
 
Progression/adaptation: 1-RM was amended as required (when an individual could 
surpass the prescribed dose of 3 sets of 8 repetitions).  The results of the fortnightly 
measure of leg press and knee extension peak force were used as a guide for 
advancement and progression. 
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Figure 7.1 - Participant flow through and assessment phasing in the intervention 
study            
 
45 potential (eligible) 
participants approached  
28 expressed interest 
Took information pack 
22 returned informed 
consent 
20 attended  
pre-randomisation 
(baseline) assessments 
RANDOMISED  
 computerised block 
randomisation 
programme 
10 in RT1  
low frequency 
(once/week) resistance  
training 
6 week assessment:  
7 (4 male, 3 female) 
12 week (final) 
assessment:  
7 (4 male, 3 female) 
10 in RT3  
high frequency  
(three times/week) 
resistance training 
6 week assessment: 
10 (4 male, 6 female) 
12 week (final) 
assessment:  
10 (4 male, 6 female) 
6 did not return informed 
consent 
17 not interested 
Reasons for drop-out: 
1 lack of interest 
1 relocated to another 
area of the country 
1 suffered a hand injury 
unrelated to the 
intervention or 
assessment protocol 
Assessments at baseline, 6 
weeks, 12 weeks: 
(1) Whole body 
composition by BIA 
(2) Ultrasound of muscle 
and fat 
(3) Ultrasound muscle 
pennation angle 
(4) Peak isometric 
muscle strength 
(5) Functional capacity 
(STS60, STS5, walk 
test, PAR) 
(6) Uraemic  Symptoms 
(LUSS) 
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7.2.3 Assessments 
All participants returned to the Renal Rehabilitation gym after 6 and 12 weeks for 
follow-up assessments.  Additionally, all participants had their regional body 
composition and neuromuscular function (strength) assessed every two weeks.  
These additional assessments always preceded their participation in the first 
exercise session of the week (RT3 group), or their only session of the week (RT1 
group). 
All outcome measures were taken by a single assessor (blinded to group allocation) 
highly experienced in ultrasonography, anthropometry, and measures of physical 
strength and function, in both a clinical and laboratory setting. 
 
7.2.3.1 Body composition 
Body mass index (BMI) was calculated using [weight (kg)/height (metres)2]. 
Measurements of regional body composition were taken with participants lying in a 
supine position for a minimum of 20 minutes to allow for any fluid shifts prior to 
assessment.  Whole body multi-segmental bioelectrical impedance 
spectroscopy/analysis was used to measure total body water, fat and fat free mass 
according to the procedures described in the General Methods (Chapter 3). 
 
7.2.3.1.1 Regional body composition and muscle architecture (fortnightly) 
Remaining in a supine position throughout, participants were instructed to relax the 
muscle being assessed.  Knee extension angle was kept at zero degrees of flexion 
(straight leg). 
Ultrasound measurements of the vastus lateralis (VL) muscle thickness/depth, VL 
subcutaneous fat thickness/depth, VL anatomical cross-sectional area (VL ACSA), VL 
pennation angle, triceps brachii muscle thickness/depth, tricep brachii 
Assessments at baseline, 6 weeks, 
12 weeks: 
(1) Whole body 
composition by BIA 
(2) Ultrasound of muscle 
and fat 
(3) Ultrasound muscle 
pennation angle 
(4) Peak isometric muscle 
strength 
(5) Functional capacity 
(STS60, STS5, walk test, 
PAR) 
(6) Uraemic  Symptoms 
(LUSS) 
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subcutaneous fat thickness/depth were obtained using a 50mm, 7.7MHz linear 
array probe (Sonosite® 180 plus, Sonosite Inc., USA). 
VL muscle and subcutaneous fat thickness/depth and pennation angle measures 
were taken at 50% femur length and mid-VL width.  Images were taken with the 
probe perpendicular to the dermal surface of VL along the mid-sagittal line of the 
VL.  Fascicle length was calculated using the equation  
                                  
 
VL ACSA images were taken in the axial plane and were recorded onto SVHS 
videotape and acquired via individual frame capture software (Adobe Premier v5.1, 
Adobe Systems). Using lines cast by external markers, scans were fitted to form a 
reconstructed full image using a contour matching programme (ImageJ).  VL ACSA 
was then measured via an image analysis programme (NIH Image v1.6, NIH, MD, 
USA). 
 
7.2.3.2 Neuromuscular performance - Strength (fortnightly) 
Muscle strength was assessed using a handgrip dynamometer (Lafayette 
Instrument, Lafayette, IN), Knee Extension peak isometric force and Leg Press peak 
isometric force, assessed at 45° (Gleeson et al 2002; Chapter 3, above).  Results for 
each measure were based on the best of three attempts on the dominant side.  
 
7.2.3.3 Functional capacity (six-weekly) 
Sit-to-stand 60 (STS60, number of complete sit-to-stand movements within 60 
seconds) and sit-to-stand 5 (STS5, time taken to complete five sit-to-stand 
movements) were performed from a standard chair height of 0.42 metres.  
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The NSRI walk test (North Staffordshire Royal Infirmary walk test, Mercer et al 1998) 
involved a walk of 50-metres, a stair climb of 22 steps (3.3-metre elevation, 
individual step height 15cm), the same stair descent, and 50-metre walk back to the 
start.  Time was recorded in seconds.  
Participants were also asked to recall their physical activity over the last week 
(Physical Activity Recall; Blair et al 1985). 
 
7.2.3.4 Uraemic Symptoms (six-weekly) 
Uraemic symptoms affecting health-related quality of life were measured using the 
Leicester Uraemic Symptom Score (LUSS; Wright & Stein 1993). LUSS is a five-point 
Likert scale that evaluates symptom number (LUSS 1), frequency (LUSS 2) and 
intrusiveness (LUSS 3) of a selection of eleven symptoms commonly associated with 
kidney problems (sleep disturbance, muscle spasm/stiffness, excessive tiredness, 
pain in joints/bones, loss of muscle strength/power, poor concentration/mental 
alertness, restless legs, impotence/lack of sex drive, shortness of breath, itching, 
and loss of appetite).   
 
7.2.4 Statistics 
Following screening of data for normality, standard statistical methods were used 
for the calculation of mean and standard deviations.  Group comparison (RT1 vs 
RT3) at baseline was assessed by Student’s unpaired t-test for all measures. 
Mixed model repeated measures ANOVA (3x2) was employed (SPSS v21.0) to assess 
time and group effect and interactions. 
Data are reported as mean ± standard deviation unless otherwise stated.    
Statistical significance was accepted at p<0.05.  
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7.3 Results 
There were no significant baseline differences (p>0.05) in the demographic and 
physical characteristics of the groups completing the study (Table 7.1).  
 
Table 7.1 – Participant characteristics at baseline (t0)  
 RT1 RT3 
Sample size  n (M:F) 7 (4:3) 10 (4:6) 
Age (yrs)   
(range) 
52.9 ± 16.5  
(34 – 76) 
59.7 ± 9.9  
(44 – 73) 
Weight (kg) 79.4 ± 9.1 75.8 ± 16.7 
BMI (kg/m2) 29.7 ± 4.7 27.3 ± 4.1 
% fat 35.4 ± 11.7 33.25 ± 9.0 
Fat mass (kg) 28.3 ± 10.4 25.0 ± 8.5 
FFM (kg) 51.1 ± 9.3 50.8 ± 14.1 
TBW (litres) 37.4 ± 6.8 37.2 ± 10.3 
CCr (mL/min) 49.1 ± 9.6 47.1 ± 6.5 
SerumCr (umol/L) 135 ± 87 176 ± 45.5 
Urea (mmol/L) 11.2 ± 6.3 15.0 ± 4.6 
Albumin (g/L) 42.7 ± 2.2 40.5 ± 2.7 
Hb (g/dL) 13.7 ± 1.4 13.0 ± 2.0 
CO2 (mmol/L) 28 ± 2.3 26.4 ± 2.6 
GFR (mL/min) 36.1 ± 12.9 36.6 ± 15.8 
Presented as mean ± standard deviation; BMI = body mass index; FFM = fat free 
mass; TBW = total body water; CCr = creatinine clearance; Hb = haemoglobin; CO2 = 
carbon dioxide in blood serum; GFR = glomerular filtration rate 
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7.3.1 Upper body “control data” to assess potential systemic effects related to any 
dietary change 
Measurements of upper arm muscle thickness, subcutaneous fat, and handgrip 
strength were made immediately prior to and following the 12-week intervention 
period.  This data was collected as a form of “verification control” check to ensure 
that any adaptation due to change in nutritional status or pathophysiology was 
reflected at a body-site not involved in the lower body resistance training 
intervention. 
 
No significant differences were observed between RT1 and RT3 groups (Table 7.2).  
Measures of upper body strength (handgrip dynamometry) and upper arm muscle 
thickness (bicep brachii and tricep brachii muscle depth) showed no significant 
change over the 12-week period (tendency for triceps muscle to reduce in size).  
There was however a significant decrease in subcutaneous tricep fat depth (p=0.02, 
t0: 2.17 ± 0.99 cm, t6: 2.05 ± 0.98 cm, t12: 2.04 ± 0.97cm) with a similar trend evident 
in subcutaneous bicep fat depth (trend, p=0.09, t0: 1.80 ± 0.78 cm, t12: 1.50 ± 0.69 
cm). 
 
Table 7.2 - Changes in upper arm muscle thickness/depth, upper arm subcutaneous 
fat thickness/depth, and handgrip strength across the 12-week intervention period  
 RT1 t0 RT1 t12 RT3 t0 RT3 t12 Time effect 
(p-value) 
Handgrip (kg) 25.9 ± 11.3 26.1 ± 10.7 28.5 ± 12.2 29.1 ± 13.5 Ns 
Tricep brachii depth (cm) 4.3 ± 0.8 4.1 ± 0.8 3.9 ± 0.8 3.6 ± 0.9 Ns 
Tricep fat depth (cm) 2.2 ± 1.2 2.2 ± 1.2 2.1 ± 0.8 1.9 ± 0.8 0.02 
Bicep brachii depth (cm) 2.8 ± 0.8 2.8 ± 0.8 2.9 ± 0.6 2.9 ± 0.7 Ns 
Bicep fat depth (cm) 1.9 ± 0.8 1.7 ± 0.8 1.7 ± 0.8 1.3 ± 0.6 Ns 
Presented as mean ± standard deviation; Ns = non-significant result  
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Measures of upper body strength, fat, and muscle showed no beneficial change in 
muscle size or strength over the 12-week intervention, providing some reassurance 
that changes detected in the primary outcome measures might reasonably be 
attributed to the intervention, not other systemic effect mediated changes.  
 
7.3.2 Body composition 
There was no statistically significant interaction for measures of whole body 
composition assessed by Bioelectrical Impedance Analysis (Table 7.3, p>0.05).  
There was also no significant group effect.  
 
Weight increased steadily over the 12-weeks in both groups, but did not quite reach 
statistical significance (p=0.051, t0: 77.29 ± 13.84 kg, t12: 78.49 ± 13.42 kg, Table 
7.3).  This was probably driven by the (statistically non-significant, p>0.05) increase 
in FFM of RT3 (2.1kg); three times that of RT1 (0.7kg). 
 
Table 7.3  - Total body composition measurements (by Bioelectrical Impedance) 
throughout the 12-week study period   
 RT1 t0 RT1 t12 RT3 t0 RT3 t12 
Weight (kg) 79.4 ± 9.1 81.1 ± 9.9 75.8 ± 16.7 78.1 ± 15.9 
BMI (kg/m2) 29.7 ± 4.7 30.3 ± 4.6 27.2 ± 4.1 28.1 ± 3.6 
Fat (%) 35.4 ± 11.7 36.0 ± 10.9 33.3 ± 9.0 32.6 ± 10.6 
Fat mass (kg) 28.3 ± 10.4 29.5 ± 9.6 25.0 ± 8.5 25.3 ± 9.4 
FFM (kg) 51.1 ± 9.3 51.8 ± 9.0 50.8 ± 14.1 52.9 ± 14.5 
FFM (ratio) 
Truncal/ appendicular 
1.20 
27.9 / 23.2  
1.18 
28.0 / 23.7 
1.25 
28.2 / 22.6 
1.24 
29.3 / 23.6 
TBW (litres) 37.4 ± 6.8 37.8 ± 6.7 37.2 ± 10.3 38.7 ± 10.6 
Presented as mean ± standard deviation; BMI = body mass index; FFM = fat free 
mass; TBW = total body water 
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BMI, total body water, fat free mass and fat did not change significantly (p>0.05) in 
either group over the 12-week intervention (Table 7.3). 
 
Table 7.4 – Primary and secondary outcome measures at baseline (t0)   
Presented as mean ± standard deviation (SD) and to two decimal places (2dp) 
  
RT1 
(n=7) 
RT3 
(n=10) 
Total 
(n=17) 
Ultrasound 
measures 
at mid-VL 
point 
VL ACSA (cm2) 19.15 ± 3.15 18.24 ± 6.91 18.61 ± 5.55 
VL depth (cm) 2.54 ± 0.24 2.27 ± 0.38 2.38 ± 0.35 
Total muscle depth 
(cm) 
4.03 ± 0.31 3.88 ± 0.60 3.95 ± 0.49 
Fat depth (cm) 1.27 ± 0.87 1.24 ± 0.68 1.25 ± 0.74 
VL pennation angle 
(degrees) 
15.44 ± 2.35 16.83 ± 1.61 16.26 ± 2.01 
VL fascicle (fibre) 
length (cm) 
3.35 ± 1.07 3.36 ± 1.52 3.36 ± 1.48 
Isometric 
muscle 
strength  
Knee extension peak 
force  45 (Newtons) 
266.13 ± 126.33 343.86 ± 114.14 311.85 ± 121.93 
Leg press peak force 
(Newtons) 
314.86 ± 161.08 217.25 ± 99.81 257.44 ± 133.36 
Physical 
Function 
and 
Activity 
Sit-to-stand 5 (secs) 12.29 ± 2.04 12.38 ± 2.04 12.34 ± 4.17 
Sit-to-stand 60 (count) 21.57 ± 5.91 25.30 ± 5.91 23.76 ± 6.73 
NSRI walk test (secs) 90.81 ± 19.55 79.82 ± 15.30 84.35 ± 17.49 
Physical Activity Recall 
(kcal/kg/week) 
246.04 ± 11.17 255.13 ± 26.53 251.38 ± 21.54 
Uraemic 
Symptoms 
LUSS 1 (number) 6.71 ± 2.87 5.10 ± 2.87 5.77 ± 2.44 
LUSS 2 (frequency) 14.00 ± 8.98 13.10 ± 8.98 13.47 ± 7.80 
LUSS 3 (intrusiveness) 7.00 ± 5.94 6.50 ± 5.94 6.71 ± 4.82 
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7.3.2.1 Regional body composition: 
7.3.2.1.1 Vastus Lateralis muscle and total thigh muscle depth 
Figures 7.2 and 7.3 show that both VL-only and total thigh muscle depth at the mid-
VL point increased significantly (p<0.01) over the 12-week intervention, irrespective 
of group allocation (no group difference at any point; VL depth: to 2.38 ± 0.35 cm, 
t12 2.61 ± 0.41 cm, total thigh muscle depth: t0 3.95 ± 0.49 cm, t12 4.29 ± 0.70 cm).   
 
 
Figure 7.2 - Ultrasound measures of VL depth at mid-VL site 
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Figure 7.3 - Ultrasound measures of total thigh muscle depth at mid-VL site 
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7.3.2.1.2 Subcutaneous (mid-VL) Fat depth 
Fat depth in the same location (mid—VL point) decreased over time, though not 
significantly (t0 1.25 ± 0.74 cm, t12 1.13 ± 0.67 cm, p=0.090).  All changes remained 
relatively linear throughout (t0 - t12).  There were no significant differences between 
groups at any point (Figure 7.4). 
 
 
Figure 7.4 - Ultrasound measures of subcutaneous fat thickness/depth at mid-VL 
site 
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7.3.2.1.3 VL ACSA 
VL ACSA had highly significant changes over time (12-weeks, p=0.000, Figure 7.5), 
and between groups (p=0.002, Figure 7.5); RT3 increased ACSA at mid-VL by an 
additional 3.1 cm2 when compared to RT1 (RT3: t0 18.24 ± 6.91 cm
2, t12 23.88 ± 6.13 
cm2, RT1: t0 19.15 ± 3.15 cm
2, t12 21.67 ± 3.25 cm
2).   
This equates to an increase of 30.8% in RT3 and 13.2% in RT1 over the 12-weeks 
(Figure 7.5).  
 
 
Figure 7.5 - Relative (percentage) change over 12-weeks of VL ACSA at mid-VL site 
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7.3.2.1.4 Muscle architecture 
7.3.2.1.4.1 Pennation Angle (θ) 
There was a significant interaction (group*time) in pennation angle over the 12-
weeks (p=0.048).  Figure 7.6 demonstrates an increase in both groups over time to 
t12 (t0 16.26 ± 2.01 degrees, t12 20.89 ± 3.65 degrees, p=0.000).  
 
 
Figure 7.6 - Pennation angle within VL muscle at mid-VL site 
 
 
The overall change equates to an increased angle of 36.3% in RT3 by t12; twice that 
seen in group RT1 (RT1 increased 17.5% over 12-weeks). 
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7.3.2.1.4.2 Fascicle (fibre) length  
Fascicle length at the same location (mid—VL point) increased marginally over time, 
though this was not significant (t0 3.36 ± 1.48 cm, t6 4.28 ± 1.05, t12 4.25 ± 1.36 cm, 
p>0.05).    Despite the greater increase in RT3 than RT1 (Figure 7.7) there was also 
no significant group difference (or interaction) at any point (p>0.05). 
 
 
Figure 7.7 - Calculated individual fascicle (fibre) length within the VL muscle at the 
mid-VL  
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7.3.3 Neuromuscular performance (Strength measures) 
7.3.3.1 Leg press and knee extension peak force 
Both leg press (Figure 7.8) and knee extension peak isometric force (Figure 7.9) 
increased significantly over time (p<0.01) but with no significant group differences.   
Leg press peak force increased by 57% over the 12-weeks (t0 257.44 ± 133.36 N, t12 
403.89 ± 148.92 N, p=0.003), with the largest improvement of 42% by the mid-
point.   
 
Figure 7.8 - Leg press peak force (Newtons)    
 
Despite the LP scores at baseline appearing to be 31% lower (~100N difference) in 
the RT3 group (Figure 7.8), this was not statistically significant (p>0.05).   
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Figure 7.9 - Knee extension peak force (Newtons) 
 
 
 
Knee extension peak force increased by 30% over the 12-week intervention period 
(t0 311.85 ± 121.93 N, t12 404.59 ± 129.84 N, p=0.001), this time the larger 
improvement was in the second half of the intervention, as improvement only 
reached 11% by the mid-point. 
 
Approximately two-thirds of the improvement in LP occurred in the first half of the 
intervention whereas KE almost two-thirds of the improvement took place in the 
second half of the intervention.  
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7.3.4 Functional Capacity 
7.3.4.1 Sit-to-Stand  
Figure 7.10 (STS5) shows no statistical differences between groups, but with 
significant improvements (p=0.000) over time.  Most notable improvements 
occurred in the first six weeks (STS5: t0 12.34 ± 4.17 secs, t6 8.42 ± 2.26 secs, t12 7.85 
± 1.86 secs) though both periods were significant. 
 
 
Figure 7.10 - Improvements in STS5 over 12-weeks   
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Figure 7.11 - Improvement in STS60 over 12-weeks    
 
 
There were highly significant (p=0.000) improvements over the 12-week period, 
(STS60: t0 23.76 ± 6.73, t6 32.88 ± 8.05, t12 35.59 ± 8.06), though more significant in 
the first 6-week (p=0.000) than the second 6-week period (p=0.004) again. 
 
There were no group differences over the complete 12-weeks, but when analysed 
separately differences can be seen in the second six-week period, with significant 
differences between groups (p=0.015) from the mid-point (t6) to the end (t12) as 
group RT1 continued to improve at a greater rate (Figure 7.11).  This is likely due to 
their slightly lower scores throughout. 
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7.3.4.2 NSRI Walk test 
Figure 7.12 clearly shows that a significant (p=0.000) and relatively linear change 
over time occurred in both groups in the walk test, improving (reducing the time 
taken) by an average of 14.7 ± 9.1% in 12-weeks.  There were no differences 
between groups. 
 
 
 Figure 7.12 - Time to complete walk test (seconds) 
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7.3.4.3 Physical Activity Recall (PAR) 
Figure 7.13 demonstrates a positive change (increased energy expended 
participating in physical activity each week, kcal/kg/week) in both groups over the 
time period (p=0.017, t0: 251.38 ± 21.54 kcal/kg/week, t6: 260.59 ± 11.71 
kcal/kg/week, t12: 261.54 ±12.55 kcal/kg/week).   
 
Figure 7.13 - Self-reported PAR (kcal/kg/week) 
 
 
Self-reported physical activity in group RT1 grew steadily throughout the 
intervention whereas RT3 showed larger increases from baseline to t6 then 
plateaued (small decrease) to t12 (p=0.027).  The standard deviation also decreased 
in RT3 between t0 and t12 (Figure 7.13).  The greater increase in the first six weeks in 
group RT3, and smaller standard deviation is likely due to the set additional 
supervised training sessions as part of the intervention. 
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7.3.5 Uraemic Symptoms (Leicester Uraemic Symptom Scores)  
7.3.5.1 LUSS 1 (number), 2 (frequency), 3 (intrusiveness), and summative (total) 
score  
Figure 7.14 shows the change in self-reported uraemic symptoms over the 12-week 
intervention period.  No differences occurred between groups over the 12-week 
intervention as number (Figure 7.14a, LUSS1), frequency (Figure 7.14b, LUSS2) and 
intrusiveness (Figure 7.14c, LUSS3) of symptoms, and consequently total score 
(Figure 7.14d) fell significantly (p<0.05).   
 
As with the functional tests this was most notable in the initial 6-week period, 
particularly the number (Figure 7.14a, LUSS1: t0 5.8 ± 2.4, t6 4.9 ± 2.3, t12 4.6 ± 2.7, 
p=0.006) and frequency (Figure 7.14b, LUSS 2: t0 13.5 ± 7.8, t69.8 ± 5.8, t12 8.4 ± 5.5, 
p=0.002) of uraemic symptoms.   
 
Significant reductions were also seen in the intrusiveness (Figure 7.14c, LUSS3) of 
uraemic symptoms (LUSS 3: t0 6.7 ± 4.8, t12 3.7 ± 2.7, p=0.018) and total LUSS score 
(Figure 7.14d, t0 25.9 ± 13.9, t12 16.7 ± 10.0, p=0.002) over the 12-weeks.  
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Figure 7.14a - LUSS1 (Number of symptoms; max score = 11) 
 
 
 
Figure 7.14b - LUSS2 (Frequency of symptoms; max score = 44) 
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Figure 7.14c - LUSS3 (Intrusiveness of symptoms; max score = 44) 
 
 
Figure 7.14d - Total score of LUSS (out of a possible 99; summative score) 
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7.4 Discussion 
It was hypothesized that the effects of exposure to the intervention (resistance 
training programme) once per week (RT1) would be significantly different from 
those patients exposed three times per week (RT3).  However, the results of the 
study show that there were no discernible (statistical) differences between the 
training groups in strength, function, and uraemic symptoms. The changes over 
time were consistently greatest in the first half of the intervention (t0-t6).  In 
contrast, VL muscle size and architecture showed most notable changes from the 
mid-point onwards, with group differences becoming more pronounced as the 
intervention continued. 
 
7.4.1 Whole and regional body composition 
7.4.1.1 Subcutaneous (mid-VL) fat depth 
The non-significant reduction, or no change, in subcutaneous fat depth at the mid-
VL point (↓0.12cm, t0 1.25 ± 0.74 cm, t12 1.13 ± 0.67 cm) falls below the established 
MDC (0.22cm; Table 5.3).  This was not unexpected as there were no significant or 
observable changes in overall fat mass (Table 7.3) and previous studies where the 
intervention is purely resistance training (with no cardiovascular element) have 
found similar responses (CKD HD, PEAK study, Cheema et al 2007). 
 
7.4.1.2 Mid-VL site muscle 
7.4.1.2.1 VL ACSA 
The actual (absolute) increase in VL ACSA in group RT1 after only twelve sessions 
(12-weeks; RT1t12 ↑2.51 ± 0.8 cm
2) showed similar improvements as group RT3 did 
after 18 sessions (six-weeks; RT3t6 ↑2.56 ± 1.4 cm
2).  The percentage (relative) 
change also indicates that the total increase in ACSA in RT1 (12 sessions; RT1t12 
↑13.2%) also occurred between 12 and 18 sessions (between t4 and t6) (RT3t4 
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10.8%, RT3t12 15.4%); a very similar improvement brought about over fewer 
sessions (but a longer period of time). 
 
Figure 7.15 - Relative (percentage) VL ACSA measured every four weeks, showing 
significance over time from baseline (t0) to t8 (p=0.000), and the last four weeks (t8 – 
t12, p=0.000), and non-significant differences between groups from baseline (t0) to 
t8 (p>0.05, ns), and the last four weeks (t8 – t12; p=0.057, ns, trend) 
 
 
 
Rate of change over 12 weeks (Figure 7.5, RT1: y=0.4108x, RT3: y=0.9165x) indicates 
more than twice the gradient in RT3, however this is likely due to the last four 
weeks (t8 - t12) when the rate of change was almost three times greater in RT3 than 
RT1 (fig 7.15, RT1: y=0.509x, RT3: y=1.3456x). 
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Muscle hypertrophy is unlikely to occur in the first four weeks of a resistance 
programme (Moritani & deVries 1979; Folland & Williams 2007) and this is seen as 
the group difference is visible only from t4 (ACSA Fig 7.15) though it is not significant 
at this point (p>0.05).  The delay in muscular adaptation for at least four weeks may 
be even more applicable to older/frail individuals whose hypertrophic adaptations 
are compromised compared to young/healthy adults (Welle et al 1996; Bickel et al 
2011). 
 
7.4.1.2.2 Muscle architecture  
7.4.1.2.2.1 Pennation angle  
Similar patterns are seen for pennation angle and ACSA measures; actual (absolute) 
increases in pennation angle in group RT1 after 12 sessions (12 weeks) are very 
similar to RT3 after a greater number of sessions (24 sessions, 8 weeks) but over a 
shorter time period (RT1t12 2.65 ± 1.2°, RT3t8 2.67 ± 2.2°).  In terms of percentage 
(relative) change, this equates to RT1 at t8 (11.72 ± 13.2%, 8 sessions) and RT3 at t6 
(11.37 ± 9.7%, 18 sessions).  A larger cohort is needed to claim statistical 
significance at each time-point; however, the data (and graphical representation; 
Figure 7.16a-b) does indicate this strongly.  Remodelling of muscle architecture has 
been shown to precede gains in muscle CSA (Seynnes et al 2007). 
 
A larger pennation angle (angle at which fascicles attach to aponeuroses of the 
muscle) allows more contractile material to be accommodated along the tendon 
length, leading to a larger physiological cross-sectional area (PCSA) and greater 
force production by the muscle (change in pennation angle alone does not affect 
the anatomical cross-sectional area [ACSA] as greatly as it does PCSA).   
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The increased pennation angle is most notable from t8 when RT3 continued at a 
significantly (p=0.009) greater rate of change to t12 (t0  16.83 ± 1.61°, t8 19.49 ± 
3.11°, t12 22.85 ± 3.24°)  than RT1 (t0  15.44 ± 2.35°, t8 17.15 ± 2.75°, t12 18.09 ± 
2.08°), with no significant group differences between baseline and t8 (Figures 7.16a-
b).  
 
Figure 7.16a  - Vastus Lateralis pennation angle measured every four weeks, 
showing significance over time from baseline (t0) to t8, and the last four weeks (t8 – 
t12), and between groups from baseline (t0) to t8 (ns), and the last four weeks (t8 – 
t12; p=0.009) 
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Figure 7.16b - Relative change in VL pennation angle from baseline every four weeks 
 
 
 
 
The increase in pennation angle over 12-weeks for both groups was significant (RT1 
17.5 ± 9.8%, RT3 36.3 ± 15.5%) and comparable to other studies (35.5%, Aagaard et 
al 2001; 35%, Reeves et al 2009).  Studies that described smaller significant 
increases had less variety within the “lower body” resistance training intervention 
(5%, 9-weeks, leg extension exercise only, Erskine et al  2010) or a much shorter 
intervention period (7.7%, 35-days, Seynnes et al 2007) than the others.     
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7.4.1.2.2.2 Fascicle length 
The results from this study showed no significant change in fibre length over the 12-
week intervention or between groups.  This is in agreement with a review of 
resistance training studies (Blazevich 2006) that reported increases in pennation 
angle and the physiological cross-sectional area (PCSA) but little or no changes in 
the length of the muscle fascicle (bundle of individual muscle fibres). 
   
The lack of change in muscle fascicle length described by Blazevich et al (2006) and 
also seen here suggests that a major contribution to the larger VL ACSA (RT3 t12 
30.8%) was in fact the larger pennation angle (RT3 t12 36.3%).  Though to directly 
use this to approximate the PCSA of a pennate-fibre muscle, such as the vastus 
lateralis, may result in an underestimation of the PCSA true value; suggesting that it 
could be theorised that the PCSA would have grown by at least 30.8% 
(approximately one-third) with maximal force production increasing accordingly.  
This is in agreement with the strength results of this study (leg press peak force 
↑57%, Figure 7.8, knee extension peak force ↑30%, Figure 7.9). 
Vitally though, the differential group increase in size of both ACSA and pennation 
angle of the vastus lateralis muscle only became significant from week eight (t8) 
onwards (Figures 7.15 - 7.16), suggesting it may take at least eight-weeks before the 
muscle is able to adapt more efficiently to the different training volumes. 
 
7.4.2 Strength – Handgrip, Leg Press and Knee Extension Peak Force 
RT3 handgrip strength was ~2.5kg greater than RT1 at baseline. This was not a 
significant group difference and lies below the minimally detectable change (MDC) 
for this measure calculated in the previous literature (3.4kg, CKD HD, Segura-Orti & 
Martinez-Olmos 2011; 4kg, diabetes, Alfonso-Rosa et al 2013; 5.1-5.2kg, cardiac 
rehab, Puthoff & Saskowski 2013).   
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It is possible that the gender proportions in each group may have driven the 
baseline differences observed in the leg press and handgrip results (RT1 43% 
female, RT3 60% female) as a larger percentage of females in one group would 
normally lower the average in strength tests, though this was not reflected in either 
the baseline handgrip (RT3>RT1) or knee extension (RT3>RT1) strength scores.  
Additionally, already within the first two-weeks, RT3 leg press peak force had 
increased the average maximal leg press from 217.25 ± 99.81 N to 274.03 ± 101.09 
N, suggesting it was more likely a technical error that skewed the data.  Therefore if 
we void the RT3t0 and instead use RT3t2 as a baseline point in group RT3 to account 
for this possible technical error, the overall improvement within the pooled data set 
(using t2 as baseline in both groups) is still highly significant (37% increase from t2 to 
t12, p=0.002) by the final assessment point (t2 295.00 ± 124.19 N, t12 403.89 ± 148.92 
N) with 24% improvement by the (t6) mid-point (t2 to t6). 
 
It is generally accepted that there is a delay before the onset of muscle hypertrophy 
and that the initial strength gain is mostly due to the intervention of neural factors 
(Seynnes et al 2007; Moritani & deVries 1979).  Several investigators have reported 
a rapid increase in neural drive, during a maximal contraction, within a few weeks of 
strength training, demonstrated by an increase in integrated electro-myographic 
(EMG) activity (Narici et al 1989, Hakkinen et al 1996).  The improvement in 
strength and function within the first half of the intervention can therefore be 
attributed to neural adaptation, which largely occurs within the first 6-weeks of a 
training programme (Enoka 1997; Blazevich 2006), and not the change in muscle 
size or structure. 
 
The varying rate of improvement between the leg press and knees extension peak 
force tests (LP greater improvement in the first six weeks, KE greater proportion of 
 220 
 
the improvement in the second six weeks), may be due to the greater contribution 
of the “hamstrings” in conjunction with the quadriceps in the leg press action 
compared to the quadriceps-isolating movement of the knee extension exercise.  
The usual hamstring to quadriceps ratio is 50-80% (where 100 percent would be 
equal strength; Rosene et al 2001), implying that the hamstrings are usually weaker 
than the quadriceps (with women having even lower ratios than men; Jaiyesimi & 
Jegede 2005), hence the greater rate of improvement initially in hamstring strength 
relative to the start point (represented in the leg press peak force). 
 
7.4.3 Function – STS, NSRI walk test, PAR 
The increase in the leg press peak force, especially in the first six-weeks of the 
intervention, is also reflected in the sit-to-stand test results which used the same 
movement pattern as employed in the resistance training programme.  However, 
the sit-to-stand assessments do not isolate the muscles in use and instead must 
factor in other possible influences such as balance and speed of movement. 
 
The more endurance-based sit-to-stand-60 highlighted greater improvement 
compared to the speed-assessed sit-to-stand-5 despite the movement pattern 
being identical. This is not in agreement with the conclusions of a recent systematic 
review of exercise in CKD (Heiwe & Jacobsen 2011) that found no improved 
muscular endurance (assessed by sit-to-stand-60) over a longer intervention (six-
months, high intensity RT) though this analysis was based on only one study that 
used a resistance training intervention and assessed muscular endurance by STS60 
(Segura-Orti et al 2009).  The greater improvement of STS60 in this present study 
could be due to a number of reasons.  The resistance training programme 
concentrated on repeated movement with a controlled and steady technique 
throughout the movement and not the speed.  Simultaneously, the training may 
have affected the efficiency of oxygen uptake by the muscle, allowing the 
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participant to utilise the muscle more fully (Jang & Kim 2009).  This could also offer 
some explanation of the dramatic improvements within the first 6-weeks in 
strength and function not attributed to either the change in muscle size (cross-
sectional area), fibre alignment within the muscle (pennation angle), or neural 
adaptations, also noted in the walk test improvements to t6. 
 
The NSRI walk test has been validated and assessed as a proxy measure of VO2peak 
in CKD patients (Mercer et al 1998).  The reduced time recorded for both RT1 and 
RT3 groups suggests an improvement in this measure of maximal oxygen uptake, 
but once again with no differences between the group-frequency of training.   Using 
the equation from a validation study;  
[VO2peak (ml/kg/min) = (-0.0767 x walk time in seconds) + (27.327)] 
(Mercer et al 1998, p2024) 
the improvement (change in walk time: ↓12.49secs, t0 84.35 secs, t12 71.86 
secs) in VO2peak over the 12-weeks is approximately 1.0 ml/kg/min, though this 
falls below the SEE (1.9 ml/kg/min, Mercer et al 1998).  The larger increase in 
physical activity recall (PAR) in the first six weeks in group RT3 and smaller standard 
deviation is likely due to the set additional supervised training sessions as part of 
the intervention.  The linear increase in activity over the complete 12-week 
intervention period would also suggest small increments in the participants’ 
involvement in day-to-day activities which may also have contributed in a small way 
to the improved functional tests in both groups. 
 
The dramatic changes of these functional tests potentially occurred earlier than the 
mid-point (t6) but were not assessed as regularly as the body composition or 
strength measures. 
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7.4.4 Uraemic Symptoms 
The reduction in each section of LUSS indicates an improvement in health-related 
quality of life as uraemic symptoms are reduced in number, frequency, 
intrusiveness, and total (summative) score.  A cross-sectional study of HRQoL in CKD 
patients showed distinct differences in LUSS scores depending on the disease status 
(advanced CKD, moderate CKD, normal renal function; Pugh-Clarke et al 2006).  The 
reduction as a result of this RT intervention represents a fall from 
advanced/moderate CKD levels to those more usually seen in patients with CKD 
with normal renal function (stages 1-2, GFR>60ml/min).   
 
A six-month walking intervention (30-mins, five times/week, RPE 12-14) in pre-
dialysis CKD 4 and 5, described a significant (p<0.05) reduction (improvement) in 
LUSS2 (frequency of symptoms), LUSS3 (intrusiveness of symptoms), and total score 
in the Leicester Uraemic Symptom Score but no change in the reported number 
(LUSS1) of symptoms (Kosmadakis et al 2012).  This clearly shows the benefit of an 
exercise regime, as their control group (no walking exercise) demonstrated small 
(non-significant) increases or no change in all four areas (a worsening of symptoms 
in non-exercisers).  However, the present study using resistance training for just 12-
weeks, brought about significant improvements (p<0.05) in LUSS3 (intrusiveness) 
and highly significant improvements (p<0.01) in all other measures of uraemic 
symptoms (LUSS1, number; LUSS2, frequency; and total) with fewer training 
sessions (once or thrice per week) than the walking intervention (five times per 
week, Kosmadakis et al 2012). 
 
The increased benefit of RT over walking in ameliorating the perceived number, 
frequency, and intrusiveness of uraemic symptoms will have been most noticeable 
in “loss of muscular strength or power” as significant strength gains were made 
across the intervention.  The participants here reported a reduction on average of 
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slightly over one symptom (LUSS1, number, t0 5.8 ± 2.4, t12 4.6 ± 2.7), so others 
could be directly influenced by the RT intervention, including “restless legs, muscle 
spasm or stiffness, and pain in joints”.   
 
This strongly indicates that resistance training in non-dialysis patients can lessen, 
and almost normalise, the day-to-day symptoms experienced by NDD, moderate 
CKD patients.  Significant improvements were noticed within the first six-weeks in 
both training groups, and continued almost linearly through to the conclusion of the 
intervention (Figures 7.14a-d).  Whether some of these improvements can be 
maintained following the cessation of exercise remains to be seen, or if the benefits 
would continue to progress at the same rate if the regimen was continued 
indefinitely. 
 
7.4.5 Training Frequency/Volume 
In young, healthy individuals a dose-response relationship between exercise 
frequency/volume and strength has been identified where increased volume leads 
to increased strength and muscle mass (Rhea et al 2003).  Despite this, long-term 
resistance training of healthy untrained older adults where three different 
frequencies were implemented (once, twice, or three times per week) showed no 
group differences in muscle or strength gains after 24-weeks (Taaffe et al 1999).  
Shorter studies have replicated these findings, also showing no additional benefit 
with more frequent training (three times per week compared to only twice per 
week for 6-weeks, Candow & Burke 2007; three times or four times with split loads 
for 8-weeks, Benton et al 2011; two or three times per week for 8-weeks, torso 
strength, Murlasits et al 2012). 
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It has been suggested that for individuals that are deconditioned - such as those 
with chronic illness, the frail, or elderly - a training threshold may exist.  That is, for 
initial training adaptations amongst the most deconditioned, when a threshold-
stimulus is met, further increases in volume load or frequency may not result in 
greater gains in strength (Benton et al 2011).  The results of this study reflect this 
proposition, as the significant group differences noted in body composition and 
structure did not occur in the initial stages and it was only with prolonged exposure 
(over eight-weeks) that they became apparent.  
 
7.5 Study Strengths and Limitations 
7.5.1 Limitations 
The small study size (n=17) is limiting in the analysis as larger numbers may have 
increased the power (improved the significance) either between groups or over 
time as some indications of “trends” can be seen here in these results.  The large 
variability in some of the baseline characteristics (e.g. age, weight, serum 
creatinine, Table 7.1), in conjunction with the small sample size, may account in 
part for the lack of statistically significant results later in the intervention. 
 
Also, the relatively short duration of the intervention (12-weeks) is potentially 
limiting as group differences only began to appear later in the intervention.  A 
continued programme of training beyond 12-weeks may have further highlighted 
the group differences in muscle size and structure, and may have developed 
differences between groups over time in functional and clinical outcome measures 
with a lengthier intervention. 
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Lastly, the lack of a true control group could be deemed a potential study limitation.  
However, the upper body verification/control data allowed us to observe the 
untrained muscle groups as the surrogate control for the training programme. 
 
7.5.2 Research design strengths of the Study 
Assessment of upper body strength and size clearly show that the untrained areas 
were unaffected (Table 7.2), allowing us to infer that any adaptations in the trained 
(lower body) can be attributed to the intervention.  
 
In addition, each of the documented significant changes observed over the 12-week 
intervention were greater than the established error/ smallest detectable 
difference/ minimal detectable change.  For instance, VL muscle depth increased by 
0.23cm and total thigh muscle depth increased by 0.34cm (VL muscle thickness 
MDC 0.14cm, total muscle thickness MDC 0.19cm; Table 5.3). 
 
This was also the case for the functional measures; NSRI walk time fell by 14.7% 
(SEE 11%, Mercer et al 1998), STS5 improved (decreased) by 4.49 seconds (minimal 
detectable change 1.7secs, COPD, Jones et al 2013; 2.5secs, older females, Goldberg 
et al 2012; 3.12sec, cardiac rehab, Puthoff & Saskowski 2013) and STS60 increased 
by 11.83 repetitions (MDC 4-repetitions, HD CKD, Segura-Orti & Martinez-Olmos 
2011). 
 
7.5.3 Relevance to CKD patient population 
These results are very relevant to a broader population of CKD3 patients as this 
sample is similar to participant samples used in other studies (age, weight, BMI), 
despite group RT1 being slightly younger (53 years old) than RT3 (60 years old).  
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Body weight is also comparable; other studies have shown gender differences of 
approximately 10kg (women ~60kg, men ~70kg; Bellizzi et al 2006) and following 
drop-out in this study - group RT1 had lost 3 women - resulting in the mean weight 
of RT1 being greater (predominantly male) than RT3 at baseline.   
 
7.6 Clinical Implications 
Results of this study clearly show that for larger gains in ACSA and pennation angle 
of a resistance trained muscle, three sessions per week is better than one session 
per week.  However, this was not reflected in the strength, function, or clinical 
tests.  Therefore, implementing a programme of resistance training for those 
diagnosed with Chronic Kidney Disease early on is feasible and would be beneficial 
to those participating in terms of a reduction in uraemic symptoms as well as 
improved strength and function.  For all outcome measures assessed in this study, 
the difference between training once or three times per week was statistically 
insignificant (over the first eight-weeks), suggesting that resistance training just 
once per week is adequate to bring about improvements relevant to the clinical 
population; delaying both the transition to dialysis and a possible diagnosis of 
frailty.  Interventions should also be at least eight weeks in duration to overcome 
the apparent training threshold or adaptation limitation prior to this point. 
 
7.7 Conclusions 
Resistance training is feasible, practical, and effective in CKD3 patients. 
Despite the group differences seen in the physiological adaptations in the measured 
VL muscle whether training once or three times per week, the functional and clinical 
response was similar, which is statistically significant and clinically beneficial in this 
population. 
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Resistance training once per week may therefore be an effective introduction or 
pre-habilitation programme for more elderly and deconditioned patients where 
improved strength, function, and health-related quality of life (through reduced 
uraemic symptoms) are the main objectives. 
 
7.8 Further Research 
Whether the gains in muscle size, strength, function, and reduction in uraemic 
symptoms, were maintained after the intervention was not examined and this limits 
our understanding of the long-term effects of the intervention in this study.  Long-
term follow-up comparing the group-frequency and usual care (or those unable to 
participate in the RT programme) could provide further information about whether 
a resistance training programme/intervention of this nature can bring about a delay 
before it become medically necessary to initiate dialysis. 
 
Further research can to be done into prolonging the intervention to examine 
whether training once or thrice per week over a longer period brings about 
continued or greater improvements or whether a threshold is reached.  
Additionally, measuring changes in glucose and insulin sensitivity following the 
resistance training intervention would be of interest as diabetes is now the 
commonest cause of end stage renal disease (Collins et al 2005; Cheema et al 2007).     
 
The state of inflammation (analysis of inflammatory markers) throughout the 
intervention period could also be of interest as this is also a major manifestation of 
CKD. 
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CHAPTER 8 – General Discussion 
 
8.1 Introduction 
This thesis set out to make an original contribution to knowledge in relation to 
methods of assessing muscle size and architecture in the Chronic Kidney Disease 
and End-stage Renal Disease population and to assess the ability to improve these 
muscle measurements by implementing an anabolic intervention (resistance 
exercise training) in the non-dialysis dependent CKD population. 
 
As outlined in the introduction (Chapter 1), accurate measurement is vital to gain a 
deeper understanding of the relationship between the general atrophy observed in 
CKD patients both in early stages and once dialysis has been initiated, and the 
functional limitations that become instigators of frailty and reduced independence 
in this group. 
 
The purpose of this final chapter is to consider and synthesize the findings from the 
four study chapters in greater depth and to evaluate these findings in the context of 
the existing literature.  This chapter will also consider the limitations of the studies 
and discuss the implications for investigators and policy makers regarding 
measurement of total and regional body composition and the implementation of 
resistance exercise training as an anabolic therapy in CKD patients.  Table 8.1 
summarizes the research questions and key findings of this thesis. 
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Table 8.1 – Key findings of the thesis 
Research question/ study Key findings of study 
Are there statistically significant differences 
between early-stage CKD and end-stage 
CKD in terms of body composition, strength 
and function?  (Chapter 4) 
 There is a statistical difference between CKD3 and CKD5 (CKD5 faring worse) in  -  
 clinical measures (Hb and Albumin, p<0.01) 
 body composition (anthropometry p<0.01) 
 strength (handgrip and KEPF45 p<0.05) 
 function (STS5 p<0.05, STS60 ns, weekly PAR p<0.01) 
 uraemic symptom reporting (p<0.01) 
Are current methods of assessment of body 
composition sufficiently discriminatory to 
track an individual’s change over time, or 
from an intervention, using repeated 
measures, in CKD?  (Chapter 4) 
 SGA, BMI, body weight, %body fat are not precise enough to distinguish between the two stages. 
 Anthropometrical measures are sufficiently sensitive to distinguish different stages of the disease. 
 Circumference/girth measures (anthropometry) cannot distinguish between muscle and fat. 
Is Ultrasound a valid form of measurement 
of regional body composition in CKD, when 
compared to a gold standard tool such as 
MRI?  (Chapter 5) 
 2-D B-mode ultrasound is valid compared to MRI in measures of fat and muscle at the mid-VL site in 
CKD.  
 ICCs: VL ACSA 0.96, VL thickness 0.99, fat thickness 0.98 
 Typical error: VL ACSA 0.61 cm2 (2.6%), VL thickness 0.04 cm (1.8%), fat thickness 0.05 cm (6.0%) 
Is Ultrasound reliable for use in the CKD 
population for repeated measures of 
regional body composition?  (Chapter 5) 
 2-D B-mode US is reliable in repeated measures (by a single assessor) of fat and muscle at mid-VL.   
 ICCs: VL thickness 0.98, total muscle thickness 0.97, fat thickness 0.99 
 MDC:  VL thickness 0.14 cm, total muscle thickness 0.19cm, fat thickness 0.22 cm 
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Research question/ study Key findings of study 
Are accurate measures of muscle mass and 
muscle architecture by US related/correlated 
with functional and neuromuscular (strength) 
performance measures in early-stage CKD?  
(Chapter 6) 
 Site specific body composition measures by US were highly correlated (p<0.01) to 
 Anthropometry (VL depth r=0.38-0.44, total muscle depth r=0.50-0.53, fat depth r=0.41-0.67) 
 Strength (VL ACSA r=0.35-0.45, fat thickness (-ve) 0.49-0.67) 
 Function (pennation angle r=0.45, fat thickness (-ve) 0.42-0.44) 
Are any of the measurements used to assess 
body composition, frailty, and malnutrition in 
CKD patients related/correlated with patient-
reported uraemic symptoms?  (Chapter 6) 
 Uraemic symptoms (frequency and intrusiveness) are highly correlated (p<0.01) to 
 VL muscle pennation angle (r= (-ve) 0.42-0.51) 
 anthropometry (MTC, MAC, r=0.35-0.40) 
 function (STS5 r=0.39-0.46, STS60 r= (-ve) 0.49-0.52, NSRI walk r=0.35-0.40) 
Is there a greater difference in muscle size 
and/or architecture (at the mid-VL site) brought 
about a greater frequency of a 12-week 
resistance training intervention; three times per 
week compared to once per week?  (Chapter 7) 
 VL thickness: (p<0.01) improvement (increase) over time, ns between groups (RT3=RT1) 
 Total muscle thickness: (p<0.01) improvement (increase) over time, ns between groups (RT3=RT1) 
 Fat thickness: ns change over time, ns between groups (RT3=RT1) 
 VL ACSA: (p<0.01) improvement (increase) over time, (p<0.01)  between groups (RT3>RT1) 
 Pennation angle: (p<0.01) improvement (increase) over time, (p<0.05) between groups (RT3>RT1) 
 Fascicle length: ns change over time, ns between groups (RT3=RT1) 
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Research question/ study Key findings of study 
Does a 12-week resistance training intervention 
bring about change in objectively measured 
strength and function, and patient-reported 
(subjective) uraemic symptoms?  Does the 
frequency of the intervention affect this?  
 (Chapter 7) 
 LPPF45: (p<0.01) improvement (increase) over time, ns between groups (RT3=RT1) 
 KEPF45: (p<0.01)improvement  (increase) over time, ns between groups (RT3=RT1) 
 STS5: (p<0.01) improvement (reduction) over time, ns between groups (RT3=RT1) 
 STS60: (p<0.01) improvement (increase) over time, ns between groups (RT3=RT1) 
 NSRI walk: (p<0.01) improvement (reduction) over time, ns between groups (RT3=RT1) 
 PAR: (p<0.05) improvement (increase) over time, (p<0.05) between groups (RT3>RT1) 
 LUSS1 (number): (p<0.01) improvement (reduction) over time, ns between groups (RT3=RT1) 
 LUSS 2 (frequency): (p<0.01) improvement (reduction) over time, ns between groups (RT3=RT1) 
 LUSS 3 (intrusiveness): (p<0.01) improvement (reduction) over time, ns between groups (RT3=RT1) 
 Total LUSS score: (p<0.01) improvement (reduction) over time, ns between groups (RT3=RT1) 
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8.2 Discussion of key findings 
Table 8.1 summarises the key findings in each study, in response to the research 
questions and aims set out in the introduction (Chapter 1) and literature review 
(Chapter 2). 
 
8.2.1 Using 2-D B-mode Ultrasound for body composition assessment 
The key findings table (Table 8.1) shows that 2-D B-mode US is a valid method for 
assessing muscle and fat depth (thickness) at the mid-VL site when compared to a 
gold standard measurement technique (MRI) in the CKD population.  The intra-rater 
reliability of all measurements was very high, showing excellent reproducibility at 
the mid-VL site. 
 
Ultrasound (2-D B-mode) is valid and reliable method of body composition 
measurement to evaluate site-specific fat and muscle mass.  US also allows 
measurement of muscle architecture (the muscle fibre arrangement within the 
muscle) which is not possible with other forms of portable/near bed-side 
assessment equipment (MAC, MTC, skinfold, BIA, muscle biopsy).  Therefore 
utilising ultrasound to assess regional body composition provides an additional layer 
of information for researchers to assess the effectiveness of an intervention, or to 
track an individual over the course of the disease progression; possibly even 
providing objective, quantifiable, and accurate feedback to the patient  regarding 
the need to intervene, or demonstrate progress (whether positive or negative).  
 
Using US to assess muscle and fat depths at specific sites - such as the mid-VL used 
throughout the studies within this thesis - allows increased accuracy and specificity 
in the measurement of the different tissues.  Some intervention studies have 
compared US to a “gold standard” for assessing muscular size adaptation (DEXA) 
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and found that US actually picked up on significant improvements in VL cross 
sectional area, whereas DEXA did not note the increased lean thigh mass (Scanlon 
et al 2014).  Unsurprisingly, the US depth measures of the mid-VL correlated 
strongly and significantly with anthropometric (girth measures) assessment of the 
mid-thigh (MTC) (VL depth, total muscle depth, fat depth, r=0.44-0.67, p<0.01, 
Table 6.2).  However, fat depth correlations with MTC alone suggests it is adipose 
tissue that drives the association (r2= 0.45) and not the muscle mass, architecture, 
efficiency of contraction or force-production. 
 
 One major advantage of using US over anthropometric measures of the same site 
(e.g. mid-thigh circumference) is the ability to measure the muscle size and depth 
with greater accuracy without being as affected by possible oedema (swelling due 
to water retention).  However, there are still limitations of using US in chronically 
and critically ill patient groups who are often vulnerable to oedema (as in the CKD 
population).  US measurements can be confounded by oedema as it can distort the 
images and can cause problems in attempting to de-limit individual muscles within a 
muscle group (Gerovasili et al 2009).  An example of this is the primary muscle 
group examined in this thesis; the vastus lateralis within the vastus group of the 
quadriceps (particularly determining the aponeurosis between the vastus lateralis 
[VL] and vastus intermedius [VI]).  Despite this limitation, it is still a better choice for 
increased accuracy of measurement, as a skilled technician is able to determine 
early on whether the image brightness and tone can be adjusted to improve 
viewing or if some measures are not feasible in an individual (e.g. a 
researcher/clinician/ technician can still take a measure of total muscle depth, if 
unable to measure VL-only depth due to an indistinguishable aponeurosis). 
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8.2.1.1 Muscle quality 
The advantage of a pennate-muscle is the increased potential for force production 
within the muscle.  Comparative research examining body builders and sedentary 
individuals demonstrated that greater muscle hypertrophy was strongly linked to 
greater angle between the muscle aponeurosis and an individual muscle fibre 
(pennation angle; Kawakami et al 1993).  The larger angle reflects the larger 
quantity of protein within both the muscle and systemically (assessed by the 
concentration of serum albumin), whether due to the CKD stage (later stages, less 
protein, smaller pennation angle; Chapter 4 and Chapter 6) or as a result of a 
training programme (increased anabolism and/or decreased catabolism, leading to 
increased protein stores, larger/steeper pennation angle and muscular 
hypertrophy; Chapter 7). 
 
Muscle quality is assessed by a variety of methods; one is as muscle-force per unit 
of mass (force per physiological cross-sectional area [PCSA], Matschke et al 2010a).  
Muscle quality can also be assessed as echo intensity using ultrasound scanning, 
where an increase in the echo-intensity of a muscle represents changes caused by 
increased intramuscular connective and adipose tissues (improved muscle 
composition of connective to contractile tissue; Fukumoto et al 2012; Scanlon et al 
2014).  This thesis did not examine echo-intensity as a descriptor or marker for 
muscle quality but instead focused on other components that contribute to 
assessment of muscle force - namely fibre (fascicle length), pennation angle, muscle 
thickness and ACSA (not PCSA).   
 
The specific tension of a muscle is determined as muscle force per PCSA.  However, 
to calculate the PCSA of a muscle, volume, muscle fibre length, and fibre pennation 
angle must be determined (Kawakami et al 1994; Aagaard et al 2001) which in itself 
is time consuming and hard to measure precisely.  Depending on the speed of 
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movement in the maximal strength tests, best measurement practise has been 
shown to vary; in knee extension exercise, muscle volume had the highest 
correlation at slower speeds but was not statistically better than ACSA and PCSA. At 
faster speeds PCSA x fascicle length and ACSA were better predictors than volume. 
However, muscle ACSA consistently came second at all speeds (Blazevich et al 
2009), deeming it potentially the most useful measure across the board.  
Unfortunately, of the muscle measures taken using ultrasound in this thesis, ACSA 
was shown to have the greatest typical error (0.61 cm2, Chapter 5).  As previously 
mentioned, this is likely due to the greater potential for error in the configuration of 
individual images to form the full ACSA image, which is then measured.  Due to the 
larger error within repeated measures, or between subjects, utilising another 
measure as a representative for ACSA would be a reasonable suggestion and the 
strong correlations (Chapter 6) observed between US-derived measures of muscle 
size showed potential (total muscle depth and VLACSA, r=0.48, n=17, p=0.04; total 
muscle depth and VL depth, r=0.85, n=20, p=0.00; pennation angle and mid-VL 
depth, r=0.58, n=8, p=0.08 [ns]; correlations between architecture [pennation 
angle] and mid-VL depth may have reached significance with a greater sample size).   
When incorporating results from the intervention study (Chapter 7) where only VL 
ACSA and VL pennation angle showed interaction effects (greater effect size with 
greater training frequency or volume), the use of a single measure of either total 
muscle depth or VL muscle depth, would not have captured this highly significant 
difference.  However, it is feasible that a single measure that did detect the 
differential effect of training frequency (VLACSA or pennation angle) alongside 
another simpler muscle (depth or thickness) measure would provide sufficient 
information to describe and interpret the results of an intervention (or 
observational) study effectively. 
 
An alternative proposal that VLACSA and pennation angle could be used 
interchangeably, or as proxy measures/markers for each other was shown to be 
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invalid based on these results, as correlations between the two were far from the 
accepted level of significance (VLACSA and pennation angle, r=0.54, p=0.11), though 
once again this may be due to the small sample size (n=8).  Previous studies into the 
relationship between muscle ACSA and architecture (pennation angle) have found 
instead that they are indeed significantly correlated, though were in very different 
populations (tricep brachii, body builders, r=0.83, p<0.001; weightlifters, r=0.68, 
p<0.001, Ikegawa et al 2008). 
 
The US used in this thesis was a 2-D B-mode US, providing a two-dimensional image 
in a single plane at any one time.  This can be used to measure muscle thickness (or 
depth) and to build an image (from several) to assess ACSA.  However, to determine 
muscle quality it has been deemed useful to have a measure of muscle volume to 
calculate PCSA and using muscle force (strength) per PCSA to assess quality 
(efficiency).  Previous literature has examined the validity of using a 2-D US to 
measure muscle volume (and compared it to volume measured by MRI).  The 
authors (Miyatani et al 2004) found that muscle thickness is a good predictor of 
muscle volume when combined with limb length but found large variability of the 
contribution of muscle thickness to volume (i.e. they could not develop prediction 
equations based on thickness and limb or muscle length alone; Miyatani et al 2004).  
Based on the mathematical principles developed by Cavalieri (the method of 
indivisibles: e.g. the volume of a sphere or cone; Weisstein, 2014), others have 
calculated muscle volume with great accuracy (ICC>0.8, error 0.4 ± 6.9 %) from VL 
ACSA measures using two-dimensional US, with results validated against hydrostatic 
weighing (cadavers) (Infantolino et al 2007).  However this is very time-consuming 
as it relies upon obtaining accurate ACSA outlines (perimeters) at multiple points 
along the muscle.  An alternative - though very crude - version of this method would 
be to use one ACSA value and multiply by the muscle or limb length.  Obvious 
inaccuracies ensue as neither the VL or quadriceps muscle is a standard cylinder, 
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and thus would either over- or under-estimate the true muscle volume, depending 
on the site of the measured ACSA. 
Three-dimensional US is a viable option to reduce error in assessing the volume of 
non-standard shapes.  It has been tested for validity in animal models against 
hydrostatic weighing (water displacement) to assess organ volume.  As with 2-D US 
(and Cavalieri’s method) there was a small error of 0.6% (Martins et al 2007).  
  
Relevant and helpful though muscle volume is - particularly in establishing the 
degree of muscle quality - it is not necessary in repeated measures to track the 
wasting or hypertrophy of an individual or group.  The limb length will remain 
unchanged, and the muscle length variability will be negligible across an 
intervention or observational study.  Any atrophy or hypertrophy generally is most 
noticeable at the bulk of the muscle (e.g. the mid-point of the VL muscle) and thus 
for purposes of reporting change, using the ACSA is feasible, practical and reliable. 
 
 
8.2.2 Comparison of early and late stage CKD 
Initial findings show that there is a distinct difference between early stage CKD 
(CKD3) and those on dialysis (CKD5/ESRD/RRT).  This was particularly evident in 
clinical measures, uraemic symptoms, and anthropometric (limb girth) measures as 
the lower levels of serum albumin - the most abundant protein in human blood 
plasma - reflects the comparatively reduced total body protein assumed through 
loss of muscle/other lean mass in the later stages of CKD (CKD5). 
 
The expectation is that reduced strength and function comes with reduced muscle 
mass and activity level. However, whether the loss of strength and functional 
capability (increased fatigue, generalised weakness) associated with CKD is caused 
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by the loss of muscle mass, or conversely the loss of protein due to uraemia leads to 
decreased muscle - and therefore reduced activity level and consequent decline in 
strength and function - remain unclear.  Nevertheless, the correlations between 
disease-stage, muscle (protein) mass, strength, function and frailty are evident 
throughout this thesis (Chapters 4 and 6) and previous literature (Castaneda et al 
2001; John et al 2013; Johansen et al 2013).  As mentioned previously, loss of 
muscle mass only partially explains the loss of muscle strength (loss of strength, 
dynapaenia; Manini & Clark 2012; Clark & Manini 2008) and previous research into 
a healthy but aged population demonstrated that the area of the quadriceps muscle 
only explains approximately 6-8% of variability between subjects in knee extension 
muscle strength (Delmonico et al 2009).  Suggesting that muscle weakness is 
possibly more related to impairments in neural (central) activation and reductions 
in the intrinsic force generating capacity of skeletal muscle (Kostek & Delmonico 
2011). 
 
It is well known that muscular strength (Kamel 2003) and function (Bohannon et al 
1984) also generally decrease with age, and epidemiological data shows the 
incidence and prevalence of CKD increases with age (2012 UK Renal Registry annual 
report, 2013), inferring that the loss of muscular strength and function will go hand-
in-hand with increased risk of developing CKD.  A number of studies have reported a 
deterioration of physical function in dialysis patients (Painter 2005; Johansen 2007; 
Johansen et al 2013) but only a few have examined physical function in pre-dialysis 
CKD patients (Hiraki et al 2013; John et al 2013).  According to those reports, 
patients with pre-dialysis CKD are similar to dialysis patients in that they show lower 
knee extensor muscle strength and reduced exercise tolerability compared to 
healthy subjects (Heiwe et al 2001; Padilla et al 2008).  The results from this thesis 
were not compared to a healthy population; however, a similar difference was seen 
between the two groups (CKD3 and CKD5) as was previously reported by Hiraki et al 
(2013) for these same stages which indicated even more specifically that this 
downward trajectory accelerates significantly after CKD stage 3 (CKD2-3 mild-
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moderate reduction in GFR relatively stable functional ability), as CKD4-5 patients 
(severe reduction in GFR and renal failure) have significantly reduced physical 
strength and function compared to both the earlier stages and healthy (matched) 
controls (Hiraki et al 2013).   These results were comparable to the measures within 
this thesis (Chapter 4), reporting similar clinical and strength measures in each 
group (Table 8.2).  Although the subjects in the published data were stronger in 
both groups, the reduction was at a similar rate (e.g. KEPF). 
 
 
Table 8.2 – Comparison of published results (Hiraki et al 2013) with current thesis 
(Chapter 4) 
 
CKD3 
(Chapter 4) 
CKD3 
(Hiraki et al 2013) 
CKD5 
(Hiraki et al 2013) 
CKD5 
(Chapter 4) 
GFR (mL/min) 45.7 ± 7.0 42.8 ± 9.8 10.1  ± 1.3 ≤15 
Hb (g/dL) 13.7 ± 1.8 12.8 ± 1.8 9.8 ± 1.1 11.5 ± 1.3 
Serum Alb (g/L)* 41.8 ± 3.0 40.0 ± 3.0 38.0 ± 3.0 38.2 ± 4.3 
Handgrip (kg) 27.4 ± 11.8 30.8  ± 10.3 22.4 ± 7.9 31.3 ± 10.0 
KEPF (Newtons) * 303.7 ± 134.5 384.0  ± 8.3 282.0  ± 9.6 254.0 ± 72.0 
*data converted from alternative units in Hiraki et al (2013) to allow direct 
comparison; Presented as mean ± standard deviation; GFR = glomerular filtration 
rate; Hb = haemoglobin; KEPF = knee extension peak force 
 
Further differences between CKD3 and CKD5 arise when examining the correlations 
between US-derived measures of muscle size and fat depths at the mid-VL site with 
muscular strength (knee extension peak force).  The expectation was that 
correlations would be similar across the disease trajectory stages, but this was not 
the case.  Table 8.3a highlights these different correlations and associations with 
knee extension peak force (muscular strength). 
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Table 8.3a – Comparison of US measures of muscle size and fat depth, correlated 
with strength (KEPF45) at early (CKD3) and late-stage (CKD5) CKD 
Participant demographics 
CKD3  
(Chapter 6) 
CKD5  
(Chapter 5) 
N (M:F) 51 (28:23) 20 (18:2) 
Age (years) 59.9 ± 13.9 56.5 ± 16.7   
Height (cm) 165.2 ± 9.3 170.1 ± 7.4 
Body mass or weight (kg) 77.3 ± 14.2 78.0 ± 15.4 
BMI (kg/m2) 28.1 ± 4.5 26.8 ± 3.8 
Total body fat (%) 32.5 ± 9.0 No data 
KEPF45 (Newtons) 303.7 ± 134.5 Correlation (r) 254.14 ± 108.00 Correlation (r) 
VL ACSA (cm2) 17.5 ± 3.6 0.35*  (n=34) 17.8 ± 2.8 0.61** (n=19) 
VL depth (cm) 2.2 ± 0.4 -0.12    (n=39) 1.9 ± 0.4 0.50 * (n=22) 
Total muscle depth (cm) 3.9 ± 0.7 0.13     (n=39) 3.6 ± 0.7 0.49 * (n=22) 
Fat depth (cm) 1.3 ± 1.0 -0.65**(n=39) 1.1 ± 1.0 0.23    (n=22) 
Presented as mean ± standard deviation; BMI = body mass index; KEPF45 = knee 
extension peak force at 45 degrees; VL = vastus lateralis; ACSA = anatomical cross 
sectional area 
 
Based on the demographics shown here (Table 8.3a) and in the earlier chapters, it is 
clear that CKD5 patients are statistically worse-off than CKD3 patients, as expected 
(lower peak force measures, alongside generally smaller muscle mass).  However, 
the confusion of the correlations suggests other elements are in process here.  
Examining the participant demographics, it is notable that they are a relatively 
homogenous group (close in age and BMI).  However, the gender split is not an even 
one (CKD3 55% male; CKD5 90% male) which will have contributed to the height, 
weight, BMI and body fat percentage difference and subsequently the varying 
correlations (gender difference in CKD3: height, body fat %, VLACSA, fat depth, 
KEPF45, p<0.01; and additionally body weight in CKD5, p<0.01, but not VLACSA).  
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By examining male-only data (Table 8.3b), we can see that the strength difference 
between the groups becomes greater as does the muscle size (though not to the 
same extent) which could theoretically change the consistency of the correlations. 
 
Table 8.3b – Male-only demographics and US-derived body composition measures 
in early (CKD3) and late-stage (CKD5) CKD 
Participant 
demographics (male 
only) 
CKD3  
(Chapters 4 and 6) 
CKD5  
(Chapters 4 and 5) 
Age (years) 59.8 ± 15.2 (n=28) 58.0 ± 15.0 (n=90) 
Height (cm) 170.9 ± 7.6 (n=28) 172.5 ± 7.5 (n=79) 
Body mass or weight (kg) 80.2 ± 15.0 (n=28) 81.8 ± 16.0 (n=90) 
BMI (kg/m2) 27.3 ± 3.9 (n=28) 27.9 ± 5.0 (n=79) 
Total body fat (%) 26.3 ± 5.7 (n=28) 24.0 ± 8.4 (n=9) 
KEPF45 (Newtons) 382.6 ± 120.1 (n=20) 273.3 ± 68.9 (n=39) 
VL ACSA (cm2) 19.4 ± 3.1 (n=19) 18.1 ± 3.8 (n=18) 
VL depth (cm) 2.2 ± 0.5 (n=28) 2.0 ± 0.3 (n=19) 
Total muscle depth (cm) 4.0 ± 0.8 (n=28) 3.6 ± 0.7 (n=19) 
Fat depth (cm) 0.6 ± 0.2 (n=28) 0.6 ± 0.2 (n=19) 
Presented as mean ± standard deviation; BMI = body mass index; KEPF45 = knee 
extension peak force at 45 degrees; VL = vastus lateralis; ACSA = anatomical cross 
sectional area 
 
This could be explored in greater detail with larger samples as a change in 
correlations between muscle size and strength (or function) and other factors along 
the disease trajectory could further inform the relative contributions of muscle 
wasting with neuromuscular strength and functional capacity.  Similar investigations 
have been undertaken, examining the relationships between strength, function, 
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muscle fibre type, total body potassium (as an indicator for protein stores) and 
serum albumin with inflammatory markers (Castaneda et al 2001, 2004).   
 
The research group (Castaneda et al 2001, 2004) found that the adaptations from a 
(12-week, 3x8@80%1RM) resistance training intervention (with low protein diet) in 
a NDD population, were correlated with a reduction in pro-inflammatory cytokines 
(IL-6 and the size of type I muscle fibres r=-0.58, p=0.02, and type II muscle fibres r=-
0.68, p=0.05).  The authors concluded that RT may therefore reverse the 
malnutrition-inflammation complex syndrome of CKD implicated in poor prognosis 
(Castaneda et al 2004).  These clinical measures (markers of inflammation) may help 
develop prediction models for adaptation to a training intervention (based on 
circulating cytokines), or measure responsiveness to the exercise stimulus. 
 
 
8.2.3 Anabolic (resistance exercise training) intervention 
The 12-week resistance exercise training in early stage CKD patients had a positive 
effect for measures of muscle size and architecture, strength, function, and uraemic 
symptoms (HRQoL).  This beneficial change was broadly similar in both groups (RT1 
and RT3) except in measures of VL ACSA and VL pennation angle at the VL mid-point 
(summarized in Table 8.1).   
 
This general improvement was anticipated, though the expectation would be that 
greater volume (frequency) of exercise would bring about a greater volume of 
adaptation even if not at the same rate (dose-response).  However, it has been 
suggested that for individuals that are deconditioned - such as those with chronic 
illness, the frail or elderly - a training threshold may exist.  That is, for initial training 
adaptations amongst the most deconditioned, when a threshold-stimulus is met, 
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further increases in volume load or frequency may not result in greater gains in 
strength (Benton et al 2011).  The results of this intervention study (Chapter 7) 
reflect this proposition, as the significant group differences noted in body 
composition and structure did not occur in the initial stages, and it was only with 
more prolonged exposure (beyond eight-weeks of training) that they became 
apparent, and group responses began to diverge.  
 
Whether this was the most effective intervention programme (3 sets of 8 
repetitions at 80% of 1-RM) that could have been implemented is debatable.  
Literature has suggested that using an alternative “single set to failure”, instead of 
the standard multiple-set protocol, may be a greater stimulus to promote 
adaptation in strength and muscular hypertrophy.  The theory is that as the motor 
units used to perform the exercise are fatigued, the continued resistance causes 
higher threshold motor units to be employed (greater contribution from type 
2b/fast twitch muscle fibres), which are capable of the greatest increases in 
strength and hypertrophy.  Training to failure, when implemented, should be at a 
high enough intensity to stimulate an adaptation; suggested at 80% 1-RM (Stone et 
al 1996); the same intensity as instigated in the intervention study here (Chapter 7).  
However, training to failure should not be performed repeatedly for long periods 
due to the high potential for over-training or injury (reviewed by Willardson 2007), 
and it is not recommended for older adults, and those with pre-existing 
musculoskeletal or cardiovascular conditions (Stone et al 1996), and thus would 
exclude a large proportion of CKD patients (CVD is the number one cause of death 
due to complications as CKD progresses to ESRD; Go et al 2004). 
 
8.2.3.1 Muscle size, architecture and force production 
The inconsistency of muscle size adaptation and strength in response to the 
intervention (no group difference in maximal strength, but a dose-response [group 
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difference] in VLACSA and pennation angle) may appear initially to be 
counterintuitive as muscle force-generating properties are strongly influenced by 
the architectural arrangement of the fibres (Malas et al 2013).  However, these 
results have previously been observed (reviewed by Kawakami 2005).  It is now 
widely accepted that muscle hypertrophy accompanies an increase in pennation 
angle, reaching values as high as 55° (Kawakami et al 1993, Kawakami 2005) but an 
increase in pennation angle can lead to a muscle force deficit due to change in the 
efficiency of force transmission from the fibres to the tendon (Kawakami 2005).  
This has been disputed, with the expectation of increased muscle force and 
performance with increased pennation angle (in pennation angles below 45°; Malas 
et al 2013).  The variation in the literature may be in part due to the methods used 
for the assessment of muscle strength.  By measuring the change in peak isometric 
force using leg press and knee extension but only the change in pennation angle 
(and ACSA) of one of the multitude of muscles involved in the movement, one may 
suggest that many other important factors are not being assessed.  The VL 
(measured in this intervention) is only one of four muscles of the quadriceps, which 
does not bring about movement and force in isolation of the others (Blazevich et al 
2009). 
 
A recent study of healthy, older (>60 years old) people showed no significant 
changes in pennation angle of the vastus lateralis muscle (3.3% increase, 6-week 
duration, Scanlon et al 2014).  This is in contrast to the initial 6-weeks of the current 
intervention, where gains of approximately 10% (Figure 7.16b) were observed.  This 
may be due to the slightly lower intensity of training dose experienced by the 
participants (~70-85% 1RM based on a subjective assessment of RPE of 5-6/10; 
Scanlon et al 2014) in contrast to this study.  However, the population sample, 
though aged and therefore likely to have decreased muscle size and pennation 
angle (Doherty 2003; Cadore et al 2012), were not categorised as frail or 
deconditioned, nor were they uraemic; all factors potentially influencing the 
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baseline pennation angle.  However, previous interventions have shown gains 
varying from 13-22% over an intervention period of 12-14 weeks (Reeves et al 2004; 
Suetta et al 2008) with suggestions of up to 35% improvements with eccentric 
training (Reeves et al 2009), closer to the results observed here (RT3 pennation 
angle ↑36% by week 12, Figures 7.6 and 7.16b). 
 
As with the VL pennation angle, VL ACSA increased at different rates over the 12-
weeks between the groups (RT3 ↑30.8% ↑5.64cm2, RT1 ↑13.2% ↑2.52cm2) 
culminating in a 3.12cm2 difference between the two groups.  These significant 
changes did not correspond with the changes in muscle thickness (total muscle 
depth and VL-only depth) in that these measures showed no group differences over 
the 12-weeks and the mean change was not to the same extent (VL only ↑9.7%, 
total muscle ↑8.6%).  Initially this seems counter-intuitive but this has also been 
observed previously, where no significant change was observed in muscle thickness 
but dramatic (significant) change in VLACSA (VLACSA, ↑7.4%, p<0.05, VL depth, 
↓7.3%, ns, Scanlon et al 2014).   
 
Anatomical cross-sectional area has therefore been suggested as providing a more 
sensitive assessment of total hypertrophy as it has been reported to better relate to 
the hypertrophic and force-producing characteristics associated with muscle size 
(Bemben 2002).  There is some variation in reporting, as often studies report total 
ACSA at the mid-VL point (“total quadriceps”, or “knee extensor” area) and not just 
VL ACSA. Healthy individuals’ quadriceps ACSA assessed by highly sensitive MRI 
showed initial growth and adaptation from 10-days into a high intensity resistance 
training programme (bilateral leg extension, 4 sets of 7 reps, “maximal”, 3/week, 
Seynnes et al 2007).  As previously mentioned, the deconditioning observed in the 
present study sample may have delayed the onset of muscular hypertrophy; 
however, the decision to measure VL ACSA alone (not total quadriceps ACSA) may 
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also have contributed to the delay as muscular hypertrophy will have taken effect in 
other trained muscles of the quadriceps, not just the VL. 
 
8.2.3.2 Strength and Function, and the link with frailty 
Muscular hypertrophy and changes to the architecture do not improve strength and 
functional performance alone.  It is well-established that initial improvements in 
performance are instead due to neural adaptations as some studies have 
demonstrated increased strength in untrained limbs when the opposite was 
specifically trained (Enoka 1997; Zhou 2000).  The intervention in the present study 
did not compare unilaterally trained limbs, but did examine upper body strength to 
control for systemic or pathophysiological adaptation.  As reported in Chapter 7, 
handgrip strength did increase in both groups (RT1 ↑ 0.2kg, RT3 ↑ 0.6kg) over the 
12-week intervention though neither measured change was significant (p>0.05) and 
were far below the MDC established in the literature (3.4kg, CKD HD, Segura-Orti & 
Martinez-Olmos 2011). 
 
The pooled results from this intervention (Chapter 7) show a large adaptation effect 
in strength and function, especially when compared to patients later in the disease 
process.  The two STS functional tests showed significant improvement over the 12-
week intervention.  It can be seen from Figures 8.1a-b that, on average, the 
resistance exercise intervention returned the functional capacity to within a normal 
“healthy” range by the mid-point (week six).  The sample cohort for the intervention 
assessed in this thesis (CKD3) had a mean age of 56.9 ± 13.0 years.  
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Figure 8.1a – Change in STS5 (time) over the 12-week resistance training 
intervention 
 
 
 STS5: Dashed line shows average values in a healthy population of the same age 
range (50-59yrs) and shaded area shows the normal range (mean ± SD) within the 
healthy population (age 50-59 years, n=15, 7.1 ± 1.5 secs; average community 
dwelling adults, all ages 18-89yrs, mean 51 ± 20.8 years = 7.6 ± 2.7 secs; Bohannon 
2007).  The thick black line represents the CKD5 average (13.0 ± 6.9secs, Chapter 4). 
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Figure 8.1b – Change in STS60 (count) over the 12-week resistance training 
intervention 
 
 
STS60: Dashed line shows the reference values from the 50th percentile for the 55-59 
year age group, and shaded area the 25-75th percentile (25th percentile: 30 
[female], 33 [male], 50th percentile: 36 [female], 41[male], 75th percentile: 
43[female], 48[male]; Strassman et al 2013).  The thick black line represents the 
CKD5 average (21.5 ± 7.5, Chapter 4). 
 
 
 
The improvements in function - comfortably bringing the participants into the 
healthy (average) range - are an indication of increased independence and reduced 
frailty as these two measures (physical function and exhaustion) are commonly 
used in diagnosing frailty in the elderly or chronically ill populations.  This is 
important as those deemed frail (low physical function, self-reported exhaustion, 
weak grip strength, slow gait speed and unintentional weight loss; Fried et al 2001) 
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are often transferred on to dialysis earlier in the disease process where dependence 
increases alongside a reduced HRQoL. Frailty has also been linked with increased 
risk of falls and increased hospitalization (Johansen et al 2013).  
 
The STS5 outcome measure is usually cut-off (test is stopped) between 12 and 15-
seconds (>65 years old, Buatois et al 2010; community dwelling elderly, Mong et al 
2010; >60 years old community dwelling, Bohannon 2006), as over this duration the 
participant should be assessed for an increased risk of falls, with estimated values 
(mean time) for normal performance in community dwelling older adults falling 
around the 12-second mark (60-69 years, 11.4 sec; 70-79 years, 12.6 sec; 80-89 
years, 12.7 sec; Bohannon 2006).  Figure 8.1 clearly demonstrates the sample 
population from this intervention reducing the average scores from that cut-off 
point where there is increased risk of falls to a level much more appropriate for the 
age group.  Although it would also appear that the improved function did not reach 
the upper-half of the healthy-average from this 12-week resistance training 
intervention. 
 
 
8.2.4 Responders and non-responders to the intervention 
It has been previously demonstrated that for 20-25% of participants undertaking an 
exercise programme there is little to no favourable response (Davidsen et al 2011; 
Timmons et al 2010; Timmons & Phillips 2014) whilst a small percentage (5-10%) 
suffer adverse events (Bouchard et al 2012).  Fortunately in this intervention there 
were no reported adverse events but approximately one-third of participants did 
not meet or exceed the MDC in VL depth, indicating a lack of response to the 
exercise intervention (Figure 8.2).   
 
Similar non-responsiveness to an exercise intervention has been reported in ESRD 
patients where average results demonstrated a significant increase, but the wide 
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standard deviations indicated a large heterogeneity within the sample (6-months, 
aerobic training, Koufaki et al 2002).  With individual assessment, the authors 
identified non-responders (61% responded by 3-months, 89% by six-months in 
VO2peak) as those not reaching the standard error of the mean (similar to MDC 
[MDC = (1.96)(√2)(SEM)]), and gave potential reasons as non-compliance (unable to 
complete the exercise prescription), the limiting effect of co-morbidities, or a 
genetic pre-disposition to non-adaptation to an exercise stimulus.  The genetic 
influence on adaptation/ responsiveness has been postulated previously (review 
update: Perusse et al 2013), though this has largely examined aerobic/endurance 
training responses (VO2peak/VO2max, submaximal performance, cholesterol, blood 
pressure, and heart rate; reviewed by Bouchard & Rankinen 2001) and requires 
further investigation, especially within specific populations (such as CKD), though it 
is likely to be applicable to all populations due to the nature of genetics. 
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Figure 8.2 – Individual change data from baseline, dashed lines represent the MDC 
using 2-D B-mode ultrasound in the CKD population (VL depth MDC: ± 0.14cm, 
chapter 5).  Participants 1-10 were in group RT3, and 11-17 in RT1 
 
 
The non-responders - determined by change in VL depth - appear to be distributed 
across the two groups, with a greater proportion in RT1 (3/10 not reaching the MDC 
by week 12 in RT3, 4/7 in RT1). 
 
From the graphed individual change data for strength (Figure 8.3), function (Figure 
8.4), and uraemic symptoms (Figure 8.5), it can again be seen that the non-
responders are equally distributed across the two groups (participants 1-10 in RT3, 
and 11-17 in RT1) for outcome measures that showed no group*time interaction. 
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Figure 8.3 – Individual change data for strength (KEPF45 and LPPF45) (MDC: KEPF 
46-79N; Bohannon 2012) 
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Figure 8.4 – Individual change data for functional tests – STS60, STS5, NSRI walk 
test.  Dashed lines represent the minimal detectable change (MDC).  Change greater 
than this line represents a response to the intervention (MDCs: STS60: 4-
repetitions, Segura-Orti & Martinez-Olmos 2011; STS5: 1.7 - 3.12 seconds, Jones et 
al 2013, Goldberg et al 2012, Puthoff & Saskowski 2013). 
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Figure 8.5 – Individual change data for uraemic symptoms (LUSS) from baseline to 
week 12 
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Table 8.4 – Overview of responders and non-responders (by participant number) 
based on outcome measures with previously calculated or published MDCs 
By week 12 VL depth KE PF 45 STS 60 STS 5 LUSS 1 
LUSS 2 
and 3 
Apparent non-
responders 
2, 3, 4, 13, 
14, 15 
3, 4, 5, 6, 
11, 14, 16 
2 
1, 2, 6, 7, 
10, 13, 14 
4, 5, 7, 8, 
9, 12, 13 
1, 7, 8, 
9 
Largest 
response 
7, 11, 16 8, 15, 17 8, 9, 17 4 
10, 15, 
16 
4, 6, 
15 
 
Table 8.4 summarizes the responders and non-responders to the full 12-week 
intervention.  It is apparent that some participants struggled to make gains in some 
assessments but not in others.  For example, some of the best responders to the 
intervention with regards to muscle size were participants #7, 11, and 16 though 
each also appeared as non-responders in strength (KEPF: #11, 16), function (STS5: 
#7) and uraemic symptoms (LUSS: #7) and vice versa (non-responder in VL depth, 
but greatest response in KEPF, and LUSS: #15).  This suggests that adaptations are 
made by each participant in a response to the intervention; however, not all 
participants adapt in the same manner. 
 
The suggestion that all participants adapt in some way to the intervention is 
highlighted further when examining group differences for outcome measures with a 
group*time effect (pennation angle and VLACSA).   
 
Figures 8.6 and 8.7 clearly demonstrate that all participants adapted to some extent 
to the intervention (all show a positive change by week 12), and demonstrate an 
apparent dose-response (RT3>RT1), as the individual change of the pennation angle 
and VL ACSA show the increased rate of change in those training three-times per 
week, compared to once per week. 
 256 
 
 
 
Figure 8.6 – Individual change data for pennation angle of the VL muscle.  
Participants 1-10 were in group RT3, 11-17 in RT1. 
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Figure 8.7 – Individual change data for ACSA of the VL muscle.  Participants 1-10 
were in group RT3, 11-17 in RT1. 
 
  
 
 
 
 
The correlations calculated (Chapter 6) indicate that the change observed in both 
VLACSA and pennation angle at the mid-VL site is linked with change in strength 
(KEPF45 in particular; VLACSA and pennation angle both r=0.35, p<0.05, Table 6.2), 
so other factors account for the majority (r2= 0.12) of the varying response rates (no 
10
15
20
25
30
35
40
45
0 12
V
L 
A
C
SA
 (
cm
2
) 
RT3 individual results 
10
15
20
25
30
35
40
45
0 12
V
L 
A
C
SA
 (
cm
2
) 
RT1 individual results 
0
2
4
6
8
10
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
in
d
iv
id
u
al
 c
h
an
ge
 in
 V
LA
C
SA
 (
cm
2
) 
change by week 12 change by week 6
 258 
 
group*time interaction for strength measures) and no simple relationship between 
ACSA or pennation angle, and strength exist. 
 
For more exact prediction equations, or stronger relationships with muscle force 
production, it has been suggested that the physiological cross-sectional area (PCSA) 
is used.  To calculate the PCSA, data is required regarding fibre length, pennation 
angle, and muscle volume (Aagaard et al 2001).  Maximal contractile force relative 
to PCSA has been reported as remaining consistent across a variety of muscles in 
various animal models (Close 1972); though more recently a suggestion of greater 
variation in human skeletal muscle has been made (Aagaard et al 2001). 
 
When examining individual data for VL ACSA and pennation angle, where there was 
a group*time interaction (differential response to training volume; RT1 or RT3) it is 
clear that all participants in this sample adapted in response to training.  How this 
adaptation manifested varied between individuals. 
 
Despite initial individual analyses showing a split of responders and non-responders, 
certain measures showed improvements for all participants (ACSA and pennation 
angle), alongside varying responsiveness in other outcome measures.  Firstly, these 
results need to be replicated as the sample was small, and a larger (and broader) 
cohort may not demonstrate the favourable adaptations seen here.  Assuming 
these results are accurate, then all CKD3 patients may have the ability to adapt to a 
resistance exercise stimulus in some capacity, though a more tailored approach 
(personalised medicine) may be necessary to elicit the required and/or desired 
response.  Knowledge of the genetic phenotype of an individual may contribute to 
improved interventions as this is likely to be the most influential factor. 
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8.2.5 Summary 
The common pathway of protein-energy wasting and frailty has clearly been 
described (Delgado et al 2013), with the need for early intervention paramount to 
delay further deterioration.   
 
Some studies that have brought about (or observed) improved protein synthesis, 
increased muscle size (measured by anatomical or physiological cross-sectional 
area, muscle depth/thickness, muscle volume) or improved architectural structure 
(pennation angle) have not necessarily demonstrated equivalent improvements in 
muscular strength or functional performance measures, and vice versa (peak force, 
sit-to-stand tests, walk tests; MacDonald et al 2005; Song & Sohng 2012; Tables 
2.7a-b), though these variations were predominantly in dialysis (CKD5/ESRD) 
patient studies.   
 
Decreased testosterone levels in CKD have been shown even in the early stages of 
the disease progression, which further contributes to the pro-catabolic environment 
that leads to muscle wasting and loss of muscular strength (CKD2-4; Cigarrán et al 
2013).  Increasing lean mass (through promotion of anabolism and hindering 
catabolism) via (non-medical anabolic) exercise interventions is the preferred 
method due to the other beneficial side-effects associated with exercise.  However, 
prescribing a generic resistance programme may not be optimal, depending on the 
primary outcome objective.  
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8.3 Limitations of this thesis 
The results of the intervention study are robust due to the effect size and 
significance of the adaptation to the intervention.  However, results from the 
intervention study should be interpreted with some caution due to the small 
sample size recruited from a heterogeneous population (varying age, medical 
history and physical activity background), though this bias was reduced through the 
randomisation applied after baseline measures were taken. 
 
With a larger sample size for the main intervention study it may have been possible 
to stratify the results into responders and non-responders to the intervention.  This 
theory has been explored in previous exercise studies (in general population 
samples, Buford et al 2013; Stroke, Bowden et al 2013; COPD, Troosters et al 2001; 
CKD, Koufaki et al 2002). This would enable future interventions of this nature to be 
tailored to the individual based on the expectation of effective adaptation 
response; for example, if the non-responders had been limited by co-morbidities 
such as diabetes, other medical history, baseline outcome measures, clinical results 
or other factors. 
 
A larger sample size would have also allowed inclusion of other intervention groups, 
including a standard control or usual care group.  The lack of inactive control group 
means the results cannot be compared to the ongoing disease progression seen 
with usual care.  It is possible that the additional (control) group may have affected 
the significance of the results either way and the ideal study design would have had 
four groups; RT1 and RT3, a standard control or usual care group, and finally a 
group with no structured or supervised intervention but advice to include resistance 
training into their lifestyle (to examine the effect of supervision and structure).  This 
was not feasible in this study due to constraints of time and recruitment 
(participant availability).  Additionally, whereas it was previously believed that for 
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CKD patients any intervention which induces movement or some form of physical 
activity (placebo, sham, or advice only) was sufficient to bring about a beneficial 
result, recent literature showed this theory (in layman’s terms: anything is better 
than nothing) to be incorrect (Wang et al 2009).  If this is the case, then excluding a 
group from the anabolic intervention by randomization to a control or usual care 
group could be deemed unethical (withholding a known beneficial form of 
treatment). 
 
A further limitation of this thesis is that the comparison and correlation studies 
(Chapters 4 and 6) were only cross-sectional by design and did not follow the 
patient groups longitudinally to accurately describe and quantify the decline in 
mass, strength, function, and health-related quality of life.  The inference that CKD5 
fare worse than CKD3 across the variety of outcome measures is instead based on 
average measures in two distinct groups and cannot be reported with the same 
weight as individual change data denoting the natural history of decline across the 
established disease trajectory.  This was again due to time-constraints and used a 
convenience sample at the two stages as only a small percentage of CKD3 patients 
would deteriorate/progress to CKD5/ESRD within a given time period (4% risk of 
progression to ESRD in 5.5-year follow-up; Drey et al 2003). 
 
The validation and reliability of 2-D B-mode ultrasound was tested (Chapter 5) in 
CKD peritoneal dialysis patients (CKD5 CAPD), showing excellent results.  However, 
the protocol, MDC, and typical error were then applied to early stage (NDD) 
patients.  Both groups (PD and NDD) were CKD patients - of similar demographics - 
but this may have compromised the external validity of the measurement as it has 
been reported that ultrasound measures in different stages of wasting 
(sarcopaenia, Strasser et al 2013) have varying echogenicity or image quality 
(healthy muscle tissue is normally echo-lucent or dark, Mayans et al 2012).  
Fortunately, these studies have found that image quality and reliability is actually 
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enhanced in younger or healthier muscle tissue (Pillen & van Alfen 2011; English et 
al 2012), suggesting non-dialysis dependent (NDD) stages will give clearer images 
compared to those in dialysis dependent patients. 
 
Finally, the Leicester Uraemic Symptom Score (LUSS) - used here as a proxy  
indicator for some aspects of HRQoL - is an assessment of eleven commonly 
reported symptoms of uraemia, of which approximately half are associated with 
weakness and muscle wasting.  It was therefore not entirely unexpected that the 
reported symptom number, frequency and intrusiveness would reduce with the RT 
intervention as functionality and strength improved.  Utilising another HRQoL test 
may have been more appropriate to gauge the more general changes or 
adaptations that may have occurred as a result of the intervention (or at different 
CKD stages).  The Kidney Disease QoL (KDQOL) and the Short-Form 36 Health Survey 
(SF-36) have both previously been used in this population and found to be valid, 
with the SF-36 also being implemented in other chronic and critical illnesses.  
However, the LUSS design allows frequency of symptoms and intrusiveness to be 
assessed separately to prioritise treatment; a symptom may occur frequently but is 
not deemed intrusive to the individual patient.  If the LUSS design was extended to 
include other common symptoms of uraemia (e.g. pruritus, anaemia, 
tachypnea/rapid breathing, dyspnea/shortness of breath, urination problems; Table 
2.2) it could be of greater value in the assessment of HRQoL from an intervention. 
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Table 8.5 – Overview of the limitations of the thesis 
Limitations 
 Small sample size in the intervention study 
 Lack of standard control group for the intervention study 
 Cross-sectional study design for assessing differences between CKD stages 
 External validity of US to the CKD3 intervention sample 
 LUSS focus on only eleven symptoms 
 
 
8.4 Implications for research, practice, and policy makers arising from this thesis 
8.4.1 Policy-makers 
Current guidelines for Chronic Kidney Disease include the advice that “CKD patients 
should be encouraged to take exercise” (NICE CG 73, 2008; Holt & Goldmith, The 
Renal Association 2011); however, there is no formal route or prescription/ 
explanation of exercise type, duration or intensity.  This thesis provides evidence 
that a structured PRT programme brings about benefits to a number of the essential 
criteria that contribute to improved health-related quality of life (greater 
independence through improved strength, function and reduced uraemic 
symptoms).   
 
Formal rehabilitation programmes exist for other chronic illnesses in the UK, 
implemented by the NHS or associated foundations/agencies (cardiac: British 
Association of Cardiac Prevention and Rehabilitation; pulmonary:  British Lung 
Society) and advice exists to exercise during dialysis, but not in NDD patients. A 
recent systematic review and meta-analysis of PRT in all CKD stages also concluded 
that policy-makers and clinicians should look to prescribe PRT to induce muscular 
hypertrophy and improve strength and health-related QoL (Cheema et al 2014).  
This thesis provides a strong foundation for the initiation (or piloting) of a 
 264 
 
programme similar to the exercise groups recommended for cardiopulmonary 
rehabilitation; with sessions held on a weekly basis.  
 
8.4.2 Clinicians and Researchers  
Other chronic illnesses have utilised 2-D B-mode ultrasound where muscle atrophy 
is a complication and limitation of the disease.  This thesis has demonstrated that 2-
D B-mode ultrasound is clearly accurate and sensitive enough to detect individual 
patient and group change over time in the CKD population, whether it is used to 
track the muscle size or architecture to monitor the effect of the disease 
progression, or in response to an intervention (anabolic: exercise, nutrition, 
hormonal; RRT: dialysis or transplant).  Accurate measurement of body mass and 
composition is vital, and currently-used anthropometric, body mass and subjective 
global assessments do not have the level of sensitivity required. 
 
The body-site used in this thesis (mid-VL) was selected for measurement (and 
training) due to the contribution of the quadriceps to many functional activities 
required for independence in daily life.  The advantage being this is also a pennate 
muscle and the exercise intervention could affect the muscle architecture.  Other 
pennate-muscles could be used to assess change (pennation angle; architecture) 
from training, disuse, or disease-related atrophy, though these other muscles/sites 
would need separate validation. 
 
Table 8.6 – Overview of implications for research, practice, and policy-makers 
Implications 
 Policy-makers: look to implement a standard progressive resistance training 
(PRT) prehabilitation programme for early-stage CKD patients. 
 Researchers and Clinicians: using ultrasound is a practical and accurate way 
to measure and track muscle size and architecture at localised areas of the 
body.   
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8.5 Suggestions for future research studies arising from this thesis 
A number of research studies can be suggested based on this thesis in 
participant/population, intervention, control/comparison, and outcome measures. 
 
8.5.1 Participants/population and comparisons 
The two main population comparisons would be firstly to include healthy or 
asymptomatic (disease-free) groups.  This is important to confirm that CKD3 
patients are already frailer than asymptomatic individuals as shown in the earlier 
literature (Wilhelm-Leen et al 2009) and to compare the adaptation rate in 
response to the training interventions performed here (RT1 and RT3).  This would 
allow researchers to comment on the rate of change of the non-CKD compared to 
CKD individuals, to determine if there is a limitation enforced by the inflammation 
and uraemia experienced by these early-stage CKD patients. 
 
The second population comparison to be introduced would be CKD4 patients.  Once 
again the aim of the study would be to examine the adaptation rate, and extent of 
the adaptation possible, in comparison to both CKD3 and non-CKD participants.  It 
has been strongly suggested that weakness and frailty in CKD becomes particularly 
pronounced in the transition from CKD3 to CKD4 (Hiraki et al 2013).  Would this 
reduced strength, function and health-related quality of life remain below those of 
CKD3 and asymptomatic participants with the implementation of the RT 
programme? Or do these patients have the same potential for adaptation as these 
other two groups, considering that the previously implemented RT programmes in 
late-stage CKD (CKD5/ESRD/dialysis-dependent) patients have reported mixed 
results (improvements, no change, or reduction in muscle size and/or strength; 
Segura-Orti et al 2009; Headley et al 2002; Cheema et al 2011)? 
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8.5.2 Intervention 
Follow-up of the current intervention sample would be interesting and important to 
determine the maintenance potential of the outcome measures (improved muscle, 
strength, function, health-related quality of life) and simultaneously examine the 
participants who continue with the intervention (without instruction or supervision) 
of their own accord (compare and contrast characteristics of those who do and do 
not continue, maintain, or respond). 
 
Based on the results from this thesis, depending on the primary aim of the study 
would determine the intervention training frequency; if the primary aim is to (1) 
bring about improvements in strength, function and HRQoL, or to (2) bring about 
change in muscle size and architecture, will determine the intervention programme 
design - 
(1) The results of the intervention in this thesis (Chapter 7) implied a greater 
adaptation rate per exercise training session in group RT1 compared to RT3, 
as similar changes from baseline were observed in VL ACSA after 18 sessions 
in RT3 and just 12 sessions in RT1, and pennation angle (RT3 18 sessions, 
RT1 8 sessions).  From this it would be informative to extend the once per 
week training sessions (RT1) for a total number of sessions equivalent to 
those completed in 12-weeks in RT3 (36 sessions = 12-weeks RT3 = 36-weeks 
RT1), to observe whether this increased “efficiency” translates to a greater 
overall improvement over the complete 36 sessions.  Advancing and 
extending this RT intervention once per week would also provide guidance 
to policy-makers initiating a programme of exercise for CKD patients. 
(2) To bring about maximal change in muscle ACSA and pennation angle, with 
minimal participant time, intrusiveness, or commitment; implementing a 
training programme once per week for the initial six or eight-weeks, 
followed by increased frequency (to thrice per week) could bring about 
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equivalent growth as the current RT3 group (thrice per week from the 
beginning).  This hypothesis is founded upon the similar improvements 
observed in the two intervention groups up to week eight, at which point 
muscle measures began to diverge.  Additionally, by increasing the dose by 
this point (between 6-8 weeks) may stimulate greater improvement in 
strength, function, and uraemic symptoms in the second six-weeks instead 
of the relative plateau observed in both groups from the mid-point as they 
became accustomed to the stimulus frequency, even with the progressive 
nature of the training intensity (80%1RM); adaptation/recovery is 
accelerated allowing greater intensity within an individual session, even with 
the increased frequency (reduced recovery time). 
 
8.5.3 Outcome measures 
Objectively measuring physical activity outside of the intervention would allow 
researchers to eliminate the effect of outside influence.  In the current study, the 
patient-reported physical activity recall (PAR) attempted to assess these differences 
between groups. However, due to the subjective nature of the test, precision may 
not be high enough for use as a co-variate (individual opinion of what is 
high/medium/low intensity, despite instruction and definitions provided).  
Introducing accelerometers would allow greater accuracy of activity levels outside 
of the intervention. 
 
To minimise the time-taken and potential for error in the reconstruction of the 
ACSA image prior to measurement, introducing a proxy (or prediction equation 
based on simpler and consistently accurate US-derived measures) would be 
beneficial.  This would have to be grounded on outcomes with high correlation 
between ACSA and the suggested proxy measures.  Based on the correlations of US 
muscle measures taken in Chapter 6 and results of the intervention (Chapter 7), VL 
or total muscle depth (thickness) would not be able to provide sufficient 
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information alone (no difference was observed between groups whereas ACSA 
showed a significant difference).  However, combining the thickness (depth) 
measure with pennation angle (which showed a group effect as well as time effect) 
may be sufficient.  This would require a significantly larger sample than those used 
in this thesis but could be developed in healthy populations (for recruitment 
convenience) and adapted for the chronically ill populations if necessary. 
 
Finally, as previously mentioned in the thesis limitations section, the LUSS could be 
further developed to provide more information on a broader array of symptoms 
that are associated with the inflammation and uraemia manifested in CKD patients, 
at any stage of the disease process. 
 
Table 8.7 – Overview of suggested further research  
Further research 
Participants and comparisons: 
 Healthy comparison/control group 
 Implement intervention in CKD4 
Intervention: 
 Follow-up current sample to examine maintenance levels 
 Extend the RT1 intervention to compare adaptations at the same total 
session number as RT3 
 Examine starting the intervention at RT1 then increasing frequency to RT3 
from 6-8 weeks 
Outcome measures: 
 Objectively measure physical activity levels outside of the intervention 
(possibly use accelerometers) 
 Find a proxy measure and/or develop equations using simpler muscle 
measures than reconstructing VL ACSA from separate images 
 Develop the LUSS to include other common symptoms on CKD beyond the 
current focus 
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CHAPTER 9 - Conclusions 
 
9.1 Main findings 
There were two main findings arising from this thesis – 
1. Assessing regional body composition using two-dimensional brightness-mode 
ultrasound (2-D B-mode US) as a measurement tool is valid and reliable in the 
CKD population.   
It is also very useful; differentiating between tissues such as muscle and fat as well 
as allowing clinicians and researchers alike to view structural or architectural 
adaptation that may occur as the disease progresses or in response to an 
intervention.  The main advantages of using ultrasound over other measurement 
tools which are also capable of doing this (such as MRI, CT, DEXA) are the portability 
(near-bedside method), reduced financial cost, and minimal intrusion to the 
patient/participant. 
 
2. Resistance (exercise) training in early-stage CKD patients either once or three-
times per week for 12-weeks brings about an anabolic response; significantly 
increasing muscle mass, strength, function and improving the muscle 
architecture in the trained muscles, alongside a reduction in the uraemic 
symptoms experienced by the patients/participants. 
Positive results such as these have been observed in the CKD population, though 
the focus has previously been on dialysis-dependent patients (NDD: Castaneda et al 
2001, 2004; ESRD: Cheema et al 2011; Segura-Orti et al 2009; MacDonald et al 
2005).  These previous studies have also largely compared a control (no 
intervention), endurance intervention, or placebo/sham training group to the 
resistance training intervention.  Though this is methodologically advantageous 
(RCTs being the gold standard approach), these studies have generally implemented 
an intensive RT intervention (same as the high volume group here; 12-weeks, 
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80%1RM, three-times per week).  The use of two intervention groups in this study 
has highlighted that the high volume/frequency intervention is no more beneficial 
to the patient/ participant than the low volume/frequency, as training either once 
or thrice per week brought about the same increases in strength, function and 
health-related quality of life (reduced uraemic symptom frequency and 
intrusiveness). 
 
9.2 Clinical, practice, and research implications  
The intervention results suggest implementing a resistance training (RT) form of 
“prehabilitation” in early stage (CKD3) patients just once per week is sufficient to 
bring about statistically and clinically important changes in strength and function 
that benefit the patient through reduced frequency and/or intrusiveness of uraemic 
symptoms (improved health-related quality of life), with minimal time-
commitment. 
 
Further research should examine if there is additional benefit to the significantly 
greater increases in VLACSA and pennation angle observed in RT3 with regards to 
long-term maintenance of functional improvements, and whether an RT1 or RT3 
programme delays the progression of CKD, reduces/delays the need for RRT, and 
beneficially affects patient mortality. 
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APPENDIX 2 – correlations between ultrasound derived measures of muscle mass and architecture with strength, function, and uraemic 
symptoms at completion of the intervention (12-weeks) by individual participants  
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RELATIONSHIPS USING INDIVIDUAL ASSESSMENTS AT 12 WEEKS - VL ACSA 
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APPENDIX 3 – correlations between ultrasound derived measures of muscle mass and architecture with strength, function, and uraemic 
symptoms at the mid-point of the intervention (6-weeks) by individual participants  
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RELATIONSHIP USING INDIVIDUAL ASSESSMENTS AT 6 WKS – ACSA 
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RELATIONSHIP USING INDIVIDUAL ASSESSMENTS AT 6 WKS - VL DEPTH 
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